0001437749-24-008871.txt : 20240321 0001437749-24-008871.hdr.sgml : 20240321 20240321164550 ACCESSION NUMBER: 0001437749-24-008871 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 110 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASENSUS SURGICAL, INC. CENTRAL INDEX KEY: 0000876378 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 112962080 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19437 FILM NUMBER: 24771995 BUSINESS ADDRESS: STREET 1: 1 TW ALEXANDER DRIVE STREET 2: SUITE 160 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-765-8400 MAIL ADDRESS: STREET 1: 1 TW ALEXANDER DRIVE STREET 2: SUITE 160 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: TRANSENTERIX, INC. DATE OF NAME CHANGE: 20190712 FORMER COMPANY: FORMER CONFORMED NAME: TRANSENTERIX INC. DATE OF NAME CHANGE: 20131210 FORMER COMPANY: FORMER CONFORMED NAME: SafeStitch Medical, Inc. DATE OF NAME CHANGE: 20080211 10-K 1 asxc20231231_10k.htm FORM 10-K asxc20231231_10k.htm
FY 2023 --12-31 false 0000876378 false false false false 1 0 0 5 3 3 10 0 0 0 0 0 0 4 1 1 0 4 5 25.0 15.0 6 1 10 1 0 0 1 2 1 1 0 0 0 0 0 0 0 0 0 0 00008763782023-01-012023-12-31 thunderdome:item 00008763782023-10-012023-12-31 iso4217:USD 0000876378asxc:PreclinicalEvaluationOfTheLUNASurgicalSystemMemberasxc:SynchronyLabsLLCMember2023-01-012023-12-31 xbrli:pure 0000876378asxc:SynchronyLabsLLCMemberasxc:DirectorOfAsensusMember2023-12-31 0000876378asxc:AsensusSurgicalEuropeSrlMemberasxc:ServiceSupplyAgreementMemberasxc:OneMedSaMember2022-01-012022-12-31 0000876378asxc:AsensusSurgicalEuropeSrlMemberasxc:ServiceSupplyAgreementMemberasxc:OneMedSaMember2023-01-012023-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2023-01-012023-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2023-01-012023-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMember2023-01-012023-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2023-01-012023-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:EuropeMiddleEastAndAfricaMember2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:EuropeMiddleEastAndAfricaMember2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:US2022-01-012022-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembercountry:US2022-01-012022-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2023-01-012023-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:AllCountriesMember2023-01-012023-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2023-01-012023-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembersrt:AsiaMember2023-01-012023-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMemberasxc:EuropeMiddleEastAndAfricaMember2023-01-012023-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMemberasxc:EuropeMiddleEastAndAfricaMember2023-01-012023-12-31 0000876378us-gaap:AssetsTotalMemberus-gaap:GeographicConcentrationRiskMembercountry:US2023-01-012023-12-31 0000876378asxc:LongLivedAssetsMemberus-gaap:GeographicConcentrationRiskMembercountry:US2023-01-012023-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberasxc:LicenseAndSupplyAgreementMember2023-12-31 xbrli:shares 00008763782022-01-012022-12-31 0000876378us-gaap:WarrantMember2022-01-012022-12-31 0000876378us-gaap:WarrantMember2023-01-012023-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-31 0000876378us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000876378us-gaap:EmployeeStockOptionMember2023-01-012023-12-31 0000876378asxc:WarrantsIssuedInRegisteredDirectOfferingMember2023-07-272023-07-27 0000876378asxc:CommonStockIssuedInRegisteredDirectOfferingMember2023-07-272023-07-27 utr:Y 0000876378asxc:WarrantsIssuedInRegisteredDirectOfferingMember2023-07-27 iso4217:USDxbrli:shares 0000876378asxc:The2022AtmOfferingMember2023-01-012023-12-31 0000876378asxc:The2022AtmOfferingMember2023-12-31 0000876378asxc:The2022AtmOfferingMember2022-03-18 0000876378us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2023-12-31 0000876378us-gaap:EmployeeStockOptionMember2023-01-012023-12-31 0000876378us-gaap:EmployeeStockOptionMember2023-12-31 0000876378asxc:PerformanceRestrictedStockUnitMember2022-01-012022-12-31 0000876378asxc:PerformanceRestrictedStockUnitMember2023-01-012023-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0000876378us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000876378asxc:GrantedIn2022Memberasxc:PerformanceRestrictedStockUnitMember2023-01-012023-12-31 0000876378asxc:GrantedIn2023Memberasxc:PerformanceRestrictedStockUnitMemberus-gaap:SubsequentEventMember2024-02-012024-02-28 0000876378asxc:GrantedIn2023Memberasxc:PerformanceRestrictedStockUnitMember2023-01-012023-12-31 0000876378us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0000876378srt:MaximumMember2022-01-012022-12-31 0000876378srt:MinimumMember2022-01-012022-12-31 0000876378srt:MaximumMember2023-01-012023-12-31 0000876378srt:MinimumMember2023-01-012023-12-31 00008763782023-12-31 00008763782022-12-31 0000876378asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember2023-01-012023-12-31 0000876378asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember2023-12-31 0000876378asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember2023-06-062023-06-06 00008763782021-12-31 0000876378us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMember2023-12-31 0000876378us-gaap:ForeignCountryMemberus-gaap:SwissFederalTaxAdministrationFTAMember2023-12-31 0000876378us-gaap:ForeignCountryMemberus-gaap:LuxembourgInlandRevenueMember2023-12-31 0000876378us-gaap:ForeignCountryMemberus-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember2023-12-31 0000876378us-gaap:DomesticCountryMemberus-gaap:ResearchMember2023-01-012023-12-31 0000876378us-gaap:DomesticCountryMemberus-gaap:ResearchMember2023-12-31 0000876378us-gaap:StateAndLocalJurisdictionMember2023-12-31 0000876378us-gaap:StateAndLocalJurisdictionMemberasxc:ImpactOf382OwnershipChangesMember2023-01-012023-12-31 0000876378us-gaap:DomesticCountryMember2023-12-31 0000876378us-gaap:DomesticCountryMember2023-01-012023-12-31 0000876378us-gaap:ResearchMember2022-12-31 0000876378us-gaap:ResearchMember2023-12-31 0000876378asxc:StartupCostsAndOtherIntangiblesMember2022-12-31 0000876378asxc:StartupCostsAndOtherIntangiblesMember2023-12-31 0000876378srt:MaximumMember2022-12-31 0000876378srt:MinimumMember2022-12-31 0000876378srt:MaximumMember2023-12-31 0000876378srt:MinimumMember2023-12-31 0000876378us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-31 0000876378us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-31 0000876378us-gaap:IntellectualPropertyMember2023-12-31 0000876378us-gaap:TechnologyBasedIntangibleAssetsMembersrt:WeightedAverageMember2022-12-31 0000876378us-gaap:DevelopedTechnologyRightsMembersrt:WeightedAverageMember2022-12-31 0000876378us-gaap:TechnologyBasedIntangibleAssetsMembersrt:WeightedAverageMember2023-12-31 0000876378us-gaap:DevelopedTechnologyRightsMembersrt:WeightedAverageMember2023-12-31 0000876378us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-31 0000876378us-gaap:DevelopedTechnologyRightsMember2022-12-31 0000876378us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-31 0000876378us-gaap:DevelopedTechnologyRightsMember2023-12-31 0000876378us-gaap:ConstructionInProgressMember2022-12-31 0000876378us-gaap:ConstructionInProgressMember2023-12-31 0000876378us-gaap:LeaseholdImprovementsMember2022-12-31 0000876378us-gaap:LeaseholdImprovementsMember2023-12-31 0000876378us-gaap:FurnitureAndFixturesMember2022-12-31 0000876378us-gaap:FurnitureAndFixturesMember2023-12-31 0000876378us-gaap:ComputerEquipmentMember2022-12-31 0000876378us-gaap:ComputerEquipmentMember2023-12-31 0000876378asxc:OperatingLeaseAssetsMember2022-12-31 0000876378asxc:OperatingLeaseAssetsMember2023-12-31 0000876378asxc:MachineryManufacturingAndDemonstrationEquipmentMember2022-12-31 0000876378asxc:MachineryManufacturingAndDemonstrationEquipmentMember2023-12-31 0000876378us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedTermMember2023-12-31 0000876378us-gaap:WarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-31 0000876378us-gaap:WarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2023-12-31 0000876378us-gaap:WarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-12-31 0000876378us-gaap:WarrantMember2023-12-31 0000876378us-gaap:WarrantMember2023-01-012023-12-31 0000876378us-gaap:WarrantMember2022-12-31 0000876378asxc:The2015SenhanceAcquisitionMember2023-12-31 0000876378asxc:The2015SenhanceAcquisitionMember2023-01-012023-12-31 0000876378asxc:The2015SenhanceAcquisitionMember2022-12-31 0000876378asxc:The2015SenhanceAcquisitionMember2022-01-012022-12-31 0000876378asxc:The2015SenhanceAcquisitionMember2021-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberasxc:MeasurementInputCurrencyExchangeRateMember2022-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberasxc:MeasurementInputCurrencyExchangeRateMember2023-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2022-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2023-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2022-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMember2023-12-31 0000876378us-gaap:FairValueInputsLevel3Member2022-12-31 0000876378us-gaap:FairValueInputsLevel2Member2022-12-31 0000876378us-gaap:FairValueInputsLevel1Member2022-12-31 0000876378us-gaap:FairValueInputsLevel3Member2023-12-31 0000876378us-gaap:FairValueInputsLevel2Member2023-12-31 0000876378us-gaap:FairValueInputsLevel1Member2023-12-31 0000876378us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-31 0000876378us-gaap:CorporateDebtSecuritiesMember2022-12-31 0000876378us-gaap:CommercialPaperMember2022-12-31 0000876378us-gaap:CorporateDebtSecuritiesMember2023-12-31 0000876378srt:MaximumMember2024-01-012023-12-31 0000876378srt:MinimumMember2024-01-012023-12-31 00008763782024-01-012023-12-31 0000876378asxc:LeaseMember2022-01-012022-12-31 0000876378asxc:LeaseMember2023-01-012023-12-31 0000876378us-gaap:ServiceMember2022-01-012022-12-31 0000876378us-gaap:ServiceMember2023-01-012023-12-31 0000876378asxc:InstrumentsAndAccessoriesMember2022-01-012022-12-31 0000876378asxc:InstrumentsAndAccessoriesMember2023-01-012023-12-31 0000876378asxc:SystemsMember2022-01-012022-12-31 0000876378asxc:SystemsMember2023-01-012023-12-31 0000876378us-gaap:NonUsMember2022-01-012022-12-31 0000876378us-gaap:NonUsMember2023-01-012023-12-31 0000876378asxc:LeaseMemberus-gaap:NonUsMember2022-01-012022-12-31 0000876378asxc:LeaseMemberus-gaap:NonUsMember2023-01-012023-12-31 0000876378us-gaap:ServiceMemberus-gaap:NonUsMember2022-01-012022-12-31 0000876378us-gaap:ServiceMemberus-gaap:NonUsMember2023-01-012023-12-31 0000876378asxc:InstrumentsAndAccessoriesMemberus-gaap:NonUsMember2022-01-012022-12-31 0000876378asxc:InstrumentsAndAccessoriesMemberus-gaap:NonUsMember2023-01-012023-12-31 0000876378asxc:SystemsMemberus-gaap:NonUsMember2022-01-012022-12-31 0000876378asxc:SystemsMemberus-gaap:NonUsMember2023-01-012023-12-31 0000876378country:US2022-01-012022-12-31 0000876378country:US2023-01-012023-12-31 0000876378asxc:LeaseMembercountry:US2022-01-012022-12-31 0000876378asxc:LeaseMembercountry:US2023-01-012023-12-31 0000876378us-gaap:ServiceMembercountry:US2022-01-012022-12-31 0000876378us-gaap:ServiceMembercountry:US2023-01-012023-12-31 0000876378asxc:InstrumentsAndAccessoriesMembercountry:US2022-01-012022-12-31 0000876378asxc:InstrumentsAndAccessoriesMembercountry:US2023-01-012023-12-31 iso4217:EUR 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMembersrt:MinimumMember2023-01-012023-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMember2023-01-012023-12-31 0000876378asxc:SenhanceSurgicalRoboticSystemAcquisitionMember2023-12-31 0000876378asxc:MachineryManufacturingAndDemonstrationEquipmentMembersrt:MaximumMember2023-12-31 0000876378asxc:MachineryManufacturingAndDemonstrationEquipmentMembersrt:MinimumMember2023-12-31 0000876378us-gaap:IntellectualPropertyMember2022-01-012022-12-31 0000876378us-gaap:IntellectualPropertyMember2023-01-012023-12-31 0000876378us-gaap:PatentsMember2023-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasxc:OneCustomerMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasxc:CustomerTwoMember2023-01-012023-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberasxc:CustomerOneMember2023-01-012023-12-31 0000876378us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-31 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberasxc:OneCustomerMember2022-01-012022-12-31 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberasxc:OneCustomerMember2023-01-012023-12-31 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-31 0000876378us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-31 0000876378us-gaap:AccumulatedTranslationAdjustmentMember2022-12-31 0000876378us-gaap:AccumulatedTranslationAdjustmentMember2023-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0000876378us-gaap:RetainedEarningsMember2023-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000876378us-gaap:TreasuryStockCommonMember2023-12-31 0000876378us-gaap:CommonStockMember2023-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-31 0000876378us-gaap:RetainedEarningsMember2023-01-012023-12-31 0000876378us-gaap:CommonStockMember2023-01-012023-12-31 0000876378us-gaap:TreasuryStockCommonMember2023-01-012023-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0000876378us-gaap:RetainedEarningsMember2022-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000876378us-gaap:TreasuryStockCommonMember2022-12-31 0000876378us-gaap:CommonStockMember2022-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-31 0000876378us-gaap:RetainedEarningsMember2022-01-012022-12-31 0000876378us-gaap:TreasuryStockCommonMember2022-01-012022-12-31 0000876378us-gaap:CommonStockMember2022-01-012022-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0000876378us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000876378us-gaap:RetainedEarningsMember2021-12-31 0000876378us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000876378us-gaap:TreasuryStockCommonMember2021-12-31 0000876378us-gaap:CommonStockMember2021-12-31 0000876378us-gaap:ProductMember2022-01-012022-12-31 0000876378us-gaap:ProductMember2023-01-012023-12-31 0000876378us-gaap:IntellectualPropertyMember2022-12-31 00008763782024-05-15 00008763782023-06-30
 

 

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________________________

 

FORM 10-K

_____________________________________________________________

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2023

 

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

 

Commission File Number 0-19437

_____________________________________________________________

ASENSUS SURGICAL, INC.

(Exact name of registrant as specified in its charter)

_____________________________________________________________

 

Delaware

11-2962080

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

 

1 TW Alexander Drive, Suite 160, Durham, NC 27703

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (919) 765-8400

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading Symbol(s)

  

Name of each exchange where registered

Common Stock
$0.001 par value per share

  

ASXC

  

NYSE American

 

Securities registered pursuant to Section 12(g) of the Act:

 

None

(Title of class)

___________________________________________

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒.

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐.

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

  

Accelerated filer

☐

Non-accelerated filer

☒

  

Smaller reporting company

☒
     

Emerging growth company

☐

 

 
Table of Contents

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b) ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)    Yes  ☐    No  ☒.

 

On June 30, 2023, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value (based on the average bid and asked price of its common stock on that date) of the voting stock held by non-affiliates of the registrant was $120.1 million.

 

The number of shares outstanding of the registrant’s common stock as of March 15, 2024 was 271,986,369.

 

Documents Incorporated By Reference:   Part III of this Annual Report on Form 10-K is incorporated by reference to our proxy statement to be filed in respect of our 2024 Annual Meeting of Stockholders.

 

 

 
Table of Contents

 

 

ASENSUS SURGICAL, INC.

 

ANNUAL REPORT ON FORM 10-K

 

DECEMBER 31, 2023

 

Table of Contents

 

   

Page

PART I

    

ITEM 1.

BUSINESS

1

ITEM 1.A.

RISK FACTORS

21

ITEM 1.B.

UNRESOLVED STAFF COMMENTS

35

ITEM 1.C.

CYBERSECURITY

35

ITEM 2.

PROPERTIES

36

ITEM 3.

LEGAL PROCEEDINGS

36

ITEM 4.

MINE SAFETY DISCLOSURES

36
     

PART II

    

ITEM 5.

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

37

ITEM 6.

RESERVED

37

ITEM 7.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

38

ITEM 7.A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

47

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

48

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

75

ITEM 9.A.

CONTROLS AND PROCEDURES

75

ITEM 9.B.

OTHER INFORMATION

 77

ITEM 9.C.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

77
     

PART III

    

ITEM 10.

DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE

78

ITEM 11.

EXECUTIVE COMPENSATION

78

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

78

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

79

ITEM 14.

PRINCIPAL ACCOUNTING FEES AND SERVICES

79
     

PART IV

    

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

80

ITEM 16.

FORM 10-K SUMMARY

82

 

i
Table of Contents

 

FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K, or Annual Report, contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 21E of the Securities Exchange Act of 1934, as amended or the Exchange Act. Such forward-looking statements contain information about our expectations, beliefs or intentions regarding our product development and commercialization efforts, business, financial condition, results of operations, strategies or prospects. You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.

 

Many factors could cause our actual operations or results to differ materially from the operations and results anticipated in forward-looking statements. These factors include, but are not limited to:

 

 

•

our history of operating losses;

 

 

•

our ability to continue as a going concern;

 

 

•

our ability to raise capital to finance our business activities;

 

 

•

our ability to successfully develop, clinically test and commercialize new products and services;

 

 

•

our ability to successfully finalize collaboration agreements;

 

 

•

our ability to successfully implement our digital surgery offerings and grow our business as a result;

 

 

•

our ability to successfully implement our Performance-Guided Surgery™ strategy and grow our business as a result;

 

 

•

our ability to successfully grow the sales and distribution of our products;

 

 

•

our ability to increase use of our products by existing and new customers;

 

 

•

competition from existing and new market entrants;

 

 

•

our ability to identify and pursue development of additional products;

 

 

•

the timing and outcome of the regulatory review process for our products and product candidates;

 

 

•

the impact of foreign currency fluctuations on our financial results;

 

 

•

our ability to attract and retain key management, marketing and scientific personnel;

 

 

•

our ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights;

 

 

•

changes in the healthcare regulatory environments of the United States, Europe and other jurisdictions in which the Company operates; and

 

 

•

other factors contained in the section entitled “Risk Factors” contained in this Annual Report.

 

We do not undertake any obligation to update our forward-looking statements, except as required by applicable law.

 

In February 2021, we changed our name from TransEnterix, Inc. to Asensus Surgical, Inc. In this Annual Report we refer to Asensus Surgical, Inc. and its subsidiaries collectively as the “Company,” “it,” “we,” “our” or “us.”  The Company’s subsidiaries are: Asensus Surgical US, Inc., Asensus International, Inc.; Asensus Surgical Italia S.r.l.; Asensus Surgical Europe S.à r.l.; Asensus Surgical Taiwan Ltd; Asensus Surgical Japan K.K.; Asensus Surgical Israel Ltd.; Asensus Surgical Netherlands B.V.; and Asensus Surgical Canada, Inc.

 

ii
Table of Contents

 

PART I

 

ITEM 1.         BUSINESS

 

Introduction

 

We are a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of surgery, that we refer to as Performance-Guided Surgery™, or PGS, by unlocking clinical intelligence to enable surgeons to deliver consistently superior outcomes to patients. Built upon the foundation of digital laparoscopy and laparoscopic minimally invasive surgery, or MIS, (which remains the gold standard of surgery today), the Company is pioneering PGS to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience delivered via the Senhance® Surgical System, combined with the Intelligent Surgical Unit™, or ISU™, we intend to holistically address the current clinical, surgeon performance (fatigue and ergonomics), and economic shortcomings that impact surgical outcomes in a value-based healthcare environment. We are also working to incorporate all of this in our next generation robotic system we call the LUNA™ Surgical System.

 

Our mission is focused on leveraging robotic technologies, in combination with real time computer vision and machine learning capabilities, or Augmented Intelligence, to reduce variability in surgery, drive more predictable outcomes, optimize resources and costs, and work with hospital systems that strive to employ innovative healthcare strategies. By leveraging advanced digital technologies, we aim to enable surgeons to take the best surgical practices and techniques from everywhere and utilize them to help improve outcomes, reduce variability, control the unexpected, reduce costs, as well as reduce cognitive and physical fatigue for surgeons, and provide patients with the best care possible. We believe that by digitizing the interface between the surgeon and patient, we can unlock clinical intelligence to pioneer Performance-Guided Surgery, which we believe is the missing element in surgery today.

 

Recent Developments

 

As of the date of this filing, the Company continues to manage cash prudently and believes it has cash into early June 2024. We are actively pursuing a number of financing options, including collaborations, contractual relationships and strategic transactions. However, we are aware that such alternatives are and may continue to be time consuming and that successful consummation of a transaction or transactions is not assured. We may need to pursue alternative pathways, including, but not limited to, debt financing, sale of assets or equity-based financing. If none of these alternatives are consummated, we may need to suspend our product development programs, including the LUNA System, and take other actions to preserve cash. We may also need to seek bankruptcy if these measures are insufficient or unsuccessful.

 

The disclosures in this Annual Report describe our business activities during 2023 and reflect our future product development plans if sufficient financing becomes available.

 

During 2023, we focused our research and development, or R&D, activities on advancing the LUNA Surgical System, our next generation robotic system, and the ongoing developments in our ISU and digital surgery offerings.

 

We believe the LUNA System we are developing will be a best in class robot that will use 3mm and 5mm instruments (as contrasted with most current systems available that use 8mm instruments), including TrueWrist™ fully wristed 5mm instruments. The LUNA System will also feature monopolar and bipolar electrosurgery capabilities, rapid instrument exchange with our proprietary instrument drive system, an open platform with a smaller footprint in the OR (as compared to the Senhance System), up to four-arm configuration with enhanced manipulation and dexterity, a surgeon console with 4K-3D capabilities and unconstrained handles with improved digital features while retaining haptic feedback.

 

In December 2023, we successfully hosted a surgeon lab to conduct an in vivo evaluation of the LUNA System’s hardware, software and instruments in porcine models. The lab allowed nine participating independent surgeons to evaluate the LUNA System’s functionality through thirteen surgical procedures across gynecology, urology and general surgery.

 

Also, to prepare for pilot manufacturing of the LUNA System, in 2023 we entered into an agreement with Flextronics Medical Sales and Marketing, Ltd. for the design and manufacturing support.

 

 

1
Table of Contents

 

The LUNA System will continue our tradition of providing instruments that are reusable and can be re-sterilized and re‑processed, and, with improvements in manufacturing, are expected to have lower costs per procedure compared to competitive robotic options.

 

Our 2023 development efforts for digital surgery with the ISU included:

 

 

●

initial development of an analytical tools feature set, which includes intra-operative surgical planning capabilities that will help surgeons to map out and plan for specific surgical actions intraoperatively using the ISU’s Augmented Intelligence features;

 

 

●

creation of a safety tools feature set which includes real-time identification, notifications to the surgical team, and marking of potential anatomical hazards (such as arteries or nerves) during the operation, and providing visual cues to help surgeons and surgical team protect these structures; and

 

 

●

advancing a training tools and education feature set which allows multiple team members to work together in real time by annotating, highlighting and drawing on a shared visual display of the surgical field to communicate and provide expert support.

 

During 2023 we entered into an agreement with NVIDIA to allow us to enhance the capabilities of the ISU. Using a suite of NVIDIA tools, we will refine ISU features like digital tags, 3D measurement and enhanced intra-operative camera control. We believe that the collection and analysis of surgical data transformed into insights, and when shared with our physicians, will enhance surgical planning, surgeon education and training, and promote better patient outcomes.

 

During 2023 we announced a multi-year collaboration with Google Cloud to integrate Google Cloud’s secure cloud data architecture and machine learning technologies to further expand cloud capabilities. The Asensus Cloud is being designed to enable customer access to a web portal and/or mobile application that can provide data, analytics and/or insights to assist in pre-operative surgical planning, post-operative surgical analysis and best practices guidance.

 

We are also developing an ISU that can be utilized on a stand-alone basis apart from robotic surgery. We believe, given the market opportunity in traditional laparoscopic procedures, the data collected from such stand-alone units will add significantly to our cumulative digital database and help to accelerate development of innovative solutions across the surgical continuum to reduce complications and improve efficiency.

 

Market Overview

 

Over the past three decades, laparoscopic surgery has emerged as a minimally invasive alternative to open surgery. In laparoscopic surgery, multiple incisions provide surgical access ports. Carbon dioxide gas insufflation is then used to create room in the body cavity, and long rigid instruments are introduced through ports placed in the incisions to perform surgical tasks. Millions of laparoscopic surgical procedures across a broad range of clinical applications are now performed each year worldwide, though many surgeries are still performed in an open fashion.

 

While laparoscopy has improved upon the invasive nature of many previously open procedures, it still has many limitations. Traditional, or rigid, laparoscopy still requires multiple incisions to achieve the visualization and instrument triangulation required to perform successful surgery. Traditional laparoscopy also creates physical challenges by forcing the surgeon’s hands and arms into awkward angles, requiring the surgeon to hold instruments in fixed positions for long periods of time and requiring an assistant to stabilize and move a laparoscopic camera. Another challenge associated with rigid laparoscopic surgery is the creation of a cumbersome and potentially tissue-damaging fulcrum at the patient’s abdominal wall where instruments are manipulated. Nearly all laparoscopic instruments are rigid instruments that lack distal articulation to enhance dexterity in complex tasks. Most laparoscopic surgeries are performed with two-dimensional, or 2-D, visualization of the operative field, making depth perception difficult.

 

Despite such limitations, traditional laparoscopy remains the prevalent technique in MIS. We believe that robotic devices that replicate laparoscopic motion are more straightforward for surgeons to adopt. Our Senhance System is designed to mimic laparoscopic surgery. The Senhance System is focused on the laparoscopic surgical market as we believe it separates us from our competitors and allows surgeons to perform MIS which provide improved patient outcomes compared to open surgery, while utilizing fully reusable tools, smaller instruments to broaden applicability of the laparoscopic method, including in pediatric cases, and the additional Senhance System technology such as the ISU with its Augmented Intelligence capabilities.

 

2
Table of Contents

 

Robotic and computer-controlled assistance have developed as technologies that offer the potential to improve upon many aspects of the laparoscopic surgical experience. According to DRG Global Market’s Laparoscopic Surgical Robotic Devices (September 2022), the existing laparoscopic market for soft tissue abdominal surgery is up to 19 million procedures annually. Initial widespread adoption of robotic-assisted surgery was focused on urologic and gynecologic procedures that were primarily performed in an open fashion prior to robotics, but more recently developed robotic approaches like the Senhance System have been applied to many other clinical applications, particularly in general surgery.

 

Despite recent advances and new entrants into the market, we believe there remain many limitations associated with current robotic-assisted surgery systems.

 

We digitize the surgical interface between the surgeon and the patient by providing a computer controller interface for the surgeon to manipulate surgical instruments and move the visualization system.  We believe image analytics technology will help accelerate and drive meaningful adoption of the Senhance System and, when developed, the LUNA System, and allow us to continue to expand our capabilities adding new Augmented Intelligence and decision support capabilities in the future. In addition, we believe our focus on expanding surgical data to include pre- and post-operative intelligence will help in surgical planning, review and overall evaluation.

 

Historical advances in surgery have largely focused on incremental advancements in surgical tools and techniques targeted at reducing the invasiveness of procedures. When we introduced the Senhance platform, our intention was to help surgeons minimize surgical variability in a cost-effective manner while also helping to offset the increasing physical and cognitive demands on surgeons. The next logical step in the progression is looking for ways to deliver real-time Augmented Intelligence and actionable analytics which we believe will take us from digital laparoscopy to Performance-Guided Surgery.

 

The global digital surgery technologies market continues to expand with increased investment in research and development of digital tools and capabilities. We have seen technological advancements in Augmented Intelligence, the Internet of Things, or IoT, big data capture, extended reality, or XR, offerings and digitalization of surgery. We believe we are well positioned, with our ISU, TRUST™ Registry and learnings from our Senhance System to advance our footprint in digital surgery and provide products that can be used to add value throughout the surgical process.

 

Product Overview

 

We are addressing the challenges in laparoscopy and robotic-assisted surgery with technologically advanced products and product candidates that leverage the best features of both approaches to MIS. We are also addressing the need for clinically relevant data and analysis through our PGS offerings.

 

From our inception, we have devoted a substantial percentage of our resources to research and development and start-up activities, consisting primarily of product design and development, clinical studies, manufacturing, recruiting qualified personnel and raising capital.  We are a data driven company that expects to continue to invest in research and development, market development, and generation and analysis of clinical evidence as we implement our strategy. As a result, we will need to generate significant revenue in order to achieve profitability. The Company operates in one business segment.

 

The Senhance Surgical System

On September 18, 2015, the Company entered into a Membership Interest Purchase Agreement, or the Purchase Agreement, with Sofar S.p.A., or Sofar, as seller, pursuant to which the Company acquired the Senhance System and related assets and personnel, or the Senhance Acquisition. The closing occurred on September 21, 2015.

 

The Senhance System addresses key challenges for laparoscopic surgeons and hospitals by delivering the benefits of robotics with improved control of the surgical field, enhanced visualization and camera control and improved ergonomics, coupled with the familiarity of laparoscopic motion and consistent per-procedure costs.

 

3
Table of Contents

 

Our focus over the last few years has been on seeking regulatory approvals and clearances for the Senhance System and related product offerings and instruments and pursuing commercialization of our products. The following chart describes our success in achieving regulatory clearances and approvals to date.

 

Product/Indications

FDA Clearance

CE Mark

Other Approvals

Senhance System

October 2017

January 2012

Taiwan – April 2018

Japan – May 2019

Russian Federation – December 2020

Indications for Use of Senhance System

●        Initial general surgery indications for laparoscopic colorectal and gynecologic surgery procedures

October 2017

N/A

N/A

●        Extended to cholecystectomy and inguinal hernia repair

May 2018

N/A

N/A

●        Extended to hiatal and paraesophageal hernia, sleeve gastrectomy, and sacrocolpopexy

March 2021

N/A

N/A

●        General surgery indications

March 2021

 

General laparoscopic surgical procedures and laparoscopic gynecologic surgery including a total of 31 labeled procedures, including benign and oncologic procedures, laparoscopic inguinal, hiatal and paraesophageal hernia, sleeve gastrectomy and laparoscopic cholecystectomy

For adult and pediatric laparoscopic abdominal and pelvic surgery, as well as limited adult thoracic surgeries excluding cardiac and vascular surgery and surgeries in direct contact with central nervous systems

Japan – regulatory approval and reimbursement for 98 laparoscopic procedures – July 2019

Additional 26 laparoscopic procedures approved for reimbursement in Japan during 2022

●        Pediatric indications

March 2023

February 2020

N/A

●        Intelligent Surgical Unit, or ISU

Initial - March 2020

 

Expansion of Augmented Intelligence in August 2021

January 2021

 

Expansion of Augmented Intelligence in January 2023

Japan - December 2020

Instruments and Other Products

●        5mm articulating instruments

July 2021

November 2018

Japan - October 2022

●        3mm diameter instruments

October 2018

July 2017

   Taiwan - November 2018

Japan - October 2019

●        Senhance ultrasonic system

January 2019

September 2018

Japan - October 2020

●        3mm and 5mm hooks

5mm July 2019

3mm November 2019

December 2019

Japan - December 2020

 

The Senhance System is a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera. The system builds on the success of laparoscopy by enhancing the traditional features that surgeons have come to expect from existing products and by addressing some of the limitations associated with robotic surgery systems for laparoscopic procedures. The Senhance System also offers responsible economics to hospitals through its robotic technology coupled with reusable standard instruments that yield minimal additional costs per surgery when compared to laparoscopy. The Senhance System is CE marked in the EU for laparoscopic abdominal and pelvic surgery, as well as limited adult thoracic operations excluding cardiac and vascular surgery, and surgeries in direct contact with central nervous systems.

 

4
Table of Contents

 

Key features of the Senhance System are:

 

  ●

Fully Reusable, Autoclavable Instrumentation: The Senhance System offers standard instrumentation that is cleaned and sterilized using current autoclave technology that does not require additional, non-standard sterilization methods, and that has no pre-set limitation on number of uses that require them to be disposed. Exceptions to this are ultrasonic disposals and articulating instruments;
     
  ●

Enhanced Vision, Eye-Tracking Camera Control: The Senhance System is compatible with 3DHD, vision technology, which provides the surgeon with additional depth and spatial relation of organs; and a tremor free view of the surgical field and is centered in the surgeon’s field of vision. Eye-tracking camera control, allows hands free, surgeon-controlled visualization;
     
  ●

Intelligent Surgical Unit or ISU: The ISU enables machine vision capabilities providing the ability to recognize certain objects and locations in the surgical field. This capability enhances visualization and camera control over previously available surgical technologies, and provides the foundation for additional Augmented Intelligence capabilities, with a number of enhancements added and FDA-cleared in 2021 and CE marked in early 2023. Additionally, the ISU improves surgical team collaboration by seamlessly sharing the surgeon’s console view in real-time across the entire operating room. The most recently cleared Augmented Intelligence features available in the U.S., Japan and the EU include 3D point-to-point measurement, advanced endoscopic control modalities, and intra-operative surgeon digital tagging.
     
  ●

Articulating Instruments: These instruments improve accessibility and reach around critical structures, providing two additional degrees of freedom, when working in deep anatomical spaces. They optimize efficiency for the surgeon;
     
  ●

Haptic Feedback: The Senhance System’s haptic feedback feature heightens the surgeon’s sensing of pressure/tension throughout the surgical procedure; haptics provides the surgeon with the ability to feel the tissue response of the body during a procedure;
     
  ●

Laparoscopic Motion: Digital laparoscopy maintains familiar motions, tools, and techniques that are similar to the motion used during traditional laparoscopic surgeries;
     
  ●

Improved Ergonomics: Ergonomic seating for the surgeon throughout the procedure helps to reduce fatigue and risk of musculoskeletal injuries;
     
  ●

E-Fulcrum: A digital fulcrum, setting a dynamic virtual pivot point, helps to potentially minimize incision trauma;
     
  ●

Open-Platform Architecture: The Senhance System allows the use and integration of existing OR technologies to maximize benefit from capital investments and support surgeon preference (e.g., trocars, electrosurgical units, insufflators, select vision systems, etc.); and
     
  ●

View of the Sterile Field: The Senhance System offers the user an open view of the operating room and sterile field from the ergonomically-designed console.

 

The Senhance System is manufactured for us by third-party contract manufacturers. We or our manufacturers acquire raw materials and components of the Senhance System from vendors, some of which are sole suppliers. We believe our relationships with our vendors and manufacturing contractors are good. We further believe that we have the manufacturing capacity and inventory reserves to meet our anticipated Senhance System sales for the foreseeable future.

 

2023 Senhance Surgical System Programs

The Senhance System is available for sale in Europe, the United States, Japan, Taiwan, the CIS and other selected countries. We also enter into lease arrangements with certain qualified customers. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System during or at the end of the lease term (which we refer to as a Lease Buyout). We define the initiation of a Senhance Surgical program as entering into an agreement to purchase or lease, and subsequently utilizing a Senhance System. Throughout 2023, we initiated eight Senhance System programs, one in the United States, one in Germany, one in Romania, three in Japan and two in the Commonwealth of Independent States, or CIS region.

 

5
Table of Contents

 

Pediatric Update

During 2023, we received regulatory clearance from the FDA for the Senhance System, making the Senhance System the first cleared digital laparoscopic or robotic surgery product offering 3mm instruments. The one Senhance System placement in the U.S. in 2023 was for pediatric indications, growing our global Senhance System pediatric placements in 2023 to four.

 

Procedure Volumes

In 2023, surgeons performed over 3,550 procedures utilizing the Senhance System, representing a 13% increase over the previous year. These procedures included general surgery, gynecology, urology, colorectal, bariatric and pediatric surgical procedures.

 

Senhance Connect

Senhance Connect is a tele-presence platform that allows surgeons in an operating room to connect with and communicate with other Senhance surgeons in other locations. The process allows for streaming of multiple operating room camera views and an endoscopic view simultaneously, and allows for two-way screen sharing and annotation. This product is part of PGS, enabling the ability to provide real-time digital collaboration capabilities to surgeons facilitating best practice sharing and surgical proctoring to a wider audience. Additionally, this expands surgeon flexibility and is more cost effective, enabling broader global access to clinical excellence.

 

Senhance Simulation

Senhance Simulation is a mobile platform part of our PGS offering and designed to integrate with the Senhance System. It allows surgeons to practice at the console through a series of virtual exercises, potentially minimizing the need to schedule and secure lab-based training activities with robotic manipulator arms.

 

Clinical Registry (TRUST)

We believe TRUST is the largest multi-specialty digital laparoscopy registry in the industry. In 2023, we continued to leverage the growing body of real-world clinical data through the utilization of our TRUST clinical registry, which is aimed at providing a research tool that enables physicians to monitor safety, efficacy, and feasibility of robotic assisted surgical interventions in a variety of abdominal, thoracic, urologic and gynecologic surgical cases using the Senhance System. We also continued to drive enrollment as well as support peer-reviewed publications through this registry.

 

Clinical Validation

During 2023, there were nine peer-reviewed clinical papers published providing further support for the clinical utility of the Senhance Surgical System across pediatric, gynecology, general surgery, urology, and colorectal procedures demonstrating the utility breadth and the complexity of procedures being performed with the device.

 

ISU and Digital Solutions

Our ISU is a real-time intra-operative surgical image analytics platform that leverages Augmented Intelligence to help reduce surgical variability and provides tools to reduce a surgeon’s cognitive fatigue. It is currently used to enable machine vision capabilities on the Senhance System and collect clinical data related to surgical procedures. The ISU was developed using image analytics technology that we acquired as part of our October 2018 acquisition of the assets, intellectual property and highly experienced multidisciplinary personnel of Medical Surgical Technologies, Inc., or MST, an Israeli-based medical technology company. In March 2020, we received FDA clearance for the ISU. On September 23, 2020, we announced the first surgical procedures successfully completed using the ISU. In January 2021, we received CE mark certification for the ISU, allowing us to expand our Augmented Intelligence capabilities to all global areas accepting the CE mark. We received clearance from the FDA for additional Augmented Intelligence features of the ISU in August 2021, and approval for enhanced Augmented Intelligence features for our CE mark certification in January 2023.

 

The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical fields and allows a surgeon to change the visualized field of view using the movement of their instruments. The newest ISU features expand upon these capabilities and introduce additional advanced features including 3D measurement, digital tagging, and enhanced camera control based on real-time data while performing surgery. The regulatory review of such expanded capabilities, which included a review of the Senhance System platform, made Senhance one of the first robotic surgical systems to be certified through the new, more rigorous EU Medical Device Regulation, or MDR, process.

 

6
Table of Contents

 

We are continuing to advance the utility of the ISU for the Senhance System while also adding such capabilities to the standalone ISU and the LUNA System in development.

 

Our digital solutions are the features, products and platforms that are enabled by data, generated through the digitization of the interface between the surgeon and the patient, and deployed via software. Our digital solutions are a foundational component of our PGS strategy enabling the delivery of insights in pre-operative and post-operative settings, while continuously enhancing our real-time, intra-operative Augmented Intelligence offerings. Currently, commercially available digital solutions are largely deployed via the ISU in the form of Augmented Intelligence applications including automatic camera control, digital tagging, and digital measurement. To develop these and future digital solutions, we designed and deployed the Asensus Cloud, which has been architected to efficiently manage unique surgical data automatically transferred via connected ISUs and additional sources. The Asensus Cloud provides a secure, scalable, and efficient platform for data storage, data use and computing in machine learning model development, business model innovation and future analytics delivery via portals and dashboards. We believe these analytics solutions will address numerous challenges in the pre-operative planning and post-operative assessment phases of surgery, enhancing training as well as continuing education, to help advance Performance-Guided Surgery and promote consistently superior outcomes.

 

Instruments and Other Products

Instruments

We successfully obtained FDA clearance and CE Mark for a number of instruments, including, our 3mm diameter instruments, our 3mm and 5mm hooks, and articulating instruments. The 3mm instruments enable the Senhance System to be used for micro laparoscopic surgeries, allowing for tiny incisions. We currently offer approximately 80 instruments and accessories in our portfolio.  We have also designed the Senhance System so that third-party manufactured instruments can be easily adapted for use.

 

Our articulating instruments were commercially launched in the U.S. and Japan in the fourth quarter of 2022.

 

Other Products

The Senhance ultrasonic system is an advanced energy device used to deliver controlled energy to ligate and divide tissue, while minimizing thermal injury to surrounding structures.

 

Our Performance-Guided Surgery Initiative

Performance-Guided Surgery builds upon our foundation of digital laparoscopy by adding Augmented Intelligence enabled by our machine vision and deep learning capabilities through all surgical phases to help guide improved decision making, enrich collaboration, and enhance predictability for all surgeons (independent of skill level and experience). Our Performance-Guided Surgery strategy is comprised of three strategic pillars:

 

 

●

enhanced robotic precision and manipulation capabilities, via the Senhance System today and, when developed and cleared, the LUNA System;

 

 

●

expanded intra-operative Augmented Intelligence providing clinical decision support to the surgeon via the ISU; and

 

 

●

integration of cloud and big data-enabled solutions to harness best practices across pre-, intra- and post-operative settings, and make them available to surgeons around the world via the Asensus Cloud.

 

During 2023, we developed and piloted with select Asensus Cloud connected customers across the US & EU, two iterative versions of our customer portal website with an analytics dashboard and video library. The analytics dashboard provides a variety of potentially useful information for both the surgeon and OR administration, including the number of cases completed per month, average case times compared to global averages, procedure time trends, and frequency of instrument and digital feature use with Senhance. The video library offers case specific information in addition to the endoscopic procedure video files, such as a timeline of events to help track time of setup, frequency of warnings, and times when various instruments were in use. This is the first of our customer-facing, cloud-enabled solutions related to the third strategic pillar noted above. We believe that leveraging stored videos and surgical procedure data analysis from the ISU and Asensus Cloud will provide valuable insights for both post-operative analysis and pre-operative planning.

 

7
Table of Contents

 

Our Performance-Guided Surgery strategy leverages our capabilities across robotics, Augmented Intelligence and cloud/big data and will be executed across all three phases of surgery, including:

 

  ●

Pre-operative - in what we call “intelligent preparation,” our machine learning models will take data from procedures done utilizing our current Senhance System with the ISU, such as tracking surgical motion and instrument selection, to create a large and constantly expanding database of surgeries to enable surgeons to better inform their surgical approach and setup;
     
  ●

Intra-operative – we believe the Senhance System provides, and the LUNA System will provide, “perceptive real-time guidance” for intra-operative tasks, allowing surgeons performing a procedure with such robotic system and ISU to execute multiple tasks while benefitting from the collective knowledge of other successful robotic-based procedures delivered through Augmented Intelligence in real time. Not only does this have the potential to provide the surgeon with a pathway to better outcomes, but we also believe it will ultimately help reduce the cognitive load of the surgeons, enabling more sustained peak performance over time and reducing risk of burn-out; and
     
  ●

Post-operative – finally, by tapping into the vast amount of data captured during procedures, surgeons and operating room staff will have access to “performance analytics” with actionable assessments of their performance giving them the information needed to constantly and consistently improve. We intend to establish a new standard of descriptive, diagnostic, predictive and prescriptive analytics to improve not only the skills of surgeons but move towards accessible best-practice-sharing that bridges the global surgical team community.

 

We believe that future outcomes of MIS will be enhanced through our combination of more advanced tools such as Augmented Intelligence solutions and robotic functionality which are designed to:

 

  ●

empower surgeons with improved precision, ergonomics, dexterity, visualization, perceptive real-time guidance and surgical decision support;
     
  ●

offer high patient satisfaction and enable more predictable post-operative recovery; and
     
  ●

provide a cost-effective robotic system, compared to existing alternatives today, for a wide range of clinical applications and operative sites within the healthcare system.

 

Factors plaguing the healthcare industry that amplify the urgency for Performance-Guided Surgery include:

 

  ●

Value-based care is shifting a greater responsibility for poor quality and inefficiency to hospitals and physicians; and
     
  ●

Patients are presenting with more complex conditions and treating them becomes more complicated. The absolute number of patients seeking care is increasing, and many more patients have multiple chronic conditions than they did a generation, or even a decade, ago.

 

These factors make it the ideal time to integrate advanced technology in the operating room.

 

8
Table of Contents

 

Business Strategy

 

Our strategy is to focus on the realization of Performance-Guided Surgery through the continued collection of surgical data via the ISU and Asensus Cloud leveraging the Senhance System and by other means of non-robotic laparoscopic surgery, while completing the design and development of the LUNA System and its capabilities. We believe that:

 

  ●

the LUNA System, if successfully developed and approved for use, will dramatically improve our ability to offer digital solutions to surgeons to promote better patient outcomes;
     
  ●

the ISU and Asensus Cloud will enable the structured acquisition, processing and analysis of surgical video and data and glean insights to better inform our Augmented Intelligence engines to help reduce surgical variability and drive consistently superior outcomes for patients;
     
  ●

laparoscopic robotic surgery will need to continue to evolve given the pressures of value-based healthcare and existing operating room inefficiencies, surgical variability, and workforce challenges;
     
  ●

with our robotic surgery products, surgeons can benefit from the haptic feedback for better connection to the patient, enhanced three-dimensional, high definition, or 3DHD, vision, and open console design to better connect the surgeon with the operating room; and
     
  ●

patients will continue to benefit from minimally invasive options, offering better overall patient outcomes than other MIS surgical techniques.

 

We continue the market development for and commercialization of the Senhance System, which digitizes laparoscopic MIS. The Senhance System is the first and only multi-port, digital laparoscopy platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, improved ergonomics, advanced instrumentation including 3mm micro laparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.

 

Our strategy is to focus our resources on the market development of digital surgery to create a new and unique market segment for Performance-Guided Surgery, currently with the Senhance System, the ISU and currently offered instruments, and with the LUNA System in the future, to generate procedural data to inform and elevate practice in real time.

 

We believe that:

 

  ●

our Performance-Guided Surgery framework, which focuses on leveraging robotic technologies, Augmented Intelligence and machine learning capabilities and cloud and data connectivity will assist in reducing variability in surgery, drive more predictable outcomes, optimize resources and costs, and resonate with hospital systems that seek to employ innovative healthcare strategies;
     
  ●

the Senhance System is easier to use in MIS, particularly for surgeons well versed in laparoscopic technique;
     
  ●

markets outside of the United States, particularly where laparoscopic surgery is more heavily utilized, such as Japan, may more readily adopt the use of the Senhance System;
     
  ●

because of the capital-intensive nature of the purchase of a robotic system, our strategy to lease the Senhance System to additional hospitals will increase our placements and use of our systems;
     
  ●

there are a number of hospitals and an increasing number of ambulatory surgery centers internationally and in the United States that can benefit from the addition of robotic-assisted MIS and, through the Senhance System, lower operational costs as contrasted with other robotic systems;
     
  ●

with the Senhance System, surgeons can benefit from the security of haptic feedback, enhanced 3DHD vision and open-platform architecture consistent with current laparoscopic surgery procedures;
     
  ●

the addition of advanced energy instruments, 3mm instruments and 5mm articulating instruments for the Senhance System will help to increase adoption of our products in the laparoscopic surgery market;
     
  ●

leveraging haptic feedback, 3mm instruments, independent arms and lower operating cost, the Senhance system is well suited for pediatric surgeries;
     
  ●

a standalone ISU will enable much broader access to Augmented Intelligence solutions, providing better surgeon experience and clinical outcomes in laparoscopic procedures, compared to if all ISUs needed to be part of a robotic system; and
     
  ●

the enablement of image analytics technology, Augmented Intelligence and machine vision capabilities, enabled by the ISU, will help accelerate and drive meaningful adoption of our robotic systems into the future and help clearly differentiate our offering in surgical robotics.

 

9
Table of Contents

 

Sales and Marketing

 

We utilize distributors in jurisdictions where we do not sell directly.  Our distribution agreements typically provide exclusivity in a specific territory or jurisdiction.

 

We are dependent on growing the number of hospital customers and increasing the number of customers with installed Senhance Systems. Throughout 2023, we initiated eight Senhance surgical programs, one in the U.S., one in Germany, one in Romania, three in Japan and two in the CIS region. We define the initiation of a Senhance Surgical program as entering into an agreement to purchase or lease, and subsequently utilizing a Senhance System.

 

Intellectual Property

 

We believe that our intellectual property and expertise is an important competitive resource. Our experienced research and development team has created a substantial portfolio of intellectual property, including patents, patent applications, trade secrets and proprietary know-how. We maintain an active program of intellectual property protection, both to assure that the proprietary technology developed by us is appropriately protected and, where necessary, to assure that there is no infringement of our proprietary technology by competitive technologies.

 

The following summarizes our current patent and patent application portfolio.

 

As of December 31, 2023, the Company’s patent portfolio includes approximately 90 issued or allowed United States patents, over 100 patents issued outside the United States, and more than 130 patent applications filed in the United States and internationally.  We own all rights, titles and interests in all but the approximately 38 of our patents and patent applications that are exclusively licensed to us and the approximately 25 patents and patent applications that are non-exclusively licensed to us.

 

Several of our issued patents resulted from filings related to the Senhance System.  These include 8 United States patents, and approximately 40 patents outside the United States. The earliest to expire U.S. and non-U.S. patents within this part of our portfolio will remain in force until 2027. We also have four issued U.S. patents that resulted from filings related to the LUNA System. The earliest of these LUNA-related patents will remain in force until 2039. The patent applications include over 120 that relate to the Senhance System, the LUNA System, the ISU or other features, instruments, or components for robotic-assisted surgery. Our patents and applications that we acquired from MST relate to image analytics, our digital solutions and robotic surgery, among other things. We intend to continue to seek further patent and other intellectual property protection in the United States and internationally, where available and when appropriate, as we continue our product development efforts.

 

Some of our issued patents and pending applications for the Senhance System, as well as associated technology and know-how, are exclusively licensed to Asensus Surgical Italia from the European Union. The license agreement with the European Union has a term which runs until the final licensed patent expires unless the agreement is terminated earlier by mutual consent of the parties, for the Company’s convenience, or for breach. The Company is currently in compliance with the terms of this license agreement.

 

Competition

 

Our industry is highly competitive, subject to change and significantly affected by new product introductions and other activities of industry participants. Many of our competitors have significantly greater financial and human resources than we do and have established reputations with our target customers, as well as worldwide distribution channels that are more established and developed than ours.

 

10
Table of Contents

 

There were new entrants in the market for robotic surgery in 2023 and 2022, and some forward steps by a number of existing entrants in 2023. We believe that our focus on the laparoscopic market and our Performance-Guided Surgery initiative help us to remain competitive in this growing field.

 

There are many competitive offerings in the field of MIS. Several companies have launched devices that enable reduced incision or single incision laparoscopic surgery with or without robotic assistance.  Our surgical competitors include, but are not limited to: Medtronic plc, Intuitive Surgical Inc., Vicarious Surgical, Inc., Momentis Surgical, Distalmotion SA, Medicaroid and CMR Surgical Ltd. We are aware that more entrants anticipate introducing additional robotic-based instruments in the next few years, including Johnson & Johnson.

 

There are also a number of existing and emerging competitors in the digital surgery space. Some well-established players have and are expanding their digital offerings, such as the Medtronic acquisition of Digital Surgery with their Touch Surgery offerings and Intuitive Surgical with their My Intuitive app and Intuitive Hub platforms. Several smaller companies that are exclusively focused on digital surgery solutions are currently in, or are expected to enter in the near future, the market including, but not limited to Theator Surgical, Activ Surgical and CareSyntax.

 

In addition to surgical device manufacturer competitors, there are many products and therapies designed to reduce the need for or attractiveness of surgical intervention. These products and therapies may impact the overall volume of surgical procedures and negatively impact our business.

 

Our ability to compete may be affected by the failure to fully educate physicians in the use of our products and products in development, or by the level of physician expertise. This may have the effect of making our products less attractive. We believe the Senhance System can be distinguished from other currently available robotic systems on the basis of (1) overall attractiveness to laparoscopic surgeons due to its ability to provide robotic benefits while leveraging their laparoscopic training and experience, (2) the additions we have made, including the ISU, (3) lower per procedure costs and (4) increasing indications for use, including pediatric indications. We further expect the Senhance System to differentiate in its ability to provide the surgeon with valuable tactile feedback and real-time clinical intelligence to help guide toward better outcomes. Several medical device companies are actively engaged in research and development of robotic systems, digital surgery capabilities or other medical devices and tools used in MIS procedures. We cannot predict the basis upon which we will compete with new products marketed by others.

 

Government Regulation of our Product Development Activities

 

The U.S. government and foreign governments regulate the medical device industry through various agencies, including but not limited to, the FDA, which administers the Federal Food, Drug and Cosmetic Act, or the FDCA. The design, testing, manufacturing, storage, labeling, distribution, advertising, and marketing of medical devices are subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar agencies in other countries, including in the European Union. Any device product that we develop must receive all requisite regulatory approvals or clearances, as the case may be, before it may be marketed in a particular country.

 

Device Development, Marketing Clearance and Approval

 

Medical devices are subject to varying levels of pre-market regulatory requirements. The FDA classifies medical devices into one of three classes: (i) Class I devices are relatively simple and can be manufactured and distributed with general controls; (ii) Class II devices are somewhat more complex and have heightened regulatory requirements, typically including clearance of a 510(k) notice prior to marketing; and (iii) Class III devices are new, high-risk devices, and frequently are permanently implantable or help sustain or support life, and generally require approval of a Pre-Market Approval application, or PMA, by the FDA.

 

Our current medical device products are subject to premarket notification and clearance under section 510(k) of the FDCA, and the 510(k) process is normally used for products of the type that we are developing and propose to market and sell. To obtain 510(k) clearance, we must submit to the FDA a premarket notification (510(k) notice) demonstrating that the proposed device is “substantially equivalent” to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to PMA, generally either a Class I or Class II device. A 510(k) notice must provide information supporting a claim of substantial equivalence to a single medical device, the predicate device, or multiple predicates in certain circumstances. If clinical data are required to support the 510(k) notice, these data must be gathered in compliance with the Investigational Device Exemption, or IDE, regulations for investigations performed in the United States.

 

11
Table of Contents

 

If the FDA agrees that the device is substantially equivalent to a predicate device, it will grant 510(k) clearance, which permits the company to commercially distribute the device for its intended use. If the FDA determines that the device is “not substantially equivalent” to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the “de novo” process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. Review times for de novo requests vary widely, and may take in excess of one year. 

 

The FDA review process for premarket notifications submitted pursuant to Section 510(k) of the FDCA takes, pursuant to statutory requirements, 90 days, but it can take substantially longer if the FDA has questions regarding the regulatory submission. It is possible for a 510(k) review process to take from six to twelve months, depending on the concerns raised by the FDA and the complexity of the device. There is no guarantee that the FDA will “clear” a medical device for marketing; if clearance is not granted, the device cannot be distributed in the United States. There is also no guarantee that the FDA will deem the applicable device subject to the 510(k) process, as opposed to the more time-consuming and resource-intensive de novo process described above or PMA process described below.

 

After a device receives 510(k) marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer’s determination. If the FDA disagrees with a manufacturer’s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance or PMA approval is obtained. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.

 

A new device that is high-risk and not substantially equivalent to a predicate device must obtain approval of a PMA prior to commercial distribution in the U.S. These devices are normally Class III devices. Before a company can market a product in the United States that is subject to PMA approval, it typically must collect clinical data to support the intended use of the device, and must comply with IDE regulations in connection with any human clinical investigation of the device conducted in the United States. Prior FDA approval of an IDE application is required if the device is a significant risk device (as opposed to a “non-significant risk”, or NSR, device), which is typically the case for Class III devices. The FDA must subsequently approve the company’s PMA application, which typically contains, among other things, clinical information acquired under the IDE. Additionally, devices subject to PMA approval may be subject to an Advisory Panel review and are required to pass a manufacturing facility inspection in accordance with the current “good manufacturing practices” standards prior to obtaining marketing approval. The FDA will approve the PMA application if it determines that the data and information in the PMA constitute valid scientific evidence and finds that there is reasonable assurance that the device is safe and effective for its intended use. The PMA process by statute takes 180 days, though it frequently takes substantially longer, and can take up to one to two years or more. A manufacturer of a device approved through the PMA process is not permitted to make changes to the device which affect its safety or effectiveness, including changes to the intended use/indications for use, without first submitting a PMA Supplement application and obtaining FDA approval for that supplement. In some instances, the FDA may require clinical trials to support a PMA Supplement.

 

The Company believes the Senhance System and many related products are Class II devices as evidenced by our cleared 510(k) notices. The Company intends to further develop the product line by adding additional instrumentation to and expanding the capabilities of the Senhance System.  At this time, the Company believes that the items under development are Class II devices subject to 510(k) clearance. The FDA might find that the 510(k) submission does not provide the evidence required to prove that the additional instruments or accessories for use with the Senhance System are substantially equivalent to legally-marketed Class II devices. If that were to occur, the Company would be required to undertake either the de novo reclassification process or the even more complex and costly PMA process. For either the 510(k), de novo, or the PMA process, the FDA could require the Company to conduct clinical trials, which would take more time, cost more money, and pose other risks and uncertainties. The Company does not believe it has any need to, and is not currently planning to conduct, any clinical trials.

 

If needed in the future, clinical studies conducted in the United States or used in any U.S. application on an unapproved medical device that presents a significant risk require approval from the FDA prior to initiation. Even when a clinical study has been approved by the FDA or deemed approved, the study is subject to factors beyond a sponsor's control, including, but not limited to, the fact that the institutional review board, or IRB, at a specified clinical site might not approve the study, might decline to renew approval, or might suspend or terminate the study before its completion. There is no assurance that a clinical study at any given site will progress as anticipated. In addition, there can be no assurance that the clinical study will provide sufficient evidence to assure the FDA that the product is safe and effective, a prerequisite for FDA approval of a PMA, or substantially equivalent in terms of safety and effectiveness to a predicate device, a prerequisite for 510(k) clearance. Even if the FDA approves or clears a device, it may limit its intended uses in such a way that manufacturing and distribution of the device may not be commercially feasible.

 

12
Table of Contents

 

Regulatory requirements in all jurisdictions where we seek certification, clearance or approval of our products are continuing to evolve with respect to the cybersecurity risk and prevention. Such evolving regulations may prolong the regulatory process for our products and products in development.

 

Exported devices are subject to the regulatory requirements of each country to which the device is exported, as well as certain FDA export requirements.

 

Continuing Regulation

 

After a device is placed on the market, numerous FDA and other regulatory requirements continue to apply. These include:

 

  ●

establishment registration and device listing with the FDA;
   

 
  ●

quality system regulations that require manufacturers to follow stringent design, testing, process control, documentation and other quality assurance procedures;
   

 
  ●

labeling regulations that prohibit the promotion of products for unapproved, i.e. “off label,” uses and impose other restrictions on labeling and promotional activities;
   

 
  ●

Medical Device Reporting regulations that require manufacturers to report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur;
   

 
  ●

corrections and removal reporting regulations that require manufacturers to report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; and
   

 
  ●

in some cases, requirements to conduct post-market surveillance studies to establish continued safety data.

 

We are required to, and have, registered with the FDA as a medical device manufacturer and listed the products that we currently commercialize in the U.S. We must obtain all necessary permits and licenses to operate our business in all regions in which we do business. As manufacturers, we and our suppliers are subject to announced and unannounced inspections by the FDA to determine our compliance with the Quality System Regulation, or QSR (21 CFR Part 820), and other regulations. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. These requirements impose certain procedural and documentation requirements upon us and our third-party manufacturers related to the methods used in and the facilities and controls used for designing, manufacturing, packaging, labeling and storing medical devices. As a manufacturer, we and our contract manufacturers are subject to periodic scheduled or unscheduled inspections by the FDA. Following these inspections, the FDA may assert noncompliance with QSR requirements on a Form 483, which is a report of observations from an inspection, or by way of “untitled letters” or “warning letters” that could cause us or any third-party manufacturers to modify certain activities. A Form 483 notice, if issued at the conclusion of an FDA inspection, can list conditions the FDA investigators believe may have violated QSR or other FDA requirements. We cannot be certain that we or our present or any future third-party manufacturers or suppliers will be able to comply with QSR or other FDA regulatory requirements to the agency’s satisfaction. Failure to comply with these obligations may lead to possible legal or regulatory enforcement action by the FDA.

 

13
Table of Contents

 

The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:

 

 

●

untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;

 

 

●

unanticipated expenditures to address or defend such actions;

 

 

●

customer notifications or repair, replacement, refunds, recall, detention or seizure of our products;

 

 

●

operating restrictions, partial suspension or total shutdown of production;

 

 

●

refusing or delaying our requests for regulatory approvals or clearances of new products or modified products;

 

 

●

withdrawing a PMA that has already been granted;

 

 

●

refusal to grant export approval for our products; or

 

 

●

criminal prosecution. 

 

In the EU, we comply with the requirements of the 93/42/EEC Medical Devices Directive, or MDD, for ultrasonic, and appropriately affix the CE mark on our products to attest to such compliance. We also comply with (EU) 745/17 Medical Device Regulation, or MDR, for the other products (robotic and instruments), and appropriately affix the CE mark on our products to attest such compliance. Asensus Surgical Italia S.r.l. is the legal manufacturer in the EU. Our products marketed in the EU meet the “Essential requirements” of the MDD or of MDR, as applicable, relating to safety and performance. We have undergone verification of our regulatory compliance, or conformity assessment, by a Notified Body duly authorized by an EU country and must continue to do so. The level of scrutiny of such assessment depends on the regulatory class of the product. We are subject to continued surveillance by our Notified Body and are required to report any serious incidents to the appropriate authorities. We also must comply with additional requirements of individual countries in which our products are marketed. In the EU, we are required to maintain certain quality system certifications in order to sell products. These regulations require us or our manufacturers to manufacture products and maintain documents in a prescribed manner with respect to design, manufacturing, testing, labeling and control activities.  As legal manufacturers, we and our suppliers are subject to announced and unannounced inspections by the European Notified Bodies and Competent Authorities.

 

In May 2021, the Medical Devices Directive was replaced by the new Medical Device Regulation (Regulation (EU) 2017/745), or MDR. Any of our products that were certified under the MDD have been or will have to be re-assessed by a designated Notified Body according to the new regulation before their CE Certificates of Conformity issued under the MDD expires or in case we want to make a substantial change to any product.  To date, the Senhance System (with the ISU included), instruments, and adapters for articulating instruments have been certified under the MDR process. The MDR places new requirements regarding labeling, post-market surveillance, and technical documentation on all medical device manufacturers.  In addition, Notified Bodies underwent the transition as well, leading to reduced capacity to take on new clients or review new medical devices for CE mark certification.  Currently, there are certain transitional provisions in place which allow manufacturers to continue benefiting from CE Certificates of Conformity issued under the MDD and therefore provide more time to transition to the new MDR regime. These transitional provisions allow CE Certificates of Conformity issued under the MDD to remain valid until 31 December 2027 for Class IIb implantable devices (and others) and 31 December 2028 for Class IIa devices (and others) under the following main conditions: (1) devices do not present any unacceptable risk to health and safety, (2) devices have not undergone significant changes in design or intended purpose, and (3) the manufacturers should undertake the necessary steps to launch the certification process under the MDR, such as adaptation of their quality management system to the MDR and submission of an application for MDR certification to a Notified Body. Some of our legacy devices in class IIb still require MDR transition (ultrasonic). Full transition to the MDR will take time and resources from our internal personnel and external consultants to gain compliance, which may reduce the resources available for market expansion and new product introductions. The time required to obtain a CE Certificate of Conformity from a notified body in the EU is lengthy and unpredictable - the MedTech Europe industry association has recently reported a time-to-certification of 13-18 months on average under the MDR across all device categories.

 

14
Table of Contents

 

Further, the levels of revenues and profitability of medical device companies like us may be affected by the continuing efforts of government and third-party payors to contain or reduce the costs of healthcare through various means. For example, in certain foreign markets, pricing or profitability of products is subject to governmental control. In the United States, there have been, and we expect that there will continue to be, a number of federal and state proposals to implement similar governmental controls.

 

Therefore, we cannot assure you that any of our products will be considered cost effective, or that, following any commercialization of our products, coverage and reimbursement will be available or sufficient to allow us to manufacture and sell them competitively and profitably.

 

Health Care Regulation

 

Our business activities are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. These laws include the following:

 

 

●

The U.S. Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving anything of value to induce (or in return for) the referral of business, including the purchase of a particular medical device reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between medical device manufacturers on one hand and purchasers on the other. A violation of the Anti-Kickback Statute may be established without proving actual knowledge of the statute or specific intent to violate it. The government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration to those who purchase medical devices, including certain discounts, or engaging such individuals as consultants, speakers or advisors, may be subject to scrutiny if they do not fit squarely within the exception or safe harbor.

 

 

●

The federal civil False Claims Act, or FCA, which prohibits, among other things, any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of federal funds, or knowingly making, or causing to be made, a false statement material to a false claim. Actions under the False Claims Act may be brought by private individuals known as qui tam relators in the name of the government and relators may share in any monetary recovery.

 

 

●

The Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (collectively “HIPAA”) prohibits, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors. HIPAA also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. We may obtain health information from third parties that are subject to privacy and security requirements under HIPAA and we could potentially be subject to criminal penalties if we, our affiliates, or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.

 

 

●

Many states have privacy laws similar to or more expansive than HIPAA. As noted in “Business‑International Regulation and Potential Impact” we comply with the EU GDPR regulations.

 

 

●

The majority of states also have statutes or regulations similar to the federal anti-kickback and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

 

 

●

The U.S. Physician Payment Sunshine Act, or Sunshine Act, requires tracking of payments and transfers of value to physicians, certain other health care professionals and teaching hospitals and ownership interests held by physicians and their families, and reporting to the federal government and public disclosure of these data. The failure to report appropriate data accurately, timely, and completely could subject us to significant financial penalties. Other countries and several states currently have similar laws and more may enact similar legislation.

 

15
Table of Contents

 

Efforts to ensure that our business arrangements with third parties are compliant with applicable healthcare laws and regulations will involve the expenditure of appropriate, and possibly significant, resources. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of such laws that apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, such as Medicare and Medicaid, and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.

 

Health Care Reform

 

A primary trend in the U.S. healthcare industry and elsewhere is cost containment. By way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, the Affordable Care Act, or ACA, went into effect, which, among other things, includes changes to the coverage and payment for products under government health care programs. In the United States, there have been, and we expect there to continue to be, a number of legislative and regulatory initiatives, at both the federal and state government levels, to change the healthcare system in ways that, if approved, could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our products.

 

Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2031. Sequestration is currently set at 2% and will increase to 2.25% for the first half of fiscal year 2030, to 3% for the second half of fiscal year 2030, and to 4% for the remainder of the sequestration period that lasts through the first six months of fiscal year 2031. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

 

Some of the provisions of the ACA and related laws have been, and may continue to be, subject to judicial and Congressional challenges, and to modifications in their interpretation or implementation. Congress continues to consider legislation to modify the ACA. It is unclear whether new legislation modifying the ACA will be enacted, and, if so, precisely what the new legislation will provide, when it will be enacted and what impact it will have on the availability of healthcare and containing or lowering the cost of healthcare. We plan to continue to evaluate the effect that the ACA and its possible modification may have on our business.

 

There has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing and review the relationship between pricing and manufacturer programs. Individual states in the U.S. have also become increasingly active in enacting legislation and implementing regulations designed to control product pricing. We expect that additional foreign, federal and state healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products.

 

There have been, and likely will continue to be, legislative and regulatory proposals at the national level in the U.S. and other jurisdictions globally, as well as at some regional, state and/or local levels within the U.S. or other jurisdictions, directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. Such reforms could have an adverse effect on anticipated revenues from product that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop products.

 

16
Table of Contents

 

Significant uncertainty exists regarding the coverage and reimbursement status of products approved by the FDA and other government authorities. In the United States, sales of our products depend in significant part on the availability and adequacy of coverage and reimbursement from third party payors for our product and for services that use our products. Third-party payors include government authorities, managed care providers, private health insurers, and other organizations. The process for determining whether a payor will provide coverage may be separate from the process for setting the reimbursement rate that the payor will pay for the product or service. Moreover, a payor’s decision to provide coverage does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.

 

Our products are sold or leased to facilities, such as hospitals, and are not for use in the home such that they are not durable medical equipment. Devices such as ours used in surgical procedures are normally not paid separately by payers, but are reimbursed by third-party payors as part of the payment made for the performed surgical procedure when performed on an outpatient basis, or as part of the payment made for the inpatient stay when the patient undergoing the procedure is an inpatient of a hospital. As a result, these types of devices are subject to significant price competition that can place a small manufacturer at a competitive disadvantage as facilities attempt to negotiate lower prices for products such as the ones we develop and sell.

 

Third-party payors are increasingly challenging the prices charged for, examining the medical necessity, safety, and efficacy of, and assessing the cost-effectiveness of medical procedures, including those that use our products. The U.S. government and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls and restrictions on reimbursement. Any such downward pressure on the reimbursement for the services with which our products are used could limit our ability to realize an appropriate return on our investment in product development.

 

International Regulation and Potential Impact

 

Our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations, or rules of other countries in which we operate. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, health care providers are employed by their government, therefore our dealings with these providers are subject to regulation under the FCPA. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.

 

The Company has market development and commercial activities in a number of international markets and intends to focus on such markets in the near term. Some of these markets maintain unique regulatory requirements outside of or in addition to those of the FDA and the European Union. The Senhance System is CE marked, which is the basis to allow us to offer the product for sale in a number of jurisdictions, including selected countries in Europe, the Middle East and Asia.  Due to the variations in regulatory requirements within territories, the Company may be required to perform additional safety or clinical testing or fulfill additional agency requirements for specific territories. The Company may also be required to apply for registration using third parties within those territories and may be dependent upon the third parties’ successful regulatory processes to file, register and list the product applications and associated labeling, which could lead to significant investments and resource use. These additional requirements may result in delays in international registrations and commercialization of our products in certain countries.

 

17
Table of Contents

 

Additionally, the General Data Protection Regulation, or the GDPR, including as implemented in the U.K. and in effect across the European Economic Area, or EEA, imposes many stringent requirements for controllers and processors of personal data (personally identifiable information, or PII), including ensuring the lawfulness of processing personal data (including obtaining valid consent of the individuals to whom the personal data relates, where applicable), the processing details disclosed to the individuals, the adequacy, relevance and necessity of the personal data collected, the retention of personal data collected, the sharing of personal data with third parties, the transfer of personal data out of the EEA/UK to third countries including the US, contracting requirements (such as with clinical trial sites and vendors), the use of personal data in accordance with individual rights, the security of personal data and security breach/incident notifications. Restrictions on the ability of companies to transfer personal data from the EEA/U.K. to the United States and other countries, may adversely affect our ability to transfer or receive personal data or otherwise may cause us to incur significant costs to undertake data transfer impact assessments and implement lawful data transfer mechanisms.

 

Finally, the Japanese Act on the Protection of Personal Information, as amended, includes extraterritorial application, requirements related to data transfers to third parties in foreign countries and data breach reporting obligations that are applicable to our business in Japan.

 

In addition, we are utilizing distributors and sales agents in various territories throughout Europe, the Middle East, Africa, and the CIS, and need to ensure that our activities, and the activities of our distributors and sales agents, are compliant with local law and U.S. laws governing the sales of medical devices.  We have also established subsidiaries and contracted with third parties in Asia, including Japan and Taiwan, to seek regulatory approvals to offer our products in Asia.  The laws governing the registration, approval, clearance, and sales of medical devices, such as the Senhance System, in multiple jurisdictions are complex, and the failure to comply with such laws in any given jurisdiction could subject us to financial penalties or suspension or termination of our ability to sell our products in the applicable jurisdiction.

 

Environmental, Social and Governance

 

Environmental

 

As a company, we are committed to encouraging and fostering sustainable practices to support the global environment. We comply with environmental regulations in each of our locations. We have a corporate goal of limiting the use of plastic with paper cups and recyclable materials in all of our locations. Our employees located in our European facilities are encouraged to travel by train rather than aircraft, and some employees benefit from local government incentives to use electric cars. We also put safety first in our locations through the implementation of rigorous safety protocols which are drafted and reviewed with assistance from third-party safety consultants and ongoing training programs. We also ensure health check-ups are completed in those of our locations where such check-ups are mandatory. 

 

Social

 

Company Culture

Our employees are passionate about the work they do and thrive in a collaborative environment that fosters creative solutions to complex problems. The Company fosters a significant amount of collaboration and synergy among employees. Team members at any level are encouraged to provide suggestions and input to enable the Company’s success.

 

Employee Demographics

As of December 31, 2023, we had 209 employees, including 207 full-time employees, of whom 89 were in the R&D Department, 16 were in Quality and Regulatory Affairs, 39 were in Marketing and Sales, 30 were in Corporate Administration, and 24 were in Customer Excellence. The increase in employees in our R&D Department relates to the LUNA System development efforts. As of December 31, 2023, approximately 29% of the Company’s workforce were female, and people of color represented approximately 30% of the Company’s workforce, a marked increase from 2022 which we believe resulted from our DEI activities. As of December 31, 2023, approximately 57% of the Company’s employees were in the United States and 43% were outside of the United States. In 2023, our turnover rate was approximately 18% and we hired 36 full-time employees. Our turnover rate increased to 2021 levels. We believe the increase was largely related to performance-based terminations and reduced hiring activities.

 

18
Table of Contents

 

Diversity, Equity & Inclusion (DEI)

We believe in contributing to a society that welcomes diverse voices and values differences in lived experiences, culture, religion, age, gender identity, sexual orientation, race, ethnicity, and neurodiversity. We are committed to ensuring this same environment for our employees – a culture where individuals feel safe, heard, and respected. We celebrate the uniqueness of our global workforce, especially in a company of our size, and appreciate that only through inclusion, ongoing learning, and partnership can we succeed.

 

In 2020, we created an internal webpage dedicated to DEI resources for our employees, kicked off a DEI committee and partnered with a DEI alliance to further evolve our DEI efforts. In 2023, we held biweekly meetings of the DEI committee, organized a field trip to the International Civil Rights Center & Museum, attended the Raleigh Chamber’s Diversity, Equity & Inclusivity Conference in July, shared information on our social media pages about relevant events and holidays, and held various cultural, coaching and education events including DEI focused movie watch parties with follow-up discussion groups and volunteering activities. We are also focused on incorporating DEI principles into our governance structure and believe having a mix of backgrounds and experience in our Board composition is essential to understanding and reflecting the needs of our diverse stakeholders. Currently, one of eight board members self-identifies as a woman, and two of our eight Board members self-identify as individuals from underrepresented communities (defined as an individual who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, or Alaska Native, or who self-identifies as gay, lesbian, bisexual, or transgender).

 

Health & Wellness

Throughout 2023, health and wellness was a key focus of the Company, especially in light of the ongoing pandemic and new variants. Many of our employee communications focused on the physical and mental health of our employees. We remain committed to providing our workforce with flexible remote working schedules to suit their personal needs through this challenging time. We also continue to benchmark all of our health insurance offerings to ensure plan competitiveness.

 

People Strategy

Our People Strategy is to create and maintain a culture of high performance and accountability through the attraction, engagement and development of expert talent. To enhance our employees’ satisfaction and retention, we offer ongoing training opportunities that support professional growth. We have an annual performance review process for all employees worldwide to review performance and inform compensation recommendations. We compete for top talent with effective recruitment strategies, well-defined roles and attractive total compensation packages. We keep talent engaged through appreciation, communication and the creation of a great work environment. We support employee growth professionally and personally through formal and informal opportunities and leadership support.

 

Employee Engagement

We partner with Gallup, Inc., a global analytics and advice firm, to monitor and improve the engagement of our workforce. Gallup’s Q12 survey measures employee engagement based on twelve key needs of employees. We utilize survey results to identify strengths and weaknesses and create action plans to improve engagement and ultimately team performance. In 2023, we maintained our high engagement score from the prior year and saw an increase in the percentage of actively engaged employees. We continue to incorporate Gallup’s programs into our overall People Strategy.  

 

Compensation

In addition to competitive base salaries, we offer incentive-based compensation programs tied to the performance of key objectives. We also provide compensation in the form of retention grants of restricted stock units and/or stock options, which we believe help align longer-term employee incentives with our company performance. Ensuring fair and equitable pay is also an important commitment we make to our employees.

 

19
Table of Contents

 

Governance

 

Our Board of Directors, through its Nominating and Corporate Governance Committee, evaluates the governance and management practices of the Company. We believe our corporate governance guidelines and structure provide our stockholders with a dedicated, qualified and skilled board of directors and management team. Our governance structure includes:

 

 

●

annual elections of all board members;

 

 

●

an independent Board chair and separation of the CEO/Chair role;

 

 

●

diversity in skills, gender and ethnicity in our board and management team; and

 

 

●

the ability of stockholders to propose candidates for potential nomination to the board and proposals for consideration by stockholders at annual meetings.

 

Corporate Information

 

On February 23, 2021, we changed our corporate name to Asensus Surgical, Inc. Our principal executive offices are located at 1 TW Alexander Drive, Suite 160, Durham, NC 27703. The Company was originally incorporated on August 19, 1988, as a Delaware corporation.

 

The active subsidiaries of the Company are Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc.

 

Available Information

 

The Company maintains a website at www.asensus.com. We are not incorporating our website by reference into this Annual Report. Our Code of Business Conduct and Ethics is available on our website. Our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are available free of charge on our website as soon as practicable after electronic filing of such material with, or furnishing it to, the U.S. Securities and Exchange Commission, or the SEC.

 

20
Table of Contents

 

ITEM 1.A.         RISK FACTORS

 

Our risk factors are grouped into the following categories: (1) Risks Related to the Operation of our Business; (2) Risks Related to Our Status as a Public Company; (3) Risks Related to Protection of our Intellectual Property; and (4) Risks Related to the Regulation of our Business.

 

Risks Related to the Operation of our Business

 

We have a history of operating losses, and we may not be able to achieve or sustain profitability.

We have a limited operating history. We are not profitable and have incurred losses since our inception. Our accumulated deficit was $939.4 million, and our working capital was $23.8 million as of December 31, 2023. We expect to continue to incur losses for the foreseeable future, and these losses will likely increase as we continue to develop and commercialize our products. We will continue to incur research and development and general and administrative expenses related to our operations, and sales and marketing expenses to support our commercial activities. Even if we are successful in reducing our expenses or achieving profitability in the future, we may not be able to sustain profitability in subsequent periods. 

 

Our recurring operating losses and negative cash flows raise substantial doubt about our ability to continue as a going concern. We will need additional financing to execute our business plan and fund our operations.

Since inception, we have experienced recurring operating losses and negative cash flows and we expect to continue to generate operating losses and consume significant cash resources in the foreseeable future, particularly as we increase our research and development spending as we develop and seek regulatory approval for the LUNA System and enhancements to our digital surgery and Performance-Guided Surgery product offerings. Management has concluded that substantial doubt exists about our ability to continue as a going concern as a result of anticipated capital needs in conjunction with past recurring losses and an accumulated deficit. As of December 31, 2023, our accumulated deficit was $939.4 million, and our working capital was $23.8 million. We believe that our existing cash, cash equivalents and short-term investments, together with cash received from product, service, and lease sales will be sufficient to meet our anticipated cash needs into early June 2024. However, we will need additional financing to implement our next generation products strategy. Management's plans to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into strategic collaborations, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of its markets. Management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. If sufficient funds are not received on a timely basis, the Company would then need to reduce costs further and/or pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock and we may have a more difficult time obtaining financing.

 

We will require substantial additional funding to advance our current plans.

We are focused on our development efforts for our products, including the LUNA System and enhanced digital solutions, and commercialization of the Senhance System, ISU and other products, as well as market development for our products and other research and development activities. We expect increased research and development spend associated with the development of the LUNA System, next generation versions of the ISU and enhanced digital solutions, putting additional pressure on funding requirements as we advance through regulatory processes and commercialization, if our R&D efforts are successful. We intend to advance multiple additional products through clinical and pre-clinical development in the future. We will need to raise additional capital in the future in order to fund these priorities and achieve our business objectives. Any delays in raising additional capital will delay the current anticipated timelines for development and commercialization. We cannot assure you that we will be successful in obtaining additional financing in the future on terms acceptable to the Company or at all.

 

Until we generate a sufficient amount of revenue to finance our cash requirements, which may never occur, we expect to finance future cash needs primarily through public or private equity offerings, debt financings or strategic collaborations. We do not know whether additional funding will be available on acceptable terms, or at all. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more of our research and development programs. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution; and debt financing, if available, may involve restrictive covenants that limit our operations. To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our products or grant licenses on terms that may not be favorable to us.

 

21
Table of Contents

 

Our strategic focus, on delivering tools and assistance to provide Performance-Guided Surgery opportunities, may not result in the growth of our business in the timeline we envision or at all.

On February 23, 2021, we announced a strategic focus on providing clinical intelligence to surgeons to provide Performance-Guided Surgery opportunities. We believe that the Senhance System, which digitizes the interface between the surgeon and the patient in laparoscopic surgery, can also be used, with our Augmented Intelligence offerings, to provide real-time clinical data throughout the entire surgical experience, assist in removing elements and factors that contribute to surgical variability and reduce complications. Our efforts to communicate and implement this strategy with hospitals, surgery centers and surgeons may take longer than we anticipate, may not be as successful as we contemplate, and may not result in a meaningful improvement in our business or financial condition.

 

In order to compete successfully within the surgical robotics and digital surgery industry, we need to continue to evolve our robotic surgery products and our digital surgery offerings.  Failure to develop, obtain regulatory approval for and successfully commercialize such developments could have a material adverse effect on our business and financial position.

In order to compete successfully within the highly competitive surgical robotics industry, we need to continue to advance and innovate our robotic surgery products, including the innovations associated with the assets we acquired from MST in 2018.  Our focus currently is on harnessing the image technology acquired in the MST acquisition to advance the intelligence of our products through the ISU to provide meaningful real-time Augmented Intelligence to surgeons.  In addition, we entered into an agreement with NIVDIA and need to successfully harness the additional opportunities this agreement presents to us. We have developed and received CE Mark in Europe and FDA clearance in the U.S. for articulating instruments. These assets are also vital to our Performance-Guided Surgery strategy. If we fail to continue to develop such innovations, or fail to obtain regulatory approval or clearance for or to successfully commercialize such innovations, such failure could have a material adverse effect on our business and financial position.

 

We are also focused on commercial activities related to our ISU as a vital part of our Performance-Guided Surgery initiative. If we are not successful in commercializing the ISU, including a standalone ISU, our business could be materially adversely affected. Companies such as us rely on innovation and new product development to attract and retain customers. Such development efforts take time, are expensive, and there is no certainty that we will be successful in commercializing the ISU, developing the LUNA System, or receiving regulatory clearances and approvals, on a timely basis, if at all. If we are not successful in our development efforts, such failure will have a material adverse effect on our business and financial position.

 

We are focusing our development efforts on developing the LUNA System. If our development efforts are not successful, or if the LUNA System is not a commercial success, our business opportunities and financial position will be adversely affected.

The primary focus of our product development efforts are focused on our next generation robotic LUNA System. Development of a robotic system is difficult, time-consuming and expensive. We could suffer development setbacks, not meet our projected development schedule, become unable to finance the needed development efforts, fail to receive necessary regulatory clearance or approvals, or encounter difficulties in the manufacturing process. In addition, even if we do develop the LUNA System and receive the necessary regulatory clearances and approvals, we may be unable to successfully commercialize the LUNA System. If any of these risks occur, our business and financial position will be adversely affected.

 

The success of the LUNA System development efforts will be impacted by the results of the regulatory pathway.

We believe the regulatory pathway for the LUNA System will follow the 510(k) clearance pathway applicable to our other products. If the FDA determines that the LUNA System is “not substantially equivalent” to a previously cleared device, we might then need to fulfill the more rigorous PMA requirements, or request a risk-based classification determination for the device in accordance with the “de novo” process. Either alternative pathway would add significant time to our pursuit of FDA approval of the LUNA System, which could have a material adverse effect on our business and financial position.

 

We may not be successful in realizing benefits from our collaboration agreements.

We are collaborating with Google on further developing the Asensus Cloud as a key component of our LUNA System product offerings, and agreements with NVIDIA and Flex related to our ISU and LUNA System development efforts. If we are not successful in capitalizing on these collaborations, our reputation and our operations and financial condition may be harmed.

 

22
Table of Contents

 

We cannot give any assurance that the Senhance System can be successfully commercialized.

We began our selling efforts for the Senhance System in the fourth quarter of 2015 in Europe, in the fourth quarter of 2017 in the United States, in the second quarter of 2018 in Asia and, through distributors in the Russian Federation in 2021.  We have had limited commercial success to date. We have determined to focus our energies on market development and increased usage of the Senhance Systems that have been purchased and placed, as well as on our Performance-Guided Surgery strategy. We cannot assure you that we will be able to successfully improve the commercialization of the Senhance System, for a number of reasons, including, without limitation, failure in our market development and sales efforts, the long sales cycle associated with the purchase of capital equipment, and the potential introduction by our competitors of more clinically effective or cost-effective alternatives.  In addition, we are now more focused on developing the LUNA System than on continued commercial success of the Senhance System.

 

We cannot assure you that we will be successful in continuing to grow utilization of the Senhance System and the ISU year over year.

While we believe Performance-Guided Surgery and our other tools available can assist the laparoscopic surgeon to perform successful surgeries, it is time-consuming to educate and train physicians and educate hospitals on the benefits of use of the Senhance System with the ISU. If we cannot continue to grow our procedure volume year over year, our business and financial condition will be adversely affected.

 

If we fail to attract and retain key management and professional personnel, we may be unable to successfully commercialize or develop our products.

We will need to effectively manage our operational, sales and marketing, development and other resources in order to successfully pursue our commercialization and research and development efforts for our existing and future products. Our success depends on our continued ability to attract, retain and motivate highly qualified personnel.  If we are not successful in retaining and recruiting highly qualified personnel, our business may be harmed as a result.

 

We use distributors to sell our Senhance Systems.

Purchase of a surgical robotic system such as the Senhance System represents a capital purchase by hospitals and other potential customers, which is a time-intensive process involving buy-in by surgeons and approval of the capital purchase by administration. We use distributors and sales agents in a number of geographic locations where we do not have sales personnel. We have procedures in place that require our distributors and sales agents to comply with applicable laws and regulations governing the sales of medical devices in the jurisdictions where they operate.  Failure to meet such requirements could subject us to financial penalties or the suspension or termination of our ability to sell products in such jurisdictions.  

 

The surgical robotics and digital surgery industries are increasingly competitive, which can negatively impact our commercial opportunities.

The medical device industry is highly competitive, and we face significant competition from companies that are researching and marketing products to address minimally invasive and robotic-assisted surgery, including new entrants in the market. We are currently commercializing the Senhance System in the United States with FDA 510(k) clearance, in Europe which accepts a CE Mark, the Middle East, the Commonwealth of Independent States, and selected countries in Asia. We face significant competition in such markets. Many of our competitors, including Intuitive Surgical, have significantly greater financial, manufacturing, marketing and product development resources than we do. Some of the medical device companies that we do or expect to compete with include Medtronic plc, Intuitive Surgical Inc., Vicarious Surgical, Inc., Momentis Surgical, Distalmotion SA, CMR Surgical Ltd., Activ Surgical, Inc., Theator Surgical, CareSyntax Inc. and a number of MIS and robotic surgical device manufacturers and providers of solutions that are designed to reduce the need for or attractiveness of surgical intervention. In addition, many universities and private and public research institutions are or may become active in research involving surgical devices for MIS and robotic-assisted surgery.

 

We are also expanding the potential market for robotic surgical systems with our focus on laparoscopic surgery which may lead to additional competition with companies with substantially greater resources than ours. We believe that our ability to successfully compete will depend on, among other things: the efficacy, safety and reliability of our products; our ability to commercialize and market our cleared or approved products; the completion of our development efforts and receipt of regulatory clearance or approval for instruments and accessories to support the use of the Senhance System; the lower cost of ownership and use of our products in relation to alternative devices; the timing and scope of regulatory clearances or approvals, including any expansion of the indications for use for our products; whether our competitors substantially reduce the cost of ownership and use of an alternative device; our ability to protect and defend intellectual property rights related to our products; our ability to have our partners manufacture and sell commercial quantities of any cleared or approved products to the market; the effectiveness of our sales and marketing efforts; and acceptance of future products by physicians and other healthcare providers.

 

23
Table of Contents

 

We have also seen a trend in the market for large medical device companies to acquire, invest in, or form alliances with smaller companies in order to diversify their product offerings and participate in the digital health space. We may find increased competition from other companies, many better capitalized than we are.

 

If our competitors market products that are more effective, safer, easier to use or less expensive than our products or future products, or that reach the market sooner than our products, we may not achieve commercial success. In addition, the medical device industry is characterized by rapid technological change. It may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or products obsolete or less competitive. We anticipate that the highly competitive surgical robotics environment can lead our competitors to attempt to slow or derail our commercial progress. We are using our best efforts to enter the commercial markets effectively while maintaining compliance with all regulatory and legal requirements. Responding to the actions of our competitors may distract the management team from its focus on our commercial operations and lead to increased costs of commercialization, which could have a negative impact on our financial position.

 

We also anticipate that the competitive environments will become more intense because of increased consolidation by companies in the healthcare industry looking to achieve cost reductions. Such consolidation may have an adverse effect on our business operations.

 

Use of our Senhance System requires training for surgeons, and inadequate training may lead to negative patient outcomes, which could harm our business, financial condition, and results of operations.

The successful use of our Senhance System depends in part on the training and skill of the surgeon performing the procedure and his or her comfort level with the use of a robotic device. We provide training and proctoring, as well as Senhance Connect, that allows us to provide real-time guidance as desired. We cannot be certain that all of the surgeons that use our Senhance System have received and completed sufficient training. If a surgeon uses our Senhance System incorrectly, or without adhering to or completing all relevant training, their patients could be negatively affected. Adverse safety outcomes that arise from improper or incorrect use of our Senhance System may limit adoption of our Senhance System, which could harm our sales, business, financial condition, and results of operations.

 

Issues relating to the use of artificial intelligence and machine learning in our offerings could adversely affect our business and operating results.

We integrate artificial intelligence, AI, and machine learning in our products. Issues relating to the use of new and evolving technologies such as AI and machine learning may cause us to experience brand or reputational harm, competitive harm, legal liability, and new or enhanced governmental or regulatory scrutiny, and we may incur additional costs to resolve such issues. As with many innovations, AI presents risks and challenges that could undermine or slow its adoption, and therefore harm our business. For example, perceived or actual technical, legal, compliance, privacy, security, ethical or other issues relating to the use of AI may cause public confidence in AI to be undermined, which could slow our customers’ adoption of our products and services that use AI. In addition, litigation or government regulation related to the use of AI may also adversely impact our and others’ abilities to develop and offer products that use AI, as well as increase the cost and complexity of doing so. Further, market demand and acceptance of AI technologies are uncertain, and we may be unsuccessful in our product development efforts.

 

Negative publicity, whether true or not, concerning us or our products could reduce market acceptance of our products.

There have been social media and other publications regarding us published from time to time since we started selling the Senhance System. Negative media and social media coverage, whether true or not, concerning our products or us could reduce market acceptance of our products and increase volatility in our stock price.

 

24
Table of Contents

 

We are subject to risk as a result of our international manufacturing operations.

Because most of our products are manufactured at third-party facilities located in Europe, Israel and Singapore, our operations are subject to risk inherent in doing business internationally. Such risks include the adverse effects on operations from corruption, war, international terrorism, civil disturbances, political instability, government activities such as border taxes and renegotiation of treaties, deprivation of contract and property rights and currency valuation changes. Countries may adopt other measures, such as controls on imports or exports of goods, technology, or data, that could adversely impact the Company’s operations and supply chain and limit the Company’s ability to offer our products and services as designed. These measures could require us to take various actions, including changing suppliers and restructuring business relationships. Changing our operations in accordance with new or changed trade restrictions can be expensive, time-consuming, disruptive to our operations and distracting to management. Such restrictions can be announced with little or no advance notice, and we may not be able to effectively mitigate all adverse impacts from such measures. Any of these events could increase the cost of our products and services, or otherwise have a materially adverse impact on our or our suppliers’ businesses and results of operations. We have entered into agreements related to the manufacture of portions of our LUNA System in development. If we are unable to manufacture the LUNA System under the terms of these agreements, our business could be negatively impacted.

 

Fluctuations in foreign currency exchange rates may adversely affect our financial results.

We conduct operations in several different countries, including the United States and throughout Europe, and portions of our revenues, expenses, assets and liabilities are denominated in U.S. dollars, Euros, and other currencies. Since our consolidated financial statements are presented in U.S. dollars, we must translate revenues, income and expenses, as well as assets and liabilities, into U.S. dollars at exchange rates in effect during or at the end of each reporting period. We have not historically hedged our exposure to foreign currency fluctuations.  Accordingly, increases or decreases in the value of the U.S. dollar against the Euro and other currencies could materially affect our net operating revenues, operating income and the value of balance sheet items denominated in foreign currencies.

 

Our global operations expose us to additional risks and challenges associated with conducting business internationally.

The international nature of our business, particularly in Europe, Israel, Asia, CIS and the Russian Federation, may expose us to risks inherent in conducting foreign operations. These risks include: challenges associated with managing geographically diverse operations, which require an effective organizational structure and appropriate business processes, procedures and controls; the high cost of doing business in foreign jurisdictions, including compliance with international and U.S. laws and regulations that apply to our international operations; currency exchange and interest rate fluctuations and the resulting effect on our revenue and expenses, and the cost and risk of entering into hedging transactions, if we chose to do so in the future; changes in a specific country’s or region’s political or economic environment; trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; potentially adverse tax consequences; complexities and difficulties in obtaining protection and enforcing our intellectual property; compliance with additional regulations and government authorities in a highly regulated business; difficulties associated with staffing and managing foreign operations, including differing labor relations; and general economic and political conditions outside of the U.S.

 

Significant disruptions of our information technology systems or data security incidents could harm our reputation, cause us to modify our business practices, and otherwise adversely affect our business and subject us to liability.

We are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store, process, and transmit sensitive corporate, personal, and other information, including intellectual property, proprietary business information, customer data including PII, and other confidential information. Our obligations under applicable laws, regulations, contracts, industry standards, self-certifications, and other documentation may include maintaining the confidentiality, integrity, and availability of personal information in our possession or control, maintaining reasonable and appropriate security safeguards as part of an information security program. These obligations create potential legal liability to regulators, our business partners, our customers, and other relevant stakeholders, and also impact the attractiveness of our products and services to existing and potential customers.

 

Our systems are subject to cyber-attacks, viruses, worms, malicious software programs, outages, equipment malfunction or constraints, software deficiencies, human error, hacking and other malicious intrusions, which may materially disrupt our business and compromise our data. Cyber-attacks are expected to accelerate on a global basis in both frequency and magnitude as threat actors are becoming increasingly sophisticated in using techniques and tools (including artificial intelligence) that circumvent controls, evade detection and even remove forensic evidence of the infiltration. There can be no assurance that the systems we have designed to prevent or limit the effects of cyber incidents or attacks will be sufficient to prevent or detect material consequences arising from such incidents or attacks, or avoid a material adverse impact on our systems after such incidents or attacks do occur. Even if we successfully defend our own digital technologies, we also rely on providers of third-party products, services, and networks, with whom we may share data and services, and who may be unable to effectively defend their digital technologies and services against attack.

 

25
Table of Contents

 

Unauthorized access to or modification of, or actions disabling our ability to obtain authorized access to, our customers’ data, other external data, personal data, or our own data, as a result of a cyber incident, attack or exploitation of a security vulnerability, or loss of control of our clients’ operations could result in significant damage to our reputation or disruption of the services we provide to our customers or of our customers’ businesses. In addition, allegations, reports, or concerns regarding vulnerabilities affecting our digital products or services could damage our reputation. We may not be able to anticipate and prevent such disruptions or intrusions, and we may not be able to mitigate them when and if they occur. Any failure, breach or unauthorized access to our or third-party systems could result in the loss of confidential, sensitive or proprietary information, interruptions in service or production or otherwise encumber our ability to conduct business operations and could result in potential reductions in revenue and profits, damage to its reputation or liability. Furthermore, we may incur significant costs in responding to any such disruption or intrusion and remedying our systems. In such event we may also be subject to litigation and other potential liability, which could materially impact our business and financial condition. Further, as regulatory focus on privacy and data security issues continues to increase and worldwide laws and regulations concerning the protection of information become more complex, the potential risks and costs of compliance to the company’s business will intensify.

 

Although we have implemented remote working protocols for some employees and offer work-issued devices to employees, the actions of our employees while working remotely may have a greater effect on the security of our systems and the data we process, including by increasing the risk of compromise to our systems, intellectual property, or data arising from employees’ combined personal and private use of devices, accessing our systems or data using wireless networks that we do not control, or the ability to transmit or store company-controlled data outside of our secured network.

 

We maintain insurance policies to cover certain losses relating to our information technology systems. However, there may be exceptions to our insurance coverage such that our insurance policies may not cover some or all aspects of a security incident. Even where an incident is covered by our insurance, the insurance limits may not cover the costs of complete remediation and redress that we may be faced with in the wake of a security incident. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. In addition, we cannot be sure that our existing insurance coverage and coverage for errors and omissions will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim.

 

In addition, any actual or perceived failure by us, our vendors, or our business partners to comply with our privacy, confidentiality, or data security-related legal or other obligations to customers or other third parties, or any further security incidents or other unauthorized access events that result in the unauthorized access, release, or transfer of sensitive information (which could include personal data), may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including current and potential partners, to lose trust in us (including existing or potential customers’ perceiving our products or services as less desirable), or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages.

 

The conflict in Israel and Gaza is likely to have a material adverse impact on us and our employees.

We have an office and valued employees who live and work in Israel. The current conflict in Israel could have a material adverse impact on our business and operations. Our digital surgery software development efforts are centered in our Israeli subsidiary, and the conflict could cause unexpected delays in our development efforts. Some of our employees have been called to active military duty. In addition, a third-party manufacturer of our ISU located in Israel could be negatively impacted affecting our ability to meet our supply obligations, and export of such ISUs, and other supply management activities and materials due to transport restrictions. If the conflict is prolonged or significantly worsens, these factors could have a material adverse impact on our business operations and employees.

 

26
Table of Contents

 

We face risks arising from sole suppliers of components and our ability to meet delivery schedules for sales of our products.

The Senhance System is manufactured for us under contract by a third-party manufacturer. We or our manufacturer acquire raw materials and components of the Senhance System from vendors, some of which are sole suppliers. Although we believe that we have the manufacturing capacity and inventory reserves to meet our anticipated Senhance System sales for the foreseeable future, we are currently taking steps to develop redundant manufacturing and supply alternatives. We cannot assure you that we will be successful in developing these redundant supply and manufacturing capabilities. If we are not successful, our business operations could suffer.

 

Our products require precise, high-quality manufacturing. We and our contract manufacturers will be subject to ongoing periodic unannounced inspection by the FDA and non-U.S. regulatory authorities to ensure strict compliance with the quality systems regulations, current “good manufacturing practices” and other applicable government regulations and corresponding standards. If we or our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with QSR, we may experience manufacturing errors resulting in patient injury or death, product recalls or withdrawals, delays or interruptions of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications for our products, cost overruns or other problems that could seriously harm our business.

 

The inflationary environment could materially adversely impact our business and results of operations.

Changes in economic conditions and supply chain constraints and steps taken by governments and central banks could lead to higher inflation than previously experienced or expected, which could, in turn, lead to an increase in costs. An inflationary environment could have a negative impact on our expenses, increase our labor costs and reduce our available cash flow.

 

Because our design, development and manufacturing capabilities are limited, we rely on third parties to design, develop, manufacture or supply some of our products. An inability to find additional or alternate sources for these services and products could materially and adversely affect our financial condition and results of operations.

We have used third-party design and development sources to assist in the design and development of our medical device products. In the future, we may choose to use additional third-party sources for the design and development of our products. If these design and development partners are unable to provide their services in the timeframe or to the performance level that we require, we may not be able to establish a contract and obtain a sufficient alternative supply from another supplier on a timely basis and in the manner that we require.

 

Risks Related to Our Status as a Public Company

 

Our stock price has been volatile and may experience additional volatility and fluctuation in the future. 

The market price of our common stock has been, and may continue to be, volatile, and the market price of our common stock could decrease and could cause you to lose some or all of your investment in our common stock.  During the two-year period ended December 31, 2023, the market price of our common stock fluctuated from a high of $1.19 per share to a low of $0.20 per share. The market price of our common stock may continue to fluctuate significantly. In addition, a prolonged low stock price may subject us to delisting or require us to take action, such as a reverse stock split, to maintain our listing.

 

We are currently a smaller reporting company, which may limit our ability to raise sufficient capital to advance our LUNA System and Performance-Guided Surgery development efforts.

Our stock price was below $1.00 per share during all of 2023. If our stock price continues to remain under $1.00 per share for an extended period, that makes fundraising more difficult and impacts our ability to attract long-term investors.

 

Our stockholders have experienced dilution of their percentage ownership of our stock and may experience additional dilution in the future.

We have raised significant capital through the issuance of our common stock and warrants and anticipate that we may need to raise substantial additional capital in order to continue our operations and achieve our business objectives. We cannot assure you that we will be able to sell shares or other securities in any offering at a price per share that is equal to or greater than the price per share paid by investors in previous offerings, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in previous offerings. The future issuance of the Company’s equity securities will further dilute the ownership of our outstanding common stock.  The market price of our common stock has been, and may continue to be, highly volatile, and such volatility could cause the market price of our common stock to decrease and could cause stockholders to lose some or all of their investment in our common stock.

 

27
Table of Contents

 

Risks Related to Protection of our Intellectual Property

 

Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.

Other entities may have or obtain patents or proprietary rights that could limit our ability to manufacture, use, sell, offer for sale or import products or impair our competitive position. If a third-party has proprietary rights covering our products, we may require licenses, which may not be available on commercially reasonable terms, or at all. If licenses are not available to us on acceptable terms, we will not be able to market the affected products or conduct the desired activities, unless we challenge the validity, enforceability or infringement of the third-party patent or circumvent the third-party patent, which would be costly and would require significant time and attention of our management. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing products using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations.

 

If we become involved in patent litigation or other proceedings related to proprietary rights, we could incur substantial costs and expenses, substantial liability for damages or be required to stop our product development and commercialization efforts, any of which could materially adversely affect our liquidity, business prospects and results of operations.

 

Third parties may sue us for infringing their patents. Likewise, we may need to resort to litigation to enforce our patents or to determine the scope and validity of patents of others. In addition, a third-party may claim that we have improperly obtained or used its proprietary information. Furthermore, in connection with our third-party license agreements, we generally have agreed to indemnify the licensor for costs incurred in connection with litigation relating to intellectual property rights. The cost to us of any litigation or other proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and the litigation would divert our management’s efforts. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than us because they have substantially greater resources. Uncertainties resulting from any litigation could limit our ability to continue our operations.

 

If any parties successfully claim that our activities infringe their intellectual property rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition to any damages we might have to pay, a court could require us to stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially acceptable terms, if at all. In addition, such licenses are likely to be non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to market some of our products, which could limit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations.

 

For our Senhance System, we rely on our license from the European Union, and any loss of our rights under such license agreement, or failure to properly prosecute, maintain or enforce the patent applications underlying such license agreement, could materially adversely affect our business prospects for the Senhance System.

Some of the patents and patent applications in our patent portfolio related to the Senhance System are licensed to Asensus Surgical Italia S.r.l. under a license agreement with the European Union. We rely on such licensed technology for our Senhance System. We may license additional technology from third parties in the future. The EU agreement gives us rights for the commercial exploitation of the licensed patents, subject to certain provisions of the agreement. Failure to comply with these provisions could result in the loss of our rights under the EU license agreement. Our inability to rely on these patents would have an adverse effect on our business.

 

28
Table of Contents

 

Further, our success will depend in part on the ability of us, the EU and other third-party licensors to obtain, maintain and enforce the licensed patents and, in particular, those patents to which hold exclusive rights. We, the EU or other third-party licensors may not successfully prosecute the patent applications which are licensed to us, may fail to maintain the patents, and may determine not to pursue litigation against other companies that are infringing the patents, or may pursue such litigation less aggressively than necessary to obtain an acceptable outcome from any such litigation. Without protection for the intellectual property we have licensed, other companies might be able to offer substantially identical products for sale, which could materially adversely affect our competitive business position, business prospects and results of operations.

 

If we or our licensors are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.

In addition to patent protection, we rely on other proprietary rights, including protection of trade secrets, know-how and proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we will seek to enter into confidentiality agreements with our employees, consultants and collaborators upon the commencement of their relationships with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential. Our agreements with employees also generally provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection. If our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations

 

If we are unable to obtain and enforce patent protection for our products, our business could be materially harmed.

Our success depends, in part, on our ability to protect proprietary technologies that we develop or license under the patent and other intellectual property laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold rights to some patents required for us to commercialize our proposed products. Third parties may have filed patent applications for technology covered by our patent applications without our being aware of those applications, and our patent applications may not have priority over those applications. For this and other reasons, we may be unable to secure desired patent rights, thereby losing desired exclusivity. If licenses are not available to us on acceptable terms, we will not be able to market the affected products or conduct the desired activities, unless we challenge the validity, enforceability or infringement of the third-party patent or otherwise circumvent the third-party patent.

 

Our strategy depends on our ability to promptly identify and seek patent protection for our discoveries. In addition, we may rely on third-party collaborators to file patent applications for inventions we develop jointly during certain collaborations. The process of obtaining patents is expensive and time-consuming. If our collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business will be adversely affected. Despite our efforts and the efforts of our collaborators to protect our proprietary rights, unauthorized parties may be able to develop and use information that we regard as proprietary.

 

The issuance of a patent does not guarantee that it is valid. Any patents we have obtained, or obtain in the future, may be challenged or potentially circumvented. Moreover, the US Patent and Trademark Office, or the USPTO, may commence interference proceedings involving our patents or patent applications. Any challenge to our patents or patent applications would be costly, would require significant time and attention of our management and could have a material adverse effect on our business. In addition, future court decisions may introduce uncertainty in the enforceability or scope of any patent.

 

29
Table of Contents

 

Our pending patent applications may not result in issued patents. A business’s patent position, including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in medical device patents. Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Therefore, the enforceability or scope of our owned or licensed patents in the US or in foreign countries cannot be predicted with certainty, and, as a result, such patents may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection for our pending patent applications, those we may file in the future, or those we may license from third parties.

 

We cannot assure you that any patents that issue or be licensed to us will be enforceable or valid or will not expire prior to the commercialization of our products, thus allowing others to more effectively compete with us. Therefore, any patents that we own or license may not adequately protect our future products.

 

Certain software being developed for the LUNA System and the ISU may include third-party open source software. Any failure to comply with the terms of one or more open source software licenses could adversely affect our business, subject us to litigation, or create potential liability.

Certain software being developed for the LUNA System and for the ISU may include third-party open source software and we expect to continue to incorporate open source software in the future. The use of open source software involves a number of risks, many of which cannot be eliminated and could negatively affect our business. For example, we cannot ensure that we have effectively monitored our use of open source software or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software asserting that the use of such open source software infringes the claimants’ intellectual property rights. As a result, we could be subject to suits by third parties claiming infringement on such third parties’ intellectual property rights. Litigation could be costly for us to defend, have a negative effect on our business, financial condition and results of operations, or require us to devote additional research and development resources to modify our computational drug discovery platform.

 

Risks Related to Regulation of our Business

 

For our existing product clearances, approvals, or certifications and for our future products, the terms thereof and ongoing regulation of our products may limit how we manufacture and market our products, which could materially impair our ability to generate anticipated revenues. If we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.

Once regulatory clearance, approval or certification has been obtained, the cleared, approved or certified product and its manufacturer are subject to ongoing regulatory requirements. Any cleared, approved or certified product may be promoted only for its intended uses. In addition, if the FDA, other non-U.S. regulatory authorities, or our Notified Body clear, approve, or certify any of our products, the labeling, packaging, adverse event reporting, storage, advertising and promotion for the product will be subject to extensive regulatory oversight. We and any outsourced manufacturers of our products are also required to comply with the FDA’s QSR, or similar requirements of non-U.S. regulatory authorities which includes requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation as well as other quality system requirements and regulations from non-U.S. regulatory authorities. Further, all manufacturing facilities are subject to routine regulatory inspection.

 

Regulatory authorities, such as the FDA in the U.S., and notified bodies enforce regulatory requirements through periodic inspections, among other activities. If we fail to comply with the regulatory requirements of the FDA, either before or after clearance or approval, or other non-U.S. regulatory authorities, or if previously unknown problems with our products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions, including: restrictions on our products, manufacturers or manufacturing process; adverse inspectional observations (Form 483), Warning Letters, Untitled Letters, letters incorporating inspectional observations, or consent decrees; civil or criminal penalties or fines; injunctions; product seizures, detentions or import bans; voluntary or mandatory product recalls and publicity requirements; suspension limitation or withdrawal of regulatory clearances, approvals, or certifications; total or partial suspension of production; imposition of restrictions on operations, including costly new manufacturing requirements; refusal to clear or approve pending applications or premarket notifications; and import and export restrictions.

 

30
Table of Contents

 

Any of these sanctions could have a material adverse effect on our reputation, business, results of operations and financial condition.

 

Our future success depends on our ability to develop, receive regulatory clearance, approval for, and introduce new products that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance, de-novo authorization or PMA approval, or that a Notified Body will issue the relevant CE Certificates of Conformity, of/to our future products on a timely basis, if at all, and failure to obtain necessary clearances, approvals or certifications for our future products would adversely affect our ability to grow our business.

When a 510(k) notice, de novo request, or PMA is submitted for a new product or for a change to an existing product, there is no guarantee that it will receive FDA authorization. Failure to receive clearance or approval for our new products or indications for use would have an adverse effect on our ability to expand our business. If we do not receive clearance for any device enhancements, modifications or expanded indication, we will not be able to market the modified device in the U.S. or other foreign countries until such clearance, approval, authorization or certification is obtained.

 

Our products are subject to international regulatory processes and approval or certification requirements. If we do not obtain and maintain the necessary international regulatory approvals or certifications, we will not be able to sell our products in other countries.

To be able to sell our products in other countries, we or our distributor must obtain regulatory approvals or certifications and comply with the regulations of those countries, which may differ substantially from those of the U.S. These regulations, including the requirements for approvals or certifications and the time required for regulatory review, vary from country to country. Obtaining and maintaining foreign regulatory approvals or certifications is complex, and timing to obtain clearances or certifications in those countries varies; therefore, we cannot be certain that we will receive regulatory approvals or certifications in any other country in which we plan to market our products or obtain such approvals or certifications on a favorable schedule. The time required to obtain marketing authorization in other countries might differ from that required to obtain FDA authorization. If we or our distributor fail to obtain or maintain regulatory approval or certification in any other country in which we plan to market our products, our ability to generate revenue will be harmed. Regulatory authorization of a product in one country does not ensure regulatory authorization in another, but a failure or delay in obtaining marketing authorization in one country may negatively impact the regulatory process in others.

 

One of the most significant moving targets related to the regulatory landscape is in the EU; more specifically, the medical devices regulation has recently evolved. Regulation (EU) 2017/745 on medical devices (the MDR) became applicable in the European Union on May 26, 2021. The MDR, which replaced the MDD in May 2021 (subject to certain transitional provisions) imposes significant additional premarket and post-market certification requirements on medical devices marketed in the EU. European Economic Area (EEA) Member State legislation may also restrict or impose limitations on our ability to advertise our products directly to the general public. In addition, voluntary EU and national codes of conduct provide guidelines on the advertising and promotion of our products to the general public and may impose limitations on our promotional activities with healthcare providers harming our business, operating results and financial condition. If we are unable to obtain timely certifications for our products under the MDR, or experience difficulty scheduling with a Notified Body, our business prospects in the EU could be materially adversely affected, which could have a material adverse effect on our financial results.

 

Our products may cause or contribute to adverse events or be subject to failures or malfunctions that we are required to report to the FDA or comparable foreign regulatory authorities and can result in voluntary corrective actions or agency enforcement actions.

Under the FDA’s regulations, we are required to report to the FDA any incident in which our product may have caused or contributed to a death, serious health threat or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Repeated adverse events or product malfunctions may result in a voluntary or involuntary product recall, which could divert managerial and financial resources, impair our ability to manufacture our products in a cost-effective and timely manner, and have an adverse effect on our reputation, results of operations and financial condition.

 

31
Table of Contents

 

All manufacturers bringing medical devices to market in the EEA are legally bound to report any incident that directly or indirectly led, might have led or might lead to the death or serious deterioration in the state of health of a patient, user or other person, or to a serious public health threat, and which the manufacturer’s device is suspected to be a contributory cause, to the competent authority in whose jurisdiction the incident occurred. In such case, the manufacturer must file an initial report with the relevant competent authority, which would be followed by further evaluation or investigation of the incident and a final report indicating whether further action is required. Any corrective action, whether voluntary or involuntary, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.

 

A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us.

The FDA and similar foreign governmental authorities such as the competent authorities of the EEA countries have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture or in the event that a product poses an unacceptable risk to health. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. Any future recalls of any of our products would divert managerial and financial resources and could have an adverse effect on our reputation, results of operations and financial condition, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers’ demands. We may also be required to bear other costs or take other actions that may have a negative impact on our future sales and our ability to generate profits.

 

Our employees, consultants, third-party vendors and collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk of employee, consultant, third-party vendor or collaborator fraud or other misconduct. Misconduct by our employees, consultants, third-party vendors or collaborators could include, among other things, intentional failures to comply with FDA, EU or other regulations, provide accurate information to the FDA or other regulators, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business, financial condition and results of operations, and result in the imposition of significant fines or other sanctions against us.

 

Clinical trials may be necessary to support our future product submissions to the FDA or Notified Bodies and such trials are lengthy, regulatory nuanced, interactive and involve working with third parties. These and other factors may affect our ability to complete clinical trials and may lead to delays or failures that would affect our business and financial prospects.

Initiating and completing clinical trials necessary to support any future products, including those that may require PMAs, and additional safety and efficacy data beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time-consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials. The results of preclinical studies and clinical trials of our products and product candidates conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later clinical trials. Products in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and earlier clinical trials. Failure can occur at any stage of clinical testing. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and non-clinical testing in addition to those we have planned.

 

32
Table of Contents

 

U.S. legislative, FDA regulatory reforms or global regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.

Legislative changes could significantly alter the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products. In addition, FDA regulations and guidance could be revised or reinterpreted by the FDA in ways that could significantly affect our business and our products. For example, the FDA just finalized a rule to replace the QSR by adopting ISO 13485. Companies are required to come into compliance with this new rule by February 2026. This, and any new regulations or revisions, or reinterpretations of existing regulations, may impose additional costs or lengthen review times of future products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations will be changed, and what the impact of such changes, if any, may be. We anticipate that future regulatory requirements may focus on artificial intelligence or clinical decision support products, such as our ISU, which may subject our products to additional regulations.

 

Disruptions at the FDA and other government agencies or Notified Bodies caused by funding shortages or global health concerns could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent products from being developed, cleared, certified, approved, or commercialized in a timely manner or at all, which may adversely affect our business.

The delivery of healthcare by hospitals, health systems, and physicians depends on a number of government agencies and services. Further prolonged government shutdowns or restrictions could impact inspections, regulatory review and certifications, grants or approvals, or could cause other situations that could impede their ability to effectively deliver healthcare, including attempts to reduce payments and other reimbursements to hospitals by federal healthcare programs. These situations could adversely affect our customers’ ability to perform procedures with our devices and/or their decisions to purchase additional products from us. In addition, the review and clearance, approval, or certification of new products can be affected by a variety of factors globally, including government budget and funding levels, global health concerns, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In addition, government funding of other government agencies that fund research and development activities is subject to unpredictable and ever-changing political processes. Disruptions at the FDA and other agencies or Notified Bodies for any of these or other reasons may cause significant regulatory delays and, therefore, delay our efforts to seek clearances, approvals, or certifications from the FDA, foreign authorities, and notified bodies and adversely affect business travel and import and export of products, all of which could have a material adverse effect on our business, financial condition, results of operations, or cash flows. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.

 

We may be subject, directly or indirectly, to federal and state anti-kickback, fraud and abuse, false claims, privacy and security and physician payment transparency laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

Our business activities are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our operations (including our marketing, promotion, educational programs, pricing, and relationships with healthcare providers or other entities, among other things) and expose us to areas of risk are described in the “Business-Health Care Regulation” section of this Annual Report.

 

Additionally, some state privacy laws, may include private rights of action and can lead to class action litigation. Other laws, such as the FCA, can be enforced through qui tam actions brought by individuals on behalf of the government. Efforts to ensure that our business arrangements with third parties are compliant with applicable healthcare laws and regulations will involve the expenditure of appropriate, and possibly significant, resources. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of such laws that apply to us, we may be subject to significant penalties, including, without limitation, civil, criminal, and administrative penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs such as Medicare and Medicaid, and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.

 

33
Table of Contents

 

Failure of our customers to obtain adequate reimbursement for procedures using our current or new products could limit our ability to market those products and decrease our ability to generate revenue.

Our products are sold or leased to facilities, such as hospitals, and are not for use in the home such that they are not durable medical equipment. Devices such as ours used in surgical procedures are normally not paid separately by payers, but are reimbursed by third-party payors as part of the payment made for the performed surgical procedure when performed on an outpatient basis, or as part of the payment made for the inpatient stay when the patient undergoing the procedure is an inpatient of a hospital. As a result, these types of devices are subject to significant price competition that can place a small manufacturer at a competitive disadvantage as facilities attempt to negotiate lower prices for products such as the ones we develop and sell.

 

The pricing of products and procedures have come under increasing scrutiny as part of a global trend toward healthcare cost containment. Resulting changes in healthcare law and policy, including changes to Medicare, may impact our business in ways that we cannot currently predict, which could have a material adverse effect on our business and financial condition.

The United States is considering, or has already enacted or implemented, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably, described in a streamlined manner below and are described in the “Business-Health Care Regulation” section of this Annual Report Form 10-K. We expect to experience pricing pressures in connection with the sale of any products that we develop, and the procedures in which they are used, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative and regulatory measures.

 

The U.S. government and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls and restrictions on reimbursement. If healthcare policies or reforms intended to curb healthcare costs are adopted, the prices that we charge for our products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our product and any future products, if approved, may be negatively impacted.

 

We are subject to an evolving set of complex laws and regulations relating to privacy, data protection and information collection matters.

There are numerous state, federal, and foreign laws, regulations, decisions, and directives regarding privacy rights and the processing of information relating to identified or identifiable persons (“Personal Information”) and other categories of data, the scope of which is continually evolving and subject to differing interpretations. We also must comply with the policies, procedures and business requirements of our customers relating to data privacy and security, which can vary based upon the customer, the customer’s industry or location, and the product the customer selects, and which may be more restrictive than the privacy and security measures required by law or regulation. Around the world, the privacy and data protection legal landscape is rapidly changing, which may require us to adjust aspects of our operations or expend significant time and resources to come into compliance with new laws or regulatory obligations.

 

In particular, the European Economic Area (“EEA”), the United Kingdom and Switzerland have stringent privacy laws and regulations, which may impact our ability to profitably operate in certain European countries or to offer products that meet the needs of customers subject to EU privacy laws and regulations. For example, the General Data Protection Regulation (the “GDPR”) provides that EEA Member States may make their own further laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to use and share Personal Information or could cause our costs to increase and harm our business and financial condition. Non-compliance with the GDPR and the applicable EEA Member State laws may result in fines of up to 4% of the total worldwide annual turnover of the preceding financial year and other administrative penalties, as well as adverse publicity. It also confers the right for data subjects to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.

 

Global laws such as the GDPR are increasingly restricting and regulating the cross-border transfer of Personal Information, which may require us to implement additional and, potentially, costly safeguards to receive Personal Information from overseas customers or transfer such data, including to our vendors. l For example,, in June 2021, the European Commission adopted a new set of Standard Contractual Clauses (“SCCs”), aimed at enabling lawful transfers of Personal Information to non-adequate countries outside the EEA,and on July 10, 2023 the European Commission adopted its adequacy decision for the EU-US Data Privacy Framework, meaning that personal data can now flow freely from the EEA to US companies that participate in the Data Privacy Framework. A lack of valid transfer mechanisms for Personal Information subject to GDPR could increase exposure to enforcement actions as described above, and may affect our business operations and require commercial cost (including potentially limiting our ability to collaborate/work with certain third parties and/or requiring an increase in our data processing capabilities in the EU/U.K.). Further, the EEA/U.K., and Swiss data protection laws (including laws on data transfers as set out above) may also be updated/revised, accompanied by new guidance and/or judicial/regulatory interpretations, which could entail further impacts on our compliance efforts and increased cost.

 

34
Table of Contents

 

In addition to the laws specifically discussed, numerous other federal and state laws and regulations govern privacy and security, including state data breach notification laws, state health information and/or genetic privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act, new state consumer protection laws), many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Compliance with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future. Federal regulators, state attorneys general, and plaintiffs’ attorneys have been and will likely continue to be active in this space.

 

The costs of compliance with, and other burdens imposed by, our customers’ own requirements, the privacy and security laws and regulations, as well as self-regulatory standards that are applicable to us and our customers’ businesses may limit the use and adoption of our products, reduce overall demand and may incur substantial cost or require us to change our business practices. Non-compliance with our customers’ specific requirements may lead to termination of contracts with these customers or liabilities to the customers.

 

ITEM 1.B.         UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 1.C.         CYBERSECURITY

 

We are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store, process, and transmit sensitive corporate, personal, and other information, including intellectual property, proprietary business information, customer data including PII, and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity, and availability of such information.

 

Risk Management and Strategy

 

We maintain a cybersecurity risk management program designed to identify, assess, manage, mitigate, and respond to cybersecurity threats. This program is integrated within our enterprise risk management system and addresses the corporate information technology environment, the data we collect through our products and retain in the TRUST registry and Asensus Cloud, and customer information.

 

The underlying controls of the cybersecurity risk management program are based on recognized best practices and standards for cybersecurity and information technology, including the National Institute of Standards and Technology, or NIST, Cybersecurity Framework, or CSF, and the International Organization Standardization, or ISO, 27001 Information Security Management System Requirements. We have an annual assessment, performed by a third party, of the Company’s cyber risk management program against the NIST CSF.

 

We monitor our global cybersecurity environment constantly and coordinate the investigation and remediation of any alerts. We have developed a program for incident response, including drills, to prepare support teams in the event of a significant incident. We have engaged third-party consultants to assist us with designing controls and our cybersecurity risk management framework, and to perform penetration testing. We also retain third parties to assist us with the monitoring and detection of cybersecurity threats and responding to any cybersecurity threats or incidents.

 

With respect to third parties that manage or use our information technology or data, we obtain reports to assess the security of their systems and processes. We engage in ongoing monitoring of all third-party providers to ensure compliance with our cybersecurity standards.

 

We have not encountered cybersecurity threats or incidents that have had a material impact on our business. We face risks from cybersecurity threats that could have a material adverse effect on our business, financial condition, results of operations, cash flows or reputation. See “RISK FACTORS – Risks Related to the Operation of our Business – Significant disruptions of our information technology systems or data security incidents could harm our reputation, cause us to modify our business practices, and otherwise adversely affect our business and subject us to liability.”

 

35
Table of Contents

 

Our Manager of Data and Information Technology and Vice President of Customer Excellence, with consultation and collaboration with senior management lead our cybersecurity efforts. The cybersecurity team is responsible for assessing and managing our cyber risk management program, informing executive management regarding the prevention, detection, mitigation, and remediation of cybersecurity incidents and supervises such efforts. The cybersecurity team has experience selecting, deploying, and operating cybersecurity technologies, initiatives, and processes, and relies on threat intelligence as well as other information obtained from governmental, public or private sources, including external consultants engaged by us.

 

Governance

 

The Corporate Governance and Nominating Committee of the Board of Directors oversees our cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks. The cybersecurity team briefs the Corporate Governance and Nominating Committee on the effectiveness of our cyber risk management program on a regular basis. We believe locating this oversight function in the Corporate Governance and Nominating Committee is appropriate given that the reach of our cybersecurity risk monitoring programs are not limited to financial programs or functions. In addition, cybersecurity risks are reviewed by our Board of Directors, at least annually.

 

ITEM 2.          PROPERTIES

 

Effective March 10, 2021, our principal corporate office is located at 1 TW Alexander Drive, Suite 160, Durham, North Carolina. We lease this facility, which consists of 27,807 square feet, for a ten year and five month term ending in August 2031.

 

Our Italian research and development and demonstration facilities are located at Viale dell'Innovazione 3, 20126 Milan, Italy. We lease these facilities, which consist of 11,733 square feet, for a seven-year and three month term ending on December 31, 2028, under a lease that commenced on October 1, 2021.

 

Our Israeli research and development facilities are located at Ha Kadima 9, Fibernet Building, 4th Floor, Yokne'am Illit, Israel. We lease these facilities, which consist of 8,471 square feet, for a five-year term ending on June 30, 2026, under a lease that commenced on July 1, 2021.

 

Our Japanese office is located at Gotenyama Trust Tower 12F, 4 Chome-7-35 Kitashinagawa, Shinagawa City, Toyko 140-0001, Japan. We lease this facility, which consists of 911 square feet, for a three-year term ending on August 31, 2025, under a lease that commenced on September 1, 2022.

 

Our Swiss administrative office is located at Via Serafino Balestra 12, Lugano, Switzerland. We lease this facility, which consists of 3,208 square feet, for a five-year renewal term ending on May 31, 2025, under a lease that commenced on July 1, 2018.

 

ITEM 3.          LEGAL PROCEEDINGS

 

None.

 

ITEM 4.          MINE SAFETY DISCLOSURES

 

Not applicable.

 

36
Table of Contents

 

PART II

 

ITEM 5.          MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Market Information

 

Since April 2, 2014, our common stock has been listed on the NYSE American. Our trading symbol is “ASXC,” which changed from “TRXC” on March 5, 2021, when we changed our name from TransEnterix Surgical, Inc. to Asensus Surgical, Inc.

 

Holders

 

As of March 15, 2024, there were approximately 67 record holders of our common stock (counting all shares held in single nominee registration as one stockholder).

 

Dividends

 

We have never declared or paid any cash dividends on our common stock. We intend to retain earnings for use in the operation and expansion of our business.

 

Recent Sales of Unregistered Securities and Use of Proceeds.

 

None.

 

Issuer Purchases of Equity Securities

 

None.

 

ITEM 6.         RESERVED

 

37
Table of Contents

 

ITEM 7.         MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion of our financial condition and results of operations should be read in conjunction with our “Risk Factors” and our consolidated financial statements and the related notes to our consolidated financial statements included in this Annual Report. The following discussion contains forward-looking statements. See cautionary note regarding “Forward-Looking Statements” at the beginning of this Annual Report.

 

Overview

 

Asensus Surgical, Inc. (along with its subsidiaries, the “Company”) is a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era called “Performance-Guided Surgery™”, or PGS, by unlocking clinical intelligence for surgeons to enable consistently superior outcomes to patients. Built upon the foundations of digital laparoscopy and laparoscopic minimally invasive surgery (which remains the gold standard of surgery today), the Company is pioneering PGS to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence and deep learning capabilities throughout the surgical experience delivered via the Senhance® Surgical System, combined with the Intelligent Surgical Unit™ (ISU™) the Company intends to holistically address the current clinical, surgeon performance (fatigue and ergonomics) and economic shortcomings that impact surgical outcomes in a value-based healthcare environment. The Company is also working to incorporate all of this in its next generation robotic system we call the LUNA™ Surgical System.

 

The Senhance System is available for sale in Europe, the United States, Japan, Taiwan, Russia (to the extent lawful), and select other countries. The Company also enters into lease arrangements with certain qualified customers. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System during or at the end of the lease term ("Lease Buyout").

 

During 2023, the Company focused its research and development, or R&D, activities on advancing the LUNA Surgical System, its next generation robotic system, and the ongoing developments in the ISU and digital surgery offerings.

 

We believe the LUNA System we are developing will be a “best in class” robot that will use 3mm and 5mm instruments (as contrasted with most current systems available that use 8mm instruments), including TrueWrist™ fully wristed 5mm instruments. The LUNA System will also feature monopolar and bipolar electrosurgery capabilities, rapid instrument exchange with the Company’s proprietary instrument drive system, an open platform with a smaller footprint in the OR (as compared to the Senhance System), up to four-arm configuration with enhanced manipulation and dexterity, a surgeon console with 4K-3D capabilities and unconstrained handles with improved digital features while retaining haptic feedback.

 

In December 2023, the Company successfully hosted a surgeon lab to conduct an in vivo evaluation of the LUNA System’s hardware, software and instruments in porcine models. The lab allowed nine participating independent surgeons to evaluate the LUNA System’s functionality through thirteen surgical procedures across gynecology, urology and general surgery.

 

Also, to prepare for pilot manufacturing of the LUNA System, in 2023 the Company entered into an agreement with Flextronics Medical Sales and Marketing, Ltd. for the design and manufacturing support.

 

The LUNA System will continue the Company’s tradition of providing instruments that are reusable and can be re-sterilized and reprocessed, and, with improvements in manufacturing, are expected to have lower costs per procedure compared to competitive robotic options.

 

The Company’s 2023 development efforts for digital surgery with the ISU included:

 

 

●

initial development of an analytical tools feature set which includes intra-operative surgical planning capabilities that will help surgeons to map out and plan for specific surgical actions intraoperatively using the ISU’s Augmented Intelligence features;

 

 

●

creation of a safety tools feature set which includes real-time identification, notifications to the surgical team and marking of potential anatomical hazards (such as arteries or nerves) during the operation, and providing visual cues to help surgeons and surgical team protect these structures; and

 

 

●

advancing a training tools and education feature set which allows multiple team members to work together in real time by annotating, highlighting and drawing on a shared visual display of the surgical field to communicate and provide expert support.

 

38
Table of Contents

 

During 2023 the Company entered into an agreement with NVIDIA to allow the Company to enhance the capabilities of the ISU. Using a suite of NVIDIA tools, the Company will refine ISU features like digital tags, 3D measurement and enhanced intra-operative camera control. The Company believes that the collection and analysis of surgical data transformed into insights, and when shared with our physicians, will enhance surgical planning, surgeon education and training, and promote better patient outcomes.

 

During 2023, the Company announced a multi-year collaboration with Google Cloud to integrate Google Cloud’s secure cloud data architecture and machine learning technologies to further expand cloud capabilities. The Asensus Cloud is being designed to enable customer access to a web portal and/or mobile application that can provide data, analytics and/or insights to assist in pre-operative surgical planning, post-operative surgical analysis and best practices guidance.

 

The Company is also developing an ISU that can be utilized on a stand-alone basis apart from robotic surgery. The Company believes, given the market opportunity in traditional laparoscopic procedures, the data collected from such stand-alone units will add significantly to its cumulative digital database and help to accelerate development of innovative solutions across the surgical continuum to reduce complications and improve efficiency.

 

From our inception, we devoted a substantial percentage of our resources to research and development and start-up activities, consisting primarily of product design and development, clinical studies, manufacturing, recruiting qualified personnel and raising capital. We expect to continue to invest in research and development and market development as we implement our strategy.

 

Since inception, we have been unprofitable. As of December 31, 2023, we had an accumulated deficit of $939.4 million, and there is substantial doubt about our ability to continue as a going concern. We operate in one business segment.

 

As of the date of this filing, the Company continues to manage cash prudently and believes it has cash into early June 2024. We are actively pursuing a number of financing options, including collaborations, contractual relationships and strategic transactions. However, we are aware that such alternatives are and may continue to be time consuming and that successful consummation of a transaction or transactions is not assured. We may need to pursue alternative pathways, including, but not limited to, debt financing, sale of assets or equity-based financing. If none of these alternatives are consummated, we may need to suspend our product development programs, including the LUNA System, and take other actions to preserve cash. We may also need to seek bankruptcy if these measures are insufficient or unsuccessful.

 

Recent Financing Transactions

 

2022 At-the -Market Offering

 

On March 18, 2022, the Company entered a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”), with Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could sell from time to time, at its option, up to an aggregate of $100.0 million shares of the Company’s common stock. Sales during the year ended December 31, 2023, under the 2022 ATM Offering are as follows (in thousands except for share and per share amounts):

 

   

Year Ended

December 31, 2023

  

Total shares of common stock sold

     933,672  

Average price per share

   $ 0.43  

Gross proceeds

   $ 403  

Commission paid to Agents

   $ 12  

Net proceeds

   $ 391  

 

39
Table of Contents

 

2023 Registered Direct Offering

 

On July 27, 2023, the Company sold, in a registered direct offering, an aggregate of 23,809,524 shares of common stock, and warrants to purchase 23,809,524 of the Company’s common stock shares at an exercise price of $0.42 per common share (the "warrants”), for an aggregate purchase price of $10.0 million. Warrants are exercisable at any time on or after the date of issuance and will expire five years after the date of issuance. Based on the assessment of the warrants’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815, the Company determined that warrants do not meet the requirements for equity classification. Accordingly, warrants are recorded as a liability on the Company’s balance sheet at their initial estimated fair value on the date of issuance. For additional information regarding the fair value of warrant liability, please refer to Note 6 – Fair Value Measurements.

 

The Company allocated $7.1 million of the aggregate proceeds to warrants based on their estimated fair value, with the residual amount of $2.9 million allocated to common stock. Offering related issuance costs were approximately $1.0 million and consisted primarily of placement agent’s fees and legal expenses. Issuance costs were allocated to common stock and warrant liability proportionally to the allocation of the purchase price. For the year ended December 31, 2023, the Company recorded $0.7 million of other expense in the statement of operations related to issuance costs allocated to warrant liability.

 

Results of Operations for the Years Ended December 31, 2023 and 2022

 

Revenue

Both in 2023 and 2022, revenue consisted of the sales of Senhance Systems, ongoing System leasing payments, sales of instruments and accessories, and services revenue for Senhance Systems sold or placed in Europe, Asia, and the U.S. in prior periods.

 

Product revenue for the year ended December 31, 2023 increased to $5.5 million compared to $4.3 million for the year ended December 31, 2022. The $1.2 million increase was primarily the result of three Senhance System sales in the current year compared to two Senhance System sales in the prior year.

 

Service revenue for the year ended December 31, 2023 decreased to $1.1 million compared to $1.4 million for the year ended December 31, 2022. The $0.3 million decrease was due to a decrease in the number of Senhance Systems under service contracts.

 

Lease revenue for the year ended December 31, 2023 increased to $2.0 million compared to $1.4 million for the year ended December 31, 2022. The $0.6 million increase was the result of additional lease placements in 2023.

 

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor, and manufacturing overhead incurred internally to produce the products. Shipping and handling costs incurred by the Company are included in cost of revenue. The Company expenses all inventory excess and obsolescence provisions as cost of revenue. The manufacturing overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment depreciation and operations supervision and management.

 

Product cost for the year ended December 31, 2023 increased to $6.9 million as compared to $5.3 million for the year ended December 31, 2022. The $1.6 million increase consists of a $0.9 million increase in materials costs primarily related to three Senhance System sales in the current year compared to two Senhance System sales in the prior year, a $0.5 million increase in personnel costs, a $0.1 million increase in supplies and a $0.1 million increase in consulting expenses.

 

Service cost for the year ended December 31, 2023 increased to $2.3 million as compared to $2.2 million for the year ended December 31, 2022. The $0.1 million increase primarily relates to a $0.2 million increase in supplies and a $0.1 million increase in personnel costs partially offset by a $0.1 million decrease in material costs and a $0.1 million decrease in consulting expenses. Service cost typically exceeds revenue primarily due to part replacements under maintenance plans, which are expensed when incurred, along with salaries for the field service teams.

 

40
Table of Contents

 

Lease cost for the year ended December 31, 2023 increased to $4.0 million as compared to $3.4 million for the year ended December 31, 2022. The $0.6 million increase primarily relates to a $0.3 million increase in material costs as a result of a higher number of systems under lease and a $0.3 million increase in depreciation.

 

Research and Development

Research and development, or R&D, expenses primarily consist of engineering, product development and regulatory expenses incurred in the design, development, testing and enhancement of products and legal services associated with the Company’s efforts to obtain and maintain broad protection for the intellectual property related to its products. In future periods, the Company expects R&D expenses to continue to substantially increase as it invests in the LUNA™ Surgical System and digital laparoscopy platform. R&D expenses are expensed as incurred.

 

R&D expenses for the year ended December 31, 2023 increased 28% to $37.0 million as compared to $28.9 million for the year ended December 31, 2022 as the Company continues to invest in basic research, clinical studies, and product development in the areas of robotics and digital technologies supporting the LUNA System and its digital laparoscopy platform. All activities are in the effort of building the future for Performance-Guided Surgery. The $8.1 million increase primarily relates to a $2.9 million increase in personnel costs, a $2.3 million increase in contract engineering services, consulting, and other outside services, an $1.4 million increase in IT costs, an $1.3 million increase in supplies costs and a $0.2 million increase in testing and enhancement of our products.

 

Sales and Marketing

Sales and marketing expenses include costs for sales and marketing personnel, travel, demonstration product, market development, physician training, tradeshows, marketing clinical studies and consulting expenses.

 

Sales and marketing expenses for the year ended December 31, 2023 increased 14% to $16.9 million compared to $14.8 million for the year ended December 31, 2022. The $2.1 million increase was primarily related to a $2.7 million increase in personnel costs and a $0.2 million increase in supplies, partially offset by a $0.4 million decrease in consulting expenses, $0.2 million decrease in depreciation and $0.2 million decrease in other costs.

 

General and Administrative

General and administrative expenses consist of personnel costs related to the executive, finance, legal, IT and human resource functions, as well as professional service fees, legal fees, accounting fees, insurance costs, and general corporate expenses.

 

General and administrative expenses for the year ended December 31, 2023 decreased 5% to $19.2 million compared to $20.2 million for the year ended December 31, 2022. The $1.0 million decrease was primarily related to a $1.1 million reduction in IT costs, an $0.8 million decrease in personnel costs and an $0.2 million decrease in corporate insurance expenses, partially offset by an $0.8 million increase in amortization of the implementation costs of the enterprise resource planning system and software licensing fees, and a $0.3 million increase in consulting expenses.

 

Amortization of Intangible Assets

Amortization of intangible assets for the year ended December 31, 2023 decreased to $0.5 million compared to $7.7 million for the year ended December 31, 2022. The $7.2 million decrease is primarily related to the developed technologies intangibles that fully depreciated during the year ended December 31, 2022.

 

Change in Fair Value of Contingent Consideration

The change in fair value of contingent consideration in connection with the Senhance Acquisition was a $1.0 million increase for the year ended December 31, 2023 compared to a $1.1 million reduction for the year ended December 31, 2022. The increase was primarily due to changes in market assumptions and the discount rate utilized.

 

Property and Equipment Impairment

During the year ended December 31, 2023, the Company recorded an impairment charge of $0.4 million compared to $1.4 million for the year ended December 31, 2022, to reduce the carrying value of property and equipment to its estimated fair value. The change was primarily related to lower returned Senhance Systems under operating leases and a reduction in Senhance Systems under operating leases that are not expected to generate future cash flows sufficient to recover their net book value.

 

41
Table of Contents

 

Other Income, net

The Company recognized $1.3 million other income for the year ended December 31, 2023, compared to $0.4 million other income for the year ended December 31, 2022. The change was primarily related to a $1.2 million increase in the fair value of warrant liabilities recorded in the year ended December 31, 2023, a $0.4 million increase in interest income and a decrease in interest expense of $0.4 million, partially offset by a $1.1 million increase in other expenses as a result of $0.7 million in issuance costs allocated to warrant liability and $0.4 million in other expenses.

 

Income Tax Expense

The Company recognized $0.3 million income tax expense for the year ended December 31, 2023 and 2022.

 

Liquidity and Capital Resources

 

Going Concern

The Company’s consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $939.4 million and working capital of $23.8 million as of December 31, 2023. The Company has not established sufficient revenues to cover its operating costs and will require additional capital to continue as a going concern. As of December 31, 2023, the Company had cash, cash equivalents, short-term investments and long-term investments, excluding restricted cash, of approximately $21.1 million. The Company believes that existing cash, cash equivalents, short-term investments and long-term investments, together with cash received from product, service, and lease sales will be sufficient to meet its anticipated cash needs into early June 2024.

 

The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of its markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. If sufficient funds are not received on a timely basis, the Company would then need to purse a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: the historical lack of profitability; the Company’s ability to raise additional capital, the success of the Company’s LUNA System development plans and its ability to fund such plans, the Company’s ability to grow its placements and increase utilization of the Senhance System by customers; its ability to successfully develop, clinically test, obtain regulatory clearance for and commercialize its products and products in development; negative impacts on the Company's operations caused by the hostilities in the Middle East and other geopolitical factors; the success of its market development efforts; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic and digital surgical devices; and its ability to identify and pursue development of additional products.

 

Sources of Liquidity

Our principal sources of liquidity to date have been cash proceeds from issuance of common stock pursuant to public offerings, incurrence of debt and proceeds from sales and maturities of investments.

 

42
Table of Contents

 

Consolidated Cash Flow Data

 

   

Year Ended December 31,

  

 

  

2023

    

2022

  
    (in millions)  

Net cash (used in) provided by

                

Operating activities

   $ (63.6 )   $ (58.9 )

Investing activities

     64.5       47.5  

Financing activities

     9.6       (0.3 )

Effect of exchange rate changes on cash and cash equivalents

     0.8       (0.1 )

Net increase (decrease) in cash, cash equivalents and restricted cash

   $ 11.3     $ (11.8 )

 

Operating Activities

For the year ended December 31, 2023, cash used in operating activities of $63.6 million consisted of a net loss of $78.4 million, offset by changes in non-cash items of $11.7 million, and operating assets and liabilities of $3.1 million. The non-cash items primarily consisted of $7.9 million of stock-based compensation expense, $3.3 million of depreciation, $1.0 change in fair value of contingent consideration, $0.4 million of amortization of intangible assets, $0.4 million of property and equipment impairment, $0.3 million change in inventory reserves, and $0.1 million deferred tax expense partially offset by $1.2 million change in fair value of warrant liabilities and $0.5 million in accretion of discounts and premiums on investments. The increase in cash from changes in operating assets and liabilities primarily relates to a $1.2 million decrease in other current and long-term assets, $0.9 million increase in accrued employee compensation and benefits, $0.6 million increase in accounts payable, $0.6 million decrease in employee retention tax credit receivable, $0.4 million decrease in prepaid expenses, $0.4 million increase in accrued expenses, $0.2 million increase in deferred revenue, $0.1 million decrease in inventory net of transfers to property and equipment and $0.1 million decrease in operating lease liabilities, partially offset by $1.2 million increase in accounts receivable and $0.2 million increase in operating lease right-of-use assets.

 

For the year ended December 31, 2022, cash used in operating activities of $58.9 million consisted of a net loss of $75.6 million, changes in operating assets and liabilities of $4.7 million, offset by non-cash items of $21.4 million. The non-cash items primarily consisted of $8.4 million of stock-based compensation expense, $7.7 million of amortization of intangible assets, $3.4 million of depreciation, $1.4 million of property and equipment impairment, $0.6 million change in inventory reserves, $0.6 million net amortization of discounts and premiums on investments, $0.3 million deferred tax expense, and $0.1 million loss on disposal of property and equipment, offset by $1.1 million of change in fair value of contingent consideration. The decrease in cash from changes in operating assets and liabilities primarily relates to a $3.9 million decrease in accrued expenses, $2.3 million increase in inventory net of transfers to property and equipment, $2.1 million increase in other current and long-term assets, $1.5 million increase in accounts receivable and $0.4 million increase in prepaid expenses, offset by $4.5 million increase in accrued employee compensation and benefits, $0.8 million decrease in employee retention tax credit receivable, and $0.2 million decrease in operating lease right-of-use assets.

 

Investing Activities

For the year ended December 31, 2023, net cash provided by investing activities was $64.5 million. This amount consists of $77.3 million of proceeds from maturities of available-for-sale investments, offset by $12.3 million of purchases of available-for-sale investments and $0.5 million purchases of property and equipment.

 

For the year ended December 31, 2022, net cash provided by investing activities was $47.5 million. This amount consists of $82.7 million of proceeds from maturities of available-for-sale investments, offset by $33.9 million of purchases of available-for-sale investments and $1.3 million purchases of property and equipment.

 

Financing Activities

For the year ended December 31, 2023, net cash used in financing activities was $9.6 million, primarily related to proceeds from issuance of common stock and warrants of $10.1 million, offset by $0.5 million taxes paid for the net share settlement of vesting of restricted stock units.

 

For the year ended December 31, 2022, net cash used in financing activities was $0.3 million, primarily related to taxes paid for the net share settlement of vesting of restricted stock units.

 

43
Table of Contents

 

Operating Capital and Capital Expenditure Requirements

 

The Company intends to spend substantial amounts on research and development activities, including product development, regulatory and compliance, and clinical studies in support of the development of the LUNA System and its digital solutions platform. The Company intends to use financing opportunities strategically to continue to strengthen its financial position as it looks to extend its available cash for operations.

 

Cash and cash equivalents held by foreign subsidiaries totaled $4.9 million as of December 31, 2023, including restricted cash. The Company does not intend or currently foresee a need to repatriate cash and cash equivalents held by its foreign subsidiaries. If these funds are needed in the United States, the Company believes that the potential U.S. tax impact to repatriate these funds would be immaterial.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2023, the Company did not have any off-balance sheet arrangements.

 

Critical Accounting Estimates

 

The discussion and analysis of the Company’s financial condition and results of operations set forth above under the headings “Results of Operations” and “Liquidity and Capital Resources” have been prepared in accordance with U.S. GAAP and should be read in conjunction with the Company’s consolidated, audited financial statements and notes thereto appearing in Item 8 of this Annual Report. The preparation of these consolidated, audited financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its critical accounting policies and estimates, including identifiable intangible assets, contingent consideration, stock-based compensation, inventory, revenue recognition and income taxes. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. A more detailed discussion on the application of these and other accounting policies can be found in Note 2 in the Notes to the Consolidated Financial Statements which are included in Item 8 of this Annual Report. Actual results may differ from these estimates under different assumptions and conditions.

 

While all accounting policies impact the consolidated financial statements, certain policies may be viewed as critical. Critical accounting estimates are those that are both most important to the portrayal of financial condition and results of operations and that require management’s most subjective or complex judgments and estimates. Our management believes the policies that fall within this category are the policies on accounting for identifiable intangible assets, contingent consideration, stock-based compensation, inventory, revenue recognition and income taxes.

 

Stock-Based Compensation

 

The Company recognize as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. We use the Black-Scholes-Merton model to estimate the fair value of our stock-based payments. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted by us has been determined based upon the simplified method, because we do not have sufficient historical information regarding our options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and do not anticipate paying cash dividends on our shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimate forfeitures based on our historical experience and adjust the estimated forfeiture rate based upon actual experience.

 

Inventories

 

Inventory, which includes material, labor and overhead costs, is stated at the lower of cost, determined on a first-in, first-out basis, or net realizable value. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

 

44
Table of Contents

 

Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires us to estimate the portion of on-hand inventory that can be realized over the upcoming twelve months.

 

Revenue Recognition

 

The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on consideration specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements could include a five-year service period; the first year of service is generally free and included in the Senhance System sale arrangement with an option to purchase the remaining four years at a stated service price.

 

The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.

 

For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services; however due to limited sales to date, standalone selling prices may not be directly observable. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer, and market conditions. The Company regularly reviews estimated standalone selling prices and updates these estimates if necessary.

 

The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows: 

 

 

•

System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when we receive an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

 

 

•

Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.

 

 

•

Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

 

45
Table of Contents

 

The Company enters into lease arrangements for our Senhance Systems with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, we consider the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased Senhance System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2023, are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage and is presented as lease revenue. 

 

The Company invoices our customers based on the billing schedules in its sales arrangements. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period.

 

In connection with assets recognized from the costs to obtain a contract with a customer, the Company has determined that sales incentive programs for our sales team do not meet the requirements to be capitalized as we do not expect to generate future economic benefits from the related revenue from the initial sales transaction.

 

Income Taxes

 

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of our assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. Determination of the realizability of deferred tax assets requires management’s judgment. Valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the estimated amounts expected to be realized. 

 

U.S. shareholders are subject to tax on global intangible low-taxed income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to account for GILTI in the year the tax is incurred. As of December 31, 2023 and 2022, no GILTI tax has been recorded.

 

Recent Accounting Pronouncements

 

See “Note 2. Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data” of this Annual Report for a full description of recent accounting pronouncements including the respective expected dates of adoption and effects on our Consolidated Balance Sheets and Consolidated Statements of Operations and Comprehensive Loss.

 

46
Table of Contents

 

ITEM 7.A.         QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We are exposed to changes in foreign currency exchange rates. Operations outside of the United States accounted for 92% and 89% of revenue for years ended December 31, 2023 and 2022, respectively, and are concentrated principally in Europe. We translate the revenue and expenses of our foreign operations using average exchange rates prevailing during the period. The effect of a 10% change in the average foreign currency exchange rates among the U.S. dollar versus the Euro for the year ended December 31, 2023, would result in revenue changing by $0.8 million. This change would not be material to our cash flows and our results of operations.

 

47
Table of Contents

 

 

ITEM 8.         FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

Page

Report of Independent Registered Public Accounting Firm

(BDO USA, LLP; Raleigh, NC; PCAOB ID #243)

49
   

Consolidated Financial Statements:

  

Consolidated Balance Sheets as of December 31, 2023 and 2022

51

Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022

52

Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022

53

Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022

54

Notes to Consolidated Financial Statements

55

 

48
Table of Contents

 

Report of Independent Registered Public Accounting Firm

 

Shareholders and Board of Directors

Asensus Surgical, Inc.

Durham, North Carolina

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Asensus Surgical, Inc. (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern Uncertainty

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has not generated positive cash flows from operations which raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

49
Table of Contents

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

 

Valuation of Senhance Surgical System Inventories

 

As indicated in Note 2 to the consolidated financial statements, inventories are stated at the lower of cost or net realizable value. Management considers historical activity and forecast demand in relation to the inventories on hand, competitiveness of product offerings, and product life cycles when estimating net realizable value. As indicated in Note 7 to the consolidated financial statements, the Company recorded $11.2 million of inventories as of December 31, 2023, including $9.2 million of finished goods.

 

We identified management’s estimation of the net realizable value of Senhance Surgical Systems included in finished goods inventories as a critical audit matter. The Company’s limited sales history and development plans for new systems require management to make significant judgments and assumptions with respect to future demand and product life cycles for the Company’s Senhance Surgical Systems that affect the estimation of the net realizable value of Senhance Surgical System inventories. Auditing these elements involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters.

 

The primary procedures we performed to address this critical audit matter included:

 

 

●

Evaluating the reasonableness of management’s forecasted demand for Senhance Surgical Systems based on the results of historical sales and leasing efforts, expectations with respect to future sales and lease placements, and expectations with respect to Sehance product life cycles.
 

●

Testing management’s estimation of the net realizable value of completed Senhance Surgical Systems, included in finished goods inventories, by comparing the cost of finished Senhance Systems to recent system sales.

 

/s/ BDO USA, P.C.

 

We have served as the Company's auditor since 2013.

 

Raleigh, North Carolina

March 21, 2024

 

50
Table of Contents

 

 

Asensus Surgical, Inc.

Consolidated Balance Sheets

(in thousands, except share amounts)

 

   

December 31, 2023

    

December 31, 2022

  

Assets

                

Current Assets:

                

Cash and cash equivalents

   $ 17,096     $ 6,329  

Short-term investments, available-for-sale

     3,971       64,195  

Accounts receivable, net

     3,508       2,256  

Inventories

     7,172       8,284  

Prepaid expenses

     3,143       3,584  

Employee retention tax credit receivable

     -       554  

Other current assets

     1,496       1,671  

Total Current Assets

     36,386       86,873  
                 

Restricted cash

     1,642       1,141  

Long-term investments, available-for-sale

     -       3,865  

Inventories, net of current portion

     4,043       5,469  

Property and equipment, net

     8,959       9,542  

Intellectual property, net

     1,237       1,576  

Net deferred tax assets

     44       174  

Operating lease right-of-use assets, net

     5,165       4,950  

Other long-term assets

     1,610       2,463  

Total Assets

   $ 59,086     $ 116,053  
                 

Liabilities and Stockholders' Equity

                

Current Liabilities:

                

Accounts payable

   $ 4,145     $ 3,348  

Accrued employee compensation and benefits

     5,390       4,508  

Accrued expenses and other current liabilities

     1,636       1,293  

Operating lease liabilities - current portion

     1,036       800  

Deferred revenue

     421       465  

Total Current Liabilities

     12,628       10,414  
                 

Long-Term Liabilities:

                

Deferred revenue - less current portion

     290       -  

Contingent consideration

     2,220       1,256  

Warrant liabilities

     5,888       -  

Noncurrent operating lease liabilities

     4,646       4,738  

Total Liabilities

     25,672       16,408  
                 

Commitments and Contingencies (Note 16)

                
                 

Stockholders' Equity:

                

Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2023 and December 31, 2022; 264,921,526 and 236,895,440 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively

     265       237  

Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022

     -       -  

Additional paid-in capital

     973,129       962,731  

Accumulated deficit

     (939,368 )     (860,935 )

Accumulated other comprehensive loss

     (612 )     (2,388 )

Total Stockholders' Equity

     33,414       99,645  

Total Liabilities and Stockholders' Equity

   $ 59,086     $ 116,053  

 

See accompanying notes to consolidated financial statements.

 

51
Table of Contents

 

 

Asensus Surgical, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands except per share amounts)

 

   

Years Ended

 
   

December 31,

 
   

2023

    

2022

  

Revenue:

                

Product

   $ 5,519     $ 4,327  

Service

     1,052       1,373  

Lease

     2,006       1,387  

Total revenue

     8,577       7,087  
                 

Cost of revenue:

                

Product

     6,866       5,303  

Service

     2,293       2,174  

Lease

     3,996       3,395  

Total cost of revenue

     13,155       10,872  

Gross loss

     (4,578 )     (3,785 )
                 

Operating expenses:

                

Research and development

     37,023       28,942  

Sales and marketing

     16,921       14,756  

General and administrative

     19,155       20,172  

Amortization of intangible assets

     453       7,708  

Change in fair value of contingent consideration

     964       (1,115 )

Impairment of property and equipment

     374       1,431  

Total operating expenses

     74,890       71,894  

Operating loss

     (79,468 )     (75,679 )
                 

Other income (expense), net

                

Change in fair value of warrant liabilities

     1,232       -  

Interest income

     1,553       1,141  

Interest expense

     -       (410 )

Other expense, net

     (1,436 )     (295 )

Total other income (expense), net

     1,349       436  
                 

Loss before income taxes

     (78,119 )     (75,243 )

Income tax expense

     (314 )     (318 )

Net loss

     (78,433 )     (75,561 )
                 

Net loss per common share attributable to common stockholders - basic and diluted

   $ (0.31 )   $ (0.32 )

Weighted average number of shares used in computing net loss per common share - basic and diluted

     249,685       236,492  
                 

Comprehensive loss:

                

Net loss

     (78,433 )     (75,561 )

Foreign currency translation gain (loss)

     1,280       (1,867 )

Unrealized gain (loss) on available-for-sale investments

     496       (257 )

Comprehensive loss

   $ (76,657 )   $ (77,685 )

 

See accompanying notes to consolidated financial statements.

 

52
Table of Contents

 

 

Asensus Surgical, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

(in thousands)

 

   

Common Stock

    

Treasury Stock

                                  
   

Shares

    

Amount

    

Shares

    

Amount

    

Additional Paid-in

Capital

    

Accumulated Deficit

    

Accumulated Other Comprehensive

Loss

    

Total Stockholders'

Equity

  

Balance, December 31, 2021

     235,219     $ 235       -     $ -     $ 954,649     $ (785,374 )   $ (264 )   $ 169,246  

Stock-based compensation

     -       -       -       -       8,416       -       -       8,416  

Exercise of stock options

     43       -       -       -       18       -       -       18  

Issuance of common stock related to vesting of restricted stock units

     1,633       2       -       -       -       -       -       2  

Shares withheld related to net share settlement of equity awards

     -       -       443       -       (352 )     -       -       (352 )

Cancellation of treasury stock

     -       -       (443 )     -       -       -       -       -  

Other comprehensive loss

     -       -       -       -       -       -       (2,124 )     (2,124 )

Net loss

     -       -       -       -       -       (75,561 )     -       (75,561 )

Balance, December 31, 2022

     236,895     $ 237       -     $ -     $ 962,731     $ (860,935 )   $ (2,388 )   $ 99,645  

Stock-based compensation

     -       -       -       -       7,918       -       -       7,918  

Exercise of stock options

     13       -       -       -       5       -       -       5  

Issuance of common stock related to vesting of restricted stock units

     3,270       2       -       -       -       -       -       2  

Shares withheld related to net share settlement of equity awards

     -       -       657       1       (497 )     -       -       (496 )

Cancellation of treasury stock

     -       -       (657 )     (1 )     -       -       -       (1 )

Issuance of common stock, net of issuance costs

     24,744       26       -       -       2,972       -       -       2,998  

Other comprehensive income

     -       -       -       -       -       -       1,776       1,776  

Net loss

     -       -       -       -       -       (78,433 )     -       (78,433 )

Balance, December 31, 2023

     264,922     $ 265       -     $ -     $ 973,129     $ (939,368 )   $ (612 )   $ 33,414  

 

See accompanying notes to consolidated financial statements.

 

53
Table of Contents

 

 

Asensus Surgical, Inc.

Consolidated Statements of Cash Flows

(in thousands)

 

   

Years Ended December 31,

  
   

2023

    

2022

  
Operating Activities:                

Net loss

   $ (78,433 )   $ (75,561 )

Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:

                

Depreciation

     3,276       3,368  

Amortization of intangible assets

     453       7,708  

(Accretion) amortization of discounts and premiums on investments, net

     (482 )     565  

Stock-based compensation

     7,918       8,416  

Deferred tax expense

     132       318  

Change in inventory reserves

     324       620  

Bad debt expense

     -       9  

Property and equipment impairment

     374       1,431  

Loss on disposal of property and equipment

     -       122  

Change in fair value of warrant liabilities

     (1,232 )     -  

Change in fair value of contingent consideration

     964       (1,115 )
                 

Changes in operating assets and liabilities:

                

Accounts receivable

     (1,178 )     (1,528 )

Inventories

     129       (2,302 )

Operating lease right-of-use assets

     (206 )     232  

Prepaid expenses

     424       (450 )

Employee retention tax credit receivable

     554       757  

Other current and long-term assets

     1,173       (2,101 )

Accounts payable

     574       35  

Accrued employee compensation and benefits

     881       4,523  

Accrued expenses

     365       (3,955 )

Deferred revenue

     233       (55 )

Operating lease liabilities

     130       26  

Net cash and cash equivalents used in operating activities

     (63,627 )     (58,937 )
                 

Investing Activities:

                

Purchase of available-for-sale investments

     (12,268 )     (33,886 )

Proceeds from maturities of available-for-sale investments

     77,335       82,702  

Purchase of property and equipment

     (561 )     (1,279 )

Net cash and cash equivalents provided by investing activities

     64,506       47,537  
                 

Financing Activities:

                

Proceeds from issuance of common stock and warrants, net of issuance costs

     10,118       -  

Taxes paid related to net share settlement of vesting of restricted stock units

     (497 )     (350 )

Proceeds from exercise of stock options and warrants

     5       18  

Net cash and cash equivalents provided by (used in) financing activities

     9,626       (332 )
                 

Effect of exchange rate changes on cash and cash equivalents

     763       (81 )

Net increase (decrease) in cash, cash equivalents and restricted cash

     11,268       (11,813 )

Cash, cash equivalents and restricted cash, beginning of period

     7,470       19,283  

Cash, cash equivalents and restricted cash, end of period

   $ 18,738     $ 7,470  
                 

Supplemental Disclosure for Cash Flow Information

                

Cash paid for leases

   $ 1,475     $ 984  

Cash paid for taxes

   $ 352     $ 165  
                 

Supplemental Schedule of Non-cash Investing and Financing Activities:

                

Transfer of inventories to property and equipment

   $ 2,941     $ 2,693  

Lease liabilities arising from obtaining right-of-use assets

   $ 1,143     $ 577  

 

See accompanying notes to consolidated financial statements.

 

54
Table of Contents

 

Asensus Surgical, Inc.

Notes to Consolidated Financial Statements

 

 

1.

Description of the Business

 

Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) (the "Company") is a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The Company is focused on the market development for and commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3mm micro-laparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.

 

 

2.

Summary of Significant Accounting Policies

 

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.

 

Going Concern

The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $939.4 million and working capital of $23.8 million as of December 31, 2023. The Company has not established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

 

The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

Principles of Consolidation and Foreign Currency Considerations

The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.

 

The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity which was $0.6 million and $1.9 million as of December 31, 2023 and 2022, respectively.

 

The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 were not material.

 
55
Table of Contents

 

Risk and Uncertainties

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: the historical lack of profitability; the Company’s ability to raise additional capital; its ability to successfully develop, clinically test, obtain regulatory clearance for and commercialize its products and products in development; negative impacts on the Company's operations caused by the hostilities in the Middle East and other geopolitical factors; the success of its market development efforts; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic and digital surgical devices; and its ability to identify and pursue development of additional products.

 

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term investments, changes in inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.

 

Cash and Cash Equivalents, Restricted Cash, and Investments

The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents.

 

Restricted cash as of December 31, 2023 and 2022 includes $1.6 million and $1.1 million, respectively, in cash accounts held as collateral primarily under the terms of office operating leases, credit cards, and automobile leases, and a guarantee required by the government of a country for a 2019 VAT refund.

 

The Company’s investments as of December 31, 2023 consisted of corporate bonds that were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion are included in interest expense, net. There were no gross realized gains or loss for the years ended December 31, 2023 and 2022.

 

Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. 

 

There have been no credit losses for the years ended December 31, 2023 and 2022, and no allowance for credit losses as of December 31, 2023 and 2022. Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.

 
56
Table of Contents

 

Fair Value Measurements

The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level 3 inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.

 

Concentrations and Credit Risk

The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.

 

The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company had one customer that accounted for 83% and 69% of the Company’s net accounts receivable as of December 31, 2023 and December 31, 2022, respectively. The Company had two customers that accounted for 33% and 19% of revenue in 2023, and one customer who accounted for 47% of revenue in 2022, respectively.

 

Accounts Receivable

Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current and future economic conditions that may affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million as of December 31, 2023 and 2022.

 

Inventories

Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

 

Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve months.

 

Definite-Lived Intangible Assets - Intellectual Property

Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&D”) assets related to (i) the Senhance System acquired in 2015 and reclassified in 2017 and (ii) a 2018 acquisition and reclassified in 2020. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 7 years.

 

57
Table of Contents

 

The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. No impairment of intellectual property was identified during the years ended December 31, 2023 and 2022.

 

Property and Equipment

Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

 

   

Years

  

Operating lease assets – Senhance System leasing

     5    

Machinery, manufacturing, and demonstration equipment

   3 - 5  

Computer equipment

     3    

Furniture

     5    

Leasehold improvements

  

Lesser of lease term or 3-10

  

 

The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.

 

During the years ended December 31, 2023 and 2022, the Company recorded a non-cash asset impairment charge of $0.4 million and $1.4 million, respectively, to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss.

 

 

Operating Leases

The Company has operating leases for its corporate office buildings, vehicles, and machinery and equipment. At inception, the Company determines whether an agreement represents a lease, and at commencement, it evaluates each lease agreement to determine whether the lease constitutes an operating or financing lease.

 

The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do not provide a significant economic incentive and are therefore excluded from the lease term. While its operating leases range from one year to ten years, some may include options to extend the lease generally between one year and six years, and some may include options to terminate the leases within one year.

 

The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.

 
58
Table of Contents

 

Implementation Costs in a Cloud Computing Arrangement

The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.

 

Employee Retention Tax Credit Receivable

The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended December 31, 2021, the Company submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received $0.7 million of the ERTC refund during the year ended December 31, 2022 and received the remaining $0.6 million during the year ended December 31, 2023.

 

Contingent Consideration

Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 

On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in 2016, as of December 31, 2023, the Company has accrued $2.2 million of estimated fair value of remaining contingent consideration related to a milestone of €15.0 million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least €25.0 million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In 2022, Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.

 

Warrant Liabilities

The Company’s warrants (see “Note 14 – Equity Offerings,”) are measured at fair value using a Black-Scholes-Merton model option-pricing model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected stock price volatility, the expected dividend yield which is assumed to be zero since The Company has not paid and does not anticipate paying cash dividends on its shares of common stock and the risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the term of the warrant (see “Note 6 – Fair Value,”). The warrant liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on considerations specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements could include a five-year service period; the first year of service is generally free and included in the Senhance System sale arrangement with an option to purchase the remaining four years at a stated service price.

 

59
Table of Contents

 

The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.

 

For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services.

 

The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:

 

 

●

System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

 

 

●

Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.

 

 

●

Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

 

The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements and are included in accounts receivable.

 

In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not meet the requirements to be capitalized as the Company does not expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.

 

Senhance System Leasing

The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended December 31, 2023 and 2022, variable lease revenue related to usage-based arrangements was not material.  

 

60
Table of Contents

 

In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2023 are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of December 31, 2023, future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next one to two years.

 

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.

 

Research and Development Costs

Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.

 

Stock-Based Compensation

The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjusts the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.

 

The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note 13 – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.

 

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.

 

The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not sustain the position following audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.

 

61
Table of Contents

 

Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may be subject to examination by authorities for all previously filed income tax returns.

 

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

 

Segments

The Company operates in one business segment—the research, development and sale of medical device robotics to improve MIS. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

 

Impact of Recently Issued Accounting Standards

In November 2023, the FASB issued Accounting Standards Update, or ASU, No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU looks to provide improvements to the segment disclosure by providing users with more decision-useful information about reportable segments in a public entity. The main provisions require a company to disclose, on an annual and interim basis, significant expenses included within each reported measure of segment profit or loss, an amount for other segment items by reportable segment and a description of its composition. It also requires all annual disclosures about a reportable segments’ profit or loss and assets to be reported on an interim basis.

 

The ASU is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.

 

In December 2023, the FASB issues ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU looks to enhance the transparency and decision usefulness of income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The main provisions to the rate reconciliation disclosure require public entities on an annual basis to: disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The main provisions to the income taxes paid disclosure require that all entities disclose on an annual basis: the amount of income taxes paid disaggregated by federal, state and foreign taxes and the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid meets a quantitative threshold. This ASU also requires all entities to disclose: income (loss) from continuing operations before income tax expense (benefit) disaggregated between domestic and foreign and income tax expense (benefit) from continuing operations disaggregated by federal, state and foreign.

 

This ASU is to be applied on a prospective basis with an effective date for all public entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.

 

 

3.

Revenue Recognition

 

The following table presents revenue disaggregated by type and geography:

 

   

Years Ended December 31,

 
   

2023

    

2022

  
    (in thousands)  

U.S.

                

Instruments and accessories

   $ 205     $ 211  

Services

     294       300  

Leases

     196       256  

Total U.S. revenue

     695       767  
                 

Outside of U.S. ("OUS")

                

Systems

     3,645       2,551  

Instruments and accessories

     1,669       1,565  

Services

     758       1,073  

Leases

     1,810       1,131  

Total OUS revenue

     7,882       6,320  
                 

Total

                

Systems

     3,645       2,551  

Instruments and accessories

     1,874       1,776  

Services

     1,052       1,373  

Leases

     2,006       1,387  

Total revenue

   $ 8,577     $ 7,087  

 

Remaining Performance Obligations

The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to service obligations performed under the Company's system sales contracts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations as of December 31, 2023 was $0.9 million, which is expected to be recognized over one to four years. 

 

62
Table of Contents

 

Contract Assets and Liabilities

Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2023 and 2022 was $0.5 million, which was included in the deferred revenue balance of $0.5 million as of December 31, 2022 and 2021.

 

The following information summarizes the Company’s contract assets and liabilities:

 

   

December 31, 2023

    

December 31, 2022

  
   

(in thousands)

  

Contract assets

   $ 95     $ 116  

Deferred revenue

   $ 711     $ 465  

 
 

4.

Cash, Cash Equivalents, and Restricted Cash

 

Cash, cash equivalents and restricted cash consist of the following:

 

   

December 31,

    

December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Cash

   $ 4,588     $ 3,473  

Money market

     5,521       2,856  

U.S. treasuries

     6,987       -  

Total cash and cash equivalents

   $ 17,096     $ 6,329  

Restricted cash

     1,642       1,141  

Total

   $ 18,738     $ 7,470  

 

Restricted cash at December 31, 2023 and 2022 includes $1.6 million and $1.1 million, respectively, in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, automobile leases, and a guarantee required by the government of a country for a 2019 VAT refund.

 

 

5.

Investments, available-for-sale

 

The aggregate fair values of investment securities along with cumulative unrealized gains and losses determined on an individual investment security basis and included in other comprehensive loss are as follows:

 

   

December 31, 2023

  
   

Amortized

Cost

    

Unrealized

Gain

    

Unrealized

Loss

    

Fair

Value

    

Short-term

investments

  
                (in thousands)              

Corporate bonds

   $ 3,981     $ -     $ (10 )   $ 3,971     $ 3,971  

Total investments

   $ 3,981     $ -     $ (10 )   $ 3,971     $ 3,971  

 

   

December 31, 2022

  
   

Amortized

Cost

    

Unrealized

Gain

    

Unrealized

Loss

    

Fair

Value

    

Short-term

investments

    

Long-term

investments

  
                (in thousands)              

Commercial paper

   $ 12,364     $ -     $ (49 )   $ 12,315     $ 12,315     $ -  

Corporate bonds

     55,201       -       (447 )     54,754       50,889       3,865  

U.S. government agencies

     999       -       (8 )     991       991       -  

Total investments

   $ 68,564     $ -     $ (504 )   $ 68,060     $ 64,195     $ 3,865  

 

The following table summarizes the contractual maturities of the Company’s available-for-sale investments:

 

   

December 31, 2023

  
   

Amortized

Cost

    

Fair Value

  
    (in thousands)  

Mature in less than one year

   $ 3,981     $ 3,971  

Total

   $ 3,981     $ 3,971  

 

Actual maturities may differ from contractual maturities because certain borrowers have the right to call or prepay certain obligations. There were no sales of investments for the years ended December 31, 2023 or 2022, respectively. There were no realized gains or losses for the years ended December 31, 2023 and 2022 respectively.

 

63
Table of Contents

 
 

6.

Fair Value

 

The following are categories of assets and liabilities measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

 

 

   

December 31, 2023

  

 

  

Quoted Prices
in Active

Markets for
Identical Assets
(Level 1)

    

Significant
Other
Observable
Inputs (Level 2)

    

Significant
Unobservable
Inputs (Level 3)

    

Total

  
Description         (in thousands)        

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 17,096     $ -     $ -     $ 17,096  

Restricted cash

     1,642       -       -       1,642  

Short-term investments

     -       3,971       -       3,971  

Total assets measured at fair value

   $ 18,738     $ 3,971     $ -     $ 22,709  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 2,220     $ 2,220  
Warrant Liabilities     -       -       5,888       5,888  

Total liabilities measured at fair value

   $ -     $ -     $ 8,108     $ 8,108  

 

   

December 31, 2022

  

 

  

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

    

Significant

Other

Observable

Inputs (Level 2)

    

Significant Unobservable

Inputs (Level 3)

    

Total

  
Description         (in thousands)        

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 6,329     $ -     $ -     $ 6,329  

Restricted cash

     1,141       -       -       1,141  

Short-term investments

     -       64,195       -       64,195  

Long-term investments

     -       3,865       -       3,865  

Total assets measured at fair value

   $ 7,470     $ 68,060     $ -     $ 75,530  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 1,256     $ 1,256  

Total liabilities measured at fair value

   $ -     $ -     $ 1,256     $ 1,256  

 

(1) Includes investments that are readily convertible to cash with original maturities of 90 days or less.

 

The carrying values of accounts receivable, prepaid expenses, employee retention tax credit receivables, other current assets, accounts payable, accrued employee compensation and benefits, accrued expenses, deferred revenue, and other current liabilities as of December 31, 2023 and December 31, 2022, approximate to their fair values due to the short-term nature of these items and are considered to be Level 1.

 

The Company’s financial liabilities consisted of contingent consideration payable to Three Heads Investment S.r.l., related to the Company’s 2015 acquisition of the Senhance Surgical System from an assignor to Three Heads Investment S.r.l. (the “Senhance Acquisition”). Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statements of operations and comprehensive loss.

 

64
Table of Contents

 

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements for contingent consideration utilizing a Monte-Carlo simulation as of December 31, 2023 and December 31, 2022:

 

 

 

Valuation
Methodology
 

  

Significant
Unobservable

Input

  

December 31,
2023
 

    

December 31,
2022
 

  
                       

Contingent consideration

Probability
weighted
income
approach

  

Milestone dates

  

2032

    

2032

  
     

Discount rate

     10.0 %     16.5 %
     

Revenue volatility

     35.0 %     45.0 %
     

EUR-to-USD exchange rate

     1.10       1.07  

 

The following table presents the long-term portion of the contingent consideration for the year ended December 31, 2023 and summarizes the change in fair value, as determined by Level 3 inputs for the contingent consideration for the year ended December 31, 2023 and 2022:

 

 

 

  

Fair Value

  
   

(in thousands)

  

Balance at December 31, 2021

   $ 2,371  

Change in fair value

     (1,115 )

Balance at December 31, 2022

   $ 1,256  

Change in fair value

     964  

Balance at December 31, 2023

   $ 2,220  

 

Warrant Liabilities

 

During 2023, the Company recorded warrant liabilities related to common stock warrants issued in the registered direct offering in July 2023 (for additional information about the offering, please refer to Note 14 -Equity Offerings).

 

Warrant liabilities were recorded at their initial estimated fair value. Adjustments associated with changes in fair value of the warrant liabilities are included in the Company’s consolidated statements of operations and comprehensive loss. The following table summarizes changes in estimated fair value of the warrant liabilities for the warrants issued in July 2023 as of December 31, 2023:

 

 

 

  

Fair Value

  
    (in thousands)  

Balance at December 31, 2022

   $ -  

Issuance of warrants

     7,120  

Change in fair value

     (1,232 )

Balance at December 31, 2023

   $ 5,888  

 

65
Table of Contents

 

The fair value of the warrant liabilities were estimated using the Black-Scholes option pricing model, which is based on unobservable inputs and is designated as Level 3 in the fair value hierarchy. The following table summarizes the assumptions used in determining fair value of warrant liabilities:

 

   

As of December 31,

2023

  

Expected dividend yield

     0 %

Expected volatility

     117 %

Risk-free interest rate

     3.8 %

Expected life (in years)

     4.6  

 
 

7.

Inventories

 

The components of inventories are as follows:

 

   

December 31, 2023

    

December 31, 2022

  
   

(in thousands)

  

Finished goods

   $ 9,200     $ 11,208  

Raw materials

     2,015       2,545  

Total inventories

   $ 11,215     $ 13,753  
                 

Current Portion

   $ 7,172     $ 8,284  

Long-term portion

     4,043       5,469  

Total inventories

   $ 11,215     $ 13,753  

 
 

8.         Property and Equipment

 

Property and equipment consisted of the following:

 

   

December 31,

    

December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Machinery, manufacturing, and demonstration equipment

   $ 9,089     $ 8,450  

Operating lease assets - Senhance System leasing

     12,848       10,251  

Computer equipment

     603       600  

Furniture

     715       831  

Leasehold improvements

     1,721       1,654  

Construction in process

     70       436  

Total property and equipment

     25,046       22,222  

Accumulated depreciation and amortization

     (16,087

)

     (12,680

)

Property and equipment, net

   $ 8,959     $ 9,542  

 

Depreciation expense was approximately $3.3 million and $3.4 million for the years ended December 31, 2023 and 2022, respectively.

 

66
Table of Contents

 
 

9.         Intellectual Property

 

The components of gross intellectual property, accumulated amortization, and net intellectual property are as follows:

 

   

December 31, 2023

  
   

Gross Carrying Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net Carrying

Amount

  
          (in thousands)        

Developed technology

   $ 68,838     $ (66,902 )   $ (837 )   $ 1,099  

Technology and patents purchased

     400       (279 )     17       138  

Total intellectual property

   $ 69,238     $ (67,181 )   $ (820 )   $ 1,237  

 

   

December 31, 2022

  
   

Gross Carrying Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net Carrying

Amount

  
          (in thousands)        

Developed technology

   $ 68,838     $ (66,562 )   $ (874 )   $ 1,402  

Technology and patents purchased

     400       (239 )     13       174  

Total intellectual property

   $ 69,238     $ (66,801 )   $ (861 )   $ 1,576  

 

The weighted average remaining useful life of the developed technology and technology and patents purchased was 3.2 years and 3.3 years, respectively, as of December 31, 2023. The weighted average remaining useful life of the developed technology and technology and patents purchased was 4.2 years and 4.3 years, respectively as of December 31, 2022.

 

The estimated future amortization expense of intellectual property as of December 31, 2023 is as follows (in thousands):

 

   

Year Ending
December 31, 2023

  

2024

   $ 388  

2025

     388  

2026

     389  

2027

     72  

Total

   $ 1,237  

 
 

10.         Leases

 

Lessee Information

Components of operating lease expense are primarily recorded in general and administrative on the consolidated statements of operations and comprehensive loss were as follows:

 

   

Years Ended December 31,

  
   

2023

      

2022

  
     

(in thousands)

  

Long-term operating

   $ 1,888       $ 1,557  

 

67
Table of Contents

 

Supplemental balance sheet information related to operating leases was as follows:

 

   

Years Ended December 31,

  
   

2023

    

2022

  

 

  

 

    

 

  

Weighted-average remaining lease term (in years)

     5.7         6.8    

Weighted-average discount rate

     9.2%         8.4%    

Incremental borrowing rate

   7.1% - 23.0%     6.1% - 14.5%  

 

Maturities of finance and operating lease obligations as of December 31, 2023 were as follows (in thousands):

 

Fiscal Year

        

2024

   $ 1,491  

2025

     1,377  

2026

     1,160  

2027

     904  

2028

     834  

Thereafter

     1,406  

Total minimum lease payments

   $ 7,172  

Less: Amount of lease payments representing interest

     (1,490 )

Present value of future minimum lease payments

   $ 5,682  

 
 

11.         Accrued Expenses and Other Current Liabilities

 

The following table presents the components of accrued expenses and other current liabilities:

 

   

Years Ended December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Consulting and other vendors

   $ 461     $ 155  

Royalties

     9       24  

Legal and professional fees

     411       275  

Taxes and other assessments

     755       839  

Total

   $ 1,636     $ 1,293  

 

68
Table of Contents

 
 

12.         Income Taxes

 

The components for the income tax expense are as follows for the years ended December 31 (in thousands):

 

   

2023

    

2022

  
    (in thousands)  

Current income taxes

                

Federal

   $ -     $ -  

State

     -       -  

Foreign

     196       239  

Deferred income taxes

     -          

Federal

     -       -  

State

     -       -  

Foreign

     118       79  

Total income tax expense

   $ 314     $ 318  

 

The United States and foreign components of loss from operations before taxes are as follows for the years ended December 31 (in thousands):

 

   

2023

    

2022

  
    (in thousands)  

United States

   $ (53,226 )   $ (44,802 )

Foreign

     (24,893 )     (30,441 )

Total loss from operations before taxes

   $ (78,119 )   $ (75,243 )

 

Significant components of the Company’s deferred tax assets consist of the following at December 31 (in thousands):

 

   

2023

    

2022

  
    (in thousands)  

Deferred Tax assets:

                

Stock-based compensation

   $ 3,119     $ 2,840  

Accrued expenses and other

     2,666       2,538  

Research credit carryforward

     2,859       1,341  

Fixed assets

     319       162  

Capitalized start-up costs and other intangibles

     644       921  

Capitalized research costs

     9,064       4,382  

Net operating loss carryforwards

     93,332       83,908  
      112,003       96,092  

Valuation allowance

     (110,511 )     (94,704 )

Net deferred tax asset

     1,492       1,388  

Deferred tax liabilities

                

Fixed assets and other

     (1,448 )     (1,214 )

Net deferred tax liability

     (1,448 )     (1,214 )

Net deferred tax asset

   $ 44     $ 174  

 

At December 31, 2023 and 2022, the Company has provided a full valuation allowance against its net deferred assets in the U.S., Canada, Italy, Luxembourg, Switzerland, and Taiwan tax jurisdictions, since realization of these benefits is not more likely than not. The valuation allowance increased approximately $15.8 million from the prior year. At December 31, 2023, the Company had U.S. federal net operating loss carryforwards of $446.7 million, of which $253 million are expected to expire unused under the limitations imposed by Internal Revenue Code Section 382. Of the total amount of Federal NOLs (notwithstanding the 382 limitation), $254.5 million begin to expire in 2027, while the remaining $192.2 million carry forward indefinitely. At December 31, 2023, the Company had U.S. state net operating loss carryforwards of $336.3 million, of which $199 million are expected to expire unused under the state tax law equivalents of Internal Revenue Code Section 382. Of this amount (notwithstanding the 382 limitations), $323.0 million of state NOLs begin to expire in 2024, while the remaining $13.3 million carry forward indefinitely. At December 31, 2023, the Company had federal research credit carryforwards in the amount of $11.7 million. These carryforwards begin to expire in 2027. However, under the limitations of Internal Revenue Code Section 383, it is expected that $8.8 million of this carryforward will expire unused. The utilization of the federal net operating loss carryforwards and credit carryforwards will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the carryforwards.

 

At December 31, 2023, the Company had foreign operating loss carryforwards in Italy of approximately $25.0 million, which can be carried forward indefinitely; foreign operating loss carryforwards in Luxembourg of approximately $95.6 million, which will begin to expire in 2034; foreign operating loss carryforwards in Switzerland of approximately $135.3 million, which begin to expire in 2024, and foreign operating loss carryforwards in Canada of approximately $1.4 million, which begin to expire in 2040.

 

The Company has evaluated its tax positions to consider whether it has any unrecognized tax benefits. As of December 31, 2023, the Company had gross unrecognized tax benefits of approximately $0.7 million. Of the total, none would reduce the Company’s effective tax rate if recognized. The Company does not anticipate a significant change in total unrecognized tax benefits or the Company’s effective tax rate due to the settlement of audits or the expiration of statutes of limitations within the next twelve months. Furthermore, the Company does not expect any cash settlement with the taxing authorities as a result of these unrecognized tax benefits as the Company has sufficient unutilized carryforward attributes to offset the tax impact of these adjustments.

 

69
Table of Contents

 

The following is a tabular reconciliation of the Company’s change in gross unrecognized tax positions at December 31 (in thousands):

 

   

2023

    

2022

  
    (in thousands)  

Beginning balance

   $ 335     $ 141  

Gross increases for tax positions related to current periods

     328       194  

Gross decreases related to 382 limitations

     52       -  

Ending balance

   $ 715     $ 335  

 

The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2023 and 2022, the Company had no accrued interest or penalties related to uncertain tax positions.

 

The Company has analyzed its filing positions in all significant federal, state, and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, the Company is no longer subject to United States Federal, state, and local tax examinations by tax authorities for years before 2020, although carryforward attributes that were generated prior to 2020 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.

 

Taxes computed at the then-current statutory federal income tax rate of 21% are reconciled to the provision for income taxes as follows for the years ended December 31:

 

    2023     2022  
   

Amount

   

Percent of

Pretax

Earnings

   

Amount

   

Percent of

Pretax

Earnings

 
    (in thousands)  

United States federal tax at statutory rate

   $ (16,405 )     21.0 %   $ (15,801 )     21.0 %

State taxes (net of deferred benefit)

     (2,493 )     3.2 %     (2,912 )     3.9 %

Nondeductible expenses

     755       (1.0 %)     1,077       (1.4 %)

Change in fair market value of contingent consideration

     244       (0.3 %)     (283 )     0.4 %

Warrant remeasurement and financing costs

     (140 )     0.2 %     -       -  

Research & development

     (1,898 )     2.4 %     (970 )     1.3 %

Change in unrecognized tax benefits

     380       (0.5 %)     194       (0.3 %)

Foreign tax rate differential

     3,176       (4.1 %)     2,676       (3.6 %)

True-up to stock compensation - cancellations

     -       -       49       (0.1 %)

Change in enacted tax rates and other, net

     659       (0.8 %)     (96 )     0.0  

Change in valuation allowance

     16,036       (20.5 %)     16,384       (21.8 %)

Income tax expense (benefit)

   $ 314       (0.4 %)   $ 318       (0.4 %)

 
 

13.         Stock-Based Compensation

 

Incentive Compensation Plan Information

 

On June 6, 2023, at the 2023 Annual Meeting of Stockholders, the Company’s stockholders voted to approve an amendment and restatement of the Company’s Incentive Compensation Plan (“the Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. As of December 31, 2023, there were 54,072,307 shares authorized for issuance, and 22,185,899 shares available for future issuance under the Plan. To date all equity awards under the Plan have consisted of nonqualified stock options, incentive stock options, restricted stock units and stock awards.

 

Under the Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock units, restricted stock or stock awards to employees, officers, non-employee directors, consultants, and vendors. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company’s shares at the date of grant. Additionally, no stock options or stock appreciation rights granted under the Plan may have a term exceeding ten years.

 

70
Table of Contents

 

Stock Options

 

The following table summarizes the Company’s stock option activity, including grants to non-employees, for the year ended December 31, 2023:

 

   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

  

Balance at December 31, 2022

     7,584,967     $ 4.22       5.31  

Granted

     3,047,615       0.71          

Forfeited

     (149,430 )     0.78          

Cancelled

     (25,173 )     27.32          

Exercised

     (13,300 )     0.38          

Balance at December 31, 2023

     10,444,679     $ 3.20       4.80  

 

The weighted-average grant date fair value of stock options was $0.59 during the years ended December 31, 2023 and 2022. The aggregate intrinsic value of stock options exercised under the Company’s stock plans was not material during the years ended December 31, 2023 and 2022.

 

The following table summarizes information about stock options outstanding at December 31, 2023:

 

   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average Remaining

Contractual Term (Years)

    

Aggregate

Intrinsic Value (Millions)

  

Exercisable at December 31, 2023

     5,726,280     $ 5.02       4.12     $ -  

Vested or expected to vest at December 31, 2023

     10,105,084     $ 3.28       4.77     $ -  

 

The fair value of options granted were estimated using the Black-Scholes-Merton option pricing model based on the assumptions in the table below:

 

    Years Ended December 31,  
    2023     2022  

Expected dividend yield

     0%         0%    

Expected volatility

   124% - 130%     126% - 133%  

Risk-free interest rate

   3.53% - 4.14%     1.25% - 4.40%  

Expected life (in years)

   3.8 - 4.5     3.8 - 4.5  

 

Restricted Stock Units

 

The following is a summary of the restricted stock unit activity, including performance restricted stock units, for the year ended December 31, 2023:

 

   

Number of

Restricted Stock

Units Outstanding

    

Weighted-Average

Grant Date Fair

Value

  

Unvested December 31, 2022

     8,483,491     $ 1.04  

Granted

     8,616,931       0.70  

Vested

     (3,937,130 )     1.10  

Forfeited

     (837,115 )     0.76  

Unvested December 31, 2023

     12,326,177     $ 0.81  

 

71
Table of Contents

 

Performance Restricted Stock Units

 

In 2023 and 2022, the Company granted performance-based restricted stock units (“PRSUs”). The number of shares earnable under the 2023 and 2022 awards were based on achieving certain operational targets by December 31, 2023 (for the PRSUs granted in 2023) and October 1, 2023 (for the PRSUs granted in 2022), respectively. In February 2024, the Board determined that the operational targets for PRSU awards granted in 2023 were 50% achieved and as a result, the 2023 PRSUs were 50% earned and remain subject to three-year time-based vesting requirements. The other 50% of the 2023 PRSUs were forfeited. The operational targets were achieved for the PRUSs granted in 2022, therefore the 2022 PRSUs were fully earned and remain subject to three-year time-based vesting requirements.

 

Stock-based Compensation Expense

 

The following table summarizes non-cash stock-based compensation expense by award type for the years ended December 31, 2023, and 2022:

 

   

Years Ended December 31,

 
   

2023

      

2022

  
   

(in thousands)

  

Stock options

   $ 2,338       $ 3,654  

Restricted stock units

     3,954         3,319  

Performance restricted stock units

     1,626         1,443  
    $ 7,918       $ 8,416  

 

As of December 31, 2023, the unrecognized stock-based compensation expense related to unvested stock options was approximately $1.6 million, which is expected to be recognized over an estimated weighted-average period of 1.4 years. As of December 31, 2023, the unrecognized stock-based compensation expense related to unvested restricted stock units and performance restricted stock units was approximately $4.4 million, which is expected to be recognized over a weighted average period of approximately 1.2 years.

 

 

14.         Equity Offerings

 

Equity financing transactions for the years ended December 31, 2023 and 2022, include:

 

 

2022 At-The-Market Offering

 

On March 18, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”) with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc., collectively, “the Agents”. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could offer and sell, from time to time, at its option, shares of its common stock for an aggregate offering price of up to $100.0 million. The aggregate compensation payable to the Agents was 3.0% of the aggregate gross proceeds from each sale of the Company’s common stock. No shares were sold under the 2022 ATM Offering in 2022.

 

The following table presents details about common stock issued pursuant to the 2022 ATM Offering (in thousands, except share and per share amounts):

 

   

Year Ended

December 31, 2023

  

Total shares of common stock sold

     933,672  

Average price per share

   $ 0.43  

Gross proceeds

   $ 403  

Commission paid to agents

   $ 12  

Net proceeds

   $ 391  

 

72
Table of Contents

 

2023 Registered Equity Offering

 

On July 27, 2023, the Company sold, in a registered direct offering, an aggregate of 23,809,524 shares of common stock, and warrants to purchase 23,809,524 of the Company’s common stock shares at an exercise price of $0.42 per common share (the “warrants”), for an aggregate purchase price of $10.0 million. The warrants are exercisable at any time on or after the date of issuance and will expire five years after the date of issuance. Based on the assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 – Distinguishing Liabilities from Equity and ASC 815 – Derivatives and Hedging, the Company determined that warrants did not meet the requirements for equity classification. Accordingly, the warrants were recorded as a liability on the Company’s balance sheet at their initial estimated fair value on the date of issuance. For additional information regarding the fair value of warrant liabilities, please refer to Note 4 – Fair Value Measurements.

 

The Company allocated $7.1 million of the aggregate proceeds to warrants based on their estimated fair value, with the residual amount of $2.9 million allocated to common stock. Offering related issuance costs were approximately $1.0 million and consisted primarily of placement agent’s fees and legal expenses. Issuance costs were allocated to common stock and warrant liability proportionally to the allocation of the purchase price. During the year ended December 31, 2023, the Company recorded $0.7 million of other expense, net, in the consolidated statement of operations related to issuance costs allocated to warrant liabilities.

 

 

15.         Basic and Diluted Net Loss per Share

 

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all potential dilutive common shares that were outstanding during the period. Potential dilutive common shares consist of incremental shares issuable upon exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding common shares figures for the years ended December 31, 2023 or 2022 as the assumed exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.

 

Potential common shares not included in calculating diluted net loss per share are as follows:

 

   

December 31,

 
   

2023

    

2022

  

Stock options

     10,444,679       7,584,967  

Nonvested restricted stock units

     12,326,177       8,483,491  

Stock warrants

     24,830,500       1,021,076  

Total

     47,601,356       17,089,534  

 
 

16.         Commitments and Contingencies

 

License and Supply Agreements

As part of the Company’s acquisition of the Senhance System in 2015, the Company assumed certain license and supply agreements. The Company has purchase orders with various suppliers for certain tooling, supplies, contract engineering and research services. Commitments related to license agreements and purchase orders are as follows (in thousands):

 

Fiscal Year

        

2024

   $ 3,263  

2025

     300  

2026

     320  

Total commitments

   $ 3,883  

 

73
Table of Contents

 
 

17.         Segments and Geographic Areas

 

The Company operates in one business segment—the research, development, and sale of medical devices to improve MIS. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

 

The following table presents consolidated assets and long-lived assets by geographic area, which includes property and equipment, intellectual property, and operating lease assets:

 

   

December 31, 2023

  
   

Long-Lived Assets

    

Total Assets

  

US

     29 %     46 %

EMEA

     68 %     52 %

Asia

     3 %     2 %

Total

     100 %     100 %

 

   

December 31, 2022

  
   

Long-Lived Assets

    

Total Assets

  

US

     35 %     72 %

EMEA

     62 %     27 %

Asia

     3 %     1 %

Total

     100 %     100 %

 

The following table presents sales by geographic area based on the country in which the customer is based.

 

   

Years Ended December 31,

 
   

2023

    

2022

  

US

     8 %     11 %

EMEA

     82 %     77 %

Asia

     10 %     12 %

Total

     100 %     100 %

 
 

18.         Related Party Transactions

 

In March 2018, Asensus Surgical Europe S.à r.l. entered into a Service Supply Agreement with 1 Med S.A. for certain regulatory consulting services. Andrea Biffi, a current member of the Company’s Board of Directors, owns a non-controlling interest in 1 Med S.A. Expenses under the Service Supply Agreement were approximately $0.1 million and $0.3 million for the years ended December 31, 2023 and 2022, respectively.

 

In October 2023, Asensus Surgical US, Inc. entered into an agreement with Synchrony Labs, LLC to support preclinical evaluation of the LUNA Surgical System. William Starling, a current member of the Company’s Board of Directors, owns more than 10% of Synchrony Labs, LLC. Expenses under the agreement were approximately $0.1 million for the year ended December 31, 2023.

 

74
Table of Contents

 
 

ITEM 9.         CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9.A.      CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2023. We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2023, our disclosure controls and procedures were not effective due to ongoing remediation efforts described below. 

 

Material Weakness in Internal Control over Financial Reporting

 

For the period ended December 31, 2022, management identified a material weakness related to information technology general controls (“ITGCs”) in user access over certain information technology (“IT”) systems that support the Company’s financial reporting processes.  Remediation of this material weakness has extended into the year ended December 31, 2023, and is currently ongoing.

 

The 2022 material weakness did not result in any material misstatements in our consolidated financial statements included in this Annual Report. Our management concluded that the consolidated financial statements included in this Annual Report, present fairly, in all material respects, our financial position, results of operations, and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States.

 

Management’s Plan to Remediate the Material Weakness

 

Our remediation efforts are ongoing and we will continue our initiatives to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. We are committed to making the necessary changes and improvements to our system of controls to address the material weakness in internal control over financial reporting described above.

 

Our renewed emphasis of designing and implementing improved processes and controls will involve but is not limited to the following:

 

 

●

Expand available resources with experience designing and implementing control activities, including ITGCs and automated controls, both by hiring internally and the use of third-party consultations and specialists.

 

 

●

Adjust access profiles in IT systems and relevant software, and adjust access review and user activity review controls accordingly.

 

 

●

Refine the IT policies and procedures that relate to the provisioning of access, reviewing of access, and reviewing of user activity.

 

 

●

Refine control activities related to the information used in the controls for further completeness and accuracy regarding the provisioning of access, reviewing of access, and reviewing of user activity.

 

We are in the process of implementing the remediation activities as of the date of this report and believe that upon completion, we will have remediated the identified material weakness. However, material weaknesses are not considered remediated until new internal controls have been operational for a period of time, are tested, and management concludes that these controls are operating effectively. We expect to complete the remediation activities in the fiscal year 2024. We will continue to monitor the effectiveness of these remediation measures, and we will make any changes to the design of this plan and take such other actions that we deem appropriate given the circumstances.

 

75
Table of Contents

 

Management’s Report on Internal Control Over Financial Reporting 

 

We are responsible for establishing and maintaining adequate internal control over financial reporting. As defined in the securities laws, internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officer and effected by our Board of Directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the acquisitions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

For the year ended December 31, 2023, pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, management (with the participation of our principal executive officer and principal financial officer) conducted an evaluation of the effectiveness of our internal control over financial reporting, based on the original framework established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, management concluded that, as of December 31, 2023, our internal control over financial reporting was not effective.

 

Changes in Internal Controls Over Financial Reporting

 

We developed a plan to remediate the material weakness in fiscal year 2023. Except for the remediation efforts described above, including the initiation of new internal controls and conducting testing in respect to the material weakness, there were no changes in the Company’s internal control over financial reporting during the quarter ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.   

 

76
Table of Contents

 

We are taking additional measures to address the material weakness and may need to modify the planned remediation steps.  We cannot be certain that the measures we have taken, and expect to take, to improve our internal controls will be sufficient to address the issues identified, to ensure that our internal controls are effective or to ensure that the identified material weakness will not result in a material misstatement of our annual consolidated financial statements. Moreover, we cannot assure you that we will not identify additional material weaknesses in our internal control over financial reporting in the future. If we are unable to remediate the material weakness, our ability to record, process and report financial information accurately, and to prepare financial statements with the time periods specified by the rules and forms of the Securities and Exchange Commission, could be adversely affected.

 

Notwithstanding the identified material weakness, management does not believe that the deficiencies had an adverse effect on our reported operating results or financial condition, and management has determined that the financial statements and other information included in this report and other periodic filings present fairly in all material respects our financial condition and results of operations at and for the periods presented.

 

 

ITEM 9.B.       OTHER INFORMATION

 

 

During the three months ended December 31, 2023, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as such terms are defined in Item 408 of Regulation S-K.
 

 

ITEM 9.C.       DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

77
Table of Contents

 

PART III

 

ITEM 10.         DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to April 29, 2024.

 

ITEM 11.         EXECUTIVE COMPENSATION.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to April 29, 2024.

 

ITEM 12.         SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to April 29, 2024.

 

Securities Authorized for Issuance Under Equity Compensation Plans 

 

The Company currently has one equity compensation plan under which it makes awards, the Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan (the “Plan”). The Plan was originally approved by the Board of Directors of the Company, or the Board, and adopted by the majority of stockholders on November 13, 2007. The Plan was subsequently amended, approved by the Board, and approved by stockholders as follows:

 

No.

Amendment Purpose

Date of Stockholders’ approval

1

increase the number of shares of common stock authorized under the Plan to 918,462 shares, and to make other changes

May 7, 2015

2

increase the number of shares reserved for issuance under the Plan to 1,456,923 shares, and to make other changes

June 8, 2016

3

increase the number of shares reserved for issuance under the Plan to 1,995,385 shares

May 25, 2017

4

increase the number of shares reserved for issuance under the Plan to 3,149,231 shares

May 24, 2018

5

increase the number of shares reserved for issuance under the Plan to 4,072,308 shares, and to make other changes

April 24, 2019

6

increase the number of shares reserved for issuance under the Plan to 10,072,307 shares, and to make other changes

June 8, 2020

7

Increase the number of shares reserved for issuance under the Plan to 32,072,307 shares.

July 22, 2021

8

Increase the number of shares reserved for issuance under the Plan to 54,072,307 shares

June 6, 2023

 

The Plan is used for plan-based awards for officers, other employees, consultants, advisors and non-employee directors.

 

78
Table of Contents

 

The following table gives information about the Company’s common stock that may be issued upon the exercise of options and other equity awards as of December 31, 2023:

 

Plan Category

  

Number of
securities to

be
issued upon
exercise of
outstanding
options and

other

equity

awards (1)

    

Weighted
average

exercise
price of
outstanding
options

    

Number of
securities
remaining
available
for future
issuance (2)

  

Equity compensation plans approved by security holders

     22,620,856       3.24       22,185,899  

Equity compensation plans not approved by security holders (3)

     150,000       0.42       0  

Total

     22,770,856               22,185,899  

(1)

Includes 10,294,679 shares underlying outstanding stock options awarded under the Plan and 12,326,177 restricted stock units awarded under the Plan.

 

(2)

These shares are all available for future awards under the Plan.

 

(3)

Represents 150,000 shares underlying outstanding stock options issued as an employment inducement grant as an exception to the NYSE American stockholder approval rules.

 

ITEM 13.         CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to April 29, 2024.

 

 

ITEM 14.         PRINCIPAL ACCOUNTING FEES AND SERVICES.

 

The information required by this item is incorporated by reference from the information contained in our proxy statement for the Annual Meeting of Stockholders expected to be filed with the SEC on or prior to April 29, 2024.

 

79
Table of Contents

 

PART IV

 

ITEM 15.         EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a).

 

 

(1)

The following consolidated financial statements are filed as a part of this Annual Report:

 

 

Page

Consolidated Financial Statements:

  
   

Report of Independent Registered Public Accounting Firm

49

Consolidated Balance Sheets as of December 31, 2023 and 2022

51

Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022

52

Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2023 and 2022

53

Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022

54

 

 

(2)

Consolidated Financial Statement Schedules: The information required by this item has been omitted in this report because they are not applicable, not required under these instructions, or included in the consolidated financial statements or related notes thereto contained in Item 8 of this Annual Report.

 

 

(3)

Exhibits: The following exhibits are filed as part of, or incorporated by reference into, this Annual Report.

 

Exhibit
No.

  

Description

2.1

  

Membership Interest Purchase Agreement, dated September 18, 2015, by and among Sofar S.p.A., Vulcanos S.r.l., the Registrant and TransEnterix International, Inc. filed as Exhibit 2.1 to our Current Report on Form 8-K, filed with the SEC on September 21, 2015 and incorporated by reference herein).

2.1(a)

  

Amendment to Membership Interest Purchase Agreement by and among TransEnterix, Inc., TransEnterix International, Inc., and Sofar, S.p.A., dated December 30, 2016 (filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on January 5, 2017 and incorporated by reference herein).

3.1.1

  

Amended and Restated Certificate of Incorporation of Asensus Surgical, Inc. (filed as Exhibit 3.1 to our Current Report on Form 8-K, filed with the SEC on February 25, 2021 and incorporated by reference herein).

3.2

  

Amended and Restated Bylaws of Asensus Surgical, Inc. (filed as Exhibit 3.2 to our Current Report on Form 8‑K, filed with the SEC on February 25, 2021 and incorporated by reference herein).

4.1

  

Specimen Certificate for Common Stock of Asensus Surgical, Inc. (incorporated by reference to Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2020).

4.2

  

Form of Service Warrant to purchase common stock for warrants issued to third party vendor (filed as Exhibit 4.4 to our Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2017 and incorporated by reference herein).

4.3

  

Form of Common Stock Purchase Warrant (Series C and Series D Warrants) (filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on March 6, 2020 and incorporated herein by reference).

4.4

  

Form of Warrant Agency Agreement by and between the Registrant and Continental Stock Transfer & Trust Company (filed as Exhibit 4.2 to our Current Report on Form 8-K, filed with the SEC on March 6, 2020 and incorporated herein by reference).

4.5

  

Description of Listed Securities (filed as Exhibit 4.8 to our Annual Report on Form 10-K, filed with the SEC on March 11, 2021 and incorporated herein by reference).

4.6

  

Form of Common Stock Purchase Warrant (filed as Exhibit 4.1 to our Current Report on Form 8-K, filed with the SEC on July 28, 2023, and incorporated herein by reference).

 

80
Table of Contents

 

10.1 +

  

Employment Agreement, dated March 6, 2018, and effective as of March 1, 2018, by and between the Registrant and Anthony Fernando (filed as Exhibit 10.7 to our Annual Report on Form 10-K, filed with the SEC on March 8, 2018 and incorporated by reference herein).

10.2+

  

Employment Agreement, dated August 14, 2020, by and between Asensus Canada, Inc., on behalf of the Registrant, and Shameze Rampertab (filed as Exhibit 10.1 to our Current Report on Form 8-K/A, filed with the SEC on August 14, 2020 and incorporated by reference herein).

10.2.1+

  

Amendment to Employment Agreement, dated September 16, 2020, by and between Asensus Canada, Inc., on behalf of the Registrant, and Shameze Rampertab (filed as Exhibit 10.1.2 to our Registration Statement on Form S-8, filed with the SEC on November 6, 2020 and incorporated by reference herein).

10.3 +

  

Asensus Surgical Amended and Restated Incentive Compensation Plan, as amended and restated June 6, 2023 (filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on June 6, 2023 and incorporated herein by reference).

10.3.1 +

  

Form of Employee Stock Option Award Notice (incorporated by reference to Exhibit 10.4.1 to our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022).

10.3.2 + *

  

Form of Employee Restricted Stock Unit/Performance Restricted Stock Unit Award Notice.

10.3.3 +

  

Form of Non-Employee Director Stock Option Agreement pursuant to the Plan (filed as Exhibit 10.4.5 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and incorporated herein by reference).

10.3.4 +

  

Form of Non-Employee Director Restricted Stock Unit Agreement pursuant to the Plan (filed as Exhibit 10.4.6 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and incorporated herein by reference).

10.3.5 +

  

Form of Non-Employee Director Other Stock Award Agreement (filed as Exhibit 10.4.7 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and incorporated herein by reference).

10.3.6 +

  

Form of Non-Employee Director Stock Option Grant in Lieu of Cash Retainer (filed as Exhibit 10.4.8 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and incorporated herein by reference).

10.4+

  

Non-Qualified Deferred Compensation Plan, adopted December 8, 2021 (incorporated by reference to Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022).

10.5 ++

  

License Contract between the European Union and Vulcanos S.r.l. (now known as Asensus Surgical Italia S.r.l.), dated September 18, 2015 (filed as Exhibit 10.5 to our Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2015 and incorporated by reference herein).

10.5.1 +++

  

Amendment to License Contract between the European Union and Asensus Surgical Italia S.r.l., effective July 2, 2021 (incorporated by reference to Exhibit 10.6.1 to our Annual Report on Form 10‑K for the year ended December 31, 2021, filed with the SEC on February 28, 2022).

10.6 +

  

Asensus Surgical Non-Employee Director Compensation Plan effective July 1, 2021 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on April 30, 2021).

10.7

  

Securities Purchase Agreement, dated as of July 27, 2023, among the Company and the purchasers signatory thereto (filed as Exhibit 10.1 to our Current Report on Form 8-K, filed with the SEC on July 28, 2023 and incorporated herein by reference).
21.1 *   Subsidiaries of the Registrant

23.1 *

  

Consent of BDO USA, P.C.

31.1 *

  

Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).

31.2 *

  

Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).

32.1 *

  

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 *

  

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

97 *

  

Compensation Recoupment Policy of Asensus Surgical, Inc., effective October 2, 2023.

101.INS *

  

Inline XBRL Instance Document.

101.SCH *

  

Inline XBRL Taxonomy Extension Schema Document.

 

81
Table of Contents

 

101.CAL *

  

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF *

  

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB *

  

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE *

  

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104

  

The cover page from the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, formatted in Inline XBRL (included in Exhibit 101).

 

+

A management contract, compensatory plan or arrangement required to be separately identified.

++

Confidential treatment has been granted for certain portions of the agreement pursuant to a confidential treatment request filed with the Commission on November 9, 2015. Such provisions have been filed separately with the Commission.

+++

Portions of this exhibit have been omitted because the information is not material and would likely cause competitive harm if publicly disclosed.

*

Filed herewith.

 

ITEM 16.         FORM 10-K SUMMARY.

 

Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.

 

82
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

March 21, 2024

Asensus Surgical, Inc.
     
 

By:

/s/ Anthony Fernando
   

Anthony Fernando
   

President, Chief Executive Officer
   

and a Director
   

(principal executive officer)

 

POWER OF ATTORNEY

 

We, the undersigned officers and directors of Asensus Surgical, Inc., hereby severally constitute and appoint Anthony Fernando and Shameze Rampertab, our true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution in him for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

 

Signature

  

Title(s)

Date
       

/s/ Anthony Fernando

  

President, Chief Executive Officer and a Director

March 21, 2024

Anthony Fernando

  

(principal executive officer)

  
       

/s/ Shameze Rampertab

  

Executive Vice President and Chief Financial Officer

March 21, 2024

Shameze Rampertab

  

(principal financial officer and principal accounting officer)

  
       

/s/ David B. Milne

  

Chairman of the Board and a Director

March 21, 2024

David B. Milne

      
       

/s/ Andrea Biffi

  

Director

March 21, 2024

Andrea Biffi

      
       

/s/ Kevin Hobert

  

Director

March 21, 2024

Kevin Hobert

      
       

/s/ Elizabeth Kwo, M.D.

  

 Director

 March 21, 2024

Elizabeth Kwo, M.D.

      
       

/s/ Richard C. Pfenniger, Jr.

  

Director

March 21, 2024

Richard C. Pfenniger, Jr.

      
       

/s/ William N. Starling, Jr.

  

Director

March 21, 2024

William N. Starling, Jr.

      

 

83
 EX-10.32 2 ex_642544.htm EXHIBIT 10.3.2 ex_642544.htm

Exhibit 10.3.2

 

ASENSUS SURGICAL, INC.
[RESTRICTED STOCK UNITS] [PERFORMANCE RESTRICTED STOCK UNITS] AWARD NOTICE

 

Asensus Surgical, Inc., a Delaware corporation (the “Company”), has granted [performance-based] restricted stock units award [the “RSUs”)][(the “PRSUs”)] to acquire shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) to the individual named below. The terms and conditions of the [RSUs][PRSUs] are set forth in this award cover sheet and in the attachment (collectively, the “Award Notice”) and in the Company’s Amended and Restated Incentive Compensation Plan (as further amended or amended and restated, the “Plan”). The [RSUs][PRSUs] are awarded to the Participant as a Deferred Stock Award under the Plan. All capitalized terms used in this Award Notice without definition have the meanings set forth in the Plan.

 

Grant Number: Click here to enter text.

 

Grant Date: Click here to enter text.

 

Name of Participant:

Number of Shares of Common Stock Underlying the [RSUs][PRSUs]:

 

 

[Percentage of Shares of Common Stock Underlying the PRSUs shall be applicable to Goal[s]]

 

 

[Performance Goals: ]

 

 

Lapse of Forfeiture Restrictions (Vesting Schedule):

 

Date

Shares
   
   
   

 

Thank you for your efforts on behalf of the Company.

____________________

Name: Click here to enter text.

 

This is not a stock certificate or a negotiable instrument.

 

 
 

 

[Performance Vesting

If a Performance Goal is achieved prior to the end of the ____ Performance Period, then the PRSUs associated with the attainment of such attained Goal will vest in full and be earned on each Vesting Date. If a Performance Goal is not achieved by the end of the Performance Period, the PRSUs associated with the attainment of such Goal shall be forfeited and shall not vest. The number of Shares underlying the PRSUs vested and earned shall be adjusted if the Company engages in any stock split, reverse stock split or other capitalization affecting all common stock during the Performance Period.]

 

Settlement

Upon vesting of all or any portion of the [RSUs][PRSUs], settlement will be made by issuance of the number of Shares equal to the vesting [RSUs][PRSUs].

 

No Dividend Equivalents

No dividend equivalents are authorized as part of this award of [RSUs][PRSUs].

 

Withholding

The Participant shall pay to the Company promptly upon request, and in any event at the time the Participant recognizes taxable income in respect of the [RSUs][PRSUs], an amount equal to the federal, state or local taxes the Company determines it is required to withhold with respect to the vesting [RSUs][PRSUs]. Such payment shall be made by check or, for (1) employees other than executive officers, (2) employees not in possession of material non-public information, or (3) employees in jurisdictions that do not allow “sell to cover,” by selling Shares on the open market to cover the tax obligations. Upon approval by the Committee or the Board, the Participant may pay the applicable withholding by having the Company withhold from the Shares which would otherwise be delivered to the Participant hereunder Shares with a Fair Market Value sufficient to satisfy the minimum withholding required with respect thereto to the extent permitted by the Company, or in a combination of such methods, as irrevocably elected by the Participant prior to the applicable tax due date with respect to such [RSUs][PRSUs]. [The net settlement of the Shares underlying the vested [RSUs][PRSUs] and the delivery of Shares previously owned are hereby specifically authorized alternatives for the satisfaction of the foregoing withholding obligation.] The Company provides no advice regarding the availability of “sell to cover” at any specific point in time.

 

Issuance of Shares

Following the applicable vesting date with respect to the [RSUs][PRSUs], and subject to the terms and conditions of the Plan, the Company will cause to be issued a direct registration/book-entry statement (“DRS”) for the Shares issuable with respect to such vested [RSUs][PRSUs]. Such issuance shall take place as soon as practicable following the applicable vesting date (but in no event later than two and one-half months following the end of the calendar year in which the vesting date occurs). The certificates or DRS representing the Shares issued in respect of the [RSUs][PRSUs] shall be subject to such stop transfer orders and other restrictions as the Committee may determine is required by the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which such Shares are listed, any applicable federal or state laws and the Company’s Certificate of Incorporation and Bylaws, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

 

2
 

 

Transferability of [RSUs][PRSUs]

The [RSUs][PRSUs] are not transferable and may not be sold, assigned, transferred, disposed of, pledged or otherwise encumbered by the Participant, other than by will or the laws of descent and distribution. Upon such transfer (by will or the laws of descent and distribution), such transferee in interest shall take the rights granted herein subject to all the terms and conditions hereof.

 

Transferability of Shares

Shares issued to the Participant with respect to vested [RSUs][PRSUs] can only be sold by the Participant following registration of such Shares under the Securities Act of 1933, as amended, or pursuant to an exemption therefrom.

 

Change in Control

The provisions of Article 9 of the Plan shall apply to the [RSUs][PRSUs] under this Agreement.

 

Imposition of Other Requirements

The Company reserves the right to impose other requirements on the [RSUs][PRSUs] and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Award, and to require the Participant to sign any agreements or undertakings that may be necessary to accomplish the foregoing. The Participant agrees, upon demand of the Company or the Committee, to do all acts and execute, deliver and perform all documents, instruments and agreements which may be reasonably required by the Company or the Committee, as the case may be, to implement the provisions and purposes of this Award Notice.

 

No Stockholder Rights

Neither the Participant nor any personal representative (or beneficiary) shall be, or shall have any of the rights and privileges of, a stockholder of the Company with respect to any Shares issuable upon the vesting of the [RSUs][PRSUs], in whole or in part, prior to the date on which the Shares are issued.

 

No Right to Continued Employment

Neither the [RSUs][PRSUs] nor this Award Notice shall confer upon the Participant any right to continued employment or service with the Company.

 

Interpretation/Provisions of Plan Control

This Award Notice is subject to all the terms, conditions and provisions of the Plan, including, without limitation, the amendment provisions thereof, and to such rules, regulations and interpretations relating to the Plan adopted by the Committee as may be in effect from time to time. If and to the extent that this Award Notice conflicts or is inconsistent with the terms, conditions and provisions of the Plan, the Plan shall control, and this Award Notice shall be deemed to be modified accordingly. The Participant accepts the [RSUs][PRSUs] subject to all of the terms and provisions of the Plan. All decisions or interpretations of the Committee upon any questions arising under the Plan shall be binding, conclusive and final, unless shown to have been made in an arbitrary and capricious manner.

 

Notices

Any notice under this Award Notice shall be in writing and shall be deemed to have been duly given when delivered personally or when deposited in the United States mail, registered, postage prepaid, and addressed, in the case of the Company, to the Company’s Secretary at 1 TW Alexander Drive, Suite 160, Durham NC 27703, or if the Company should move its principal office, to such principal office, and, in the case of the Participant, to the Participant’s last permanent address as shown on the Company’s records, subject to the right of either to designate some other address at any time hereafter in a notice satisfying the requirements of this Notice section.

 

3
 

 

Data Privacy

In order to administer the Plan, the Company may process personal data about you. Such data includes, but is not limited to the information provided in this Award Notice and any changes thereto, other appropriate personal and financial data about you such as home address and business addresses and other contact information, payroll information and any other information that might be deemed appropriate by the Company to facilitate the administration of the Plan.

 

By accepting these [RSUs][PRSUs], you give explicit consent to the Company to process any such personal data. You also give explicit consent to the Company to transfer any such personal data outside the country in which you work or are employed, including, with respect to non-U.S. resident grantees, to the United States, to transferees who shall include the Company and other persons who are designated by the Company to administer the Plan.

 

Consent to Electronic Delivery

The Company may choose to deliver certain statutory materials relating to the Plan (if any) in electronic form. By accepting this grant you agree that the Company may deliver the Plan prospectus and the Company’s annual report to you in an electronic format. If at any time you would prefer to receive paper copies of these documents, as you are entitled to, the Company would be pleased to provide copies. Please contact the Company’s Secretary to request paper copies of these documents.

 

Code Section 409A

For U.S. taxpayers, it is intended that this Award comply with Section 409A of the Code (“Section 409A”) or an exemption to Section 409A, and shall be interpreted and administered accordingly. To the extent that the Company determines that the Participant would be subject to the additional 20% tax imposed on certain nonqualified deferred compensation plans pursuant to Section 409A as a result of any provision of any this Award Notice, such provision shall be deemed amended to the minimum extent necessary to avoid application of such additional tax. The nature of any such amendment shall be determined by the Company.

 

Notwithstanding anything to the contrary in the Plan, neither the Company, any Affiliate, the Board, nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on you under Section 409A, and neither the Company, any Affiliate, the Board, nor the Committee shall have any liability to you or other person for such tax or penalty.

 

No Tax Advice

Except for the information provided in any prospectus applicable to U.S. taxpayers, the Company is not providing the Participant with any information, advice or recommendations with respect to the tax consequences of this Award including, without limitation, whether this Award is taxable upon grant or lapse of forfeiture restrictions. Please consult with your tax advisor to determine the tax consequences in your tax jurisdiction.

 

4
 EX-21.1 3 ex_640044.htm EXHIBIT 21.1 ex_640044.htm

Exhibit 21.1

 

Subsidiaries

 

(As of March 15, 2024)

 

Name of Subsidiary Jurisdiction of Incorporation
   
Asensus Surgical US, Inc. Delaware
   
Asensus International, Inc. Delaware
   
Asensus Surgical Italia, S.r.l. Italy
   
Asensus Surgical Europe S.à r.l. Luxembourg
   
Asensus Surgical Netherlands B.V. Netherlands
   
Asensus Surgical Israel Ltd Israel
   
Asensus Surgical Canada, Inc. Ontario, Canada
   
Asensus Surgical Japan K.K.  Japan
   
Asensus Taiwan Ltd. Taiwan

 

 
 EX-23.1 4 ex_640045.htm EXHIBIT 23.1 ex_640045.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

 

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333‑238471), Form S-3 (No. 333-263711), and Forms S-8 (No. 333-161291, No. 333-190184, No. 333-193234, No. 333-203950, No. 333-211972, No. 333-219111, No. 333-225231, No. 333-231078, No. 333-239018, No. 333-249895, No. 333-258160 and No. 333-27253) of Asensus Surgical, Inc. of our report dated March 21, 2024, relating to the consolidated financial statements which appear in this Annual Report on Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

 

 

/s/ BDO USA, P.C.

 

 

Raleigh, North Carolina

March 21, 2024

 

 
 EX-31.1 5 ex_640046.htm EXHIBIT 31.1 ex_640046.htm

 

Exhibit 31.1

 

SECTION 302 CERTIFICATION

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

 

I, Anthony Fernando, certify that:

(1) I have reviewed this Annual Report on Form 10-K of Asensus Surgical, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its unconsolidated investments, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 21, 2024

By: /s/ Anthony Fernando
 

Anthony Fernando

President and Chief Executive Officer (Principal Executive Officer)

 

 
 EX-31.2 6 ex_640047.htm EXHIBIT 31.2 ex_640047.htm

Exhibit 31.2

 

SECTION 302 CERTIFICATION

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

 

I, Shameze Rampertab, certify that:

(1) I have reviewed this Annual Report on Form 10-K of Asensus Surgical, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its unconsolidated investments, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 21, 2024

By: /s/ Shameze Rampertab
 

Shameze Rampertab

Executive Vice President and Chief Financial Officer (Principal Financial Officer)

 

 
 EX-32.1 7 ex_640048.htm EXHIBIT 32.1 ex_640048.htm

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the accompanying Annual Report on Form 10-K of Asensus Surgical, Inc. for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Asensus Surgical, Inc.

 

Date: March 21, 2024

 

By:

/s/ Anthony Fernando
   

Anthony Fernando
   

President and Chief Executive Officer (Principal Executive Officer)

 

 

The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document of Asensus Surgical, Inc. or the certifying officers.

 
 EX-32.2 8 ex_640049.htm EXHIBIT 32.2 ex_640049.htm

Exhibit 32.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the accompanying Annual Report on Form 10-K of Asensus Surgical, Inc. for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Asensus Surgical, Inc.

 

Date: March 21, 2024

 

By:

/s/ Shameze Rampertab
   

Shameze Rampertab
   

Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

 

The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document of Asensus Surgical, Inc. or the certifying officers.

 
 EX-97 9 ex_640996.htm EXHIBIT 97 ex_640996.htm

Exhibit 97

 

Asensus Surgical, Inc.

 

Compensation Recoupment Policy

 

Approved – November 30, 2023, Effective October 2, 2023

 

1.

INTRODUCTION

 

The Board of Directors (the “Board”) of Asensus Surgical, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incentive Compensation that is received by Covered Officers under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 7 below.

 

This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (“Rule 10D-1”) and Section 311 of the NYSE American Company Guide (the “Listing Standards”).

 

2.

EFFECTIVE DATE

 

This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the “Effective Date”). Incentive Compensation is deemed “received” in the Company’s fiscal period in which the Financial Reporting Measure(s) specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.

 

3.

ADMINISTRATION

 

Except as specifically set forth herein, this Policy shall be administered by the Committee. The Committee shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Committee with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Committee is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to applicable law, the Committee may authorize and empower any officer or employee of the Company to take any and all actions that the Committee, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).

 

Any members of the Committee, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law, any agreement with the Company and any Company insurance policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law, any agreement with the Company or Company insurance policy.

 

 
 

 

 

4.

RECOUPMENT

 

(a)    Applicability of Policy. This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period.

 

(b)    Required Recoupment. Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company’s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.

 

(c)    Impracticability of Recovery. Recoupment may be determined to be impracticable if, and only if:

 

(i)    the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or

 

(ii)    recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.

 

(d)    Sources of Recoupment. To the extent permitted by applicable law, the Committee shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Committee may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Committee may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, e.g., base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Committee need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.

 

(e)    No Indemnification of Covered Officers. Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company’s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.

 

(f)    No “Good Reason” for Covered Officers. Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) “good reason” for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.

 

5.

NO IMPAIRMENT OF OTHER REMEDIES

 

Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer’s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. If a Covered Officer fails to repay Recoverable Incentive Compensation that is owed to the Company under this Policy at the time and in the manner contemplated by this Policy, the Covered Officer shall be required to reimburse the Company for all expenses (including legal expenses) incurred by the Company in recovering such Recoverable Incentive Compensation.

 

This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (“SOX 304”) that are applicable to the Company’s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.

 

2
 

 

6.

MISCELLANEOUS

 

(a)    Amendment and Termination. The Committee may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Committee shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.

 

(b)    Severability. If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.

 

(c)    Successors. This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.

 

7.

DEFINITIONS

 

“Accounting Restatement” means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.

 

“Accounting Restatement Date” means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.

 

“Committee” means the Compensation Committee of the Board or, in the absence of such committee, the Board.

 

“Code” means the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.

 

“Covered Officer” means each current and former Executive Officer.

 

“Exchange” means The NYSE American.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“Executive Officer” means the Company’s president, principal executive officer, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.

 

3
 

 

“Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (“TSR”). A measure need not be presented in the Company’s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.

 

“Incentive Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure or Financial Reporting Measures.

 

“Lookback Period” means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.

 

“Recoverable Incentive Compensation” means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (i.e., on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Committee will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.

 

“SEC” means the Securities and Exchange Commission.

 

*         *         *         *         *

 

4
 

 

Adopted by the Board: November 30, 2023

 

5
 

 

 

Asensus Surgical, Inc.

 

Compensation Recoupment Policy

 

Form of Acknowledgment

 

 

I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Asensus Surgical, Inc. Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the “Policy”). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Asensus Surgical, Inc. (the “Company”) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.

 

In the event that the Committee (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement, including executing any further acknowledgment or documents reasonably requested by the Committee. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.

 

 

Agreed and Acknowledged:

 

 

   
     
Name:    
     
Title:    
     
Date:    

 

 
 EX-101.SCH 10 asxc-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Description of the Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Investments, Available-for-sale link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Fair Value link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Inventories link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Intellectual Property link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Leases link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Equity Offerings link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 16 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 17 - Segments and Geographic Areas link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 18 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 3 - Revenue Recognition (Tables) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 5 - Investments, Available-for-sale (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 6 - Fair Value (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 7 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 8 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 9 - Intellectual Property (Tables) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 10 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 12 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 13 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 14 - Equity Offerings (Tables) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 16 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 17 - Segments and Geographic Areas (Tables) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 3 - Revenue Recognition 1 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 3 - Revenue Recognition 2 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 5 - Investments, Available-for-sale (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants (Details) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 7 - Inventories - Components of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 8 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 8 - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 9 - Intellectual Property (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 9 - Intellectual Property - Intellectual Property (Details) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 10 - Leases - Components of Operating Lease Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 10 - Leases -Supplemental Balance Sheet Information (Details) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 10 - Leases - Minimum Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities - Components of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 12 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995512 - Disclosure - Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) link:calculationLink link:definitionLink link:presentationLink 995513 - Disclosure - Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) link:calculationLink link:definitionLink link:presentationLink 995514 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995515 - Disclosure - Note 12 - Income Taxes - Unrecognized Tax Positions (Details) link:calculationLink link:definitionLink link:presentationLink 995516 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) link:calculationLink link:definitionLink link:presentationLink 995517 - Disclosure - Note 13 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995518 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995519 - Disclosure - Note 13 - Stock-based Compensation - Stock Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 995520 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995521 - Disclosure - Note 13 - Stock-based Compensation - RSU Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995522 - Disclosure - Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 995523 - Disclosure - Note 14 - Equity Offerings (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995524 - Disclosure - Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) link:calculationLink link:definitionLink link:presentationLink 995525 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995526 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995527 - Disclosure - Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) link:calculationLink link:definitionLink link:presentationLink 995528 - Disclosure - Note 17 - Segments and Geographic Areas (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995529 - Disclosure - Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 995530 - Disclosure - Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) link:calculationLink link:definitionLink link:presentationLink 995531 - Disclosure - Note 18 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 11 asxc-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 asxc-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Note To Financial Statement Details Textual Significant Accounting Policies Mature in less than one year, amortized cost United States federal tax at statutory rate, amount Note 2 - Summary of Significant Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Risk-free interest rate Note 3 - Revenue Recognition Mature in less than one year, fair value Note 4 - Cash, Cash Equivalents, and Restricted Cash Note 5 - Investments, Available-for-sale Note 6 - Fair Value Long-Term Liabilities: Note 7 - Inventories Note 8 - Property and Equipment Note 9 - Intellectual Property Income Tax Disclosure [Text Block] asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOperationEarned Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Operation, Earned Percentage of operational targets earneed under share based payment arrangement. Note 10 - Leases Unrealized gain (loss) on available-for-sale investments Note 11 - Accrued Expenses and Other Current Liabilities Note 12 - Income Taxes us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Expected volatility Note 13 - Stock-based Compensation us-gaap_LiabilitiesCurrent Total Current Liabilities Note 14 - Equity Offerings Note 15 - Basic and Diluted Net Loss Per Share Note 16 - Commitments and Contingencies Note 17 - Segments and Geographic Areas us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Expected life (in years) (Year) Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) Note 6 - Fair Value - Summary of Change in Fair Value for Warrants (Details) Restricted stock units, Granted, weighted average grant date fair value (in dollars per share) Note 7 - Inventories - Components of Inventories (Details) Restricted stock units, Vested, weighted average grant date fair value (in dollars per share) Note 8 - Property and Equipment - Summary of Property and Equipment (Details) Restricted stock units, Forfeited, weighted average grant date fair value (in dollars per share) Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Note 9 - Intellectual Property - Intellectual Property (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Beginning of period, Restricted stock units, Unvested, weighted average grant date fair value (in dollars per share) Unvested December 31, 2022 (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Restricted stock units, Forfeited (in shares) Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) Note 10 - Leases - Components of Operating Lease Expense (Details) Foreign currency translation gain (loss) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Beginning of period, Restricted stock units, Unvested (in shares) Unvested (in shares) Note 10 - Leases -Supplemental Balance Sheet Information (Details) us-gaap_DeferredRentCreditCurrent Taxes and other assessments Note 10 - Leases - Minimum Lease Payments (Details) us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-Sale Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term (Year) Note 11 - Accrued Expenses and Other Current Liabilities - Components of Accrued Expenses (Details) US Government Agencies Debt Securities [Member] Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) Proceeds from maturities of available-for-sale investments Restricted stock units, Granted (in shares) Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) Corporate Debt Securities [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Restricted stock units, Vested (in shares) Note 12 - Income Taxes - Deferred Tax Assets (Details) Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Note 12 - Income Taxes - Unrecognized Tax Positions (Details) Options, Vested and Expected to Vest, Exercisable, Number of Shares (in shares) Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share) Note 13 - Stock-based Compensation - Stock Option Activity (Details) Options, Vested or Expected to Vest, Aggregate Intrinsic Value Note 13 - Stock-based Compensation - Stock Options Outstanding (Details) Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block] Note 13 - Stock-based Compensation - RSU Activity (Details) Other comprehensive income (loss) Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) Options, Exercisable, Weighted Average Exercise Price (in dollars per share) Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Options, Exercisable, Weighted Average Remaining Contractual Term (Year) Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) Options, Exercisable, Aggregate Intrinsic Value Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Options, Exercisable, Number of Shares (in shares) Options, Outstanding, Weighted Average Remaining Contractual Term (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share) us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Purchase of available-for-sale investments Contingent consideration, measurement input Financial Instruments [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options, Outstanding, Weighted Average Exercise Price (in dollars per share) Options, Outstanding, Weighted Average Exercise Price (in dollars per share) Options, Forfeitures in Period, Weighted Average Exercise Price (in dollars per share) Deferred revenue Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share) Financial Instrument [Axis] Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share) us-gaap_AccruedLiabilitiesCurrent Total Accrued employee compensation and benefits Lessee, Operating Leases [Text Block] us-gaap_AccountsPayableCurrent Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options, Outstanding, Number of Shares (in shares) Options, Outstanding, Number of Shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Options, Cancelled, Number of Shares (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_AccruedProfessionalFeesCurrent Legal and professional fees us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) us-gaap_AccruedMarketingCostsCurrent Consulting and other vendors us-gaap_AccruedRoyaltiesCurrent Royalties us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Cash paid for taxes Current Liabilities: Developed Technology Rights [Member] Operating lease liabilities Product [Member] us-gaap_Assets Total Assets Patents [Member] Technology-Based Intangible Assets [Member] Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Intellectual Property [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Net deferred tax assets Finite-Lived Intangible Assets by Major Class [Axis] Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Shares withheld related to net share settlement of equity awards Contract assets Award Type [Domain] Award Date [Axis] Award Date [Domain] Restricted cash us-gaap_RestrictedCashAndCashEquivalents Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Net loss Net loss Award Type [Axis] us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Finite-Lived Intangible Assets, Accumulated Amortization Intellectual property, net Total Restricted Stock Units (RSUs) [Member] Finite-Lived Intangible Assets, Gross Share-Based Payment Arrangement, Option [Member] Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Property and equipment, net Property, plant and equipment, gross Canada Revenue Agency [Member] Investing Activities: Fair Value Total, fair value Earnings Per Share [Text Block] us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Accrued employee compensation and benefits Related Party Transactions Disclosure [Text Block] us-gaap_IncomeTaxExpenseBenefit Income tax expense Total income tax expense Accounts payable us-gaap_OperatingExpenses Total operating expenses us-gaap_RestrictedCashAndCashEquivalentsNoncurrent Restricted cash General and administrative us-gaap_RestrictedCash Restricted Cash us-gaap_Cash Cash Cash and cash equivalents Total cash and cash equivalents us-gaap_USGovernmentSecuritiesAtCarryingValue U.S. treasuries us-gaap_AllocatedShareBasedCompensationExpense Share-based compensation us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Change in fair value us-gaap_MoneyMarketFundsAtCarryingValue Money market Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss dei_CityAreaCode City Area Code us-gaap_TreasuryStockSharesRetired Cancellation of treasury stock (in shares) Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_GainLossOnSaleOfPropertyPlantEquipment Loss on disposal of property and equipment us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred revenue Common Stock, Shares, Outstanding (in shares) Preferred Stock, Shares Outstanding (in shares) us-gaap_IncreaseDecreaseInOtherOperatingAssets Other current and long-term assets Current Fiscal Year End Date Accrued expenses and other current liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered, excluding employee related liabilities. Lease [Member] Represents Lease. us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-Sale, Realized Gain (Loss) Weighted-average discount rate Document Fiscal Period Focus Proceeds from exercise of stock options and warrants The cash inflow from stock options and warrants exercised. Document Fiscal Year Focus Transfer of inventories to property and equipment Amount of inventory transferred to property and equipment. Consolidation, Policy [Policy Text Block] Lease, Cost [Table Text Block] dei_DocumentPeriodEndDate Document Period End Date Lease liabilities arising from obtaining right-of-use assets us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses Measurement Input, Currency Exchange Rate [Member] Measurement input using currency exchange rate. Weighted-average remaining lease term (in years) (Year) dei_EntityFileNumber Entity File Number asxc_WorkingCapital Working Capital The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities. Europe, Middle East, and Africa [Member] Europe, Middle East, and Africa. Entity Emerging Growth Company asxc_ProceedsFromIssuanceOfEquityNet Net proceeds The cash inflow from issuance of equity, net of issuance cost. All Countries [Member] Represents all countries. dei_DocumentType Document Type Performance Restricted Stock Unit [Member] Represents performance restricted stock unit. Entity Small Business dei_EntityShellCompany Entity Shell Company Long-term Operating Amount of long-term lease cost. Incremental borrowing rate Incremental borrowing rate for operating lease. Document Information [Line Items] Document Information [Table] Service [Member] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance dei_EntityPublicFloat Entity Public Float Lessee, Operating Lease, Disclosure [Table Text Block] Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Entity Filer Category dei_EntityCurrentReportingStatus Entity Current Reporting Status asxc_NumberOfMajorCustomers Number of Major Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. dei_EntityVoluntaryFilers Entity Voluntary Filers dei_EntityWellKnownSeasonedIssuer Entity Well-known Seasoned Issuer us-gaap_ImpairmentOfIntangibleAssetsFinitelived Impairment of Intangible Assets, Finite-Lived Issuance of warrants us-gaap_LessorOperatingLeasePaymentsToBeReceived Lessor, Operating Lease, Payment to be Received asxc_PeriodOfServiceSaleArrangement Period Of Service Sale Arrangement (Year) Represents the period of service sale arrangement. Senhance Surgical Robotic System Acquisition[Member] Represents Senhance Surgical Robotic System acquisition. Stock-based compensation us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Concentration risk, percent Percentage Concentration Risk, Percentage Entity Tax Identification Number Impairment of property and equipment asxc_PeriodOfServiceSaleArrangementAtStatedServicePrice Period of Service Sale Arrangement at Stated Service Price (Year) Represents the period of service sale arrangement at stated service price. Entity Central Index Key dei_EntityRegistrantName Entity Registrant Name Liability Class [Axis] Substantial Doubt about Going Concern [Policy Text Block] Disclosure of accounting policy for substantial doubt about going concern. Fair Value by Liability Class [Domain] Contingent Consideration [Policy Text Block] Disclosure accounting policy for contingent consideration. Entity [Domain] Cancellation of treasury stock Cancellation of treasury stock Customer Concentration Risk [Member] Legal Entity [Axis] dei_EntityAddressAddressLine1 Entity Address, Address Line One us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Systems [Member] Represents the systems, a product of the company. Amortization of intangible assets Instruments and Accessories [Member] Represents instruments and accessories, a type of products of the company. ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] dei_EntityAddressCityOrTown Entity Address, City or Town Geographic Concentration Risk [Member] ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] dei_EntityAddressPostalZipCode Entity Address, Postal Zip Code Supplemental Disclosure for Cash Flow Information Warrant Liabilities [Policy Text Block] Disclosure of accounting policy warrant liabilities. Schedule of Property Plant and Equipment Useful Life [Table Text Block] Tabular disclosure of the useful life of property, plant and equipment during the reporting period. dei_EntityAddressStateOrProvince Entity Address, State or Province Concentration Risk Type [Axis] Machinery, Manufacturing and Demonstration Equipment [Member] Represents machinery, manufacturing and demonstration equipment. ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss Material Terms of Trading Arrangement [Text Block] dei_EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding (in shares) asxc_BusinessCombinationContingentConsiderationArrangementsTargetRevenue Business Combination Contingent Consideration Arrangements Target Revenue The target revenue to be achieved pursuant to the business combination agreement. Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Revenue Benchmark [Member] Accounts Receivable [Member] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Finite-Lived Intangible Assets, Foreign Currency Translation Impact The accumulated impact of foreign currency translation for finite-lived intangible assets. Assets, Total [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] dei_LocalPhoneNumber Local Phone Number Exercise of stock options (in shares) Options, Exercised, Number of Shares (in shares) us-gaap_TableTextBlock Notes Tables Issuance of common stock related to vesting of restricted stock units (in shares) Exercise of stock options Issuance of common stock related to vesting of restricted stock units Related Party, Type [Axis] Related Party, Type [Domain] Bad debt expense Options, Granted, Number of Shares (in shares) Measurement input us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Options, Forfeited, Number of Shares (in shares) Schedule of Sales Under Sales Agency Agreement [Table Text Block] Schedule of sales under sales agency agreement. Sales and marketing us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Total shares of common stock sold (in shares) Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues us-gaap_OperatingCostsAndExpenses Related Party Transaction, Expenses from Transactions with Related Party (Deprecated 2023) us-gaap_LiabilitiesAndStockholdersEquity Total Liabilities and Stockholders' Equity Issuance of common stock, net of issuance costs UNITED STATES Related Party Transaction [Axis] Related Party Transaction [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Research and development Accumulated other comprehensive loss Measurement Input, Discount Rate [Member] us-gaap_InterestExpense Interest expense Measurement Input, Price Volatility [Member] Changes in operating assets and liabilities: Measurement Input, Risk Free Interest Rate [Member] us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Noncurrent operating lease liabilities Measurement Input, Expected Dividend Rate [Member] Inventory Disclosure [Text Block] Subsequent Event [Member] Measurement Input, Expected Term [Member] Schedule of Inventory, Current [Table Text Block] Restricted cash Deferred tax expense Present value of future minimum lease payments us-gaap_OperatingLeaseLiability Operating lease liabilities - current portion Subsequent Event Type [Axis] Subsequent Event Type [Domain] Operating lease right-of-use assets, net us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total minimum lease payments Capitalization of Internal Costs, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: Amount of lease payments representing interest Measurement Input Type [Axis] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2026 Measurement Input Type [Domain] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2027 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive 2028 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Thereafter Fair Value Measurement, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2025 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree 2026 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour 2027 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2024 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2025 Debt Securities, Available-for-Sale [Table Text Block] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Segment Reporting, Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2024 Lessor, Leases [Policy Text Block] Change in fair value of warrant liabilities Change in fair value of warrant liabilities Other long-term assets us-gaap_ShareBasedCompensation Stock-based compensation Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Lessee, Leases [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Finite-Lived Intangible Assets, Remaining Amortization Period (Year) us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) Comprehensive Income, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Total assets measured at fair value us-gaap_AssetsFairValueDisclosure us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Amortization of discounts and premiums on investments, net Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract (Year) us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Research and Development Expense, Policy [Policy Text Block] Long-term investments Long-term investments, available-for-sale Depreciation Depreciation Total liabilities measured at fair value us-gaap_LiabilitiesFairValueDisclosure Shares withheld related to net share settlement of equity awards (in shares) Intangible Assets Disclosure [Text Block] Average price per share (in dollars per share) us-gaap_SharesIssuedPricePerShare Inventories, net of current portion us-gaap_AssetsCurrent Total Current Assets Cash and cash equivalents us-gaap_CashAndCashEquivalentsFairValueDisclosure Share-Based Payment Arrangement [Policy Text Block] Equity [Text Block] Change in fair value of contingent consideration Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2023 and December 31, 2022; 264,921,526 and 236,895,440 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: Common Stock, Shares Authorized (in shares) Commercial Paper [Member] Common Stock, Shares, Issued (in shares) Common Stock, Par or Stated Value Per Share (in dollars per share) us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Asia [Member] Deferred Tax Asset [Domain] us-gaap_DeferredTaxAssetsValuationAllowance Valuation Allowance Cash paid for leases Statistical Measurement [Domain] Supplemental Schedule of Non-cash Investing and Financing Activities: Maximum [Member] Minimum [Member] Weighted Average [Member] Valuation Allowance by Deferred Tax Asset [Axis] Other current assets Product and Service [Axis] Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Net deferred tax asset Statistical Measurement [Axis] Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022 us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax asset (liability) Preferred Stock, Shares Issued (in shares) The 2022 ATM Offering [Member] Represents the 2022 ATM offering. Prepaid expenses asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOperationTargetsAchieved Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Operation Targets Achieved Percentage of operational targets achieved under share based payment arrangement. Geographical [Axis] Property, Plant and Equipment Disclosure [Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Geographical [Domain] us-gaap_DeferredTaxAssetsGross Deferred Tax Assets, Gross asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAwardForfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Award Forfeited Percentage of award forfeited under share based payment arrangement. Property, Plant and Equipment [Table Text Block] Preferred Stock, Shares Authorized (in shares) us-gaap_DeferredIncomeTaxLiabilities Net deferred tax liability Inventories Preferred Stock, Par or Stated Value Per Share (in dollars per share) EMEA [Member] asxc_OwnershipPercentage Ownership Percentage Percentage of ownership. Director of Asensus [Member] Represents the director of Asensus. Synchrony Labs, LLC [Member] Represents Synchrony Labs, LLC. Fair Value, Inputs, Level 3 [Member] Granted in 2023 [Member] Represents granted in 2023. Granted in 2022 [Member] Represents granted in 2022. Finished goods, gross Customer One [Member] Related to customer one. Fair Value Hierarchy and NAV [Domain] Customer [Axis] Customer Two [Member] Related to customer two. Customer [Domain] Fair Value, Inputs, Level 1 [Member] Current Portion, gross Fair Value, Inputs, Level 2 [Member] Preclinical Evaluation of the LUNA Surgical System [Member] Represents preclinical evaluation of the LUNA Surgical System. Fixed Assets asxc_IncreaseDecreaseInAccruedLiabilitiesNotIncludingEmployeeRelatedLiabilities Accrued expenses The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid, not including employee related liabilities. Fair Value Hierarchy and NAV [Axis] Raw materials, gross Warrants Issued in Registered Direct Offering [Member] Represents warrants issued in registered direct offering. Property and equipment, estimated useful lives (Year) Construction in Progress [Member] Operating Activities: Revenue [Policy Text Block] Statement [Line Items] Accounts receivable, net Furniture and Fixtures [Member] us-gaap_NumberOfOperatingSegments Number of Operating Segments Stock-based compensation us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Revenue: Additional paid-in capital AOCI Attributable to Parent [Member] Stockholders' Equity: asxc_ProceedsFromEmployeeRetentionTaxCredit Proceeds From Employee Retention Tax Credit The amount of cash inflow from employee retention tax credit. Capitalized costs Short-term investments Short-term investments, available-for-sale Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] us-gaap_OtherNonoperatingExpense Other Nonoperating Expense Other expense, net Start-up Costs and Other Intangibles [Member] Related to start-up costs and other intangibles. us-gaap_NonoperatingIncomeExpense Total other income (expense), net Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Net operating loss carryforwards Research credit carryforward Cash, Cash Equivalents, and Restricted Cash Disclosure [Text Block] The complete disclosure for cash, cash equivalents, and restricted cash. Current Assets: Long-lived Assets [Member] Represents information regarding long-lived assets. Fair Value Disclosures [Text Block] Risk And Uncertainties, Policy [Policy Text Block] Disclosure of accounting policy for risk and uncertainties for the reporting period. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Total Inventory, Policy [Policy Text Block] Contractual Obligation, Fiscal Year Maturity [Table Text Block] Interest income Schedule of Cash, Cash Equivalents, and Restricted Cash [Table Text Block] Tabular disclosure of cash, cash equivalents, and restricted cash. us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net (decrease) increase in cash, cash equivalents and restricted cash us-gaap_Liabilities Total Liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash and cash equivalents (used in) provided by financing activities Sale of Stock [Axis] Effect of exchange rate changes on cash and cash equivalents Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Operating loss Other Income (Expense), net us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash and cash equivalents used in operating activities us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash and cash equivalents provided by (used in) investing activities asxc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets Operating lease right-of-use assets The amount of increase (decrease) in right-of-use assets. us-gaap_GrossProfit Gross loss us-gaap_CostOfGoodsAndServicesSold Cost of revenue asxc_OperatingLossCarryforwardsSubjectToExpiration Operating Loss Carryforwards, Subject to Expiration Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. asxc_OperatingLossCarryforwardsNotSubjectToExpiration Operating Loss Carryforwards, Not Subject to Expiration Amount of operating loss carryforward that are not subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws. Accrued expenses and other Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities classified as noncurrent. Deferred revenue us-gaap_ContractWithCustomerLiability asxc_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent Change in unrecognized tax benefits, percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits. us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued asxc_EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationPercent Change in fair market value of contingent consideration, percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in the fair market value of contingent consideration. asxc_EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsPercent Warrant remeasurment and financing costs, percent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant remeasurement and financing costs. Accrued Liabilities [Text Block] The entire disclosure for accrued liabilities at the end of the reporting period. Change in fair market value of contingent consideration, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in fair market value of contingent consideration. . Warrant remeasurment and financing costs, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant remeasurement and financing costs. Change in unrecognized tax benefits, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits. Commisssion paid to agents us-gaap_PaymentsOfStockIssuanceCosts Concentration Risk, Credit Risk, Policy [Policy Text Block] Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan [Member] Information related to the "Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan". us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Taxes paid related to net share settlement of vesting of restricted stock units The 2015 Senhance Acquisition [Member] Pertains to the 2015 Senhance Acquisition. us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Fixed assets and other License and Supply Agreement [Member] Represents license and supply agreement. Asensus Surgical Europe S.à.R.L [Member] Represents Asensus Surgical Europe S.à.R.L . Cost of revenue: Gross proceeds us-gaap_ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity Operating Expenses: Cost of Goods and Service [Policy Text Block] us-gaap_ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants 1 Med S.A. [Member] Represents 1 Med S.A. Service Supply Agreement [Member] Represents the service supply agreement. Retained Earnings [Member] Revenue State us-gaap_ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit State Treasury Stock, Common [Member] Foreign us-gaap_DeferredForeignIncomeTaxExpenseBenefit Foreign Additional Paid-in Capital [Member] Common Stock [Member] Federal us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal Equity Components [Axis] Equity Component [Domain] us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights us-gaap_RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Foreign us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income taxes us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic United States us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Luxembourg Inland Revenue [Member] dei_IcfrAuditorAttestationFlag ICFR Auditor Attestation Flag Ministry of Economic Affairs and Finance, Italy [Member] Swiss Federal Tax Administration (FTA) [Member] State and Local Jurisdiction [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority [Axis] Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] Foreign Tax Authority [Member] Revenue from Contract with Customer [Text Block] Document Annual Report Computer Equipment [Member] Receivable [Policy Text Block] Entity Incorporation, State or Country Code asxc_InventoryCurrentAndNoncurrentGross Total inventories, gross The value of gross inventory before allowance, both current and noncurrent. General and Administrative Expense [Member] us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits Beginning balance Ending balance Long-term portion, gross The amount of inventory before valuation allowance classified as noncurrent. Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report dei_DocumentFinStmtErrorCorrectionFlag Document Financial Statement Error Correction [Flag] Basis of Accounting, Policy [Policy Text Block] asxc_IncreaseDecreaseInInventoryReserve Change in inventory reserves Represents the changes in inventory reserve. Gross decreases related to 382 limitations dei_EntityInteractiveDataCurrent Entity Interactive Data Current asxc_IncreaseDecreaseInTaxCreditCarryforward Increase (Decrease) in Tax Credit Carryforward The amount of increase (decrease) in tax credit carryforward. Security Exchange Name asxc_IncreaseDecreaseInOperatingLossCarryforwards Increase (Decrease) in Operating Loss Carryforwards The amount of increase (decrease) in operating loss carryforwards. Gross increases for tax positions related to current periods Title of 12(b) Security Income Statement Location [Axis] Income Statement Location [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] dei_AuditorName Auditor Name Common Stock Issued in Registered Direct Offering [Member] Relating to common stock issued registered direct offering. dei_AuditorFirmId Auditor Firm ID dei_AuditorLocation Auditor Location us-gaap_ContractualObligation Total commitments us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number of Shares Outstanding, Diluted, Adjustment us-gaap_TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount us-gaap_ContractualObligationDueInNextTwelveMonths 2024 Research Tax Credit Carryforward [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) us-gaap_ContractualObligationDueInSecondYear 2025 us-gaap_ContractualObligationDueInThirdYear 2026 Tax Credit Carryforward [Axis] Non-US [Member] Tax Credit Carryforward, Name [Domain] us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards Operating Lease Assets [Member] Related to operating lease assets. Statement [Table] Statement of Financial Position [Abstract] Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares) us-gaap_EffectiveIncomeTaxRateContinuingOperations Income tax expense (benefit), percent asxc_StockOfferingAgreementMaximumShareValue Stock Offering Agreement, Maximum Share Value The maximum share value issuable under a stock offering agreement. Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share) Business Acquisition [Axis] us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Change in enacted tax rates and other, net, percent asxc_StockOfferingAgreementCommissionPercent Stock Offering Agreement, Commission, Percent The percent commission payable under a stock offering agreement. Business Acquisition, Acquiree [Domain] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Change in valuation allowance, percent us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-Sale, Allowance for Credit Loss Statement of Cash Flows [Abstract] us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not to Sell before Recovery, Credit Loss, Previously Recorded, Expense (Reversal) Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Revenue from External Customers by Geographic Areas [Table Text Block] Contingent consideration us-gaap_BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability Long-Lived Assets by Geographic Areas [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense Nondeductible expenses, percent Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Research & Development, percent Contingent consideration us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes State taxes (net of deferred benefit), percent asxc_IncreaseDecreaseInTaxCreditReceivable Employee retention tax credit receivable Amount of increase (decrease) during the period in tax credit receivable. us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Foreign tax rate differential, percent Fair Value, Assets Measured on Recurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Financing Activities: Employee retention tax credit receivable Represents the amount of employer retention tax credit receivable as of the specified date. us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Cash and Cash Equivalents, Restricted Cash, and Investments, Policy [Policy Text Block] Disclosure of accounting policy for cash and cash equivalents, restricted cash, and investments. Change in enacted tax rates and other, net, amount Change in valuation allowance, amount Employer Retention Tax Credit, Policy [Policy Text Block] Disclosure of accounting policy related to the Employer Retention Tax Credit under the CARES Act. One Customer [Member] Represents one of the major customers. Proceeds from issuance of common stock, net of issuance costs The cash inflow from issuance of common stock, net of issuance cost. Impact of 382 Ownership Changes [Member] Represents the impact of 382 ownership changes. Warrant liabilites Warrant liabilities asxc_PropertyPlantAndEquipmentIncludingPurchasedSoftwareImpairmentCharges Property, Plant and Equipment, Including Purchased Software, Impairment Charges Represents the amount of impairment charges associated with property, plant and equipment (including purchased software) during the period. asxc_BusinessCombinationContingentConsiderationLiabilityRelatedMilestone Business Combination, Contingent Consideration, Liability, Related Milestone Represents the milestone amount associated with the specified liability arising from contingent consideration in a business combination. asxc_EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsPercent True-up to Stock Compensation - Cancellations, percent Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to true-up to stock compensation cancellations. True-up to Stock Compensation - Cancellations, amount Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to true-up to stock compensation cancellations. Deferred revenue - less current portion us-gaap_StockholdersEquity Total Stockholders' Equity Equity, Attributable to Parent Balance Balance Comprehensive loss: Nondeductible expenses, amount Class of Stock [Axis] us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Unrealized Loss Unrealized Gain Amortized Cost Total, amortized cost State taxes (net of deferred benefit), amount Foreign tax rate differential, amount us-gaap_IncomeTaxReconciliationTaxCreditsResearch Research & Development, amount EX-101.PRE 13 asxc-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.CAL 14 asxc-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
May 15, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Document Transition Report false    
Entity File Number 0-19437    
Entity Registrant Name ASENSUS SURGICAL, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 11-2962080    
Entity Address, Address Line One 1 TW Alexander Drive, Suite 160    
Entity Address, City or Town Durham    
Entity Address, State or Province NC    
Entity Address, Postal Zip Code 27703    
City Area Code 919    
Local Phone Number 765-8400    
Title of 12(b) Security Common Stock    
Trading Symbol ASXC    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 120.1
Entity Common Stock, Shares Outstanding (in shares)   271,986,369  
Auditor Firm ID 243    
Auditor Name BDO USA, P.C.    
Auditor Location Raleigh, North Carolina    
Entity Central Index Key 0000876378    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current Assets:    
Cash and cash equivalents $ 17,096 $ 6,329
Short-term investments, available-for-sale 3,971 64,195
Accounts receivable, net 3,508 2,256
Inventories 7,172 8,284
Prepaid expenses 3,143 3,584
Employee retention tax credit receivable 0 554
Other current assets 1,496 1,671
Total Current Assets 36,386 86,873
Restricted cash 1,642 1,141
Long-term investments, available-for-sale 0 3,865
Inventories, net of current portion 4,043 5,469
Property and equipment, net 8,959 9,542
Intellectual property, net 1,237 1,576
Net deferred tax assets 44 174
Operating lease right-of-use assets, net 5,165 4,950
Other long-term assets 1,610 2,463
Total Assets 59,086 116,053
Current Liabilities:    
Accounts payable 4,145 3,348
Accrued employee compensation and benefits 5,390 4,508
Accrued expenses and other current liabilities 1,636 1,293
Operating lease liabilities - current portion 1,036 800
Deferred revenue 421 465
Total Current Liabilities 12,628 10,414
Long-Term Liabilities:    
Deferred revenue - less current portion 290 0
Contingent consideration 2,220 1,256
Warrant liabilities 5,888 0
Noncurrent operating lease liabilities 4,646 4,738
Total Liabilities 25,672 16,408
Stockholders' Equity:    
Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2023 and December 31, 2022; 264,921,526 and 236,895,440 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively 265 237
Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022 0 0
Additional paid-in capital 973,129 962,731
Accumulated deficit (939,368) (860,935)
Accumulated other comprehensive loss (612) (2,388)
Total Stockholders' Equity 33,414 99,645
Total Liabilities and Stockholders' Equity 59,086 116,053
Intellectual Property [Member]    
Current Assets:    
Intellectual property, net $ 1,237 $ 1,576
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 $ 0.001
Common Stock, Shares Authorized (in shares) 750,000,000 750,000,000
Common Stock, Shares, Issued (in shares) 264,921,526 236,895,440
Common Stock, Shares, Outstanding (in shares) 264,921,526 236,895,440
Preferred Stock, Par or Stated Value Per Share (in dollars per share) $ 0.01 $ 0.01
Preferred Stock, Shares Authorized (in shares) 25,000,000 25,000,000
Preferred Stock, Shares Issued (in shares) 0 0
Preferred Stock, Shares Outstanding (in shares) 0 0
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue:    
Revenue $ 8,577 $ 7,087
Cost of revenue:    
Cost of revenue 13,155 10,872
Gross loss (4,578) (3,785)
Operating Expenses:    
Research and development 37,023 28,942
Sales and marketing 16,921 14,756
General and administrative 19,155 20,172
Amortization of intangible assets 453 7,708
Change in fair value of contingent consideration 964 (1,115)
Impairment of property and equipment 374 1,431
Total operating expenses 74,890 71,894
Operating loss (79,468) (75,679)
Other Income (Expense), net    
Change in fair value of warrant liabilities 1,232 0
Interest income 1,553 1,141
Interest expense 0 (410)
Other expense, net (1,436) (295)
Total other income (expense), net 1,349 436
Loss before income taxes (78,119) (75,243)
Income tax expense (314) (318)
Net loss $ (78,433) $ (75,561)
Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share) $ (0.31) $ (0.32)
Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares) 249,685 236,492
Comprehensive loss:    
Net loss $ (78,433) $ (75,561)
Foreign currency translation gain (loss) 1,280 (1,867)
Unrealized gain (loss) on available-for-sale investments 496 (257)
Comprehensive loss (76,657) (77,685)
Product [Member]    
Revenue:    
Revenue 5,519 4,327
Cost of revenue:    
Cost of revenue 6,866 5,303
Service [Member]    
Revenue:    
Revenue 1,052 1,373
Cost of revenue:    
Cost of revenue 2,293 2,174
Lease [Member]    
Revenue:    
Revenue 2,006 1,387
Cost of revenue:    
Cost of revenue $ 3,996 $ 3,395
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Treasury Stock, Common [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance (in shares) at Dec. 31, 2021 235,219,000 0        
Balance at Dec. 31, 2021 $ 235 $ 0 $ 954,649 $ (785,374) $ (264) $ 169,246
Stock-based compensation $ 0   8,416 0 0 8,416
Exercise of stock options (in shares) 43,000 0        
Exercise of stock options $ 0 $ 0 18 0 0 18
Issuance of common stock related to vesting of restricted stock units (in shares) 1,633,000 0        
Issuance of common stock related to vesting of restricted stock units $ 2 $ 0 0 0 0 2
Shares withheld related to net share settlement of equity awards (in shares) 0 443,000        
Shares withheld related to net share settlement of equity awards $ 0 $ 0 (352) 0 0 (352)
Cancellation of treasury stock (in shares) 0 (443,000)        
Cancellation of treasury stock $ 0 $ 0 0 0 0 0
Other comprehensive income (loss) 0 0 0 0 (2,124) (2,124)
Net loss 0 0   (75,561) 0 (75,561)
Cancellation of treasury stock $ (0) $ (0) (0) (0) (0) (0)
Balance (in shares) at Dec. 31, 2022 236,895,000 0        
Balance at Dec. 31, 2022 $ 237 $ 0 962,731 (860,935) (2,388) 99,645
Stock-based compensation $ 0   7,918 0 0 $ 7,918
Exercise of stock options (in shares) 13,000 0       13,300
Exercise of stock options $ 0 $ 0 5 0 0 $ 5
Issuance of common stock related to vesting of restricted stock units (in shares) 3,270,000 0        
Issuance of common stock related to vesting of restricted stock units $ 2 $ 0 0 0 0 2
Shares withheld related to net share settlement of equity awards (in shares) 0 657,000        
Shares withheld related to net share settlement of equity awards $ 0 $ 1 (497) 0 0 (496)
Cancellation of treasury stock (in shares) 0 (657,000)        
Cancellation of treasury stock $ 0 $ 1 0 0 0 (1)
Other comprehensive income (loss) 0     0 1,776 1,776
Net loss 0     (78,433) 0 (78,433)
Cancellation of treasury stock $ (0) $ (1) (0) (0) (0) 1
Issuance of common stock, net of issuance costs (in shares) 24,744,000 0        
Issuance of common stock, net of issuance costs $ 26     0 0 2,998
Balance (in shares) at Dec. 31, 2023 264,922,000 0        
Balance at Dec. 31, 2023 $ 265 $ 0 $ 973,129 $ (939,368) $ (612) $ 33,414
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating Activities:    
Net loss $ (78,433) $ (75,561)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:    
Depreciation 3,276 3,368
Amortization of intangible assets 453 7,708
Amortization of discounts and premiums on investments, net (482) 565
Stock-based compensation 7,918 8,416
Deferred tax expense 132 318
Change in inventory reserves 324 620
Bad debt expense 0 9
Impairment of property and equipment 374 1,431
Loss on disposal of property and equipment 0 122
Change in fair value of warrant liabilities (1,232) (0)
Change in fair value of contingent consideration 964 (1,115)
Changes in operating assets and liabilities:    
Accounts receivable (1,178) (1,528)
Inventories 129 (2,302)
Operating lease right-of-use assets (206) 232
Prepaid expenses 424 (450)
Employee retention tax credit receivable 554 757
Other current and long-term assets 1,173 (2,101)
Accounts payable 574 35
Accrued employee compensation and benefits 881 4,523
Accrued expenses 365 (3,955)
Deferred revenue 233 (55)
Operating lease liabilities 130 26
Net cash and cash equivalents used in operating activities (63,627) (58,937)
Investing Activities:    
Purchase of available-for-sale investments (12,268) (33,886)
Proceeds from maturities of available-for-sale investments 77,335 82,702
Purchase of property and equipment (561) (1,279)
Net cash and cash equivalents provided by (used in) investing activities 64,506 47,537
Financing Activities:    
Proceeds from issuance of common stock, net of issuance costs 10,118 0
Taxes paid related to net share settlement of vesting of restricted stock units (497) (350)
Proceeds from exercise of stock options and warrants 5 18
Net cash and cash equivalents (used in) provided by financing activities 9,626 (332)
Effect of exchange rate changes on cash and cash equivalents 763 (81)
Net (decrease) increase in cash, cash equivalents and restricted cash 11,268 (11,813)
Cash, cash equivalents and restricted cash, beginning of period 7,470 19,283
Cash, cash equivalents and restricted cash, end of period 18,738 7,470
Supplemental Disclosure for Cash Flow Information    
Cash paid for leases 1,475 984
Cash paid for taxes 352 165
Supplemental Schedule of Non-cash Investing and Financing Activities:    
Transfer of inventories to property and equipment 2,941 2,693
Lease liabilities arising from obtaining right-of-use assets $ 1,143 $ 577
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Note 1 - Description of the Business
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]

1.

Description of the Business

 

Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) (the "Company") is a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The Company is focused on the market development for and commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3mm micro-laparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

2.

Summary of Significant Accounting Policies

 

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.

 

Going Concern

The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $939.4 million and working capital of $23.8 million as of December 31, 2023. The Company has not established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

 

The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

Principles of Consolidation and Foreign Currency Considerations

The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.

 

The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity which was $0.6 million and $1.9 million as of December 31, 2023 and 2022, respectively.

 

The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 were not material.

 

Risk and Uncertainties

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: the historical lack of profitability; the Company’s ability to raise additional capital; its ability to successfully develop, clinically test, obtain regulatory clearance for and commercialize its products and products in development; negative impacts on the Company's operations caused by the hostilities in the Middle East and other geopolitical factors; the success of its market development efforts; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic and digital surgical devices; and its ability to identify and pursue development of additional products.

 

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term investments, changes in inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.

 

Cash and Cash Equivalents, Restricted Cash, and Investments

The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents.

 

Restricted cash as of December 31, 2023 and 2022 includes $1.6 million and $1.1 million, respectively, in cash accounts held as collateral primarily under the terms of office operating leases, credit cards, and automobile leases, and a guarantee required by the government of a country for a 2019 VAT refund.

 

The Company’s investments as of December 31, 2023 consisted of corporate bonds that were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion are included in interest expense, net. There were no gross realized gains or loss for the years ended December 31, 2023 and 2022.

 

Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. 

 

There have been no credit losses for the years ended December 31, 2023 and 2022, and no allowance for credit losses as of December 31, 2023 and 2022. Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.

 

Fair Value Measurements

The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level 3 inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.

 

Concentrations and Credit Risk

The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.

 

The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company had one customer that accounted for 83% and 69% of the Company’s net accounts receivable as of December 31, 2023 and December 31, 2022, respectively. The Company had two customers that accounted for 33% and 19% of revenue in 2023, and one customer who accounted for 47% of revenue in 2022, respectively.

 

Accounts Receivable

Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current and future economic conditions that may affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million as of December 31, 2023 and 2022.

 

Inventories

Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

 

Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve months.

 

Definite-Lived Intangible Assets - Intellectual Property

Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&D”) assets related to (i) the Senhance System acquired in 2015 and reclassified in 2017 and (ii) a 2018 acquisition and reclassified in 2020. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 7 years.

 

The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. No impairment of intellectual property was identified during the years ended December 31, 2023 and 2022.

 

Property and Equipment

Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

 

   

Years

  

Operating lease assets – Senhance System leasing

     5    

Machinery, manufacturing, and demonstration equipment

   3 - 5  

Computer equipment

     3    

Furniture

     5    

Leasehold improvements

  

Lesser of lease term or 3-10

  

 

The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.

 

During the years ended December 31, 2023 and 2022, the Company recorded a non-cash asset impairment charge of $0.4 million and $1.4 million, respectively, to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss.

 

 

Operating Leases

The Company has operating leases for its corporate office buildings, vehicles, and machinery and equipment. At inception, the Company determines whether an agreement represents a lease, and at commencement, it evaluates each lease agreement to determine whether the lease constitutes an operating or financing lease.

 

The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do not provide a significant economic incentive and are therefore excluded from the lease term. While its operating leases range from one year to ten years, some may include options to extend the lease generally between one year and six years, and some may include options to terminate the leases within one year.

 

The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.

 

Implementation Costs in a Cloud Computing Arrangement

The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.

 

Employee Retention Tax Credit Receivable

The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended December 31, 2021, the Company submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received $0.7 million of the ERTC refund during the year ended December 31, 2022 and received the remaining $0.6 million during the year ended December 31, 2023.

 

Contingent Consideration

Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 

On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in 2016, as of December 31, 2023, the Company has accrued $2.2 million of estimated fair value of remaining contingent consideration related to a milestone of €15.0 million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least €25.0 million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In 2022, Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.

 

Warrant Liabilities

The Company’s warrants (see “Note 14 – Equity Offerings,”) are measured at fair value using a Black-Scholes-Merton model option-pricing model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected stock price volatility, the expected dividend yield which is assumed to be zero since The Company has not paid and does not anticipate paying cash dividends on its shares of common stock and the risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the term of the warrant (see “Note 6 – Fair Value,”). The warrant liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on considerations specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements could include a five-year service period; the first year of service is generally free and included in the Senhance System sale arrangement with an option to purchase the remaining four years at a stated service price.

 

The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.

 

For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services.

 

The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:

 

 

●

System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

 

 

●

Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.

 

 

●

Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

 

The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements and are included in accounts receivable.

 

In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not meet the requirements to be capitalized as the Company does not expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.

 

Senhance System Leasing

The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended December 31, 2023 and 2022, variable lease revenue related to usage-based arrangements was not material.  

 

In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2023 are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of December 31, 2023, future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next one to two years.

 

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.

 

Research and Development Costs

Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.

 

Stock-Based Compensation

The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjusts the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.

 

The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note 13 – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.

 

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.

 

The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not sustain the position following audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.

 

Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may be subject to examination by authorities for all previously filed income tax returns.

 

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

 

Segments

The Company operates in one business segment—the research, development and sale of medical device robotics to improve MIS. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

 

Impact of Recently Issued Accounting Standards

In November 2023, the FASB issued Accounting Standards Update, or ASU, No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU looks to provide improvements to the segment disclosure by providing users with more decision-useful information about reportable segments in a public entity. The main provisions require a company to disclose, on an annual and interim basis, significant expenses included within each reported measure of segment profit or loss, an amount for other segment items by reportable segment and a description of its composition. It also requires all annual disclosures about a reportable segments’ profit or loss and assets to be reported on an interim basis.

 

The ASU is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.

 

In December 2023, the FASB issues ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU looks to enhance the transparency and decision usefulness of income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The main provisions to the rate reconciliation disclosure require public entities on an annual basis to: disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The main provisions to the income taxes paid disclosure require that all entities disclose on an annual basis: the amount of income taxes paid disaggregated by federal, state and foreign taxes and the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid meets a quantitative threshold. This ASU also requires all entities to disclose: income (loss) from continuing operations before income tax expense (benefit) disaggregated between domestic and foreign and income tax expense (benefit) from continuing operations disaggregated by federal, state and foreign.

 

This ASU is to be applied on a prospective basis with an effective date for all public entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Revenue Recognition
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

3.

Revenue Recognition

 

The following table presents revenue disaggregated by type and geography:

 

   

Years Ended December 31,

 
   

2023

    

2022

  
    (in thousands)  

U.S.

                

Instruments and accessories

   $ 205     $ 211  

Services

     294       300  

Leases

     196       256  

Total U.S. revenue

     695       767  
                 

Outside of U.S. ("OUS")

                

Systems

     3,645       2,551  

Instruments and accessories

     1,669       1,565  

Services

     758       1,073  

Leases

     1,810       1,131  

Total OUS revenue

     7,882       6,320  
                 

Total

                

Systems

     3,645       2,551  

Instruments and accessories

     1,874       1,776  

Services

     1,052       1,373  

Leases

     2,006       1,387  

Total revenue

   $ 8,577     $ 7,087  

 

Remaining Performance Obligations

The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to service obligations performed under the Company's system sales contracts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations as of December 31, 2023 was $0.9 million, which is expected to be recognized over one to four years. 

 

Contract Assets and Liabilities

Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2023 and 2022 was $0.5 million, which was included in the deferred revenue balance of $0.5 million as of December 31, 2022 and 2021.

 

The following information summarizes the Company’s contract assets and liabilities:

 

   

December 31, 2023

    

December 31, 2022

  
   

(in thousands)

  

Contract assets

   $ 95     $ 116  

Deferred revenue

   $ 711     $ 465  

 
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Cash, Cash Equivalents, and Restricted Cash
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Cash, Cash Equivalents, and Restricted Cash Disclosure [Text Block]

4.

Cash, Cash Equivalents, and Restricted Cash

 

Cash, cash equivalents and restricted cash consist of the following:

 

   

December 31,

    

December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Cash

   $ 4,588     $ 3,473  

Money market

     5,521       2,856  

U.S. treasuries

     6,987       -  

Total cash and cash equivalents

   $ 17,096     $ 6,329  

Restricted cash

     1,642       1,141  

Total

   $ 18,738     $ 7,470  

 

Restricted cash at December 31, 2023 and 2022 includes $1.6 million and $1.1 million, respectively, in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, automobile leases, and a guarantee required by the government of a country for a 2019 VAT refund.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Investments, Available-for-sale
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

5.

Investments, available-for-sale

 

The aggregate fair values of investment securities along with cumulative unrealized gains and losses determined on an individual investment security basis and included in other comprehensive loss are as follows:

 

   

December 31, 2023

  
   

Amortized

Cost

    

Unrealized

Gain

    

Unrealized

Loss

    

Fair

Value

    

Short-term

investments

  
                (in thousands)              

Corporate bonds

   $ 3,981     $ -     $ (10 )   $ 3,971     $ 3,971  

Total investments

   $ 3,981     $ -     $ (10 )   $ 3,971     $ 3,971  

 

   

December 31, 2022

  
   

Amortized

Cost

    

Unrealized

Gain

    

Unrealized

Loss

    

Fair

Value

    

Short-term

investments

    

Long-term

investments

  
                (in thousands)              

Commercial paper

   $ 12,364     $ -     $ (49 )   $ 12,315     $ 12,315     $ -  

Corporate bonds

     55,201       -       (447 )     54,754       50,889       3,865  

U.S. government agencies

     999       -       (8 )     991       991       -  

Total investments

   $ 68,564     $ -     $ (504 )   $ 68,060     $ 64,195     $ 3,865  

 

The following table summarizes the contractual maturities of the Company’s available-for-sale investments:

 

   

December 31, 2023

  
   

Amortized

Cost

    

Fair Value

  
    (in thousands)  

Mature in less than one year

   $ 3,981     $ 3,971  

Total

   $ 3,981     $ 3,971  

 

Actual maturities may differ from contractual maturities because certain borrowers have the right to call or prepay certain obligations. There were no sales of investments for the years ended December 31, 2023 or 2022, respectively. There were no realized gains or losses for the years ended December 31, 2023 and 2022 respectively.

 

 
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Fair Value
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

6.

Fair Value

 

The following are categories of assets and liabilities measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):

 

 

   

December 31, 2023

  

 

  

Quoted Prices
in Active

Markets for
Identical Assets
(Level 1)

    

Significant
Other
Observable
Inputs (Level 2)

    

Significant
Unobservable
Inputs (Level 3)

    

Total

  
Description         (in thousands)        

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 17,096     $ -     $ -     $ 17,096  

Restricted cash

     1,642       -       -       1,642  

Short-term investments

     -       3,971       -       3,971  

Total assets measured at fair value

   $ 18,738     $ 3,971     $ -     $ 22,709  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 2,220     $ 2,220  
Warrant Liabilities     -       -       5,888       5,888  

Total liabilities measured at fair value

   $ -     $ -     $ 8,108     $ 8,108  

 

   

December 31, 2022

  

 

  

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

    

Significant

Other

Observable

Inputs (Level 2)

    

Significant Unobservable

Inputs (Level 3)

    

Total

  
Description         (in thousands)        

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 6,329     $ -     $ -     $ 6,329  

Restricted cash

     1,141       -       -       1,141  

Short-term investments

     -       64,195       -       64,195  

Long-term investments

     -       3,865       -       3,865  

Total assets measured at fair value

   $ 7,470     $ 68,060     $ -     $ 75,530  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 1,256     $ 1,256  

Total liabilities measured at fair value

   $ -     $ -     $ 1,256     $ 1,256  

 

(1) Includes investments that are readily convertible to cash with original maturities of 90 days or less.

 

The carrying values of accounts receivable, prepaid expenses, employee retention tax credit receivables, other current assets, accounts payable, accrued employee compensation and benefits, accrued expenses, deferred revenue, and other current liabilities as of December 31, 2023 and December 31, 2022, approximate to their fair values due to the short-term nature of these items and are considered to be Level 1.

 

The Company’s financial liabilities consisted of contingent consideration payable to Three Heads Investment S.r.l., related to the Company’s 2015 acquisition of the Senhance Surgical System from an assignor to Three Heads Investment S.r.l. (the “Senhance Acquisition”). Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statements of operations and comprehensive loss.

 

 

The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements for contingent consideration utilizing a Monte-Carlo simulation as of December 31, 2023 and December 31, 2022:

 

 

 

Valuation
Methodology
 

  

Significant
Unobservable

Input

  

December 31,
2023
 

    

December 31,
2022
 

  
                       

Contingent consideration

Probability
weighted
income
approach

  

Milestone dates

  

2032

    

2032

  
     

Discount rate

     10.0 %     16.5 %
     

Revenue volatility

     35.0 %     45.0 %
     

EUR-to-USD exchange rate

     1.10       1.07  

 

The following table presents the long-term portion of the contingent consideration for the year ended December 31, 2023 and summarizes the change in fair value, as determined by Level 3 inputs for the contingent consideration for the year ended December 31, 2023 and 2022:

 

 

 

  

Fair Value

  
   

(in thousands)

  

Balance at December 31, 2021

   $ 2,371  

Change in fair value

     (1,115 )

Balance at December 31, 2022

   $ 1,256  

Change in fair value

     964  

Balance at December 31, 2023

   $ 2,220  

 

Warrant Liabilities

 

During 2023, the Company recorded warrant liabilities related to common stock warrants issued in the registered direct offering in July 2023 (for additional information about the offering, please refer to Note 14 -Equity Offerings).

 

Warrant liabilities were recorded at their initial estimated fair value. Adjustments associated with changes in fair value of the warrant liabilities are included in the Company’s consolidated statements of operations and comprehensive loss. The following table summarizes changes in estimated fair value of the warrant liabilities for the warrants issued in July 2023 as of December 31, 2023:

 

 

 

  

Fair Value

  
    (in thousands)  

Balance at December 31, 2022

   $ -  

Issuance of warrants

     7,120  

Change in fair value

     (1,232 )

Balance at December 31, 2023

   $ 5,888  

 

 

The fair value of the warrant liabilities were estimated using the Black-Scholes option pricing model, which is based on unobservable inputs and is designated as Level 3 in the fair value hierarchy. The following table summarizes the assumptions used in determining fair value of warrant liabilities:

 

   

As of December 31,

2023

  

Expected dividend yield

     0 %

Expected volatility

     117 %

Risk-free interest rate

     3.8 %

Expected life (in years)

     4.6  

 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Inventories
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Inventory Disclosure [Text Block]

7.

Inventories

 

The components of inventories are as follows:

 

   

December 31, 2023

    

December 31, 2022

  
   

(in thousands)

  

Finished goods

   $ 9,200     $ 11,208  

Raw materials

     2,015       2,545  

Total inventories

   $ 11,215     $ 13,753  
                 

Current Portion

   $ 7,172     $ 8,284  

Long-term portion

     4,043       5,469  

Total inventories

   $ 11,215     $ 13,753  

 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Property and Equipment
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

8.         Property and Equipment

 

Property and equipment consisted of the following:

 

   

December 31,

    

December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Machinery, manufacturing, and demonstration equipment

   $ 9,089     $ 8,450  

Operating lease assets - Senhance System leasing

     12,848       10,251  

Computer equipment

     603       600  

Furniture

     715       831  

Leasehold improvements

     1,721       1,654  

Construction in process

     70       436  

Total property and equipment

     25,046       22,222  

Accumulated depreciation and amortization

     (16,087

)

     (12,680

)

Property and equipment, net

   $ 8,959     $ 9,542  

 

Depreciation expense was approximately $3.3 million and $3.4 million for the years ended December 31, 2023 and 2022, respectively.

 

 
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Intellectual Property
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]

9.         Intellectual Property

 

The components of gross intellectual property, accumulated amortization, and net intellectual property are as follows:

 

   

December 31, 2023

  
   

Gross Carrying Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net Carrying

Amount

  
          (in thousands)        

Developed technology

   $ 68,838     $ (66,902 )   $ (837 )   $ 1,099  

Technology and patents purchased

     400       (279 )     17       138  

Total intellectual property

   $ 69,238     $ (67,181 )   $ (820 )   $ 1,237  

 

   

December 31, 2022

  
   

Gross Carrying Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net Carrying

Amount

  
          (in thousands)        

Developed technology

   $ 68,838     $ (66,562 )   $ (874 )   $ 1,402  

Technology and patents purchased

     400       (239 )     13       174  

Total intellectual property

   $ 69,238     $ (66,801 )   $ (861 )   $ 1,576  

 

The weighted average remaining useful life of the developed technology and technology and patents purchased was 3.2 years and 3.3 years, respectively, as of December 31, 2023. The weighted average remaining useful life of the developed technology and technology and patents purchased was 4.2 years and 4.3 years, respectively as of December 31, 2022.

 

The estimated future amortization expense of intellectual property as of December 31, 2023 is as follows (in thousands):

 

   

Year Ending
December 31, 2023

  

2024

   $ 388  

2025

     388  

2026

     389  

2027

     72  

Total

   $ 1,237  

 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Leases
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]

10.         Leases

 

Lessee Information

Components of operating lease expense are primarily recorded in general and administrative on the consolidated statements of operations and comprehensive loss were as follows:

 

   

Years Ended December 31,

  
   

2023

      

2022

  
     

(in thousands)

  

Long-term operating

   $ 1,888       $ 1,557  

 

 

Supplemental balance sheet information related to operating leases was as follows:

 

   

Years Ended December 31,

  
   

2023

    

2022

  

 

  

 

    

 

  

Weighted-average remaining lease term (in years)

     5.7         6.8    

Weighted-average discount rate

     9.2%         8.4%    

Incremental borrowing rate

   7.1% - 23.0%     6.1% - 14.5%  

 

Maturities of finance and operating lease obligations as of December 31, 2023 were as follows (in thousands):

 

Fiscal Year

        

2024

   $ 1,491  

2025

     1,377  

2026

     1,160  

2027

     904  

2028

     834  

Thereafter

     1,406  

Total minimum lease payments

   $ 7,172  

Less: Amount of lease payments representing interest

     (1,490 )

Present value of future minimum lease payments

   $ 5,682  

 
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Note 11 - Accrued Expenses and Other Current Liabilities
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Accrued Liabilities [Text Block]

11.         Accrued Expenses and Other Current Liabilities

 

The following table presents the components of accrued expenses and other current liabilities:

 

   

Years Ended December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Consulting and other vendors

   $ 461     $ 155  

Royalties

     9       24  

Legal and professional fees

     411       275  

Taxes and other assessments

     755       839  

Total

   $ 1,636     $ 1,293  

 

 
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Income Taxes
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

12.         Income Taxes

 

The components for the income tax expense are as follows for the years ended December 31 (in thousands):

 

   

2023

    

2022

  
    (in thousands)  

Current income taxes

                

Federal

   $ -     $ -  

State

     -       -  

Foreign

     196       239  

Deferred income taxes

     -          

Federal

     -       -  

State

     -       -  

Foreign

     118       79  

Total income tax expense

   $ 314     $ 318  

 

The United States and foreign components of loss from operations before taxes are as follows for the years ended December 31 (in thousands):

 

   

2023

    

2022

  
    (in thousands)  

United States

   $ (53,226 )   $ (44,802 )

Foreign

     (24,893 )     (30,441 )

Total loss from operations before taxes

   $ (78,119 )   $ (75,243 )

 

Significant components of the Company’s deferred tax assets consist of the following at December 31 (in thousands):

 

   

2023

    

2022

  
    (in thousands)  

Deferred Tax assets:

                

Stock-based compensation

   $ 3,119     $ 2,840  

Accrued expenses and other

     2,666       2,538  

Research credit carryforward

     2,859       1,341  

Fixed assets

     319       162  

Capitalized start-up costs and other intangibles

     644       921  

Capitalized research costs

     9,064       4,382  

Net operating loss carryforwards

     93,332       83,908  
      112,003       96,092  

Valuation allowance

     (110,511 )     (94,704 )

Net deferred tax asset

     1,492       1,388  

Deferred tax liabilities

                

Fixed assets and other

     (1,448 )     (1,214 )

Net deferred tax liability

     (1,448 )     (1,214 )

Net deferred tax asset

   $ 44     $ 174  

 

At December 31, 2023 and 2022, the Company has provided a full valuation allowance against its net deferred assets in the U.S., Canada, Italy, Luxembourg, Switzerland, and Taiwan tax jurisdictions, since realization of these benefits is not more likely than not. The valuation allowance increased approximately $15.8 million from the prior year. At December 31, 2023, the Company had U.S. federal net operating loss carryforwards of $446.7 million, of which $253 million are expected to expire unused under the limitations imposed by Internal Revenue Code Section 382. Of the total amount of Federal NOLs (notwithstanding the 382 limitation), $254.5 million begin to expire in 2027, while the remaining $192.2 million carry forward indefinitely. At December 31, 2023, the Company had U.S. state net operating loss carryforwards of $336.3 million, of which $199 million are expected to expire unused under the state tax law equivalents of Internal Revenue Code Section 382. Of this amount (notwithstanding the 382 limitations), $323.0 million of state NOLs begin to expire in 2024, while the remaining $13.3 million carry forward indefinitely. At December 31, 2023, the Company had federal research credit carryforwards in the amount of $11.7 million. These carryforwards begin to expire in 2027. However, under the limitations of Internal Revenue Code Section 383, it is expected that $8.8 million of this carryforward will expire unused. The utilization of the federal net operating loss carryforwards and credit carryforwards will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the carryforwards.

 

At December 31, 2023, the Company had foreign operating loss carryforwards in Italy of approximately $25.0 million, which can be carried forward indefinitely; foreign operating loss carryforwards in Luxembourg of approximately $95.6 million, which will begin to expire in 2034; foreign operating loss carryforwards in Switzerland of approximately $135.3 million, which begin to expire in 2024, and foreign operating loss carryforwards in Canada of approximately $1.4 million, which begin to expire in 2040.

 

The Company has evaluated its tax positions to consider whether it has any unrecognized tax benefits. As of December 31, 2023, the Company had gross unrecognized tax benefits of approximately $0.7 million. Of the total, none would reduce the Company’s effective tax rate if recognized. The Company does not anticipate a significant change in total unrecognized tax benefits or the Company’s effective tax rate due to the settlement of audits or the expiration of statutes of limitations within the next twelve months. Furthermore, the Company does not expect any cash settlement with the taxing authorities as a result of these unrecognized tax benefits as the Company has sufficient unutilized carryforward attributes to offset the tax impact of these adjustments.

 

The following is a tabular reconciliation of the Company’s change in gross unrecognized tax positions at December 31 (in thousands):

 

   

2023

    

2022

  
    (in thousands)  

Beginning balance

   $ 335     $ 141  

Gross increases for tax positions related to current periods

     328       194  

Gross decreases related to 382 limitations

     52       -  

Ending balance

   $ 715     $ 335  

 

The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2023 and 2022, the Company had no accrued interest or penalties related to uncertain tax positions.

 

The Company has analyzed its filing positions in all significant federal, state, and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, the Company is no longer subject to United States Federal, state, and local tax examinations by tax authorities for years before 2020, although carryforward attributes that were generated prior to 2020 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.

 

Taxes computed at the then-current statutory federal income tax rate of 21% are reconciled to the provision for income taxes as follows for the years ended December 31:

 

    2023     2022  
   

Amount

   

Percent of

Pretax

Earnings

   

Amount

   

Percent of

Pretax

Earnings

 
    (in thousands)  

United States federal tax at statutory rate

   $ (16,405 )     21.0 %   $ (15,801 )     21.0 %

State taxes (net of deferred benefit)

     (2,493 )     3.2 %     (2,912 )     3.9 %

Nondeductible expenses

     755       (1.0 %)     1,077       (1.4 %)

Change in fair market value of contingent consideration

     244       (0.3 %)     (283 )     0.4 %

Warrant remeasurement and financing costs

     (140 )     0.2 %     -       -  

Research & development

     (1,898 )     2.4 %     (970 )     1.3 %

Change in unrecognized tax benefits

     380       (0.5 %)     194       (0.3 %)

Foreign tax rate differential

     3,176       (4.1 %)     2,676       (3.6 %)

True-up to stock compensation - cancellations

     -       -       49       (0.1 %)

Change in enacted tax rates and other, net

     659       (0.8 %)     (96 )     0.0  

Change in valuation allowance

     16,036       (20.5 %)     16,384       (21.8 %)

Income tax expense (benefit)

   $ 314       (0.4 %)   $ 318       (0.4 %)

 
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Stock-based Compensation
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

13.         Stock-Based Compensation

 

Incentive Compensation Plan Information

 

On June 6, 2023, at the 2023 Annual Meeting of Stockholders, the Company’s stockholders voted to approve an amendment and restatement of the Company’s Incentive Compensation Plan (“the Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. As of December 31, 2023, there were 54,072,307 shares authorized for issuance, and 22,185,899 shares available for future issuance under the Plan. To date all equity awards under the Plan have consisted of nonqualified stock options, incentive stock options, restricted stock units and stock awards.

 

Under the Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock units, restricted stock or stock awards to employees, officers, non-employee directors, consultants, and vendors. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company’s shares at the date of grant. Additionally, no stock options or stock appreciation rights granted under the Plan may have a term exceeding ten years.

 

Stock Options

 

The following table summarizes the Company’s stock option activity, including grants to non-employees, for the year ended December 31, 2023:

 

   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

  

Balance at December 31, 2022

     7,584,967     $ 4.22       5.31  

Granted

     3,047,615       0.71          

Forfeited

     (149,430 )     0.78          

Cancelled

     (25,173 )     27.32          

Exercised

     (13,300 )     0.38          

Balance at December 31, 2023

     10,444,679     $ 3.20       4.80  

 

The weighted-average grant date fair value of stock options was $0.59 during the years ended December 31, 2023 and 2022. The aggregate intrinsic value of stock options exercised under the Company’s stock plans was not material during the years ended December 31, 2023 and 2022.

 

The following table summarizes information about stock options outstanding at December 31, 2023:

 

   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average Remaining

Contractual Term (Years)

    

Aggregate

Intrinsic Value (Millions)

  

Exercisable at December 31, 2023

     5,726,280     $ 5.02       4.12     $ -  

Vested or expected to vest at December 31, 2023

     10,105,084     $ 3.28       4.77     $ -  

 

The fair value of options granted were estimated using the Black-Scholes-Merton option pricing model based on the assumptions in the table below:

 

    Years Ended December 31,  
    2023     2022  

Expected dividend yield

     0%         0%    

Expected volatility

   124% - 130%     126% - 133%  

Risk-free interest rate

   3.53% - 4.14%     1.25% - 4.40%  

Expected life (in years)

   3.8 - 4.5     3.8 - 4.5  

 

Restricted Stock Units

 

The following is a summary of the restricted stock unit activity, including performance restricted stock units, for the year ended December 31, 2023:

 

   

Number of

Restricted Stock

Units Outstanding

    

Weighted-Average

Grant Date Fair

Value

  

Unvested December 31, 2022

     8,483,491     $ 1.04  

Granted

     8,616,931       0.70  

Vested

     (3,937,130 )     1.10  

Forfeited

     (837,115 )     0.76  

Unvested December 31, 2023

     12,326,177     $ 0.81  

 

Performance Restricted Stock Units

 

In 2023 and 2022, the Company granted performance-based restricted stock units (“PRSUs”). The number of shares earnable under the 2023 and 2022 awards were based on achieving certain operational targets by December 31, 2023 (for the PRSUs granted in 2023) and October 1, 2023 (for the PRSUs granted in 2022), respectively. In February 2024, the Board determined that the operational targets for PRSU awards granted in 2023 were 50% achieved and as a result, the 2023 PRSUs were 50% earned and remain subject to three-year time-based vesting requirements. The other 50% of the 2023 PRSUs were forfeited. The operational targets were achieved for the PRUSs granted in 2022, therefore the 2022 PRSUs were fully earned and remain subject to three-year time-based vesting requirements.

 

Stock-based Compensation Expense

 

The following table summarizes non-cash stock-based compensation expense by award type for the years ended December 31, 2023, and 2022:

 

   

Years Ended December 31,

 
   

2023

      

2022

  
   

(in thousands)

  

Stock options

   $ 2,338       $ 3,654  

Restricted stock units

     3,954         3,319  

Performance restricted stock units

     1,626         1,443  
    $ 7,918       $ 8,416  

 

As of December 31, 2023, the unrecognized stock-based compensation expense related to unvested stock options was approximately $1.6 million, which is expected to be recognized over an estimated weighted-average period of 1.4 years. As of December 31, 2023, the unrecognized stock-based compensation expense related to unvested restricted stock units and performance restricted stock units was approximately $4.4 million, which is expected to be recognized over a weighted average period of approximately 1.2 years.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Note 14 - Equity Offerings
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Equity [Text Block]

14.         Equity Offerings

 

Equity financing transactions for the years ended December 31, 2023 and 2022, include:

 

 

2022 At-The-Market Offering

 

On March 18, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”) with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc., collectively, “the Agents”. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could offer and sell, from time to time, at its option, shares of its common stock for an aggregate offering price of up to $100.0 million. The aggregate compensation payable to the Agents was 3.0% of the aggregate gross proceeds from each sale of the Company’s common stock. No shares were sold under the 2022 ATM Offering in 2022.

 

The following table presents details about common stock issued pursuant to the 2022 ATM Offering (in thousands, except share and per share amounts):

 

   

Year Ended

December 31, 2023

  

Total shares of common stock sold

     933,672  

Average price per share

   $ 0.43  

Gross proceeds

   $ 403  

Commission paid to agents

   $ 12  

Net proceeds

   $ 391  

 

2023 Registered Equity Offering

 

On July 27, 2023, the Company sold, in a registered direct offering, an aggregate of 23,809,524 shares of common stock, and warrants to purchase 23,809,524 of the Company’s common stock shares at an exercise price of $0.42 per common share (the “warrants”), for an aggregate purchase price of $10.0 million. The warrants are exercisable at any time on or after the date of issuance and will expire five years after the date of issuance. Based on the assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 – Distinguishing Liabilities from Equity and ASC 815 – Derivatives and Hedging, the Company determined that warrants did not meet the requirements for equity classification. Accordingly, the warrants were recorded as a liability on the Company’s balance sheet at their initial estimated fair value on the date of issuance. For additional information regarding the fair value of warrant liabilities, please refer to Note 4 – Fair Value Measurements.

 

The Company allocated $7.1 million of the aggregate proceeds to warrants based on their estimated fair value, with the residual amount of $2.9 million allocated to common stock. Offering related issuance costs were approximately $1.0 million and consisted primarily of placement agent’s fees and legal expenses. Issuance costs were allocated to common stock and warrant liability proportionally to the allocation of the purchase price. During the year ended December 31, 2023, the Company recorded $0.7 million of other expense, net, in the consolidated statement of operations related to issuance costs allocated to warrant liabilities.
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Note 15 - Basic and Diluted Net Loss Per Share
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Earnings Per Share [Text Block]

15.         Basic and Diluted Net Loss per Share

 

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all potential dilutive common shares that were outstanding during the period. Potential dilutive common shares consist of incremental shares issuable upon exercise of stock options, restricted stock units, and warrants. No adjustments have been made to the weighted average outstanding common shares figures for the years ended December 31, 2023 or 2022 as the assumed exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.

 

Potential common shares not included in calculating diluted net loss per share are as follows:

 

   

December 31,

 
   

2023

    

2022

  

Stock options

     10,444,679       7,584,967  

Nonvested restricted stock units

     12,326,177       8,483,491  

Stock warrants

     24,830,500       1,021,076  

Total

     47,601,356       17,089,534  

 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Note 16 - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

16.         Commitments and Contingencies

 

License and Supply Agreements

As part of the Company’s acquisition of the Senhance System in 2015, the Company assumed certain license and supply agreements. The Company has purchase orders with various suppliers for certain tooling, supplies, contract engineering and research services. Commitments related to license agreements and purchase orders are as follows (in thousands):

 

Fiscal Year

        

2024

   $ 3,263  

2025

     300  

2026

     320  

Total commitments

   $ 3,883  

 

 
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Note 17 - Segments and Geographic Areas
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

17.         Segments and Geographic Areas

 

The Company operates in one business segment—the research, development, and sale of medical devices to improve MIS. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

 

The following table presents consolidated assets and long-lived assets by geographic area, which includes property and equipment, intellectual property, and operating lease assets:

 

   

December 31, 2023

  
   

Long-Lived Assets

    

Total Assets

  

US

     29 %     46 %

EMEA

     68 %     52 %

Asia

     3 %     2 %

Total

     100 %     100 %

 

   

December 31, 2022

  
   

Long-Lived Assets

    

Total Assets

  

US

     35 %     72 %

EMEA

     62 %     27 %

Asia

     3 %     1 %

Total

     100 %     100 %

 

The following table presents sales by geographic area based on the country in which the customer is based.

 

   

Years Ended December 31,

 
   

2023

    

2022

  

US

     8 %     11 %

EMEA

     82 %     77 %

Asia

     10 %     12 %

Total

     100 %     100 %

 
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Note 18 - Related Party Transactions
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Related Party Transactions Disclosure [Text Block]

18.         Related Party Transactions

 

In March 2018, Asensus Surgical Europe S.à r.l. entered into a Service Supply Agreement with 1 Med S.A. for certain regulatory consulting services. Andrea Biffi, a current member of the Company’s Board of Directors, owns a non-controlling interest in 1 Med S.A. Expenses under the Service Supply Agreement were approximately $0.1 million and $0.3 million for the years ended December 31, 2023 and 2022, respectively.

 

In October 2023, Asensus Surgical US, Inc. entered into an agreement with Synchrony Labs, LLC to support preclinical evaluation of the LUNA Surgical System. William Starling, a current member of the Company’s Board of Directors, owns more than 10% of Synchrony Labs, LLC. Expenses under the agreement were approximately $0.1 million for the year ended December 31, 2023.

 

 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
 3 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2023
Insider Trading Arr Line Items    
Material Terms of Trading Arrangement [Text Block]  

ITEM 9.B.       OTHER INFORMATION

 

 

During the three months ended December 31, 2023, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as such terms are defined in Item 408 of Regulation S-K.
Rule 10b5-1 Arrangement Adopted [Flag] false  
Rule 10b5-1 Arrangement Terminated [Flag] false  
Non-Rule 10b5-1 Arrangement Adopted [Flag] false  
Non-Rule 10b5-1 Arrangement Terminated [Flag] false  
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.

 
Substantial Doubt about Going Concern [Policy Text Block]

Going Concern

The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $939.4 million and working capital of $23.8 million as of December 31, 2023. The Company has not established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.

 

The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 
Consolidation, Policy [Policy Text Block]

Principles of Consolidation and Foreign Currency Considerations

The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.

 

The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity which was $0.6 million and $1.9 million as of December 31, 2023 and 2022, respectively.

 

The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 were not material.

 
Risk And Uncertainties, Policy [Policy Text Block]

Risk and Uncertainties

The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: the historical lack of profitability; the Company’s ability to raise additional capital; its ability to successfully develop, clinically test, obtain regulatory clearance for and commercialize its products and products in development; negative impacts on the Company's operations caused by the hostilities in the Middle East and other geopolitical factors; the success of its market development efforts; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic and digital surgical devices; and its ability to identify and pursue development of additional products.

 
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term investments, changes in inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.

 
Cash and Cash Equivalents, Restricted Cash, and Investments, Policy [Policy Text Block]

Cash and Cash Equivalents, Restricted Cash, and Investments

The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents.

 

Restricted cash as of December 31, 2023 and 2022 includes $1.6 million and $1.1 million, respectively, in cash accounts held as collateral primarily under the terms of office operating leases, credit cards, and automobile leases, and a guarantee required by the government of a country for a 2019 VAT refund.

 

The Company’s investments as of December 31, 2023 consisted of corporate bonds that were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion are included in interest expense, net. There were no gross realized gains or loss for the years ended December 31, 2023 and 2022.

 

Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. 

 

There have been no credit losses for the years ended December 31, 2023 and 2022, and no allowance for credit losses as of December 31, 2023 and 2022. Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.

 
Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level 3 inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.

 
Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations and Credit Risk

The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.

 

The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company had one customer that accounted for 83% and 69% of the Company’s net accounts receivable as of December 31, 2023 and December 31, 2022, respectively. The Company had two customers that accounted for 33% and 19% of revenue in 2023, and one customer who accounted for 47% of revenue in 2022, respectively.

 
Receivable [Policy Text Block]

Accounts Receivable

Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current and future economic conditions that may affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million as of December 31, 2023 and 2022.

 
Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.

 

Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve months.

 
Goodwill and Intangible Assets, Policy [Policy Text Block]

Definite-Lived Intangible Assets - Intellectual Property

Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&D”) assets related to (i) the Senhance System acquired in 2015 and reclassified in 2017 and (ii) a 2018 acquisition and reclassified in 2020. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 7 years.

 

The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. No impairment of intellectual property was identified during the years ended December 31, 2023 and 2022.

 
Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:

 

   

Years

  

Operating lease assets – Senhance System leasing

     5    

Machinery, manufacturing, and demonstration equipment

   3 - 5  

Computer equipment

     3    

Furniture

     5    

Leasehold improvements

  

Lesser of lease term or 3-10

  

 

The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.

 

During the years ended December 31, 2023 and 2022, the Company recorded a non-cash asset impairment charge of $0.4 million and $1.4 million, respectively, to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss.

 
Lessee, Leases [Policy Text Block]

Operating Leases

The Company has operating leases for its corporate office buildings, vehicles, and machinery and equipment. At inception, the Company determines whether an agreement represents a lease, and at commencement, it evaluates each lease agreement to determine whether the lease constitutes an operating or financing lease.

 

The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do not provide a significant economic incentive and are therefore excluded from the lease term. While its operating leases range from one year to ten years, some may include options to extend the lease generally between one year and six years, and some may include options to terminate the leases within one year.

 

The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.

 
Capitalization of Internal Costs, Policy [Policy Text Block]

Implementation Costs in a Cloud Computing Arrangement

The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.

 
Employer Retention Tax Credit, Policy [Policy Text Block]

Employee Retention Tax Credit Receivable

The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended December 31, 2021, the Company submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received $0.7 million of the ERTC refund during the year ended December 31, 2022 and received the remaining $0.6 million during the year ended December 31, 2023.

 
Contingent Consideration [Policy Text Block]

Contingent Consideration

Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 

On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in 2016, as of December 31, 2023, the Company has accrued $2.2 million of estimated fair value of remaining contingent consideration related to a milestone of €15.0 million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least €25.0 million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In 2022, Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.

 
Warrant Liabilities [Policy Text Block]

Warrant Liabilities

The Company’s warrants (see “Note 14 – Equity Offerings,”) are measured at fair value using a Black-Scholes-Merton model option-pricing model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected stock price volatility, the expected dividend yield which is assumed to be zero since The Company has not paid and does not anticipate paying cash dividends on its shares of common stock and the risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the term of the warrant (see “Note 6 – Fair Value,”). The warrant liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

 
Revenue [Policy Text Block]

Revenue Recognition

The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on considerations specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements could include a five-year service period; the first year of service is generally free and included in the Senhance System sale arrangement with an option to purchase the remaining four years at a stated service price.

 

The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.

 

For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services.

 

The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:

 

 

●

System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.

 

 

●

Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.

 

 

●

Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.

 

The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements and are included in accounts receivable.

 

In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not meet the requirements to be capitalized as the Company does not expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.

 
Lessor, Leases [Policy Text Block]

Senhance System Leasing

The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended December 31, 2023 and 2022, variable lease revenue related to usage-based arrangements was not material.  

 

In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2023 are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of December 31, 2023, future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next one to two years.

 
Cost of Goods and Service [Policy Text Block]

Cost of Revenue

Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.

 
Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.

 
Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. The Company estimates forfeitures based on its historical experience and adjusts the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.

 

The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note 13 – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.

 
Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.

 

The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not sustain the position following audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.

 

Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may be subject to examination by authorities for all previously filed income tax returns.

 
Comprehensive Income, Policy [Policy Text Block]

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

 
Segment Reporting, Policy [Policy Text Block]

Segments

The Company operates in one business segment—the research, development and sale of medical device robotics to improve MIS. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.

 
New Accounting Pronouncements, Policy [Policy Text Block]

Impact of Recently Issued Accounting Standards

In November 2023, the FASB issued Accounting Standards Update, or ASU, No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU looks to provide improvements to the segment disclosure by providing users with more decision-useful information about reportable segments in a public entity. The main provisions require a company to disclose, on an annual and interim basis, significant expenses included within each reported measure of segment profit or loss, an amount for other segment items by reportable segment and a description of its composition. It also requires all annual disclosures about a reportable segments’ profit or loss and assets to be reported on an interim basis.

 

The ASU is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.

 

In December 2023, the FASB issues ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU looks to enhance the transparency and decision usefulness of income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The main provisions to the rate reconciliation disclosure require public entities on an annual basis to: disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The main provisions to the income taxes paid disclosure require that all entities disclose on an annual basis: the amount of income taxes paid disaggregated by federal, state and foreign taxes and the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid meets a quantitative threshold. This ASU also requires all entities to disclose: income (loss) from continuing operations before income tax expense (benefit) disaggregated between domestic and foreign and income tax expense (benefit) from continuing operations disaggregated by federal, state and foreign.

 

This ASU is to be applied on a prospective basis with an effective date for all public entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Property Plant and Equipment Useful Life [Table Text Block]
   

Years

  

Operating lease assets – Senhance System leasing

     5    

Machinery, manufacturing, and demonstration equipment

   3 - 5  

Computer equipment

     3    

Furniture

     5    

Leasehold improvements

  

Lesser of lease term or 3-10

  
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Years Ended December 31,

 
   

2023

    

2022

  
    (in thousands)  

U.S.

                

Instruments and accessories

   $ 205     $ 211  

Services

     294       300  

Leases

     196       256  

Total U.S. revenue

     695       767  
                 

Outside of U.S. ("OUS")

                

Systems

     3,645       2,551  

Instruments and accessories

     1,669       1,565  

Services

     758       1,073  

Leases

     1,810       1,131  

Total OUS revenue

     7,882       6,320  
                 

Total

                

Systems

     3,645       2,551  

Instruments and accessories

     1,874       1,776  

Services

     1,052       1,373  

Leases

     2,006       1,387  

Total revenue

   $ 8,577     $ 7,087  
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   

December 31, 2023

    

December 31, 2022

  
   

(in thousands)

  

Contract assets

   $ 95     $ 116  

Deferred revenue

   $ 711     $ 465  
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Cash, Cash Equivalents, and Restricted Cash [Table Text Block]
   

December 31,

    

December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Cash

   $ 4,588     $ 3,473  

Money market

     5,521       2,856  

U.S. treasuries

     6,987       -  

Total cash and cash equivalents

   $ 17,096     $ 6,329  

Restricted cash

     1,642       1,141  

Total

   $ 18,738     $ 7,470  
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Investments, Available-for-sale (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Debt Securities, Available-for-Sale [Table Text Block]
   

December 31, 2023

  
   

Amortized

Cost

    

Unrealized

Gain

    

Unrealized

Loss

    

Fair

Value

    

Short-term

investments

  
                (in thousands)              

Corporate bonds

   $ 3,981     $ -     $ (10 )   $ 3,971     $ 3,971  

Total investments

   $ 3,981     $ -     $ (10 )   $ 3,971     $ 3,971  
   

December 31, 2022

  
   

Amortized

Cost

    

Unrealized

Gain

    

Unrealized

Loss

    

Fair

Value

    

Short-term

investments

    

Long-term

investments

  
                (in thousands)              

Commercial paper

   $ 12,364     $ -     $ (49 )   $ 12,315     $ 12,315     $ -  

Corporate bonds

     55,201       -       (447 )     54,754       50,889       3,865  

U.S. government agencies

     999       -       (8 )     991       991       -  

Total investments

   $ 68,564     $ -     $ (504 )   $ 68,060     $ 64,195     $ 3,865  
Investments Classified by Contractual Maturity Date [Table Text Block]
   

December 31, 2023

  
   

Amortized

Cost

    

Fair Value

  
    (in thousands)  

Mature in less than one year

   $ 3,981     $ 3,971  

Total

   $ 3,981     $ 3,971  
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Fair Value (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
   

December 31, 2023

  

 

  

Quoted Prices
in Active

Markets for
Identical Assets
(Level 1)

    

Significant
Other
Observable
Inputs (Level 2)

    

Significant
Unobservable
Inputs (Level 3)

    

Total

  
Description         (in thousands)        

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 17,096     $ -     $ -     $ 17,096  

Restricted cash

     1,642       -       -       1,642  

Short-term investments

     -       3,971       -       3,971  

Total assets measured at fair value

   $ 18,738     $ 3,971     $ -     $ 22,709  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 2,220     $ 2,220  
Warrant Liabilities     -       -       5,888       5,888  

Total liabilities measured at fair value

   $ -     $ -     $ 8,108     $ 8,108  
   

December 31, 2022

  

 

  

Quoted Prices in

Active Markets

for Identical

Assets (Level 1)

    

Significant

Other

Observable

Inputs (Level 2)

    

Significant Unobservable

Inputs (Level 3)

    

Total

  
Description         (in thousands)        

Assets measured at fair value

                                

Cash and cash equivalents (1)

   $ 6,329     $ -     $ -     $ 6,329  

Restricted cash

     1,141       -       -       1,141  

Short-term investments

     -       64,195       -       64,195  

Long-term investments

     -       3,865       -       3,865  

Total assets measured at fair value

   $ 7,470     $ 68,060     $ -     $ 75,530  

Liabilities measured at fair value

                                

Contingent consideration

   $ -     $ -     $ 1,256     $ 1,256  

Total liabilities measured at fair value

   $ -     $ -     $ 1,256     $ 1,256  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
 

Valuation
Methodology
 

  

Significant
Unobservable

Input

  

December 31,
2023
 

    

December 31,
2022
 

  
                       

Contingent consideration

Probability
weighted
income
approach

  

Milestone dates

  

2032

    

2032

  
     

Discount rate

     10.0 %     16.5 %
     

Revenue volatility

     35.0 %     45.0 %
     

EUR-to-USD exchange rate

     1.10       1.07  
   

As of December 31,

2023

  

Expected dividend yield

     0 %

Expected volatility

     117 %

Risk-free interest rate

     3.8 %

Expected life (in years)

     4.6  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

 

  

Fair Value

  
   

(in thousands)

  

Balance at December 31, 2021

   $ 2,371  

Change in fair value

     (1,115 )

Balance at December 31, 2022

   $ 1,256  

Change in fair value

     964  

Balance at December 31, 2023

   $ 2,220  
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

 

  

Fair Value

  
    (in thousands)  

Balance at December 31, 2022

   $ -  

Issuance of warrants

     7,120  

Change in fair value

     (1,232 )

Balance at December 31, 2023

   $ 5,888  
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Inventories (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   

December 31, 2023

    

December 31, 2022

  
   

(in thousands)

  

Finished goods

   $ 9,200     $ 11,208  

Raw materials

     2,015       2,545  

Total inventories

   $ 11,215     $ 13,753  
                 

Current Portion

   $ 7,172     $ 8,284  

Long-term portion

     4,043       5,469  

Total inventories

   $ 11,215     $ 13,753  
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   

December 31,

    

December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Machinery, manufacturing, and demonstration equipment

   $ 9,089     $ 8,450  

Operating lease assets - Senhance System leasing

     12,848       10,251  

Computer equipment

     603       600  

Furniture

     715       831  

Leasehold improvements

     1,721       1,654  

Construction in process

     70       436  

Total property and equipment

     25,046       22,222  

Accumulated depreciation and amortization

     (16,087

)

     (12,680

)

Property and equipment, net

   $ 8,959     $ 9,542  
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Intellectual Property (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Finite-Lived Intangible Assets [Table Text Block]
   

December 31, 2023

  
   

Gross Carrying Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net Carrying

Amount

  
          (in thousands)        

Developed technology

   $ 68,838     $ (66,902 )   $ (837 )   $ 1,099  

Technology and patents purchased

     400       (279 )     17       138  

Total intellectual property

   $ 69,238     $ (67,181 )   $ (820 )   $ 1,237  
   

December 31, 2022

  
   

Gross Carrying Amount

    

Accumulated Amortization

    

Foreign

Currency

Translation

Impact

    

Net Carrying

Amount

  
          (in thousands)        

Developed technology

   $ 68,838     $ (66,562 )   $ (874 )   $ 1,402  

Technology and patents purchased

     400       (239 )     13       174  

Total intellectual property

   $ 69,238     $ (66,801 )   $ (861 )   $ 1,576  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
   

Year Ending
December 31, 2023

  

2024

   $ 388  

2025

     388  

2026

     389  

2027

     72  

Total

   $ 1,237  
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Leases (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Lease, Cost [Table Text Block]
   

Years Ended December 31,

  
   

2023

      

2022

  
     

(in thousands)

  

Long-term operating

   $ 1,888       $ 1,557  
Lessee, Operating Lease, Disclosure [Table Text Block]
   

Years Ended December 31,

  
   

2023

    

2022

  

 

  

 

    

 

  

Weighted-average remaining lease term (in years)

     5.7         6.8    

Weighted-average discount rate

     9.2%         8.4%    

Incremental borrowing rate

   7.1% - 23.0%     6.1% - 14.5%  
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

Fiscal Year

        

2024

   $ 1,491  

2025

     1,377  

2026

     1,160  

2027

     904  

2028

     834  

Thereafter

     1,406  

Total minimum lease payments

   $ 7,172  

Less: Amount of lease payments representing interest

     (1,490 )

Present value of future minimum lease payments

   $ 5,682  
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Note 11 - Accrued Expenses and Other Current Liabilities (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   

Years Ended December 31,

  
   

2023

    

2022

  
   

(in thousands)

  

Consulting and other vendors

   $ 461     $ 155  

Royalties

     9       24  

Legal and professional fees

     411       275  

Taxes and other assessments

     755       839  

Total

   $ 1,636     $ 1,293  
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
   

2023

    

2022

  
    (in thousands)  

Current income taxes

                

Federal

   $ -     $ -  

State

     -       -  

Foreign

     196       239  

Deferred income taxes

     -          

Federal

     -       -  

State

     -       -  

Foreign

     118       79  

Total income tax expense

   $ 314     $ 318  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
   

2023

    

2022

  
    (in thousands)  

United States

   $ (53,226 )   $ (44,802 )

Foreign

     (24,893 )     (30,441 )

Total loss from operations before taxes

   $ (78,119 )   $ (75,243 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   

2023

    

2022

  
    (in thousands)  

Deferred Tax assets:

                

Stock-based compensation

   $ 3,119     $ 2,840  

Accrued expenses and other

     2,666       2,538  

Research credit carryforward

     2,859       1,341  

Fixed assets

     319       162  

Capitalized start-up costs and other intangibles

     644       921  

Capitalized research costs

     9,064       4,382  

Net operating loss carryforwards

     93,332       83,908  
      112,003       96,092  

Valuation allowance

     (110,511 )     (94,704 )

Net deferred tax asset

     1,492       1,388  

Deferred tax liabilities

                

Fixed assets and other

     (1,448 )     (1,214 )

Net deferred tax liability

     (1,448 )     (1,214 )

Net deferred tax asset

   $ 44     $ 174  
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
   

2023

    

2022

  
    (in thousands)  

Beginning balance

   $ 335     $ 141  

Gross increases for tax positions related to current periods

     328       194  

Gross decreases related to 382 limitations

     52       -  

Ending balance

   $ 715     $ 335  
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
    2023     2022  
   

Amount

   

Percent of

Pretax

Earnings

   

Amount

   

Percent of

Pretax

Earnings

 
    (in thousands)  

United States federal tax at statutory rate

   $ (16,405 )     21.0 %   $ (15,801 )     21.0 %

State taxes (net of deferred benefit)

     (2,493 )     3.2 %     (2,912 )     3.9 %

Nondeductible expenses

     755       (1.0 %)     1,077       (1.4 %)

Change in fair market value of contingent consideration

     244       (0.3 %)     (283 )     0.4 %

Warrant remeasurement and financing costs

     (140 )     0.2 %     -       -  

Research & development

     (1,898 )     2.4 %     (970 )     1.3 %

Change in unrecognized tax benefits

     380       (0.5 %)     194       (0.3 %)

Foreign tax rate differential

     3,176       (4.1 %)     2,676       (3.6 %)

True-up to stock compensation - cancellations

     -       -       49       (0.1 %)

Change in enacted tax rates and other, net

     659       (0.8 %)     (96 )     0.0  

Change in valuation allowance

     16,036       (20.5 %)     16,384       (21.8 %)

Income tax expense (benefit)

   $ 314       (0.4 %)   $ 318       (0.4 %)
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average

Remaining

Contractual Term

(Years)

  

Balance at December 31, 2022

     7,584,967     $ 4.22       5.31  

Granted

     3,047,615       0.71          

Forfeited

     (149,430 )     0.78          

Cancelled

     (25,173 )     27.32          

Exercised

     (13,300 )     0.38          

Balance at December 31, 2023

     10,444,679     $ 3.20       4.80  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]
   

Number of

Shares

    

Weighted-

Average Exercise

Price

    

Weighted-Average Remaining

Contractual Term (Years)

    

Aggregate

Intrinsic Value (Millions)

  

Exercisable at December 31, 2023

     5,726,280     $ 5.02       4.12     $ -  

Vested or expected to vest at December 31, 2023

     10,105,084     $ 3.28       4.77     $ -  
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
    Years Ended December 31,  
    2023     2022  

Expected dividend yield

     0%         0%    

Expected volatility

   124% - 130%     126% - 133%  

Risk-free interest rate

   3.53% - 4.14%     1.25% - 4.40%  

Expected life (in years)

   3.8 - 4.5     3.8 - 4.5  
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
   

Number of

Restricted Stock

Units Outstanding

    

Weighted-Average

Grant Date Fair

Value

  

Unvested December 31, 2022

     8,483,491     $ 1.04  

Granted

     8,616,931       0.70  

Vested

     (3,937,130 )     1.10  

Forfeited

     (837,115 )     0.76  

Unvested December 31, 2023

     12,326,177     $ 0.81  
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]
   

Years Ended December 31,

 
   

2023

      

2022

  
   

(in thousands)

  

Stock options

   $ 2,338       $ 3,654  

Restricted stock units

     3,954         3,319  

Performance restricted stock units

     1,626         1,443  
    $ 7,918       $ 8,416  
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Note 14 - Equity Offerings (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Sales Under Sales Agency Agreement [Table Text Block]
   

Year Ended

December 31, 2023

  

Total shares of common stock sold

     933,672  

Average price per share

   $ 0.43  

Gross proceeds

   $ 403  

Commission paid to agents

   $ 12  

Net proceeds

   $ 391  
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Note 15 - Basic and Diluted Net Loss Per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   

December 31,

 
   

2023

    

2022

  

Stock options

     10,444,679       7,584,967  

Nonvested restricted stock units

     12,326,177       8,483,491  

Stock warrants

     24,830,500       1,021,076  

Total

     47,601,356       17,089,534  
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Note 16 - Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Contractual Obligation, Fiscal Year Maturity [Table Text Block]

Fiscal Year

        

2024

   $ 3,263  

2025

     300  

2026

     320  

Total commitments

   $ 3,883  
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Note 17 - Segments and Geographic Areas (Tables)
 12 Months Ended
Dec. 31, 2023
Notes Tables  
Long-Lived Assets by Geographic Areas [Table Text Block]
   

December 31, 2023

  
   

Long-Lived Assets

    

Total Assets

  

US

     29 %     46 %

EMEA

     68 %     52 %

Asia

     3 %     2 %

Total

     100 %     100 %
   

December 31, 2022

  
   

Long-Lived Assets

    

Total Assets

  

US

     35 %     72 %

EMEA

     62 %     27 %

Asia

     3 %     1 %

Total

     100 %     100 %
Revenue from External Customers by Geographic Areas [Table Text Block]
   

Years Ended December 31,

 
   

2023

    

2022

  

US

     8 %     11 %

EMEA

     82 %     77 %

Asia

     10 %     12 %

Total

     100 %     100 %
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies (Details Textual)
$ in Thousands, € in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Retained Earnings (Accumulated Deficit) $ (939,368)   $ (860,935)  
Working Capital 23,800      
Equity, Attributable to Parent 33,414   99,645 $ 169,246
Restricted Cash 1,600   1,100  
Debt Securities, Available-for-Sale, Realized Gain (Loss) 0   0  
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not to Sell before Recovery, Credit Loss, Previously Recorded, Expense (Reversal) 0   0  
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0   0  
Accounts Receivable, Allowance for Credit Loss 1,600   1,600  
Property, Plant and Equipment, Including Purchased Software, Impairment Charges 400   1,400  
Proceeds From Employee Retention Tax Credit 600   700  
Business Combination, Contingent Consideration, Liability $ 2,220   $ 1,256  
Period Of Service Sale Arrangement (Year) 5 years 5 years    
Period of Service Sale Arrangement at Stated Service Price (Year) 4 years 4 years    
Lessor, Operating Lease, Payment to be Received $ 2,200      
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00% 0.00%  
Number of Operating Segments 1 1    
Senhance Surgical Robotic System Acquisition[Member]        
Business Combination, Contingent Consideration, Liability $ 2,200      
Business Combination, Contingent Consideration, Liability, Related Milestone | €   € 15    
Minimum [Member]        
Lessee, Operating Lease, Term of Contract (Year) 1 year      
Lessee, Operating Lease, Renewal Term (Year) 1 year      
Minimum [Member] | Senhance Surgical Robotic System Acquisition[Member]        
Business Combination Contingent Consideration Arrangements Target Revenue | €   € 25    
Maximum [Member]        
Lessee, Operating Lease, Term of Contract (Year) 10 years      
Lessee, Operating Lease, Renewal Term (Year) 6 years      
Patents [Member]        
Finite-Lived Intangible Asset, Useful Life (Year) 10 years      
Developed Technology Rights [Member]        
Finite-Lived Intangible Asset, Useful Life (Year) 7 years      
Intellectual Property [Member]        
Impairment of Intangible Assets, Finite-Lived $ 0   $ 0  
Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Number of Major Customers 1 1 1  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]        
Concentration Risk, Percentage 83.00% 83.00% 69.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Number of Major Customers 2 2 1  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]        
Concentration Risk, Percentage     47.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]        
Concentration Risk, Percentage 33.00% 33.00%    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]        
Concentration Risk, Percentage 19.00% 19.00%    
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]        
Equity, Attributable to Parent $ 600   $ 1,900  
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)
Dec. 31, 2023
Operating Lease Assets [Member]  
Property and equipment, estimated useful lives (Year) 5 years
Machinery, Manufacturing and Demonstration Equipment [Member] | Minimum [Member]  
Property and equipment, estimated useful lives (Year) 3 years
Machinery, Manufacturing and Demonstration Equipment [Member] | Maximum [Member]  
Property and equipment, estimated useful lives (Year) 5 years
Computer Equipment [Member]  
Property and equipment, estimated useful lives (Year) 3 years
Furniture and Fixtures [Member]  
Property and equipment, estimated useful lives (Year) 5 years
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Revenue Recognition 1 (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Contract with Customer, Liability, Revenue Recognized $ 0.5 $ 0.5
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Revenue Recognition 2 (Details Textual) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
$ in Millions
Dec. 31, 2023
USD ($)
Revenue, Remaining Performance Obligation, Amount $ 0.9
Minimum [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 1 year
Maximum [Member]  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) 4 years
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue $ 8,577 $ 7,087
UNITED STATES    
Revenue 695 767
Non-US [Member]    
Revenue 7,882 6,320
Instruments and Accessories [Member]    
Revenue 1,874 1,776
Instruments and Accessories [Member] | UNITED STATES    
Revenue 205 211
Instruments and Accessories [Member] | Non-US [Member]    
Revenue 1,669 1,565
Service [Member]    
Revenue 1,052 1,373
Service [Member] | UNITED STATES    
Revenue 294 300
Service [Member] | Non-US [Member]    
Revenue 758 1,073
Lease [Member]    
Revenue 2,006 1,387
Lease [Member] | UNITED STATES    
Revenue 196 256
Lease [Member] | Non-US [Member]    
Revenue 1,810 1,131
Systems [Member]    
Revenue 3,645 2,551
Systems [Member] | Non-US [Member]    
Revenue $ 3,645 $ 2,551
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Contract assets $ 95 $ 116
Deferred revenue $ 711 $ 465
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Restricted cash $ 1,642 $ 1,141
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Cash $ 4,588 $ 3,473
Money market 5,521 2,856
U.S. treasuries 6,987 0
Total cash and cash equivalents 17,096 6,329
Restricted cash 1,642 1,141
Total $ 18,738 $ 7,470
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Investments, Available-for-sale (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Proceeds from Sale of Debt Securities, Available-for-Sale $ 0 $ 0
Debt Securities, Available-for-Sale, Realized Gain (Loss) $ 0 $ 0
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Amortized Cost $ 3,981 $ 68,564
Unrealized Gain 0 0
Unrealized Loss (10) (504)
Fair Value 3,971 68,060
Short-term investments 3,971 64,195
Long-term investments 0 3,865
Corporate Debt Securities [Member]    
Amortized Cost 3,981 55,201
Unrealized Gain 0 0
Unrealized Loss (10) (447)
Fair Value 3,971 54,754
Short-term investments $ 3,971 50,889
Long-term investments   3,865
Commercial Paper [Member]    
Amortized Cost   12,364
Unrealized Gain   0
Unrealized Loss   (49)
Fair Value   12,315
Short-term investments   12,315
Long-term investments   0
US Government Agencies Debt Securities [Member]    
Amortized Cost   999
Unrealized Gain   0
Unrealized Loss   (8)
Fair Value   991
Short-term investments   991
Long-term investments   $ 0
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Mature in less than one year, amortized cost $ 3,981  
Mature in less than one year, fair value 3,971  
Total, amortized cost 3,981 $ 68,564
Total, fair value $ 3,971 $ 68,060
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Cash and cash equivalents [1] $ 17,096 $ 6,329
Restricted cash 1,642 1,141
Short-term investments 3,971 64,195
Total assets measured at fair value 22,709 75,530
Long-term investments 0 3,865
Contingent consideration 2,220 1,256
Warrant liabilites 5,888 0
Total liabilities measured at fair value 8,108 1,256
Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalents [1] 17,096 6,329
Restricted cash 1,642 1,141
Short-term investments 0 0
Total assets measured at fair value 18,738 7,470
Long-term investments   0
Contingent consideration 0 0
Warrant liabilites 0  
Total liabilities measured at fair value 0 0
Fair Value, Inputs, Level 2 [Member]    
Cash and cash equivalents [1] 0 0
Restricted cash 0 0
Short-term investments 3,971 64,195
Total assets measured at fair value 3,971 68,060
Long-term investments   3,865
Contingent consideration 0 0
Warrant liabilites 0  
Total liabilities measured at fair value 0 0
Fair Value, Inputs, Level 3 [Member]    
Cash and cash equivalents [1] 0 0
Restricted cash 0 0
Short-term investments 0 0
Total assets measured at fair value 0 0
Long-term investments   0
Contingent consideration 2,220 1,256
Warrant liabilites 5,888  
Total liabilities measured at fair value $ 8,108 $ 1,256
[1] Includes investments that are readily convertible to cash with original maturities of 90 days or less.
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details)
Dec. 31, 2023
Dec. 31, 2022
Measurement Input, Price Volatility [Member] | Senhance Surgical Robotic System Acquisition[Member] | Fair Value, Inputs, Level 3 [Member]    
Contingent consideration, measurement input 0.35 0.45
Measurement Input, Discount Rate [Member] | Senhance Surgical Robotic System Acquisition[Member] | Fair Value, Inputs, Level 3 [Member]    
Contingent consideration, measurement input 0.10 0.165
Measurement Input, Currency Exchange Rate [Member] | Senhance Surgical Robotic System Acquisition[Member] | Fair Value, Inputs, Level 3 [Member]    
Contingent consideration, measurement input 1.1 1.07
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]    
Measurement input 0  
Warrant [Member] | Measurement Input, Price Volatility [Member]    
Measurement input 1.17  
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Measurement input 0.038  
Warrant [Member] | Measurement Input, Expected Term [Member]    
Measurement input 4.6  
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) - The 2015 Senhance Acquisition [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Balance $ 1,256 $ 2,371
Change in fair value 964 (1,115)
Balance $ 2,220 $ 1,256
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.1
Note 6 - Fair Value - Summary of Change in Fair Value for Warrants (Details) - Warrant [Member]
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Balance $ 0
Issuance of warrants 7,120
Change in fair value (1,232)
Balance $ 5,888
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.24.1
Note 7 - Inventories - Components of Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finished goods, gross $ 9,200 $ 11,208
Raw materials, gross 2,015 2,545
Total inventories, gross 11,215 13,753
Current Portion, gross 7,172 8,284
Long-term portion, gross $ 4,043 $ 5,469
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Property and Equipment (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Depreciation $ 3,276 $ 3,368
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.24.1
Note 8 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, plant and equipment, gross $ 25,046 $ 22,222
Accumulated depreciation and amortization (16,087) (12,680)
Property and equipment, net 8,959 9,542
Machinery, Manufacturing and Demonstration Equipment [Member]    
Property, plant and equipment, gross 9,089 8,450
Operating Lease Assets [Member]    
Property, plant and equipment, gross 12,848 10,251
Computer Equipment [Member]    
Property, plant and equipment, gross 603 600
Furniture and Fixtures [Member]    
Property, plant and equipment, gross 715 831
Leasehold Improvements [Member]    
Property, plant and equipment, gross 1,721 1,654
Construction in Progress [Member]    
Property, plant and equipment, gross $ 70 $ 436
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Intellectual Property (Details Textual) - Weighted Average [Member]
Dec. 31, 2023
Dec. 31, 2022
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets, Remaining Amortization Period (Year) 3 years 2 months 12 days 4 years 2 months 12 days
Technology-Based Intangible Assets [Member]    
Finite-Lived Intangible Assets, Remaining Amortization Period (Year) 3 years 3 months 18 days 4 years 3 months 18 days
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Intellectual Property - Intellectual Property (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets, Gross $ 69,238 $ 69,238
Finite-Lived Intangible Assets, Accumulated Amortization (67,181) (66,801)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact (820) (861)
Intellectual property, net 1,237 1,576
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets, Gross 68,838 68,838
Finite-Lived Intangible Assets, Accumulated Amortization (66,902) (66,562)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact (837) (874)
Intellectual property, net 1,099 1,402
Technology-Based Intangible Assets [Member]    
Finite-Lived Intangible Assets, Gross 400 400
Finite-Lived Intangible Assets, Accumulated Amortization (279) (239)
Finite-Lived Intangible Assets, Foreign Currency Translation Impact 17 13
Intellectual property, net $ 138 $ 174
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.24.1
Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Total $ 1,237 $ 1,576
Intellectual Property [Member]    
2024 388  
2025 388  
2026 389  
2027 72  
Total $ 1,237 $ 1,576
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Leases - Components of Operating Lease Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
General and Administrative Expense [Member]    
Long-term Operating $ 1,888 $ 1,557
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Leases -Supplemental Balance Sheet Information (Details)
Dec. 31, 2023
Dec. 31, 2022
Weighted-average remaining lease term (in years) (Year) 5 years 8 months 12 days 6 years 9 months 18 days
Weighted-average discount rate 9.20% 8.40%
Minimum [Member]    
Incremental borrowing rate 7.10% 6.10%
Maximum [Member]    
Incremental borrowing rate 23.00% 14.50%
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.24.1
Note 10 - Leases - Minimum Lease Payments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
2024 $ 1,491
2025 1,377
2026 1,160
2027 904
2028 834
Thereafter 1,406
Total minimum lease payments 7,172
Less: Amount of lease payments representing interest (1,490)
Present value of future minimum lease payments $ 5,682
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.24.1
Note 11 - Accrued Expenses and Other Current Liabilities - Components of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Consulting and other vendors $ 461 $ 155
Royalties 9 24
Legal and professional fees 411 275
Taxes and other assessments 755 839
Total $ 1,636 $ 1,293
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 15,800    
Unrecognized Tax Benefits 715 $ 335 $ 141
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued $ 0 $ 0  
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 21.00%  
Domestic Tax Authority [Member]      
Operating Loss Carryforwards $ 446,700    
Increase (Decrease) in Operating Loss Carryforwards 253,000    
Operating Loss Carryforwards, Subject to Expiration 254,500    
Operating Loss Carryforwards, Not Subject to Expiration 192,200    
Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]      
Tax Credit Carryforward, Amount 11,700    
Increase (Decrease) in Tax Credit Carryforward 8,800    
State and Local Jurisdiction [Member]      
Operating Loss Carryforwards 336,300    
Operating Loss Carryforwards, Subject to Expiration 323,000    
Operating Loss Carryforwards, Not Subject to Expiration 13,300    
State and Local Jurisdiction [Member] | Impact of 382 Ownership Changes [Member]      
Increase (Decrease) in Operating Loss Carryforwards 199,000    
Foreign Tax Authority [Member] | Ministry of Economic Affairs and Finance, Italy [Member]      
Operating Loss Carryforwards 25,000    
Foreign Tax Authority [Member] | Luxembourg Inland Revenue [Member]      
Operating Loss Carryforwards, Subject to Expiration 95,600    
Foreign Tax Authority [Member] | Swiss Federal Tax Administration (FTA) [Member]      
Operating Loss Carryforwards, Subject to Expiration 135,300    
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]      
Operating Loss Carryforwards, Subject to Expiration $ 1,400    
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Federal $ 0 $ 0
State 0 0
Foreign 196 239
Federal 0 0
State 0 0
Foreign 118 79
Total income tax expense $ 314 $ 318
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
United States $ (53,226) $ (44,802)
Foreign (24,893) (30,441)
Loss before income taxes $ (78,119) $ (75,243)
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Income Taxes - Deferred Tax Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Stock-based compensation $ 3,119 $ 2,840
Accrued expenses and other 2,666 2,538
Research credit carryforward 2,859 1,341
Fixed Assets 319 162
Net operating loss carryforwards 93,332 83,908
Deferred Tax Assets, Gross 112,003 96,092
Valuation Allowance (110,511) (94,704)
Net deferred tax asset 1,492 1,388
Fixed assets and other (1,448) (1,214)
Net deferred tax liability (1,448) (1,214)
Net deferred tax asset (liability) 44 174
Start-up Costs and Other Intangibles [Member]    
Capitalized costs 644 921
Research Tax Credit Carryforward [Member]    
Capitalized costs $ 9,064 $ 4,382
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Income Taxes - Unrecognized Tax Positions (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Beginning balance $ 335 $ 141
Gross increases for tax positions related to current periods 328 194
Gross decreases related to 382 limitations 52 0
Ending balance $ 715 $ 335
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.24.1
Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
United States federal tax at statutory rate, amount $ (16,405) $ (15,801)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 21.00% 21.00%
State taxes (net of deferred benefit), amount $ (2,493) $ (2,912)
State taxes (net of deferred benefit), percent 3.20% 3.90%
Nondeductible expenses, amount $ 755 $ 1,077
Nondeductible expenses, percent (1.00%) (1.40%)
Change in fair market value of contingent consideration, amount $ 244 $ (283)
Change in fair market value of contingent consideration, percent (0.30%) 0.40%
Warrant remeasurment and financing costs, amount $ (140) $ 0
Warrant remeasurment and financing costs, percent 0.20% 0.00%
Research & Development, amount $ (1,898) $ (970)
Research & Development, percent 2.40% 1.30%
Change in unrecognized tax benefits, amount $ 380 $ 194
Change in unrecognized tax benefits, percent (0.50%) (0.30%)
Foreign tax rate differential, amount $ 3,176 $ 2,676
Foreign tax rate differential, percent (4.10%) (3.60%)
True-up to Stock Compensation - Cancellations, amount $ 0 $ 49
True-up to Stock Compensation - Cancellations, percent 0.00% (0.10%)
Change in enacted tax rates and other, net, amount $ 659 $ (96)
Change in enacted tax rates and other, net, percent (0.80%) 0.00%
Change in valuation allowance, amount $ 16,036 $ 16,384
Change in valuation allowance, percent (20.50%) (21.80%)
Total income tax expense $ 314 $ 318
Income tax expense (benefit), percent (0.40%) (0.40%)
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Stock-based Compensation (Details Textual) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Jun. 06, 2023
Feb. 28, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)     $ 0.59 $ 0.59
Performance Restricted Stock Unit [Member] | Granted in 2023 [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period     3 years  
Performance Restricted Stock Unit [Member] | Granted in 2022 [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period     3 years  
Performance Restricted Stock Unit [Member] | Subsequent Event [Member] | Granted in 2023 [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Operation Targets Achieved   50.00%    
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Operation, Earned   50.00%    
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Award Forfeited   50.00%    
Share-Based Payment Arrangement, Option [Member]        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount     $ 1.6  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     1 year 4 months 24 days  
Restricted Stock Units (RSUs) [Member]        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount     $ 4.4  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     1 year 2 months 12 days  
Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 22,000,000      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)     54,072,307  
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)     22,185,899  
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)     10 years  
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Stock-based Compensation - Stock Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Options, Outstanding, Number of Shares (in shares) 7,584,967  
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) $ 4.22  
Options, Outstanding, Weighted Average Remaining Contractual Term (Year) 4 years 9 months 18 days 5 years 3 months 21 days
Options, Granted, Number of Shares (in shares) 3,047,615  
Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) $ 0.71  
Options, Forfeited, Number of Shares (in shares) (149,430)  
Options, Forfeitures in Period, Weighted Average Exercise Price (in dollars per share) $ 0.78  
Options, Cancelled, Number of Shares (in shares) (25,173)  
Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share) $ 27.32  
Options, Exercised, Number of Shares (in shares) (13,300)  
Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share) $ 0.38  
Options, Outstanding, Number of Shares (in shares) 10,444,679 7,584,967
Options, Outstanding, Weighted Average Exercise Price (in dollars per share) $ 3.2 $ 4.22
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Stock-based Compensation - Stock Options Outstanding (Details)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Options, Exercisable, Number of Shares (in shares) | shares 5,726,280
Options, Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 5.02
Options, Exercisable, Weighted Average Remaining Contractual Term (Year) 4 years 1 month 13 days
Options, Exercisable, Aggregate Intrinsic Value | $ $ 0
Options, Vested and Expected to Vest, Exercisable, Number of Shares (in shares) | shares 10,105,084
Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares $ 3.28
Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term (Year) 4 years 9 months 7 days
Options, Vested or Expected to Vest, Aggregate Intrinsic Value | $ $ 0
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00%
Minimum [Member]    
Expected volatility 124.00% 126.00%
Risk-free interest rate 3.53% 1.25%
Expected life (in years) (Year) 3 years 9 months 18 days 3 years 9 months 18 days
Maximum [Member]    
Expected volatility 130.00% 133.00%
Risk-free interest rate 4.14% 4.40%
Expected life (in years) (Year) 4 years 6 months 4 years 6 months
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Stock-based Compensation - RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]
 12 Months Ended
Dec. 31, 2023
$ / shares
shares
Beginning of period, Restricted stock units, Unvested (in shares) | shares 8,483,491
Beginning of period, Restricted stock units, Unvested, weighted average grant date fair value (in dollars per share) | $ / shares $ 1.04
Restricted stock units, Granted (in shares) | shares 8,616,931
Restricted stock units, Granted, weighted average grant date fair value (in dollars per share) | $ / shares $ 0.7
Restricted stock units, Vested (in shares) | shares (3,937,130)
Restricted stock units, Vested, weighted average grant date fair value (in dollars per share) | $ / shares $ 1.1
Restricted stock units, Forfeited (in shares) | shares (837,115)
Restricted stock units, Forfeited, weighted average grant date fair value (in dollars per share) | $ / shares $ 0.76
Unvested (in shares) | shares 12,326,177
Unvested December 31, 2022 (in dollars per share) | $ / shares $ 0.81
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.24.1
Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based compensation $ 7,918 $ 8,416
Share-Based Payment Arrangement, Option [Member]    
Share-based compensation 2,338 3,654
Restricted Stock Units (RSUs) [Member]    
Share-based compensation 3,954 3,319
Performance Restricted Stock Unit [Member]    
Share-based compensation $ 1,626 $ 1,443
XML 95 R80.htm IDEA: XBRL DOCUMENT v3.24.1
Note 14 - Equity Offerings (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jul. 27, 2023
Dec. 31, 2023
Mar. 18, 2022
Warrants Issued in Registered Direct Offering [Member]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 23,809,524    
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.42    
Warrants and Rights Outstanding, Term 5 years    
Proceeds from Issuance of Warrants $ 7,100    
Other Nonoperating Expense $ 700    
The 2022 ATM Offering [Member]      
Stock Offering Agreement, Maximum Share Value     $ 100,000
Stock Offering Agreement, Commission, Percent     3.00%
Stock Issued During Period, Shares, New Issues   933,672  
Proceeds from Issuance or Sale of Equity   $ 403  
Common Stock Issued in Registered Direct Offering [Member]      
Stock Issued During Period, Shares, New Issues 23,809,524    
Proceeds from Issuance or Sale of Equity $ 10,000    
Proceeds from Issuance of Common Stock 2,900    
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs $ 1,000    
XML 96 R81.htm IDEA: XBRL DOCUMENT v3.24.1
Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) - The 2022 ATM Offering [Member]
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Total shares of common stock sold (in shares) | shares 933,672
Average price per share (in dollars per share) | $ / shares $ 0.43
Gross proceeds $ 403
Commisssion paid to agents 12
Net proceeds $ 391
XML 97 R82.htm IDEA: XBRL DOCUMENT v3.24.1
Note 15 - Basic and Diluted Net Loss Per Share (Details Textual) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Weighted Average Number of Shares Outstanding, Diluted, Adjustment 0 0
XML 98 R83.htm IDEA: XBRL DOCUMENT v3.24.1
Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 47,601,356 17,089,534
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 10,444,679 7,584,967
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 12,326,177 8,483,491
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 24,830,500 1,021,076
XML 99 R84.htm IDEA: XBRL DOCUMENT v3.24.1
Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) - License and Supply Agreement [Member] - Senhance Surgical Robotic System Acquisition[Member]
$ in Thousands
Dec. 31, 2023
USD ($)
2024 $ 3,263
2025 300
2026 320
Total commitments $ 3,883
XML 100 R85.htm IDEA: XBRL DOCUMENT v3.24.1
Note 17 - Segments and Geographic Areas (Details Textual)
 12 Months Ended
Dec. 31, 2023
Number of Operating Segments 1
XML 101 R86.htm IDEA: XBRL DOCUMENT v3.24.1
Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) - Geographic Concentration Risk [Member]
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
UNITED STATES | Long-lived Assets [Member]    
Percentage 29.00% 35.00%
UNITED STATES | Assets, Total [Member]    
Percentage 46.00% 72.00%
Europe, Middle East, and Africa [Member] | Long-lived Assets [Member]    
Percentage 68.00% 62.00%
Europe, Middle East, and Africa [Member] | Assets, Total [Member]    
Percentage 52.00% 27.00%
Asia [Member] | Long-lived Assets [Member]    
Percentage 3.00% 3.00%
Asia [Member] | Assets, Total [Member]    
Percentage 2.00% 1.00%
All Countries [Member] | Long-lived Assets [Member]    
Percentage 100.00% 100.00%
All Countries [Member] | Assets, Total [Member]    
Percentage 100.00% 100.00%
XML 102 R87.htm IDEA: XBRL DOCUMENT v3.24.1
Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) - Revenue Benchmark [Member] - Geographic Concentration Risk [Member]
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
UNITED STATES    
Concentration risk, percent 8.00% 11.00%
EMEA [Member]    
Concentration risk, percent 82.00% 77.00%
Asia [Member]    
Concentration risk, percent 10.00% 12.00%
All Countries [Member]    
Concentration risk, percent 100.00% 100.00%
XML 103 R88.htm IDEA: XBRL DOCUMENT v3.24.1
Note 18 - Related Party Transactions (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Synchrony Labs, LLC [Member] | Preclinical Evaluation of the LUNA Surgical System [Member]    
Related Party Transaction, Expenses from Transactions with Related Party (Deprecated 2023) $ 0.1  
Asensus Surgical Europe S.à.R.L [Member] | 1 Med S.A. [Member] | Service Supply Agreement [Member]    
Related Party Transaction, Expenses from Transactions with Related Party (Deprecated 2023) $ 0.1 $ 0.3
Synchrony Labs, LLC [Member] | Director of Asensus [Member]    
Ownership Percentage 10.00%  
EXCEL 104 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 105 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 106 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 108 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 213 431 1 true 87 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://transenterix.com/20231231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://transenterix.com/20231231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Description of the Business Sheet http://transenterix.com/20231231/role/statement-note-1-description-of-the-business Note 1 - Description of the Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Revenue Recognition Sheet http://transenterix.com/20231231/role/statement-note-3-revenue-recognition Note 3 - Revenue Recognition Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash Sheet http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash Note 4 - Cash, Cash Equivalents, and Restricted Cash Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Investments, Available-for-sale Sheet http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale Note 5 - Investments, Available-for-sale Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Fair Value Sheet http://transenterix.com/20231231/role/statement-note-6-fair-value Note 6 - Fair Value Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Inventories Sheet http://transenterix.com/20231231/role/statement-note-7-inventories Note 7 - Inventories Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Property and Equipment Sheet http://transenterix.com/20231231/role/statement-note-8-property-and-equipment Note 8 - Property and Equipment Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Intellectual Property Sheet http://transenterix.com/20231231/role/statement-note-9-intellectual-property Note 9 - Intellectual Property Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Leases Sheet http://transenterix.com/20231231/role/statement-note-10-leases- Note 10 - Leases Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities Sheet http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities Note 11 - Accrued Expenses and Other Current Liabilities Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Income Taxes Sheet http://transenterix.com/20231231/role/statement-note-12-income-taxes Note 12 - Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Stock-based Compensation Sheet http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation Note 13 - Stock-based Compensation Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Equity Offerings Sheet http://transenterix.com/20231231/role/statement-note-14-equity-offerings Note 14 - Equity Offerings Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share Sheet http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share Note 15 - Basic and Diluted Net Loss Per Share Notes 21 false false R22.htm 021 - Disclosure - Note 16 - Commitments and Contingencies Sheet http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies Note 16 - Commitments and Contingencies Notes 22 false false R23.htm 022 - Disclosure - Note 17 - Segments and Geographic Areas Sheet http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas Note 17 - Segments and Geographic Areas Notes 23 false false R24.htm 023 - Disclosure - Note 18 - Related Party Transactions Sheet http://transenterix.com/20231231/role/statement-note-18-related-party-transactions Note 18 - Related Party Transactions Notes 24 false false R25.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 25 false false R26.htm 995469 - Disclosure - Significant Accounting Policies (Policies) Sheet http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies 26 false false R27.htm 995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies 27 false false R28.htm 995471 - Disclosure - Note 3 - Revenue Recognition (Tables) Sheet http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables Note 3 - Revenue Recognition (Tables) Tables http://transenterix.com/20231231/role/statement-note-3-revenue-recognition 28 false false R29.htm 995472 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables) Sheet http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables) Tables http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash 29 false false R30.htm 995473 - Disclosure - Note 5 - Investments, Available-for-sale (Tables) Sheet http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables Note 5 - Investments, Available-for-sale (Tables) Tables http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale 30 false false R31.htm 995474 - Disclosure - Note 6 - Fair Value (Tables) Sheet http://transenterix.com/20231231/role/statement-note-6-fair-value-tables Note 6 - Fair Value (Tables) Tables http://transenterix.com/20231231/role/statement-note-6-fair-value 31 false false R32.htm 995475 - Disclosure - Note 7 - Inventories (Tables) Sheet http://transenterix.com/20231231/role/statement-note-7-inventories-tables Note 7 - Inventories (Tables) Tables http://transenterix.com/20231231/role/statement-note-7-inventories 32 false false R33.htm 995476 - Disclosure - Note 8 - Property and Equipment (Tables) Sheet http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables Note 8 - Property and Equipment (Tables) Tables http://transenterix.com/20231231/role/statement-note-8-property-and-equipment 33 false false R34.htm 995477 - Disclosure - Note 9 - Intellectual Property (Tables) Sheet http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables Note 9 - Intellectual Property (Tables) Tables http://transenterix.com/20231231/role/statement-note-9-intellectual-property 34 false false R35.htm 995478 - Disclosure - Note 10 - Leases (Tables) Sheet http://transenterix.com/20231231/role/statement-note-10-leases-tables Note 10 - Leases (Tables) Tables http://transenterix.com/20231231/role/statement-note-10-leases- 35 false false R36.htm 995479 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-tables Note 11 - Accrued Expenses and Other Current Liabilities (Tables) Tables http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities 36 false false R37.htm 995480 - Disclosure - Note 12 - Income Taxes (Tables) Sheet http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables Note 12 - Income Taxes (Tables) Tables http://transenterix.com/20231231/role/statement-note-12-income-taxes 37 false false R38.htm 995481 - Disclosure - Note 13 - Stock-based Compensation (Tables) Sheet http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables Note 13 - Stock-based Compensation (Tables) Tables http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation 38 false false R39.htm 995482 - Disclosure - Note 14 - Equity Offerings (Tables) Sheet http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables Note 14 - Equity Offerings (Tables) Tables http://transenterix.com/20231231/role/statement-note-14-equity-offerings 39 false false R40.htm 995483 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Tables) Sheet http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables Note 15 - Basic and Diluted Net Loss Per Share (Tables) Tables http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share 40 false false R41.htm 995484 - Disclosure - Note 16 - Commitments and Contingencies (Tables) Sheet http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-tables Note 16 - Commitments and Contingencies (Tables) Tables http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies 41 false false R42.htm 995485 - Disclosure - Note 17 - Segments and Geographic Areas (Tables) Sheet http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables Note 17 - Segments and Geographic Areas (Tables) Tables http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas 42 false false R43.htm 995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables 43 false false R44.htm 995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) Sheet http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details) Details 44 false false R45.htm 995488 - Disclosure - Note 3 - Revenue Recognition 1 (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-1-details-textual Note 3 - Revenue Recognition 1 (Details Textual) Details http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables 45 false false R46.htm 995489 - Disclosure - Note 3 - Revenue Recognition 2 (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual Note 3 - Revenue Recognition 2 (Details Textual) Details http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables 46 false false R47.htm 995490 - Disclosure - Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) Details 47 false false R48.htm 995491 - Disclosure - Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) Sheet http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) Details 48 false false R49.htm 995492 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual) Details http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables 49 false false R50.htm 995493 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details) Details 50 false false R51.htm 995494 - Disclosure - Note 5 - Investments, Available-for-sale (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-details-textual Note 5 - Investments, Available-for-sale (Details Textual) Details http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables 51 false false R52.htm 995495 - Disclosure - Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) Sheet http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details) Details 52 false false R53.htm 995496 - Disclosure - Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) Sheet http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details Note 5 - Investments, Available-for-sale - Contractual Maturities (Details) Details 53 false false R54.htm 995497 - Disclosure - Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 54 false false R55.htm 995498 - Disclosure - Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) Sheet http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details) Details 55 false false R56.htm 995499 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) Sheet http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details) Details 56 false false R57.htm 995500 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants (Details) Sheet http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details Note 6 - Fair Value - Summary of Change in Fair Value for Warrants (Details) Details 57 false false R58.htm 995501 - Disclosure - Note 7 - Inventories - Components of Inventories (Details) Sheet http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details Note 7 - Inventories - Components of Inventories (Details) Details 58 false false R59.htm 995502 - Disclosure - Note 8 - Property and Equipment (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-details-textual Note 8 - Property and Equipment (Details Textual) Details http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables 59 false false R60.htm 995503 - Disclosure - Note 8 - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details Note 8 - Property and Equipment - Summary of Property and Equipment (Details) Details 60 false false R61.htm 995504 - Disclosure - Note 9 - Intellectual Property (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual Note 9 - Intellectual Property (Details Textual) Details http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables 61 false false R62.htm 995505 - Disclosure - Note 9 - Intellectual Property - Intellectual Property (Details) Sheet http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details Note 9 - Intellectual Property - Intellectual Property (Details) Details 62 false false R63.htm 995506 - Disclosure - Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) Sheet http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details) Details 63 false false R64.htm 995507 - Disclosure - Note 10 - Leases - Components of Operating Lease Expense (Details) Sheet http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details Note 10 - Leases - Components of Operating Lease Expense (Details) Details 64 false false R65.htm 995508 - Disclosure - Note 10 - Leases -Supplemental Balance Sheet Information (Details) Sheet http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details Note 10 - Leases -Supplemental Balance Sheet Information (Details) Details 65 false false R66.htm 995509 - Disclosure - Note 10 - Leases - Minimum Lease Payments (Details) Sheet http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details Note 10 - Leases - Minimum Lease Payments (Details) Details 66 false false R67.htm 995510 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities - Components of Accrued Expenses (Details) Sheet http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details Note 11 - Accrued Expenses and Other Current Liabilities - Components of Accrued Expenses (Details) Details 67 false false R68.htm 995511 - Disclosure - Note 12 - Income Taxes (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual Note 12 - Income Taxes (Details Textual) Details http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables 68 false false R69.htm 995512 - Disclosure - Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) Sheet http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details) Details 69 false false R70.htm 995513 - Disclosure - Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) Sheet http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details) Details 70 false false R71.htm 995514 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets (Details) Sheet http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details Note 12 - Income Taxes - Deferred Tax Assets (Details) Details 71 false false R72.htm 995515 - Disclosure - Note 12 - Income Taxes - Unrecognized Tax Positions (Details) Sheet http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details Note 12 - Income Taxes - Unrecognized Tax Positions (Details) Details 72 false false R73.htm 995516 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Sheet http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details) Details 73 false false R74.htm 995517 - Disclosure - Note 13 - Stock-based Compensation (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual Note 13 - Stock-based Compensation (Details Textual) Details http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables 74 false false R75.htm 995518 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Activity (Details) Sheet http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details Note 13 - Stock-based Compensation - Stock Option Activity (Details) Details 75 false false R76.htm 995519 - Disclosure - Note 13 - Stock-based Compensation - Stock Options Outstanding (Details) Sheet http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details Note 13 - Stock-based Compensation - Stock Options Outstanding (Details) Details 76 false false R77.htm 995520 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details) Sheet http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details) Details 77 false false R78.htm 995521 - Disclosure - Note 13 - Stock-based Compensation - RSU Activity (Details) Sheet http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details Note 13 - Stock-based Compensation - RSU Activity (Details) Details 78 false false R79.htm 995522 - Disclosure - Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) Sheet http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details) Details 79 false false R80.htm 995523 - Disclosure - Note 14 - Equity Offerings (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual Note 14 - Equity Offerings (Details Textual) Details http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables 80 false false R81.htm 995524 - Disclosure - Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) Sheet http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details Note 14 - Equity Offerings - Summary of Sales Under Offering (Details) Details 81 false false R82.htm 995525 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-details-textual Note 15 - Basic and Diluted Net Loss Per Share (Details Textual) Details http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables 82 false false R83.htm 995526 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 83 false false R84.htm 995527 - Disclosure - Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) Sheet http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details) Details 84 false false R85.htm 995528 - Disclosure - Note 17 - Segments and Geographic Areas (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-details-textual Note 17 - Segments and Geographic Areas (Details Textual) Details http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables 85 false false R86.htm 995529 - Disclosure - Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) Sheet http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details) Details 86 false false R87.htm 995530 - Disclosure - Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) Sheet http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details) Details 87 false false R88.htm 995531 - Disclosure - Note 18 - Related Party Transactions (Details Textual) Sheet http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual Note 18 - Related Party Transactions (Details Textual) Details http://transenterix.com/20231231/role/statement-note-18-related-party-transactions 88 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 46 fact(s) appearing in ix:hidden were eligible for transformation: asxc:BusinessCombinationContingentConsiderationArrangementsTargetRevenue, asxc:BusinessCombinationContingentConsiderationLiabilityRelatedMilestone, asxc:NumberOfMajorCustomers, asxc:PeriodOfServiceSaleArrangement, asxc:PeriodOfServiceSaleArrangementAtStatedServicePrice, dei:CurrentFiscalYearEndDate, ecd:NonRule10b51ArrAdoptedFlag, ecd:NonRule10b51ArrTrmntdFlag, ecd:Rule10b51ArrAdoptedFlag, ecd:Rule10b51ArrTrmntdFlag, us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss, us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal, us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss, us-gaap:ImpairmentOfIntangibleAssetsFinitelived, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:NumberOfOperatingSegments, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued, us-gaap:WarrantsAndRightsOutstandingTerm, us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment - asxc20231231_10k.htm 10, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57 [DQC.US.0076.7653] The filer has reported a value for us-gaap:RevenueRemainingPerformanceObligation with a value of 900000.000000 using the dimension member (none) The filer has not reported a duration value for the corresponding elements of RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1. The properties of this us-gaap:RevenueRemainingPerformanceObligation fact are: Context: i_2023-12-31_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2024-01-01 Unit: USD. - asxc20231231_10k.htm 8744 - asxc20231231_10k.htm 8744 [DQC.US.0098.9531] The element (name) with a value of 500000.000000 is greater than the opening balance of us-gaap:ContractWithCustomerLiability with an opening balance of 465000.000000 on 2023-01-01 00:00:00. The element us-gaap:ContractWithCustomerLiabilityRevenueRecognized represents the amount from the opening balance that was recognized during the period. For this reason it cannot be greater than the opening balance. If representing the revenue recognized during the period as part of a rollforward including the revenue recognized from the opening balance use the extension concept ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance. If reporting the revenue recognized during the period that excludes the opening balance use the extension element ContractWithCustomerLiabilityRevenueRecognizedExcludingOpeningBalance. The properties of this us-gaap:ContractWithCustomerLiabilityRevenueRecognized fact are: Context: d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-AssetsTotalMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-EuropeMiddleEastAndAfricaMember Unit: Pure. - asxc20231231_10k.htm 8767, 8822 - asxc20231231_10k.htm 8767, 8822 asxc-20231231.xsd asxc-20231231_cal.xml asxc-20231231_def.xml asxc-20231231_lab.xml asxc-20231231_pre.xml asxc20231231_10k.htm http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 111 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "asxc20231231_10k.htm": { "nsprefix": "asxc", "nsuri": "http://transenterix.com/20231231", "dts": { "schema": { "local": [ "asxc-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "asxc-20231231_cal.xml" ] }, "definitionLink": { "local": [ "asxc-20231231_def.xml" ] }, "labelLink": { "local": [ "asxc-20231231_lab.xml" ] }, "presentationLink": { "local": [ "asxc-20231231_pre.xml" ] }, "inline": { "local": [ "asxc20231231_10k.htm" ] } }, "keyStandard": 377, "keyCustom": 54, "axisStandard": 31, "axisCustom": 0, "memberStandard": 53, "memberCustom": 30, "hidden": { "total": 50, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 33, "http://transenterix.com/20231231": 8, "http://xbrl.sec.gov/ecd/2023": 4 }, "contextCount": 213, "entityCount": 1, "segmentCount": 87, "elementCount": 655, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 890, "http://xbrl.sec.gov/dei/2023": 37, "http://xbrl.sec.gov/ecd/2023": 5, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://transenterix.com/20231231/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R3": { "role": "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R4": { "role": "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R5": { "role": "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R7": { "role": "http://transenterix.com/20231231/role/statement-note-1-description-of-the-business", "longName": "006 - Disclosure - Note 1 - Description of the Business", "shortName": "Note 1 - Description of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "longName": "008 - Disclosure - Note 3 - Revenue Recognition", "shortName": "Note 3 - Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "longName": "009 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash", "shortName": "Note 4 - Cash, Cash Equivalents, and Restricted Cash", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "longName": "010 - Disclosure - Note 5 - Investments, Available-for-sale", "shortName": "Note 5 - Investments, Available-for-sale", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://transenterix.com/20231231/role/statement-note-6-fair-value", "longName": "011 - Disclosure - Note 6 - Fair Value", "shortName": "Note 6 - Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://transenterix.com/20231231/role/statement-note-7-inventories", "longName": "012 - Disclosure - Note 7 - Inventories", "shortName": "Note 7 - Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "longName": "013 - Disclosure - Note 8 - Property and Equipment", "shortName": "Note 8 - Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "longName": "014 - Disclosure - Note 9 - Intellectual Property", "shortName": "Note 9 - Intellectual Property", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://transenterix.com/20231231/role/statement-note-10-leases-", "longName": "015 - Disclosure - Note 10 - Leases", "shortName": "Note 10 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities", "longName": "016 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities", "shortName": "Note 11 - Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:AccruedLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "longName": "017 - Disclosure - Note 12 - Income Taxes", "shortName": "Note 12 - Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "longName": "018 - Disclosure - Note 13 - Stock-based Compensation", "shortName": "Note 13 - Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "longName": "019 - Disclosure - Note 14 - Equity Offerings", "shortName": "Note 14 - Equity Offerings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "longName": "020 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share", "shortName": "Note 15 - Basic and Diluted Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "longName": "021 - Disclosure - Note 16 - Commitments and Contingencies", "shortName": "Note 16 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "longName": "022 - Disclosure - Note 17 - Segments and Geographic Areas", "shortName": "Note 17 - Segments and Geographic Areas", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "longName": "023 - Disclosure - Note 18 - Related Party Transactions", "shortName": "Note 18 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies", "longName": "995469 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "longName": "995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables", "longName": "995471 - Disclosure - Note 3 - Revenue Recognition (Tables)", "shortName": "Note 3 - Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "longName": "995472 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables)", "shortName": "Note 4 - Cash, Cash Equivalents, and Restricted Cash (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables", "longName": "995473 - Disclosure - Note 5 - Investments, Available-for-sale (Tables)", "shortName": "Note 5 - Investments, Available-for-sale (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables", "longName": "995474 - Disclosure - Note 6 - Fair Value (Tables)", "shortName": "Note 6 - Fair Value (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://transenterix.com/20231231/role/statement-note-7-inventories-tables", "longName": "995475 - Disclosure - Note 7 - Inventories (Tables)", "shortName": "Note 7 - Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables", "longName": "995476 - Disclosure - Note 8 - Property and Equipment (Tables)", "shortName": "Note 8 - Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables", "longName": "995477 - Disclosure - Note 9 - Intellectual Property (Tables)", "shortName": "Note 9 - Intellectual Property (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R35": { "role": "http://transenterix.com/20231231/role/statement-note-10-leases-tables", "longName": "995478 - Disclosure - Note 10 - Leases (Tables)", "shortName": "Note 10 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R36": { "role": "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-tables", "longName": "995479 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Note 11 - Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "asxc:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "asxc:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables", "longName": "995480 - Disclosure - Note 12 - Income Taxes (Tables)", "shortName": "Note 12 - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables", "longName": "995481 - Disclosure - Note 13 - Stock-based Compensation (Tables)", "shortName": "Note 13 - Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables", "longName": "995482 - Disclosure - Note 14 - Equity Offerings (Tables)", "shortName": "Note 14 - Equity Offerings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "asxc:ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "longName": "995483 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Tables)", "shortName": "Note 15 - Basic and Diluted Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-tables", "longName": "995484 - Disclosure - Note 16 - Commitments and Contingencies (Tables)", "shortName": "Note 16 - Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables", "longName": "995485 - Disclosure - Note 17 - Segments and Geographic Areas (Tables)", "shortName": "Note 17 - Segments and Geographic Areas (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "995486 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "asxc:WorkingCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "asxc:SubstantialDoubtAboutGoingConcernPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R44": { "role": "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "longName": "995487 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-OperatingLeaseAssetsMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-OperatingLeaseAssetsMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R45": { "role": "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-1-details-textual", "longName": "995488 - Disclosure - Note 3 - Revenue Recognition 1 (Details Textual)", "shortName": "Note 3 - Revenue Recognition 1 (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R46": { "role": "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual", "longName": "995489 - Disclosure - Note 3 - Revenue Recognition 2 (Details Textual)", "shortName": "Note 3 - Revenue Recognition 2 (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "i_2023-12-31_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2024-01-01", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis-RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain-2024-01-01", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "longName": "995490 - Disclosure - Note 3 - Revenue Recognition - Disaggregation of Revenue (Details)", "shortName": "Note 3 - Revenue Recognition - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_StatementGeographicalAxis-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R48": { "role": "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "longName": "995491 - Disclosure - Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details)", "shortName": "Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "longName": "995492 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual)", "shortName": "Note 4 - Cash, Cash Equivalents, and Restricted Cash (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "longName": "995493 - Disclosure - Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details)", "shortName": "Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "asxc:CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-details-textual", "longName": "995494 - Disclosure - Note 5 - Investments, Available-for-sale (Details Textual)", "shortName": "Note 5 - Investments, Available-for-sale (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": null, "uniqueAnchor": null }, "R52": { "role": "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "longName": "995495 - Disclosure - Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details)", "shortName": "Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R53": { "role": "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "longName": "995496 - Disclosure - Note 5 - Investments, Available-for-sale - Contractual Maturities (Details)", "shortName": "Note 5 - Investments, Available-for-sale - Contractual Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "longName": "995497 - Disclosure - Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "shortName": "Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "longName": "995498 - Disclosure - Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details)", "shortName": "Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "i_2023-12-31_BusinessAcquisitionAxis-SenhanceSurgicalRoboticSystemAcquisitionMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_BusinessAcquisitionAxis-SenhanceSurgicalRoboticSystemAcquisitionMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R56": { "role": "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "longName": "995499 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details)", "shortName": "Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "i_2022-12-31_BusinessAcquisitionAxis-The2015SenhanceAcquisitionMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-12-31_BusinessAcquisitionAxis-The2015SenhanceAcquisitionMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R57": { "role": "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details", "longName": "995500 - Disclosure - Note 6 - Fair Value - Summary of Change in Fair Value for Warrants (Details)", "shortName": "Note 6 - Fair Value - Summary of Change in Fair Value for Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2022-12-31_FairValueByLiabilityClassAxis-WarrantMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31_FairValueByLiabilityClassAxis-WarrantMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R58": { "role": "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details", "longName": "995501 - Disclosure - Note 7 - Inventories - Components of Inventories (Details)", "shortName": "Note 7 - Inventories - Components of Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:InventoryFinishedGoods", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R59": { "role": "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-details-textual", "longName": "995502 - Disclosure - Note 8 - Property and Equipment (Details Textual)", "shortName": "Note 8 - Property and Equipment (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "longName": "995503 - Disclosure - Note 8 - Property and Equipment - Summary of Property and Equipment (Details)", "shortName": "Note 8 - Property and Equipment - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R61": { "role": "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "longName": "995504 - Disclosure - Note 9 - Intellectual Property (Details Textual)", "shortName": "Note 9 - Intellectual Property (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember_RangeAxis-WeightedAverageMember", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember_RangeAxis-WeightedAverageMember", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R62": { "role": "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details", "longName": "995505 - Disclosure - Note 9 - Intellectual Property - Intellectual Property (Details)", "shortName": "Note 9 - Intellectual Property - Intellectual Property (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R63": { "role": "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "longName": "995506 - Disclosure - Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details)", "shortName": "Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-IntellectualPropertyMember", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R64": { "role": "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "longName": "995507 - Disclosure - Note 10 - Leases - Components of Operating Lease Expense (Details)", "shortName": "Note 10 - Leases - Components of Operating Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember", "name": "asxc:LongtermLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember", "name": "asxc:LongtermLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R65": { "role": "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "longName": "995508 - Disclosure - Note 10 - Leases -Supplemental Balance Sheet Information (Details)", "shortName": "Note 10 - Leases -Supplemental Balance Sheet Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "asxc:LesseeOperatingLeaseDisclosureTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "asxc:LesseeOperatingLeaseDisclosureTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R66": { "role": "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details", "longName": "995509 - Disclosure - Note 10 - Leases - Minimum Lease Payments (Details)", "shortName": "Note 10 - Leases - Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R67": { "role": "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details", "longName": "995510 - Disclosure - Note 11 - Accrued Expenses and Other Current Liabilities - Components of Accrued Expenses (Details)", "shortName": "Note 11 - Accrued Expenses and Other Current Liabilities - Components of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AccruedMarketingCostsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "asxc:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:AccruedMarketingCostsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "asxc:AccruedLiabilitiesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R68": { "role": "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual", "longName": "995511 - Disclosure - Note 12 - Income Taxes (Details Textual)", "shortName": "Note 12 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R69": { "role": "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "longName": "995512 - Disclosure - Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details)", "shortName": "Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R70": { "role": "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "longName": "995513 - Disclosure - Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details)", "shortName": "Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R71": { "role": "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "longName": "995514 - Disclosure - Note 12 - Income Taxes - Deferred Tax Assets (Details)", "shortName": "Note 12 - Income Taxes - Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R72": { "role": "http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "longName": "995515 - Disclosure - Note 12 - Income Taxes - Unrecognized Tax Positions (Details)", "shortName": "Note 12 - Income Taxes - Unrecognized Tax Positions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R73": { "role": "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "longName": "995516 - Disclosure - Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)", "shortName": "Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R74": { "role": "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "longName": "995517 - Disclosure - Note 13 - Stock-based Compensation (Details Textual)", "shortName": "Note 13 - Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R75": { "role": "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "longName": "995518 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Activity (Details)", "shortName": "Note 13 - Stock-based Compensation - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "i_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R76": { "role": "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "longName": "995519 - Disclosure - Note 13 - Stock-based Compensation - Stock Options Outstanding (Details)", "shortName": "Note 13 - Stock-based Compensation - Stock Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R77": { "role": "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "longName": "995520 - Disclosure - Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details)", "shortName": "Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "d_2022-01-01_2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_RangeAxis-MinimumMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R78": { "role": "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "longName": "995521 - Disclosure - Note 13 - Stock-based Compensation - RSU Activity (Details)", "shortName": "Note 13 - Stock-based Compensation - RSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R79": { "role": "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "longName": "995522 - Disclosure - Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details)", "shortName": "Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R80": { "role": "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "longName": "995523 - Disclosure - Note 14 - Equity Offerings (Details Textual)", "shortName": "Note 14 - Equity Offerings (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "i_2023-07-27_ClassOfWarrantOrRightAxis-WarrantsIssuedInRegisteredDirectOfferingMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-07-27_ClassOfWarrantOrRightAxis-WarrantsIssuedInRegisteredDirectOfferingMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R81": { "role": "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "longName": "995524 - Disclosure - Note 14 - Equity Offerings - Summary of Sales Under Offering (Details)", "shortName": "Note 14 - Equity Offerings - Summary of Sales Under Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-The2022AtmOfferingMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_SubsidiarySaleOfStockAxis-The2022AtmOfferingMember", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "asxc:ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "unique": true } }, "R82": { "role": "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-details-textual", "longName": "995525 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share (Details Textual)", "shortName": "Note 15 - Basic and Diluted Net Loss Per Share (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": null, "uniqueAnchor": null }, "R83": { "role": "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "longName": "995526 - Disclosure - Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R84": { "role": "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "longName": "995527 - Disclosure - Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details)", "shortName": "Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "i_2023-12-31_BusinessAcquisitionAxis-SenhanceSurgicalRoboticSystemAcquisitionMember_TypeOfArrangementAxis-LicenseAndSupplyAgreementMember", "name": "us-gaap:ContractualObligationDueInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_BusinessAcquisitionAxis-SenhanceSurgicalRoboticSystemAcquisitionMember_TypeOfArrangementAxis-LicenseAndSupplyAgreementMember", "name": "us-gaap:ContractualObligationDueInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R85": { "role": "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-details-textual", "longName": "995528 - Disclosure - Note 17 - Segments and Geographic Areas (Details Textual)", "shortName": "Note 17 - Segments and Geographic Areas (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": null, "uniqueAnchor": null }, "R86": { "role": "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "longName": "995529 - Disclosure - Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details)", "shortName": "Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-LongLivedAssetsMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-US", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-LongLivedAssetsMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-US", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R87": { "role": "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "longName": "995530 - Disclosure - Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details)", "shortName": "Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-US", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-US", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } }, "R88": { "role": "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual", "longName": "995531 - Disclosure - Note 18 - Related Party Transactions (Details Textual)", "shortName": "Note 18 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-PreclinicalEvaluationOfTheLUNASurgicalSystemMember_RelatedPartyTransactionsByRelatedPartyAxis-SynchronyLabsLLCMember", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-12-31_RelatedPartyTransactionAxis-PreclinicalEvaluationOfTheLUNASurgicalSystemMember_RelatedPartyTransactionsByRelatedPartyAxis-SynchronyLabsLLCMember", "name": "us-gaap:OperatingCostsAndExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "asxc20231231_10k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsPayableCurrent", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27", "r758" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r711" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r275", "r276" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments", "negatedLabel": "Amortization of discounts and premiums on investments, net", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r104" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedLiabilitiesCurrent", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29" ] }, "asxc_AccruedLiabilitiesExcludingEmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "AccruedLiabilitiesExcludingEmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered, excluding employee related liabilities." } } }, "auth_ref": [] }, "asxc_AccruedLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "AccruedLiabilitiesTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities [Text Block]", "documentation": "The entire disclosure for accrued liabilities at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedMarketingCostsCurrent", "terseLabel": "Consulting and other vendors", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedProfessionalFeesCurrent", "terseLabel": "Legal and professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccruedRoyaltiesCurrent", "terseLabel": "Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29", "r730" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r54", "r179", "r603" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r32", "r33", "r91", "r183", "r599", "r623", "r624" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r5", "r14", "r33", "r491", "r494", "r531", "r619", "r620", "r803", "r804", "r805", "r813", "r814", "r815" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r7", "r14", "r33", "r200", "r201", "r512", "r513", "r514", "r515", "r516", "r803" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r83" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r440", "r441", "r442", "r634", "r813", "r814", "r815", "r884", "r911" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Shares withheld related to net share settlement of equity awards", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r61", "r62", "r404" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "terseLabel": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r15", "r117" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:" } } }, "auth_ref": [] }, "asxc_AllCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "AllCountriesMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "All Countries [Member]", "documentation": "Represents all countries." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Share-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r435", "r447" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r184", "r277", "r317", "r320", "r322", "r905" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r10", "r49", "r52" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r237" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r40" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r485" ] }, "asxc_AsensusSurgicalEuropeSrlMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "AsensusSurgicalEuropeSrlMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Asensus Surgical Europe S.\u00e0.R.L [Member]", "documentation": "Represents Asensus Surgical Europe S.\u00e0.R.L ." } } }, "auth_ref": [] }, "asxc_AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan [Member]", "documentation": "Information related to the \"Asensus Surgical, Inc. Amended and Restated Incentive Compensation Plan\"." } } }, "auth_ref": [] }, "srt_AsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Asia [Member]", "documentation": "Continent of Asia." } } }, "auth_ref": [ "r913", "r914", "r915", "r916" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r132", "r182", "r214", "r246", "r261", "r266", "r314", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r486", "r488", "r508", "r595", "r662", "r758", "r771", "r845", "r846", "r893" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total Current Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r173", "r189", "r214", "r314", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r486", "r488", "r508", "r758", "r845", "r846", "r893" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total assets measured at fair value", "label": "us-gaap_AssetsFairValueDisclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r71" ] }, "us-gaap_AssetsTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsTotalMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Assets, Total [Member]", "documentation": "Total assets, when it serves as a benchmark in a concentration of risk calculation, representing the sum of all reported assets as of the balance sheet date." } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorFirmId", "terseLabel": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r775", "r776", "r777" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorLocation", "terseLabel": "Auditor Location" } } }, "auth_ref": [ "r775", "r776", "r777" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_AuditorName", "terseLabel": "Auditor Name" } } }, "auth_ref": [ "r775", "r776", "r777" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "Unrealized Gain", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r286" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Unrealized Loss", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r287" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "Amortized Cost", "totalLabel": "Total, amortized cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r283", "r326", "r594" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details" ], "lang": { "en-us": { "role": { "label": "Mature in less than one year, amortized cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r831" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details" ], "lang": { "en-us": { "role": { "label": "Mature in less than one year, fair value", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r290", "r592" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "Fair Value", "totalLabel": "Total, fair value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r284", "r326", "r587", "r822" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Short-term investments", "label": "Short-term investments, available-for-sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r280", "r326" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term investments", "label": "Long-term investments, available-for-sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r177", "r280", "r326" ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r406", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r430", "r431", "r432", "r433", "r434" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r482", "r750", "r751" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r67", "r68", "r482", "r750", "r751" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 }, "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Change in fair value of contingent consideration", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r484", "r806" ] }, "asxc_BusinessCombinationContingentConsiderationArrangementsTargetRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "BusinessCombinationContingentConsiderationArrangementsTargetRevenue", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_BusinessCombinationContingentConsiderationArrangementsTargetRevenue", "terseLabel": "Business Combination Contingent Consideration Arrangements Target Revenue", "documentation": "The target revenue to be achieved pursuant to the business combination agreement." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration", "label": "us-gaap_BusinessCombinationContingentConsiderationLiability", "terseLabel": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r2", "r69", "r483" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Contingent consideration, measurement input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r504" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Contingent consideration", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r69" ] }, "asxc_BusinessCombinationContingentConsiderationLiabilityRelatedMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "BusinessCombinationContingentConsiderationLiabilityRelatedMilestone", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_BusinessCombinationContingentConsiderationLiabilityRelatedMilestone", "terseLabel": "Business Combination, Contingent Consideration, Liability, Related Milestone", "documentation": "Represents the milestone amount associated with the specified liability arising from contingent consideration in a business combination." } } }, "auth_ref": [] }, "us-gaap_CanadaRevenueAgencyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CanadaRevenueAgencyMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Canada Revenue Agency [Member]", "documentation": "Designated tax department of the government of Canada." } } }, "auth_ref": [] }, "us-gaap_CapitalizationOfInternalCostsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizationOfInternalCostsPolicy", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Capitalization of Internal Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for capitalizing internal costs associated with exploration and production activities." } } }, "auth_ref": [ "r25", "r129" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_Cash", "terseLabel": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r142", "r596", "r635", "r657", "r758", "r771", "r797" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 0.0 }, "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r176", "r727" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "asxc_CashAndCashEquivalentsRestrictedCashAndInvestmentsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "CashAndCashEquivalentsRestrictedCashAndInvestmentsPolicyPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash, and Investments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, restricted cash, and investments." } } }, "auth_ref": [] }, "asxc_CashCashEquivalentsAndRestrictedCashDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "CashCashEquivalentsAndRestrictedCashDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Restricted Cash Disclosure [Text Block]", "documentation": "The complete disclosure for cash, cash equivalents, and restricted cash." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r102", "r211" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "totalLabel": "Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r102", "r211" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r4", "r102" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Supplemental Schedule of Non-cash Investing and Financing Activities:" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_CityAreaCode", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r376" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r376" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r115", "r765", "r766", "r767", "r768" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r114", "r345", "r346", "r712", "r842" ] }, "asxc_CommonStockIssuedInRegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "CommonStockIssuedInRegisteredDirectOfferingMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Stock Issued in Registered Direct Offering [Member]", "documentation": "Relating to common stock issued registered direct offering." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r761", "r762", "r763", "r765", "r766", "r767", "r768", "r813", "r814", "r884", "r909", "r911" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r82" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r82", "r649" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r82" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r15", "r82", "r649", "r668", "r911", "r912" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Common stock $0.001 par value, 750,000,000 shares authorized at December 31, 2023 and December 31, 2022; 264,921,526 and 236,895,440 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r82", "r598", "r758" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r34", "r195", "r197", "r204", "r589", "r609" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r41", "r44", "r74", "r75", "r274", "r711" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r41", "r44", "r74", "r75", "r274", "r625", "r711" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r41", "r44", "r74", "r75", "r274", "r711", "r785" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r77", "r147" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "verboseLabel": "Concentration risk, percent", "label": "Percentage", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r41", "r44", "r74", "r75", "r274" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r41", "r44", "r74", "r75", "r274", "r711" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r70", "r731" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "asxc_ContingentConsiderationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ContingentConsiderationPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration [Policy Text Block]", "documentation": "Disclosure accounting policy for contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r848" ] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r378", "r380", "r391" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "us-gaap_ContractWithCustomerLiability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r378", "r379", "r391" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r378", "r379", "r391" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue - less current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r378", "r379", "r391" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-1-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r392" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligation", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractualObligation", "totalLabel": "Total commitments", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r811" ] }, "us-gaap_ContractualObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInNextTwelveMonths", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractualObligationDueInNextTwelveMonths", "terseLabel": "2024", "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInSecondYear", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractualObligationDueInSecondYear", "terseLabel": "2025", "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ContractualObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractualObligationDueInThirdYear", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "parentTag": "us-gaap_ContractualObligation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractualObligationDueInThirdYear", "terseLabel": "2026", "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r812" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r747", "r749", "r908" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostOfGoodsAndServicesSold", "terseLabel": "Cost of revenue", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r96", "r572" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenueAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Cost of revenue:" } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r789" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "lang": { "en-us": { "role": { "label": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r788", "r810", "r882" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r788", "r810" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "lang": { "en-us": { "role": { "label": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r788", "r810", "r882" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r42", "r274" ] }, "asxc_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "CustomerOneMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]", "documentation": "Related to customer one." } } }, "auth_ref": [] }, "asxc_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "CustomerTwoMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "Related to customer two." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "terseLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r285", "r326", "r330", "r332" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal", "terseLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not to Sell before Recovery, Credit Loss, Previously Recorded, Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), not intended to be sold and not more likely than not will be required to sell before recovery of amortized cost basis, with previously recorded allowance." } } }, "auth_ref": [ "r331" ] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss", "terseLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r835" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r810", "r881", "r882" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Foreign", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r124", "r810", "r881" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Net deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r455", "r456" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Net deferred tax liability", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r79", "r80", "r133", "r467" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Deferred tax expense", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r104" ] }, "us-gaap_DeferredRentCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRentCreditCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredRentCreditCurrent", "terseLabel": "Taxes and other assessments", "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current." } } }, "auth_ref": [ "r140", "r799", "r891" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r810", "r881", "r882" ] }, "us-gaap_DeferredTaxAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Asset [Domain]", "documentation": "Identification of the deferred tax asset for which a valuation reserve exists." } } }, "auth_ref": [ "r63" ] }, "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsCapitalLossCarryforwards", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Capitalized costs", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards." } } }, "auth_ref": [ "r66", "r880" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r468" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax asset (liability)", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r879" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net deferred tax asset", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r879" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r66", "r880" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Fixed Assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Research credit carryforward", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r65", "r66", "r880" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r66", "r880" ] }, "asxc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesNoncurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Accrued expenses and other", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r469" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Fixed assets and other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r66", "r880" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-details-textual" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r10", "r53" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant liabilites", "label": "Warrant liabilities", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r190" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "lang": { "en-us": { "role": { "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r125" ] }, "asxc_DirectorOfAsensusMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "DirectorOfAsensusMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Director of Asensus [Member]", "documentation": "Represents the director of Asensus." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r849" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r403", "r405", "r436", "r437", "r439", "r753" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities", "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-7-inventories", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r775", "r776", "r777" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentFinStmtErrorCorrectionFlag", "terseLabel": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r775", "r776", "r777", "r779" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentPeriodEndDate", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r778" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_DocumentType", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r913", "r914", "r915", "r916" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Net loss per common share attributable to common stockholders - basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r205", "r222", "r223", "r224", "r225", "r226", "r231", "r232", "r234", "r235", "r236", "r240", "r499", "r500", "r590", "r610", "r735" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r230", "r237", "r238", "r239" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r509" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Income tax expense (benefit), percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r458" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r216", "r458", "r478" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "terseLabel": "Change in valuation allowance, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r877", "r883" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "terseLabel": "Change in enacted tax rates and other, net, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r478", "r877" ] }, "asxc_EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationAmount", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in fair market value of contingent consideration, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in fair market value of contingent consideration. ." } } }, "auth_ref": [] }, "asxc_EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationPercent": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationPercent", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "asxc_EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfContingentConsiderationPercent", "terseLabel": "Change in fair market value of contingent consideration, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in the fair market value of contingent consideration." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "terseLabel": "Foreign tax rate differential, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r877", "r883" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "terseLabel": "Nondeductible expenses, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r877", "r883" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "terseLabel": "Research & Development, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r877", "r883" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "terseLabel": "State taxes (net of deferred benefit), percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r877", "r883" ] }, "asxc_EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsAmount", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "True-up to Stock Compensation - Cancellations, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to true-up to stock compensation cancellations." } } }, "auth_ref": [] }, "asxc_EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsPercent": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsPercent", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "asxc_EffectiveIncomeTaxRateReconciliationTrueupToStockCompensationCancellationsPercent", "terseLabel": "True-up to Stock Compensation - Cancellations, percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to true-up to stock compensation cancellations." } } }, "auth_ref": [] }, "asxc_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsAmount", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in unrecognized tax benefits, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits." } } }, "auth_ref": [] }, "asxc_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "asxc_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent", "terseLabel": "Change in unrecognized tax benefits, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to unrecognized tax benefits." } } }, "auth_ref": [] }, "asxc_EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsAmount", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Warrant remeasurment and financing costs, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant remeasurement and financing costs." } } }, "auth_ref": [] }, "asxc_EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsPercent": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsPercent", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "asxc_EffectiveIncomeTaxRateReconciliationWarrantRemeasurementAndFinancingCostsPercent", "terseLabel": "Warrant remeasurment and financing costs, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrant remeasurement and financing costs." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accrued employee compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r438" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r876" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "asxc_EmployerRetentionTaxCreditPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EmployerRetentionTaxCreditPolicyPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Employer Retention Tax Credit, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy related to the Employer Retention Tax Credit under the CARES Act." } } }, "auth_ref": [] }, "asxc_EmployerRetentionTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EmployerRetentionTaxCreditReceivable", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Employee retention tax credit receivable", "documentation": "Represents the amount of employer retention tax credit receivable as of the specified date." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressAddressLine1", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressCityOrTown", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressPostalZipCode", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityAddressStateOrProvince", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r773" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCommonStockSharesOutstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityCurrentReportingStatus", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-document-and-entity-information", "http://transenterix.com/20231231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details", "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20231231/role/statement-note-10-leases-tables", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-details-textual", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-details-textual", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-1-details-textual", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-details-textual", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20231231/role/statement-note-7-inventories", "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details", "http://transenterix.com/20231231/role/statement-note-7-inventories-tables", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-details-textual", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables", "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r773" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityFileNumber", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r773" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityInteractiveDataCurrent", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r782" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityPublicFloat", "terseLabel": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityRegistrantName", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r773" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityShellCompany", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r773" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r773" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r773" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityVoluntaryFilers", "terseLabel": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_EntityWellKnownSeasonedIssuer", "terseLabel": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r783" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r171", "r199", "r200", "r201", "r217", "r218", "r219", "r221", "r227", "r229", "r241", "r315", "r316", "r377", "r440", "r441", "r442", "r473", "r474", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r510", "r512", "r513", "r514", "r515", "r516", "r531", "r619", "r620", "r621", "r634", "r691" ] }, "asxc_EuropeMiddleEastAndAfricaMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "EuropeMiddleEastAndAfricaMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Europe, Middle East, and Africa [Member]", "documentation": "Europe, Middle East, and Africa." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liabilities", "negatedLabel": "Change in fair value of warrant liabilities", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r10" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r16" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r71", "r128" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r360", "r395", "r396", "r397", "r398", "r399", "r400", "r502", "r542", "r543", "r544", "r741", "r742", "r747", "r748", "r749" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r73", "r127" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r501" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r360", "r395", "r400", "r502", "r542", "r747", "r748", "r749" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r360", "r395", "r400", "r502", "r543", "r741", "r742", "r747", "r748", "r749" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r360", "r395", "r396", "r397", "r398", "r399", "r400", "r502", "r544", "r741", "r742", "r747", "r748", "r749" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } } }, "auth_ref": [ "r71", "r128" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r17", "r73" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r505" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r72" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r17" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r360", "r395", "r396", "r397", "r398", "r399", "r400", "r542", "r543", "r544", "r741", "r742", "r747", "r748", "r749" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r318", "r319", "r323", "r324", "r325", "r327", "r328", "r329", "r361", "r374", "r496", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r608", "r740", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r835", "r836", "r837", "r838" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r180", "r341" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r339", "r340", "r341", "r342", "r573", "r574" ] }, "asxc_FiniteLivedIntangibleAssetsForeignCurrencyTranslationImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationImpact", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Impact", "documentation": "The accumulated impact of foreign currency translation for finite-lived intangible assets." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r109", "r574" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "lang": { "en-us": { "role": { "label": "Intellectual property, net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r109", "r573" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period (Year)", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r573" ] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r10" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r97", "r672" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r94" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r43", "r711" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r12", "r48" ] }, "asxc_GrantedIn2022Member": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "GrantedIn2022Member", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Granted in 2022 [Member]", "documentation": "Represents granted in 2022." } } }, "auth_ref": [] }, "asxc_GrantedIn2023Member": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "GrantedIn2023Member", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Granted in 2023 [Member]", "documentation": "Represents granted in 2023." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross loss", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r95", "r214", "r246", "r260", "r265", "r268", "r314", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r508", "r737", "r845" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_IcfrAuditorAttestationFlag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r775", "r776", "r777" ] }, "asxc_ImpactOf382OwnershipChangesMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ImpactOf382OwnershipChangesMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Impact of 382 Ownership Changes [Member]", "documentation": "Represents the impact of 382 ownership changes." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfIntangibleAssetsFinitelived", "terseLabel": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r807", "r840" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Impairment of property and equipment", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r10", "r112" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "terseLabel": "United States", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r215", "r477" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r92", "r135", "r246", "r260", "r265", "r268", "r591", "r605", "r737" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "terseLabel": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r215", "r477" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r343", "r344", "r675" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r344", "r675" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r216", "r450", "r459", "r464", "r471", "r475", "r479", "r480", "r481", "r630" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 }, "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expense", "totalLabel": "Total income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r141", "r158", "r228", "r229", "r251", "r457", "r476", "r611" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r198", "r453", "r454", "r464", "r465", "r470", "r472", "r627" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r877" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Change in enacted tax rates and other, net, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r452", "r458" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Foreign tax rate differential, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r877" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "United States federal tax at statutory rate, amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r458" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "Nondeductible expenses, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r877" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "State taxes (net of deferred benefit), amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r877" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch", "negatedLabel": "Research & Development, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r877" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r39" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "asxc_IncreaseDecreaseInAccruedLiabilitiesNotIncludingEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "IncreaseDecreaseInAccruedLiabilitiesNotIncludingEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "asxc_IncreaseDecreaseInAccruedLiabilitiesNotIncludingEmployeeRelatedLiabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid, not including employee related liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r570", "r806" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities", "terseLabel": "Accrued employee compensation and benefits", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r9" ] }, "asxc_IncreaseDecreaseInInventoryReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "IncreaseDecreaseInInventoryReserve", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "asxc_IncreaseDecreaseInInventoryReserve", "negatedLabel": "Change in inventory reserves", "documentation": "Represents the changes in inventory reserve." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r786", "r806" ] }, "asxc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "asxc_IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "negatedLabel": "Operating lease right-of-use assets", "documentation": "The amount of increase (decrease) in right-of-use assets." } } }, "auth_ref": [] }, "asxc_IncreaseDecreaseInOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "IncreaseDecreaseInOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_IncreaseDecreaseInOperatingLossCarryforwards", "terseLabel": "Increase (Decrease) in Operating Loss Carryforwards", "documentation": "The amount of increase (decrease) in operating loss carryforwards." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "negatedLabel": "Other current and long-term assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedLabel": "Prepaid expenses", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r9" ] }, "asxc_IncreaseDecreaseInTaxCreditCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "IncreaseDecreaseInTaxCreditCarryforward", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_IncreaseDecreaseInTaxCreditCarryforward", "terseLabel": "Increase (Decrease) in Tax Credit Carryforward", "documentation": "The amount of increase (decrease) in tax credit carryforward." } } }, "auth_ref": [] }, "asxc_IncreaseDecreaseInTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "IncreaseDecreaseInTaxCreditReceivable", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "asxc_IncreaseDecreaseInTaxCreditReceivable", "negatedLabel": "Employee retention tax credit receivable", "documentation": "Amount of increase (decrease) during the period in tax credit receivable." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "auth_ref": [ "r780" ] }, "asxc_InstrumentsAndAccessoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "InstrumentsAndAccessoriesMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Instruments and Accessories [Member]", "documentation": "Represents instruments and accessories, a type of products of the company." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r338" ] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntellectualPropertyMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r24" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r76", "r137", "r202", "r250", "r518", "r676", "r769", "r910" ] }, "asxc_InventoryCurrentAndNoncurrentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "InventoryCurrentAndNoncurrentGross", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "asxc_InventoryCurrentAndNoncurrentGross", "totalLabel": "Total inventories, gross", "documentation": "The value of gross inventory before allowance, both current and noncurrent." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-7-inventories" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r333" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details": { "parentTag": "asxc_InventoryCurrentAndNoncurrentGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Finished goods, gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r800" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details": { "parentTag": "asxc_InventoryCurrentAndNoncurrentGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Current Portion, gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r802" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r186", "r728", "r758" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Inventories, net of current portion", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r798" ] }, "asxc_InventoryNoncurrentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "InventoryNoncurrentGross", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details": { "parentTag": "asxc_InventoryCurrentAndNoncurrentGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Long-term portion, gross", "documentation": "The amount of inventory before valuation allowance classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r144", "r175", "r185", "r333", "r334", "r335", "r571", "r732" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details": { "parentTag": "asxc_InventoryCurrentAndNoncurrentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details" ], "lang": { "en-us": { "role": { "label": "Raw materials, gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r801" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r98", "r249" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables" ], "lang": { "en-us": { "role": { "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale" ], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r130", "r138", "r139", "r160", "r278", "r281", "r506", "r507" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r889" ] }, "asxc_LeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "LeaseMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Lease [Member]", "documentation": "Represents Lease." } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r113" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-document-and-entity-information", "http://transenterix.com/20231231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details", "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20231231/role/statement-note-10-leases-tables", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-details-textual", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-details-textual", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-1-details-textual", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-details-textual", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20231231/role/statement-note-7-inventories", "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details", "http://transenterix.com/20231231/role/statement-note-7-inventories-tables", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-details-textual", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables", "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r523" ] }, "asxc_LesseeOperatingLeaseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "LesseeOperatingLeaseDisclosureTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Disclosure [Table Text Block]", "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-tables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r890" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less: Amount of lease payments representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r528" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r888" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r888" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r519" ] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Lessor, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r153", "r154", "r155", "r529" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "terseLabel": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r530" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r28", "r214", "r314", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r487", "r488", "r489", "r508", "r648", "r736", "r771", "r845", "r893", "r894" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Stockholders' Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r87", "r134", "r601", "r758", "r809", "r839", "r887" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total Current Liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r30", "r174", "r214", "r314", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r487", "r488", "r489", "r508", "r758", "r845", "r893", "r894" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total liabilities measured at fair value", "label": "us-gaap_LiabilitiesFairValueDisclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r71" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Long-Term Liabilities:" } } }, "auth_ref": [] }, "asxc_LicenseAndSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "LicenseAndSupplyAgreementMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "lang": { "en-us": { "role": { "label": "License and Supply Agreement [Member]", "documentation": "Represents license and supply agreement." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "dei_LocalPhoneNumber", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables" ], "lang": { "en-us": { "role": { "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": [ "r21" ] }, "asxc_LongLivedAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "LongLivedAssetsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details" ], "lang": { "en-us": { "role": { "label": "Long-lived Assets [Member]", "documentation": "Represents information regarding long-lived assets." } } }, "auth_ref": [] }, "asxc_LongtermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "LongtermLeaseCost", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details" ], "lang": { "en-us": { "role": { "label": "Long-term Operating", "documentation": "Amount of long-term lease cost." } } }, "auth_ref": [] }, "us-gaap_LuxembourgInlandRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LuxembourgInlandRevenueMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Luxembourg Inland Revenue [Member]", "documentation": "Designated tax department of the government of Luxembourg." } } }, "auth_ref": [] }, "asxc_MachineryManufacturingAndDemonstrationEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "MachineryManufacturingAndDemonstrationEquipmentMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Machinery, Manufacturing and Demonstration Equipment [Member]", "documentation": "Represents machinery, manufacturing and demonstration equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r274", "r746", "r849", "r906", "r907" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r402", "r569", "r618", "r640", "r641", "r699", "r701", "r703", "r704", "r706", "r722", "r723", "r739", "r743", "r752", "r760", "r847", "r895", "r896", "r897", "r898", "r899", "r900" ] }, "asxc_MeasurementInputCurrencyExchangeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "MeasurementInputCurrencyExchangeRateMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Currency Exchange Rate [Member]", "documentation": "Measurement input using currency exchange rate." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r885" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r885" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r885" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r885" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r885" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r503" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r402", "r569", "r618", "r640", "r641", "r699", "r701", "r703", "r704", "r706", "r722", "r723", "r739", "r743", "r752", "r760", "r847", "r895", "r896", "r897", "r898", "r899", "r900" ] }, "us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinistryOfEconomicAffairsAndFinanceItalyMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Ministry of Economic Affairs and Finance, Italy [Member]", "documentation": "Designated tax department of the government of Italy." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_MoneyMarketFundsAtCarryingValue", "terseLabel": "Money market", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r781" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r274", "r746", "r849", "r906", "r907" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash and cash equivalents (used in) provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r210" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash and cash equivalents provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r210" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash and cash equivalents used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r102", "r103", "r104" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Operating Activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r93", "r104", "r136", "r172", "r193", "r196", "r201", "r214", "r220", "r222", "r223", "r224", "r225", "r228", "r229", "r233", "r246", "r260", "r265", "r268", "r314", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r500", "r508", "r606", "r670", "r689", "r690", "r737", "r769", "r845" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r781" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r913", "r914", "r915", "r916" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r99" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Other Income (Expense), net" } } }, "auth_ref": [] }, "asxc_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "asxc_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "asxc_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://transenterix.com/20231231", "localname": "NumberOfMajorCustomers", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers", "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r817" ] }, "asxc_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "OneCustomerMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "One Customer [Member]", "documentation": "Represents one of the major customers." } } }, "auth_ref": [] }, "asxc_OneMedSaMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "OneMedSaMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "1 Med S.A. [Member]", "documentation": "Represents 1 Med S.A." } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingCostsAndExpenses", "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party (Deprecated 2023)", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r246", "r260", "r265", "r268", "r737" ] }, "asxc_OperatingLeaseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "OperatingLeaseAssetsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Operating Lease Assets [Member]", "documentation": "Related to operating lease assets." } } }, "auth_ref": [] }, "asxc_OperatingLeaseIncrementalBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "OperatingLeaseIncrementalBorrowingRate", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Incremental borrowing rate", "documentation": "Incremental borrowing rate for operating lease." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Present value of future minimum lease payments", "label": "us-gaap_OperatingLeaseLiability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r521" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities - current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r521" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Noncurrent operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r521" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r522", "r524" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r520" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r527", "r757" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term (in years) (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r526", "r757" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r65" ] }, "asxc_OperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_OperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Not Subject to Expiration", "documentation": "Amount of operating loss carryforward that are not subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [] }, "asxc_OperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "OperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration", "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-1-description-of-the-business" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r105", "r106", "r107", "r126" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r188", "r758" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other long-term assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r181" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation gain (loss)", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r6" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss)", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r15", "r23", "r194", "r197", "r203", "r510", "r511", "r516", "r588", "r607", "r803", "r804" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Unrealized gain (loss) on available-for-sale investments", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r191", "r192", "r313" ] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingExpense", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherNonoperatingExpense", "terseLabel": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r100" ] }, "asxc_OwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "OwnershipPercentage", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_OwnershipPercentage", "terseLabel": "Ownership Percentage", "documentation": "Percentage of ownership." } } }, "auth_ref": [] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r125" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details": { "parentTag": "asxc_ProceedsFromIssuanceOfEquityNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Commisssion paid to agents", "label": "us-gaap_PaymentsOfStockIssuanceCosts", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Taxes paid related to net share settlement of vesting of restricted stock units", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r209" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt", "negatedLabel": "Purchase of available-for-sale investments", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r36", "r207", "r279" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r101" ] }, "asxc_PerformanceRestrictedStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "PerformanceRestrictedStockUnitMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Performance Restricted Stock Unit [Member]", "documentation": "Represents performance restricted stock unit." } } }, "auth_ref": [] }, "asxc_PeriodOfServiceSaleArrangement": { "xbrltype": "durationItemType", "nsuri": "http://transenterix.com/20231231", "localname": "PeriodOfServiceSaleArrangement", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_PeriodOfServiceSaleArrangement", "terseLabel": "Period Of Service Sale Arrangement (Year)", "documentation": "Represents the period of service sale arrangement." } } }, "auth_ref": [] }, "asxc_PeriodOfServiceSaleArrangementAtStatedServicePrice": { "xbrltype": "durationItemType", "nsuri": "http://transenterix.com/20231231", "localname": "PeriodOfServiceSaleArrangementAtStatedServicePrice", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_PeriodOfServiceSaleArrangementAtStatedServicePrice", "terseLabel": "Period of Service Sale Arrangement at Stated Service Price (Year)", "documentation": "Represents the period of service sale arrangement at stated service price." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "asxc_PreclinicalEvaluationOfTheLUNASurgicalSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "PreclinicalEvaluationOfTheLUNASurgicalSystemMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Preclinical Evaluation of the LUNA Surgical System [Member]", "documentation": "Represents preclinical evaluation of the LUNA Surgical System." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r81", "r363" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r81", "r649" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued (in shares)", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r81", "r363" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r81", "r649", "r668", "r911", "r912" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.01 par value, 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r81", "r597", "r758" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r187", "r336", "r337", "r729" ] }, "asxc_ProceedsFromEmployeeRetentionTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ProceedsFromEmployeeRetentionTaxCredit", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_ProceedsFromEmployeeRetentionTaxCredit", "terseLabel": "Proceeds From Employee Retention Tax Credit", "documentation": "The amount of cash inflow from employee retention tax credit." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfCommonStock", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r8" ] }, "asxc_ProceedsFromIssuanceOfCommonStockNet": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ProceedsFromIssuanceOfCommonStockNet", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock, net of issuance costs", "documentation": "The cash inflow from issuance of common stock, net of issuance cost." } } }, "auth_ref": [] }, "asxc_ProceedsFromIssuanceOfEquityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ProceedsFromIssuanceOfEquityNet", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "lang": { "en-us": { "role": { "label": "asxc_ProceedsFromIssuanceOfEquityNet", "totalLabel": "Net proceeds", "documentation": "The cash inflow from issuance of equity, net of issuance cost." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfWarrants", "terseLabel": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details": { "parentTag": "asxc_ProceedsFromIssuanceOfEquityNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds", "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r8", "r628" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from maturities of available-for-sale investments", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r207", "r208", "r823" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "terseLabel": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r35", "r207", "r279", "r312" ] }, "asxc_ProceedsFromStockOptionsAndWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ProceedsFromStockOptionsAndWarrantsExercised", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options and warrants", "documentation": "The cash inflow from stock options and warrants exercised." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r744" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r270", "r572", "r612", "r613", "r614", "r615", "r616", "r617", "r725", "r744", "r759", "r787", "r843", "r844", "r849", "r906" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r270", "r572", "r612", "r613", "r614", "r615", "r616", "r617", "r725", "r744", "r759", "r787", "r843", "r844", "r849", "r906" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r111", "r148", "r156", "r157" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r113", "r178", "r604" ] }, "asxc_PropertyPlantAndEquipmentIncludingPurchasedSoftwareImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "PropertyPlantAndEquipmentIncludingPurchasedSoftwareImpairmentCharges", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_PropertyPlantAndEquipmentIncludingPurchasedSoftwareImpairmentCharges", "terseLabel": "Property, Plant and Equipment, Including Purchased Software, Impairment Charges", "documentation": "Represents the amount of impairment charges associated with property, plant and equipment (including purchased software) during the period." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 }, "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r593", "r604", "r758" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r11", "r148", "r156", "r602" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r113" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, estimated useful lives (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Bad debt expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r206", "r321" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r394", "r402", "r431", "r432", "r433", "r545", "r569", "r618", "r640", "r641", "r699", "r701", "r703", "r704", "r706", "r722", "r723", "r739", "r743", "r752", "r760", "r763", "r841", "r847", "r896", "r897", "r898", "r899", "r900" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r394", "r402", "r431", "r432", "r433", "r545", "r569", "r618", "r640", "r641", "r699", "r701", "r703", "r704", "r706", "r722", "r723", "r739", "r743", "r752", "r760", "r763", "r841", "r847", "r896", "r897", "r898", "r899", "r900" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r818", "r819", "r820", "r821" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r401", "r535", "r536", "r643", "r644", "r645", "r646", "r647", "r667", "r669", "r698" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r535", "r536", "r892" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r401", "r535", "r536", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r643", "r644", "r645", "r646", "r647", "r667", "r669", "r698", "r892" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r532", "r533", "r534", "r536", "r537", "r631", "r632", "r633", "r673", "r674", "r675", "r695", "r697" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r78", "r449", "r901" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r448" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r64" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RestrictedCash", "terseLabel": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r797", "r808", "r902", "r904" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "label": "us-gaap_RestrictedCashAndCashEquivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r131", "r176", "r211", "r596" ] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r143", "r211" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r143", "r798", "r808" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r84", "r117", "r600", "r622", "r624", "r629", "r650", "r758" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r171", "r217", "r218", "r219", "r221", "r227", "r229", "r315", "r316", "r440", "r441", "r442", "r473", "r474", "r490", "r492", "r493", "r495", "r498", "r619", "r621", "r634", "r911" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r247", "r248", "r259", "r263", "r264", "r270", "r272", "r274", "r389", "r390", "r572" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r159", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r393" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables" ], "lang": { "en-us": { "role": { "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r20" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r671", "r724", "r733" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r151" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year)", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r152" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r152" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Lease liabilities arising from obtaining right-of-use assets", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r525", "r757" ] }, "asxc_RiskAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "RiskAndUncertaintiesPolicyPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Risk And Uncertainties, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for risk and uncertainties for the reporting period." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r781" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r781" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r274", "r784" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r40" ] }, "asxc_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash, Cash Equivalents, and Restricted Cash [Table Text Block]", "documentation": "Tabular disclosure of cash, cash equivalents, and restricted cash." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r123" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r122" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r121" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r50", "r51" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r810" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-7-inventories-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r26", "r88", "r89", "r90" ] }, "asxc_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property Plant and Equipment Useful Life [Table Text Block]", "documentation": "Tabular disclosure of the useful life of property, plant and equipment during the reporting period." } } }, "auth_ref": [] }, "asxc_ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ScheduleOfSalesUnderSalesAgencyAgreementTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Sales Under Sales Agency Agreement [Table Text Block]", "documentation": "Schedule of sales under sales agency agreement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r18", "r19", "r59" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r120" ] }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in unrecognized tax benefits." } } }, "auth_ref": [ "r756", "r878" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r51" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r772" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r774" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r272", "r273", "r637", "r638", "r639", "r700", "r702", "r705", "r707", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r726", "r745", "r763", "r849", "r906" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r242", "r243", "r244", "r245", "r246", "r252", "r262", "r266", "r267", "r268", "r269", "r270", "r271", "r274" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r257", "r258", "r272", "r738" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "asxc_SenhanceSurgicalRoboticSystemAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "SenhanceSurgicalRoboticSystemAcquisitionMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Senhance Surgical Robotic System Acquisition[Member]", "documentation": "Represents Senhance Surgical Robotic System acquisition." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r744" ] }, "asxc_ServiceSupplyAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ServiceSupplyAgreementMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Service Supply Agreement [Member]", "documentation": "Represents the service supply agreement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r753" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Restricted stock units, Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "Restricted stock units, Forfeited, weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "Restricted stock units, Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "Restricted stock units, Granted, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodStartLabel": "Beginning of period, Restricted stock units, Unvested (in shares)", "periodEndLabel": "Unvested (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r418", "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodStartLabel": "Beginning of period, Restricted stock units, Unvested, weighted average grant date fair value (in dollars per share)", "periodEndLabel": "Unvested December 31, 2022 (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r418", "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Restricted stock units, Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "Restricted stock units, Vested, weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r422" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r432" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r431" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r755" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options, Exercisable, Number of Shares (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options, Exercisable, Weighted Average Exercise Price (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Options, Cancelled, Number of Shares (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Options, Forfeited, Number of Shares (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Options, Granted, Number of Shares (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r414" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Options, Outstanding, Number of Shares (in shares)", "periodEndLabel": "Options, Outstanding, Number of Shares (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r410", "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Options, Outstanding, Weighted Average Exercise Price (in dollars per share)", "periodEndLabel": "Options, Outstanding, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r410", "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options, Vested or Expected to Vest, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r427" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options, Vested and Expected to Vest, Exercisable, Number of Shares (in shares)", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r427" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r119" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r427" ] }, "asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAwardForfeited": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAwardForfeited", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAwardForfeited", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Award Forfeited", "documentation": "Percentage of award forfeited under share based payment arrangement." } } }, "auth_ref": [] }, "asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOperationEarned": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOperationEarned", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOperationEarned", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Operation, Earned", "documentation": "Percentage of operational targets earneed under share based payment arrangement." } } }, "auth_ref": [] }, "asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOperationTargetsAchieved": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOperationTargetsAchieved", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOperationTargetsAchieved", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Operation Targets Achieved", "documentation": "Percentage of operational targets achieved under share based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r406", "r407", "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r430", "r431", "r432", "r433", "r434" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Options, Forfeitures in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r414" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r403", "r409", "r428", "r429", "r430", "r431", "r434", "r443", "r444", "r445", "r446" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r754" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Expected life (in years) (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r430" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r58" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options, Exercisable, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r58" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Options, Outstanding, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r118" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details" ], "lang": { "en-us": { "role": { "label": "Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r427" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Average price per share (in dollars per share)", "label": "us-gaap_SharesIssuedPricePerShare", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Shares withheld related to net share settlement of equity awards (in shares)", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r105", "r212" ] }, "asxc_StartupCostsAndOtherIntangiblesMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "StartupCostsAndOtherIntangiblesMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details" ], "lang": { "en-us": { "role": { "label": "Start-up Costs and Other Intangibles [Member]", "documentation": "Related to start-up costs and other intangibles." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r31", "r171", "r199", "r200", "r201", "r217", "r218", "r219", "r221", "r227", "r229", "r241", "r315", "r316", "r377", "r440", "r441", "r442", "r473", "r474", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r510", "r512", "r513", "r514", "r515", "r516", "r531", "r619", "r620", "r621", "r634", "r691" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r161", "r170", "r272", "r273", "r637", "r638", "r639", "r700", "r702", "r705", "r707", "r710", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r726", "r745", "r763", "r849", "r906" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details", "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20231231/role/statement-note-10-leases-tables", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-details-textual", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-details-textual", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-1-details-textual", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-details-textual", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20231231/role/statement-note-7-inventories", "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details", "http://transenterix.com/20231231/role/statement-note-7-inventories-tables", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-details-textual", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables", "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r217", "r218", "r219", "r241", "r572", "r626", "r636", "r642", "r643", "r644", "r645", "r646", "r647", "r649", "r652", "r653", "r654", "r655", "r656", "r658", "r659", "r660", "r661", "r663", "r664", "r665", "r666", "r667", "r669", "r671", "r672", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r764" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets-parentheticals", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://transenterix.com/20231231/role/statement-note-1-description-of-the-business", "http://transenterix.com/20231231/role/statement-note-10-leases-", "http://transenterix.com/20231231/role/statement-note-10-leases-components-of-operating-lease-expense-details", "http://transenterix.com/20231231/role/statement-note-10-leases-minimum-lease-payments-details", "http://transenterix.com/20231231/role/statement-note-10-leases-supplemental-balance-sheet-information-details", "http://transenterix.com/20231231/role/statement-note-10-leases-tables", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-income-tax-expense-benefit-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-rsu-activity-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-options-outstanding-details", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-details-textual", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-details-textual", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-1-details-textual", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-2-details-textual", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-details-textual", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-contractual-maturities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-details-textual", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20231231/role/statement-note-7-inventories", "http://transenterix.com/20231231/role/statement-note-7-inventories-components-of-inventories-details", "http://transenterix.com/20231231/role/statement-note-7-inventories-tables", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-details-textual", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables", "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r217", "r218", "r219", "r241", "r572", "r626", "r636", "r642", "r643", "r644", "r645", "r646", "r647", "r649", "r652", "r653", "r654", "r655", "r656", "r658", "r659", "r660", "r661", "r663", "r664", "r665", "r666", "r667", "r669", "r671", "r672", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r764" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total shares of common stock sold (in shares)", "label": "Issuance of common stock, net of issuance costs (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r15", "r81", "r82", "r117", "r628", "r691", "r708" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock related to vesting of restricted stock units (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r15", "r117" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-stock-option-activity-details" ], "lang": { "en-us": { "role": { "label": "Exercise of stock options (in shares)", "negatedLabel": "Options, Exercised, Number of Shares (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r15", "r81", "r82", "r117", "r415" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r15", "r81", "r82", "r117", "r634", "r691", "r708", "r770" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock related to vesting of restricted stock units", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r15", "r81", "r82", "r117" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r15", "r31", "r117" ] }, "asxc_StockOfferingAgreementCommissionPercent": { "xbrltype": "percentItemType", "nsuri": "http://transenterix.com/20231231", "localname": "StockOfferingAgreementCommissionPercent", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_StockOfferingAgreementCommissionPercent", "terseLabel": "Stock Offering Agreement, Commission, Percent", "documentation": "The percent commission payable under a stock offering agreement." } } }, "auth_ref": [] }, "asxc_StockOfferingAgreementMaximumShareValue": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "StockOfferingAgreementMaximumShareValue", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_StockOfferingAgreementMaximumShareValue", "terseLabel": "Stock Offering Agreement, Maximum Share Value", "documentation": "The maximum share value issuable under a stock offering agreement." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets", "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total Stockholders' Equity", "terseLabel": "Equity, Attributable to Parent", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r82", "r85", "r86", "r108", "r651", "r668", "r692", "r693", "r758", "r771", "r809", "r839", "r887", "r911" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r116", "r213", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r377", "r497", "r694", "r696", "r709" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r517", "r538" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r517", "r538" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r517", "r538" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "asxc_SubstantialDoubtAboutGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "SubstantialDoubtAboutGoingConcernPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern [Policy Text Block]", "documentation": "Disclosure of accounting policy for substantial doubt about going concern." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure for Cash Flow Information" } } }, "auth_ref": [] }, "us-gaap_SwissFederalTaxAdministrationFTAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SwissFederalTaxAdministrationFTAMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Swiss Federal Tax Administration (FTA) [Member]", "documentation": "Designated tax department of the government of Switzerland." } } }, "auth_ref": [] }, "asxc_SynchronyLabsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "SynchronyLabsLLCMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions", "http://transenterix.com/20231231/role/statement-note-18-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Synchrony Labs, LLC [Member]", "documentation": "Represents Synchrony Labs, LLC." } } }, "auth_ref": [] }, "asxc_SystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "SystemsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Systems [Member]", "documentation": "Represents the systems, a product of the company." } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TableTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-note-10-leases-tables", "http://transenterix.com/20231231/role/statement-note-11-accrued-expenses-and-other-current-liabilities-tables", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-tables", "http://transenterix.com/20231231/role/statement-note-13-stockbased-compensation-tables", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-tables", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-tables", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-tables", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-tables", "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-tables", "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-tables", "http://transenterix.com/20231231/role/statement-note-6-fair-value-tables", "http://transenterix.com/20231231/role/statement-note-7-inventories-tables", "http://transenterix.com/20231231/role/statement-note-8-property-and-equipment-tables", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r65" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-deferred-tax-assets-details", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r64" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-intellectual-property-details" ], "lang": { "en-us": { "role": { "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r22" ] }, "asxc_The2015SenhanceAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "The2015SenhanceAcquisitionMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details" ], "lang": { "en-us": { "role": { "label": "The 2015 Senhance Acquisition [Member]", "documentation": "Pertains to the 2015 Senhance Acquisition." } } }, "auth_ref": [] }, "asxc_The2022AtmOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "The2022AtmOfferingMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-summary-of-sales-under-offering-details" ], "lang": { "en-us": { "role": { "label": "The 2022 ATM Offering [Member]", "documentation": "Represents the 2022 ATM offering." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://transenterix.com/20231231/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "asxc_TransferOfInventoryToPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "TransferOfInventoryToPropertyAndEquipment", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Transfer of inventories to property and equipment", "documentation": "Amount of inventory transferred to property and equipment." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r361", "r374", "r496", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r608", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r835", "r836", "r837", "r838" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r56" ] }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "Cancellation of treasury stock", "negatedLabel": "Cancellation of treasury stock", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": [ "r15", "r55", "r82" ] }, "us-gaap_TreasuryStockSharesRetired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesRetired", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" ], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockSharesRetired", "negatedLabel": "Cancellation of treasury stock (in shares)", "documentation": "Number of shares of common and preferred stock retired from treasury during the period." } } }, "auth_ref": [ "r15", "r82", "r117" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies", "http://transenterix.com/20231231/role/statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r485" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition", "http://transenterix.com/20231231/role/statement-note-3-revenue-recognition-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale", "http://transenterix.com/20231231/role/statement-note-5-investments-availableforsale-summary-of-investment-securities-details" ], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r734", "r747", "r903" ] }, "us-gaap_USGovernmentSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentSecuritiesAtCarryingValue", "crdr": "debit", "calculation": { "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://transenterix.com/20231231/role/statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_USGovernmentSecuritiesAtCarryingValue", "terseLabel": "U.S. treasuries", "documentation": "Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r451", "r461" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r460" ] }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details" ], "lang": { "en-us": { "role": { "label": "Gross increases for tax positions related to current periods", "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return." } } }, "auth_ref": [ "r462" ] }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-unrecognized-tax-positions-details" ], "lang": { "en-us": { "role": { "label": "Gross decreases related to 382 limitations", "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations." } } }, "auth_ref": [ "r463" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r45", "r46", "r47", "r145", "r146", "r149", "r150" ] }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes", "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-12-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r466" ] }, "asxc_WarrantLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://transenterix.com/20231231", "localname": "WarrantLiabilitiesPolicyTextBlock", "presentation": [ "http://transenterix.com/20231231/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Warrant Liabilities [Policy Text Block]", "documentation": "Disclosure of accounting policy warrant liabilities." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share", "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value", "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "http://transenterix.com/20231231/role/statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r761", "r762", "r765", "r766", "r767", "r768" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://transenterix.com/20231231/role/statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details" ], "lang": { "en-us": { "role": { "label": "Measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r504" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r886" ] }, "asxc_WarrantsIssuedInRegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://transenterix.com/20231231", "localname": "WarrantsIssuedInRegisteredDirectOfferingMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-14-equity-offerings", "http://transenterix.com/20231231/role/statement-note-14-equity-offerings-details-textual" ], "lang": { "en-us": { "role": { "label": "Warrants Issued in Registered Direct Offering [Member]", "documentation": "Represents warrants issued in registered direct offering." } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://transenterix.com/20231231/role/statement-note-9-intellectual-property", "http://transenterix.com/20231231/role/statement-note-9-intellectual-property-details-textual" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "documentation": "Average of a range of values, calculated with consideration of proportional relevance." } } }, "auth_ref": [ "r722", "r723", "r895", "r897", "r900" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [ "http://transenterix.com/20231231/role/statement-note-15-basic-and-diluted-net-loss-per-share-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r816" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://transenterix.com/20231231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares used in computing net loss per common share - basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r231", "r236" ] }, "asxc_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://transenterix.com/20231231", "localname": "WorkingCapital", "crdr": "debit", "presentation": [ "http://transenterix.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "asxc_WorkingCapital", "terseLabel": "Working Capital", "documentation": "The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities." } } }, "auth_ref": [] }, "asxc_statement-statement-note-10-leases-components-of-operating-lease-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-10-leases-components-of-operating-lease-expense-details", "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Components of Operating Lease Expense (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-10-leases-minimum-lease-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-10-leases-minimum-lease-payments-details", "lang": { "en-us": { "role": { "label": "Note 10 - Leases - Minimum Lease Payments (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-10-leases-supplemental-balance-sheet-information-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-10-leases-supplemental-balance-sheet-information-details", "lang": { "en-us": { "role": { "label": "Note 10 - Leases -Supplemental Balance Sheet Information (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-10-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-10-leases-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Leases" } } }, "auth_ref": [] }, "asxc_statement-statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-11-accrued-expenses-and-other-current-liabilities-components-of-accrued-expenses-details", "lang": { "en-us": { "role": { "label": "Note 11 - Accrued Expenses and Other Current Liabilities - Components of Accrued Expenses (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-11-accrued-expenses-and-other-current-liabilities-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-11-accrued-expenses-and-other-current-liabilities-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Accrued Expenses and Other Current Liabilities" } } }, "auth_ref": [] }, "asxc_statement-statement-note-12-income-taxes-deferred-tax-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-12-income-taxes-deferred-tax-assets-details", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Deferred Tax Assets (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-12-income-taxes-domestic-and-foreign-components-of-loss-from-operations-details", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Domestic and Foreign Components of Loss from Operations (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-12-income-taxes-effective-income-tax-reconciliation-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-12-income-taxes-effective-income-tax-reconciliation-details", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Effective Income Tax Reconciliation (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-12-income-taxes-income-tax-expense-benefit-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-12-income-taxes-income-tax-expense-benefit-details", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Income Tax Expense (Benefit) (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-12-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-12-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes" } } }, "auth_ref": [] }, "asxc_statement-statement-note-12-income-taxes-unrecognized-tax-positions-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-12-income-taxes-unrecognized-tax-positions-details", "lang": { "en-us": { "role": { "label": "Note 12 - Income Taxes - Unrecognized Tax Positions (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-13-stockbased-compensation-noncash-sharebased-compensation-expense-details", "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - Non-cash Share-based Compensation Expense (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-13-stockbased-compensation-rsu-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-13-stockbased-compensation-rsu-activity-details", "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - RSU Activity (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-13-stockbased-compensation-stock-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-13-stockbased-compensation-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - Stock Option Activity (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-13-stockbased-compensation-stock-option-valuation-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - Stock Option Valuation Assumptions (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-13-stockbased-compensation-stock-options-outstanding-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-13-stockbased-compensation-stock-options-outstanding-details", "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation - Stock Options Outstanding (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-13-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-13-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 13 - Stock-based Compensation" } } }, "auth_ref": [] }, "asxc_statement-statement-note-14-equity-offerings-summary-of-sales-under-offering-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-14-equity-offerings-summary-of-sales-under-offering-details", "lang": { "en-us": { "role": { "label": "Note 14 - Equity Offerings - Summary of Sales Under Offering (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-14-equity-offerings-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-14-equity-offerings-tables", "lang": { "en-us": { "role": { "label": "Note 14 - Equity Offerings" } } }, "auth_ref": [] }, "asxc_statement-statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-15-basic-and-diluted-net-loss-per-share-antidilutive-securities-excluded-from-computation-of-earnings-per-share-details", "lang": { "en-us": { "role": { "label": "Note 15 - Basic and Diluted Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-15-basic-and-diluted-net-loss-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-15-basic-and-diluted-net-loss-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 15 - Basic and Diluted Net Loss Per Share" } } }, "auth_ref": [] }, "asxc_statement-statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-16-commitments-and-contingencies-purchase-orders-commitments-details", "lang": { "en-us": { "role": { "label": "Note 16 - Commitments and Contingencies - Purchase Orders Commitments (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-16-commitments-and-contingencies-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-16-commitments-and-contingencies-tables", "lang": { "en-us": { "role": { "label": "Note 16 - Commitments and Contingencies" } } }, "auth_ref": [] }, "asxc_statement-statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-17-segments-and-geographic-areas-consolidated-assets-and-long-lived-assets-by-geographic-area-details", "lang": { "en-us": { "role": { "label": "Note 17 - Segments and Geographic Areas - Consolidated Assets and Long Lived Assets by Geographic Area (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-17-segments-and-geographic-areas-sales-by-geographic-area-details", "lang": { "en-us": { "role": { "label": "Note 17 - Segments and Geographic Areas - Sales by Geographic Area (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-17-segments-and-geographic-areas-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-17-segments-and-geographic-areas-tables", "lang": { "en-us": { "role": { "label": "Note 17 - Segments and Geographic Areas" } } }, "auth_ref": [] }, "asxc_statement-statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-assets-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "asxc_statement-statement-note-3-revenue-recognition-contract-assets-and-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-3-revenue-recognition-contract-assets-and-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-3-revenue-recognition-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-3-revenue-recognition-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue Recognition - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-3-revenue-recognition-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-3-revenue-recognition-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Revenue Recognition" } } }, "auth_ref": [] }, "asxc_statement-statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-4-cash-cash-equivalents-and-restricted-cash-cash-cash-equivalents-and-restricted-cash-details", "lang": { "en-us": { "role": { "label": "Note 4 - Cash, Cash Equivalents, and Restricted Cash - Cash, Cash Equivalents, and Restricted Cash (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-4-cash-cash-equivalents-and-restricted-cash-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-4-cash-cash-equivalents-and-restricted-cash-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Cash, Cash Equivalents, and Restricted Cash" } } }, "auth_ref": [] }, "asxc_statement-statement-note-5-investments-availableforsale-contractual-maturities-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-5-investments-availableforsale-contractual-maturities-details", "lang": { "en-us": { "role": { "label": "Note 5 - Investments, Available-for-sale - Contractual Maturities (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-5-investments-availableforsale-summary-of-investment-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-5-investments-availableforsale-summary-of-investment-securities-details", "lang": { "en-us": { "role": { "label": "Note 5 - Investments, Available-for-sale - Summary of Investment Securities (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-5-investments-availableforsale-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-5-investments-availableforsale-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Investments, Available-for-sale" } } }, "auth_ref": [] }, "asxc_statement-statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-6-fair-value-quantitative-information-about-inputs-and-valuation-methodologies-used-for-fair-value-measurements-classification-details", "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classification (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-6-fair-value-summary-of-assets-and-liabilities-measured-at-fair-value-on-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-and-contingent-consideration-details", "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value - Summary of Change in Fair Value for Warrants and Contingent Consideration (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-6-fair-value-summary-of-change-in-fair-value-for-warrants-details", "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value - Summary of Change in Fair Value for Warrants (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-6-fair-value-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-6-fair-value-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Fair Value" } } }, "auth_ref": [] }, "asxc_statement-statement-note-7-inventories-components-of-inventories-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-7-inventories-components-of-inventories-details", "lang": { "en-us": { "role": { "label": "Note 7 - Inventories - Components of Inventories (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-7-inventories-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-7-inventories-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Inventories" } } }, "auth_ref": [] }, "asxc_statement-statement-note-8-property-and-equipment-summary-of-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-8-property-and-equipment-summary-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 8 - Property and Equipment - Summary of Property and Equipment (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-8-property-and-equipment-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-8-property-and-equipment-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Property and Equipment" } } }, "auth_ref": [] }, "asxc_statement-statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-9-intellectual-property-amortization-expense-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 9 - Intellectual Property - Amortization Expense of Intangible Assets (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-9-intellectual-property-intellectual-property-details": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-9-intellectual-property-intellectual-property-details", "lang": { "en-us": { "role": { "label": "Note 9 - Intellectual Property - Intellectual Property (Details)" } } }, "auth_ref": [] }, "asxc_statement-statement-note-9-intellectual-property-tables": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-note-9-intellectual-property-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Intellectual Property" } } }, "auth_ref": [] }, "asxc_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://transenterix.com/20231231", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "a", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "b", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(c)(2)", "SubTopic": "360", "Topic": "932", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479342/932-360-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "932", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-10(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481178/840-20-25-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-14" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479341/842-30-25-11" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 112 0001437749-24-008871-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-008871-xbrl.zip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Ð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end XML 114 asxc20231231_10k_htm.xml IDEA: XBRL DOCUMENT 0000876378 2023-01-01 2023-12-31 0000876378 2023-10-01 2023-12-31 0000876378 asxc:PreclinicalEvaluationOfTheLUNASurgicalSystemMember asxc:SynchronyLabsLLCMember 2023-01-01 2023-12-31 0000876378 asxc:DirectorOfAsensusMember asxc:SynchronyLabsLLCMember 2023-12-31 0000876378 asxc:ServiceSupplyAgreementMember asxc:OneMedSaMember asxc:AsensusSurgicalEuropeSrlMember 2022-01-01 2022-12-31 0000876378 asxc:ServiceSupplyAgreementMember asxc:OneMedSaMember asxc:AsensusSurgicalEuropeSrlMember 2023-01-01 2023-12-31 0000876378 asxc:AllCountriesMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:AllCountriesMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 srt:AsiaMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:US us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 asxc:AllCountriesMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:AllCountriesMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 srt:AsiaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 srt:AsiaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:EuropeMiddleEastAndAfricaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:EuropeMiddleEastAndAfricaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:US us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 country:US asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:AllCountriesMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 asxc:AllCountriesMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 srt:AsiaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 srt:AsiaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 asxc:EuropeMiddleEastAndAfricaMember us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 asxc:EuropeMiddleEastAndAfricaMember asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 country:US us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 country:US asxc:LongLivedAssetsMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember asxc:LicenseAndSupplyAgreementMember 2023-12-31 0000876378 2022-01-01 2022-12-31 0000876378 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000876378 us-gaap:WarrantMember 2023-01-01 2023-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000876378 asxc:WarrantsIssuedInRegisteredDirectOfferingMember 2023-07-27 2023-07-27 0000876378 asxc:CommonStockIssuedInRegisteredDirectOfferingMember 2023-07-27 2023-07-27 0000876378 asxc:WarrantsIssuedInRegisteredDirectOfferingMember 2023-07-27 0000876378 asxc:The2022AtmOfferingMember 2023-01-01 2023-12-31 0000876378 asxc:The2022AtmOfferingMember 2023-12-31 0000876378 asxc:The2022AtmOfferingMember 2022-03-18 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2023-12-31 0000876378 asxc:PerformanceRestrictedStockUnitMember 2022-01-01 2022-12-31 0000876378 asxc:PerformanceRestrictedStockUnitMember 2023-01-01 2023-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000876378 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000876378 asxc:GrantedIn2022Member asxc:PerformanceRestrictedStockUnitMember 2023-01-01 2023-12-31 0000876378 asxc:GrantedIn2023Member asxc:PerformanceRestrictedStockUnitMember us-gaap:SubsequentEventMember 2024-02-01 2024-02-28 0000876378 asxc:GrantedIn2023Member asxc:PerformanceRestrictedStockUnitMember 2023-01-01 2023-12-31 0000876378 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000876378 srt:MaximumMember 2022-01-01 2022-12-31 0000876378 srt:MinimumMember 2022-01-01 2022-12-31 0000876378 srt:MaximumMember 2023-01-01 2023-12-31 0000876378 srt:MinimumMember 2023-01-01 2023-12-31 0000876378 2023-12-31 0000876378 2022-12-31 0000876378 asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember 2023-01-01 2023-12-31 0000876378 asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember 2023-12-31 0000876378 asxc:AsensusSurgicalIncAmendedAndRestatedIncentiveCompensationPlanMember 2023-06-06 2023-06-06 0000876378 2021-12-31 0000876378 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember 2023-12-31 0000876378 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember 2023-12-31 0000876378 us-gaap:ForeignCountryMember us-gaap:LuxembourgInlandRevenueMember 2023-12-31 0000876378 us-gaap:ForeignCountryMember us-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember 2023-12-31 0000876378 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-01-01 2023-12-31 0000876378 us-gaap:DomesticCountryMember us-gaap:ResearchMember 2023-12-31 0000876378 us-gaap:StateAndLocalJurisdictionMember 2023-12-31 0000876378 us-gaap:StateAndLocalJurisdictionMember asxc:ImpactOf382OwnershipChangesMember 2023-01-01 2023-12-31 0000876378 us-gaap:DomesticCountryMember 2023-12-31 0000876378 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0000876378 us-gaap:ResearchMember 2022-12-31 0000876378 us-gaap:ResearchMember 2023-12-31 0000876378 asxc:StartupCostsAndOtherIntangiblesMember 2022-12-31 0000876378 asxc:StartupCostsAndOtherIntangiblesMember 2023-12-31 0000876378 srt:MaximumMember 2022-12-31 0000876378 srt:MinimumMember 2022-12-31 0000876378 srt:MaximumMember 2023-12-31 0000876378 srt:MinimumMember 2023-12-31 0000876378 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0000876378 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0000876378 us-gaap:IntellectualPropertyMember 2023-12-31 0000876378 srt:WeightedAverageMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000876378 srt:WeightedAverageMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000876378 srt:WeightedAverageMember us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000876378 srt:WeightedAverageMember us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000876378 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000876378 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000876378 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000876378 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000876378 us-gaap:ConstructionInProgressMember 2022-12-31 0000876378 us-gaap:ConstructionInProgressMember 2023-12-31 0000876378 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000876378 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000876378 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000876378 us-gaap:FurnitureAndFixturesMember 2023-12-31 0000876378 us-gaap:ComputerEquipmentMember 2022-12-31 0000876378 us-gaap:ComputerEquipmentMember 2023-12-31 0000876378 asxc:OperatingLeaseAssetsMember 2022-12-31 0000876378 asxc:OperatingLeaseAssetsMember 2023-12-31 0000876378 asxc:MachineryManufacturingAndDemonstrationEquipmentMember 2022-12-31 0000876378 asxc:MachineryManufacturingAndDemonstrationEquipmentMember 2023-12-31 0000876378 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0000876378 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000876378 us-gaap:WarrantMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000876378 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000876378 us-gaap:WarrantMember 2023-12-31 0000876378 us-gaap:WarrantMember 2023-01-01 2023-12-31 0000876378 us-gaap:WarrantMember 2022-12-31 0000876378 asxc:The2015SenhanceAcquisitionMember 2023-12-31 0000876378 asxc:The2015SenhanceAcquisitionMember 2023-01-01 2023-12-31 0000876378 asxc:The2015SenhanceAcquisitionMember 2022-12-31 0000876378 asxc:The2015SenhanceAcquisitionMember 2022-01-01 2022-12-31 0000876378 asxc:The2015SenhanceAcquisitionMember 2021-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member asxc:MeasurementInputCurrencyExchangeRateMember 2022-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member asxc:MeasurementInputCurrencyExchangeRateMember 2023-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2022-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2023-12-31 0000876378 us-gaap:FairValueInputsLevel3Member 2022-12-31 0000876378 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000876378 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000876378 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000876378 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000876378 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000876378 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000876378 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000876378 us-gaap:CommercialPaperMember 2022-12-31 0000876378 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000876378 srt:MaximumMember 2024-01-01 2023-12-31 0000876378 srt:MinimumMember 2024-01-01 2023-12-31 0000876378 2024-01-01 2023-12-31 0000876378 asxc:LeaseMember 2022-01-01 2022-12-31 0000876378 asxc:LeaseMember 2023-01-01 2023-12-31 0000876378 us-gaap:ServiceMember 2022-01-01 2022-12-31 0000876378 us-gaap:ServiceMember 2023-01-01 2023-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember 2022-01-01 2022-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember 2023-01-01 2023-12-31 0000876378 asxc:SystemsMember 2022-01-01 2022-12-31 0000876378 asxc:SystemsMember 2023-01-01 2023-12-31 0000876378 us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 us-gaap:NonUsMember 2023-01-01 2023-12-31 0000876378 asxc:LeaseMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 asxc:LeaseMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000876378 us-gaap:ServiceMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 us-gaap:ServiceMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000876378 asxc:SystemsMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000876378 asxc:SystemsMember us-gaap:NonUsMember 2023-01-01 2023-12-31 0000876378 country:US 2022-01-01 2022-12-31 0000876378 country:US 2023-01-01 2023-12-31 0000876378 asxc:LeaseMember country:US 2022-01-01 2022-12-31 0000876378 asxc:LeaseMember country:US 2023-01-01 2023-12-31 0000876378 us-gaap:ServiceMember country:US 2022-01-01 2022-12-31 0000876378 us-gaap:ServiceMember country:US 2023-01-01 2023-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember country:US 2022-01-01 2022-12-31 0000876378 asxc:InstrumentsAndAccessoriesMember country:US 2023-01-01 2023-12-31 0000876378 srt:MinimumMember asxc:SenhanceSurgicalRoboticSystemAcquisitionMember 2023-01-01 2023-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember 2023-01-01 2023-12-31 0000876378 asxc:SenhanceSurgicalRoboticSystemAcquisitionMember 2023-12-31 0000876378 srt:MaximumMember asxc:MachineryManufacturingAndDemonstrationEquipmentMember 2023-12-31 0000876378 srt:MinimumMember asxc:MachineryManufacturingAndDemonstrationEquipmentMember 2023-12-31 0000876378 us-gaap:IntellectualPropertyMember 2022-01-01 2022-12-31 0000876378 us-gaap:IntellectualPropertyMember 2023-01-01 2023-12-31 0000876378 us-gaap:PatentsMember 2023-12-31 0000876378 asxc:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 asxc:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 asxc:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 asxc:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000876378 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000876378 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000876378 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000876378 us-gaap:RetainedEarningsMember 2023-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000876378 us-gaap:TreasuryStockCommonMember 2023-12-31 0000876378 us-gaap:CommonStockMember 2023-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000876378 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000876378 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000876378 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000876378 us-gaap:RetainedEarningsMember 2022-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000876378 us-gaap:TreasuryStockCommonMember 2022-12-31 0000876378 us-gaap:CommonStockMember 2022-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000876378 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000876378 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000876378 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000876378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000876378 us-gaap:RetainedEarningsMember 2021-12-31 0000876378 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000876378 us-gaap:TreasuryStockCommonMember 2021-12-31 0000876378 us-gaap:CommonStockMember 2021-12-31 0000876378 us-gaap:ProductMember 2022-01-01 2022-12-31 0000876378 us-gaap:ProductMember 2023-01-01 2023-12-31 0000876378 us-gaap:IntellectualPropertyMember 2022-12-31 0000876378 2024-05-15 0000876378 2023-06-30 thunderdome:item iso4217:USD pure shares utr:Y iso4217:USD shares iso4217:EUR FY 2023 --12-31 false 0000876378 false false false false 1 0 0 P5Y P3Y P3Y P10Y 0 0 0 0 0 0 P4Y P1Y 1 0 P4Y P5Y 25000000 15000000 P6Y P1Y P10Y P1Y 0 0 1 2 1 1 0 0 0 0 0 0 0 0 0 0 10-K true 2023-12-31 false 0-19437 ASENSUS SURGICAL, INC. DE 11-2962080 1 TW Alexander Drive, Suite 160 Durham NC 27703 919 765-8400 Common Stock ASXC NYSE No No Yes Yes Non-accelerated Filer true false false false false 120100000 271986369 243 BDO USA, P.C. Raleigh, North Carolina 17096000 6329000 3971000 64195000 3508000 2256000 7172000 8284000 3143000 3584000 0 554000 1496000 1671000 36386000 86873000 1642000 1141000 0 3865000 4043000 5469000 8959000 9542000 1237000 1576000 44000 174000 5165000 4950000 1610000 2463000 59086000 116053000 4145000 3348000 5390000 4508000 1636000 1293000 1036000 800000 421000 465000 12628000 10414000 290000 0 2220000 1256000 5888000 0 4646000 4738000 25672000 16408000 0.001 0.001 750000000 750000000 264921526 264921526 236895440 236895440 265000 237000 0.01 0.01 25000000 25000000 0 0 973129000 962731000 -939368000 -860935000 -612000 -2388000 33414000 99645000 59086000 116053000 5519000 4327000 1052000 1373000 2006000 1387000 8577000 7087000 6866000 5303000 2293000 2174000 3996000 3395000 13155000 10872000 -4578000 -3785000 37023000 28942000 16921000 14756000 19155000 20172000 453000 7708000 964000 -1115000 374000 1431000 74890000 71894000 -79468000 -75679000 -1232000 -0 1553000 1141000 -0 410000 -1436000 -295000 1349000 436000 -78119000 -75243000 314000 318000 -78433000 -75561000 -0.31 -0.32 249685000 236492000 -78433000 -75561000 1280000 -1867000 496000 -257000 -76657000 -77685000 235219000 235000 0 0 954649000 -785374000 -264000 169246000 0 8416000 0 0 8416000 43000 0 0 0 18000 0 0 18000 1633000 2000 0 0 0 0 0 2000 0 -0 443000 -0 352000 -0 -0 352000 -0 -0 443000 -0 -0 -0 -0 -0 0 0 0 0 -2124000 -2124000 0 0 -75561000 0 -75561000 236895000 237000 0 0 962731000 -860935000 -2388000 99645000 0 7918000 0 0 7918000 13000 0 0 0 5000 0 0 5000 3270000 2000 0 0 0 0 0 2000 0 -0 657000 -1000 497000 -0 -0 496000 -0 -0 657000 -1000 -0 -0 -0 1000 24744000 26000 0 0 0 2998000 0 0 1776000 1776000 0 -78433000 0 -78433000 264922000 265000 0 0 973129000 -939368000 -612000 33414000 -78433000 -75561000 3276000 3368000 453000 7708000 482000 -565000 7918000 8416000 132000 318000 -324000 -620000 0 9000 374000 1431000 -0 -122000 -1232000 0 964000 -1115000 1178000 1528000 -129000 2302000 206000 -232000 -424000 450000 -554000 -757000 -1173000 2101000 574000 35000 881000 4523000 365000 -3955000 233000 -55000 130000 26000 -63627000 -58937000 12268000 33886000 77335000 82702000 561000 1279000 64506000 47537000 10118000 0 497000 350000 5000 18000 9626000 -332000 763000 -81000 11268000 -11813000 7470000 19283000 18738000 7470000 1475000 984000 352000 165000 2941000 2693000 1143000 577000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Description of the Business </b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) (the "Company") is a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The Company is focused on the market development for and commercialization of the Senhance® Surgical System, which digitizes laparoscopic minimally invasive surgery, or MIS. The Senhance System is the first and only digital, multi-port laparoscopic platform designed to maintain laparoscopic MIS standards while providing digital benefits such as haptic feedback, robotic precision, comfortable ergonomics, advanced instrumentation including 3mm micro-laparoscopic instruments, 5mm articulating instruments, eye-sensing camera control and fully-reusable standard instruments to help maintain per-procedure costs similar to traditional laparoscopy.</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><a href="#" id="note2" title="note2"></a>2.</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Summary of Significant Accounting Policies</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Basis of Presentation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Going Concern</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $939.4 million and working capital of $23.8 million as of December 31, 2023. The Company has not established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Principles of Consolidation and Foreign Currency Considerations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity which was $0.6 million and $1.9 million as of December 31, 2023 and 2022, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 were not material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Risk and Uncertainties</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: the historical lack of profitability; the Company’s ability to raise additional capital; its ability to successfully develop, clinically test, obtain regulatory clearance for and commercialize its products and products in development; negative impacts on the Company's operations caused by the hostilities in the Middle East and other geopolitical factors; the success of its market development efforts; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic and digital surgical devices; and its ability to identify and pursue development of additional products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Use of Estimates</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term investments, changes in inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cash and Cash Equivalents, Restricted Cash, and Investments</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Restricted cash as of December 31, 2023 and 2022 includes $1.6 million and $1.1 million, respectively, in cash accounts held as collateral primarily under the terms of office operating leases, credit cards, and automobile leases, and a guarantee required by the government of a country for a 2019 VAT refund.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s investments as of December 31, 2023 consisted of corporate bonds that were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion are included in interest expense, net. There were <span style="-sec-ix-hidden:c445"><span style="-sec-ix-hidden:c446">no</span></span> gross realized gains or loss for the years ended December 31, 2023 and 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">There have been <span style="-sec-ix-hidden:c447"><span style="-sec-ix-hidden:c448">no</span></span> credit losses for the years ended December 31, 2023 and 2022, and <span style="-sec-ix-hidden:c449"><span style="-sec-ix-hidden:c450">no</span></span> allowance for credit losses as of December 31, 2023 and 2022. Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Fair Value Measurements </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level 3 inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Concentrations and Credit Risk</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company had <span style="-sec-ix-hidden:c451"><span style="-sec-ix-hidden:c452">one</span></span> customer that accounted for 83% and 69% of the Company’s net accounts receivable as of December 31, 2023 and December 31, 2022, respectively. The Company had <span style="-sec-ix-hidden:c455">two</span> customers that accounted for 33% and 19% of revenue in 2023, and <span style="-sec-ix-hidden:c458">one</span> customer who accounted for 47% of revenue in 2022, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Accounts Receivable</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current and future economic conditions that may affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million as of December 31, 2023 and 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Inventories</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve months.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Definite-Lived Intangible Assets - Intellectual Property</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&amp;D”) assets related to (i) the Senhance System acquired in 2015 and reclassified in 2017 and (ii) a 2018 acquisition and reclassified in 2020. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 7 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. <span style="-sec-ix-hidden:c464"><span style="-sec-ix-hidden:c465">No</span></span> impairment of intellectual property was identified during the years ended December 31, 2023 and 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Property and Equipment</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Years</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets – Senhance System leasing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">5</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">3</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">5</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Lesser of lease term or 3-10</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the years ended December 31, 2023 and 2022, the Company recorded a non-cash asset impairment charge of $0.4 million and $1.4 million, respectively, to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Operating Leases</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has operating leases for its corporate office buildings, vehicles, and machinery and equipment. At inception, the Company determines whether an agreement represents a lease, and at commencement, it evaluates each lease agreement to determine whether the lease constitutes an operating or financing lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do not provide a significant economic incentive and are therefore excluded from the lease term. While its operating leases range from <span style="-sec-ix-hidden:c475">one</span> year to <span style="-sec-ix-hidden:c476">ten</span> years, some may include options to extend the lease generally between <span style="-sec-ix-hidden:c477">one</span> year and <span style="-sec-ix-hidden:c478">six</span> years, and some may include options to terminate the leases within one year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Implementation Costs in a Cloud Computing Arrangement</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Employee Retention Tax Credit Receivable </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended December 31, 2021, the Company submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received $0.7 million of the ERTC refund during the year ended December 31, 2022 and received the remaining $0.6 million during the year ended December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Contingent Consideration</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in 2016, as of December 31, 2023, the Company has accrued $2.2 million of estimated fair value of remaining contingent consideration related to a milestone of <span style="-sec-ix-hidden:c482">€15.0</span> million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least <span style="-sec-ix-hidden:c483">€25.0</span> million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In 2022, Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Warrant Liabilities</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s warrants (see “Note 14 – Equity Offerings,”) are measured at fair value using a Black-Scholes-Merton model option-pricing model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected stock price volatility, the expected dividend yield which is assumed to be zero since The Company has not paid and does not anticipate paying cash dividends on its shares of common stock and the risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the term of the warrant (see “Note 6 – Fair Value,”). The warrant liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revenue Recognition</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on considerations specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements could include a <span style="-sec-ix-hidden:c484">five</span>-year service period; the first year of service is generally free and included in the Senhance System sale arrangement with an option to purchase the remaining <span style="-sec-ix-hidden:c485">four</span> years at a stated service price.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tbody><tr> <td style="width:18pt;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.</p> </td> </tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tbody><tr> <td style="width: 18pt; text-align: justify;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.</p> </td> </tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tbody><tr> <td style="width: 18pt; text-align: justify;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements and are included in accounts receivable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not meet the requirements to be capitalized as the Company does not expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Senhance System Leasing</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended December 31, 2023 and 2022, variable lease revenue related to usage-based arrangements was not material.  </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2023 are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of December 31, 2023, future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next one to two years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cost of Revenue</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Research and Development Costs</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Stock-Based Compensation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be <span style="-sec-ix-hidden:c487">zero</span>. The Company estimates forfeitures based on its historical experience and adjusts the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note 13 – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Income Taxes</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not sustain the position following audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may be subject to examination by authorities for all previously filed income tax returns.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Comprehensive Loss</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Segments</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company operates in <span style="-sec-ix-hidden:c488">one</span> business segment—the research, development and sale of medical device robotics to improve MIS. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Impact of Recently Issued Accounting Standards</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In November 2023, the FASB issued Accounting Standards Update, or ASU, No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU looks to provide improvements to the segment disclosure by providing users with more decision-useful information about reportable segments in a public entity. The main provisions require a company to disclose, on an annual and interim basis, significant expenses included within each reported measure of segment profit or loss, an amount for other segment items by reportable segment and a description of its composition. It also requires all annual disclosures about a reportable segments’ profit or loss and assets to be reported on an interim basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The ASU is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In December 2023, the FASB issues ASU No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. This ASU looks to enhance the transparency and decision usefulness of income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The main provisions to the rate reconciliation disclosure require public entities on an annual basis to: disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The main provisions to the income taxes paid disclosure require that all entities disclose on an annual basis: the amount of income taxes paid disaggregated by federal, state and foreign taxes and the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid meets a quantitative threshold. This ASU also requires all entities to disclose: income (loss) from continuing operations before income tax expense (benefit) disaggregated between domestic and foreign and income tax expense (benefit) from continuing operations disaggregated by federal, state and foreign.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This ASU is to be applied on a prospective basis with an effective date for all public entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Basis of Presentation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and include the accounts of the Company and its direct and indirect wholly owned subsidiaries.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Going Concern</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. The Company had an accumulated deficit of $939.4 million and working capital of $23.8 million as of December 31, 2023. The Company has not established sufficient sales revenues to cover its operating costs and requires additional capital to proceed with its operating plan. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company will need to obtain additional financing to proceed with its business plan. Management's plan to obtain additional resources for the Company may include additional sales of equity, traditional financing, such as loans, entry into a strategic collaboration, entry into an out-licensing arrangement or provision of additional distribution rights in some or all of our markets. However, management cannot provide any assurance that the Company will be successful in accomplishing any or all of its plans. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to meet its existing obligations, and to continue as a going concern within one year from the date that these financial statements are issued. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> -939400000 23800000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Principles of Consolidation and Foreign Currency Considerations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, Asensus Surgical US, Inc., Asensus International, Inc., Asensus Surgical Italia S.r.l., Asensus Surgical Europe S.à r.l., Asensus Surgical Taiwan Ltd., Asensus Surgical Japan K.K., Asensus Surgical Israel Ltd., Asensus Surgical Netherlands B.V., and Asensus Surgical Canada, Inc. All inter-company accounts and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The functional currency of the Company’s operational foreign subsidiaries is predominantly the Euro. The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive loss as a separate component of stockholders’ equity which was $0.6 million and $1.9 million as of December 31, 2023 and 2022, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statements of operations and comprehensive loss. The net gains and losses included in net loss in the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022 were not material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 600000 1900000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Risk and Uncertainties</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company is subject to risks similar to other similarly sized companies in the medical device industry. These risks include, without limitation: the historical lack of profitability; the Company’s ability to raise additional capital; its ability to successfully develop, clinically test, obtain regulatory clearance for and commercialize its products and products in development; negative impacts on the Company's operations caused by the hostilities in the Middle East and other geopolitical factors; the success of its market development efforts; the timing and outcome of the regulatory review process for its products; changes in the healthcare regulatory environments of the United States, the European Union, Japan, Taiwan and other countries in which the Company operates or intends to operate; its ability to attract and retain key management, marketing and scientific personnel; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution company; competition in the market for robotic and digital surgical devices; and its ability to identify and pursue development of additional products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Use of Estimates</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include impairment considerations for long-lived assets, fair value estimates related to contingent consideration, stock compensation expense, revenue recognition, short-term investments, changes in inventory reserves, inventory classification between current and non-current, measurement of lease liabilities and corresponding right-of-use (“ROU”) assets, and deferred tax asset valuation allowances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cash and Cash Equivalents, Restricted Cash, and Investments</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Restricted cash as of December 31, 2023 and 2022 includes $1.6 million and $1.1 million, respectively, in cash accounts held as collateral primarily under the terms of office operating leases, credit cards, and automobile leases, and a guarantee required by the government of a country for a 2019 VAT refund.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s investments as of December 31, 2023 consisted of corporate bonds that were classified as available-for-sale. Investments classified as available-for-sale are measured at fair value, and net unrealized gains and losses are recorded as a component of accumulated other comprehensive loss on the consolidated balance sheets until realized. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity computed under the effective interest method. Such amortization and accretion are included in interest expense, net. There were <span style="-sec-ix-hidden:c445"><span style="-sec-ix-hidden:c446">no</span></span> gross realized gains or loss for the years ended December 31, 2023 and 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Investments with remaining maturities at date of purchase greater than 90 days and remaining maturities as of the reporting period less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">There have been <span style="-sec-ix-hidden:c447"><span style="-sec-ix-hidden:c448">no</span></span> credit losses for the years ended December 31, 2023 and 2022, and <span style="-sec-ix-hidden:c449"><span style="-sec-ix-hidden:c450">no</span></span> allowance for credit losses as of December 31, 2023 and 2022. Factors considered in determining whether a credit loss exists include credit ratings and other qualitative factors for each security type in the portfolio.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1600000 1100000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Fair Value Measurements </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company measures the fair value of money market funds, certain U.S. treasury securities, and equity investments with readily determinable value based on quoted prices in active markets for identical assets as Level 1 securities. Marketable securities measured at fair value using Level 2 inputs are primarily comprised of commercial paper and corporate notes and bonds without readily determinable value. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. The Company measures contingent consideration at fair value using a Monte-Carlo simulation utilizing Level 3 inputs. These inputs include the probability of achieving each of the potential milestones, revenue volatility, and an estimated discount rate associated with the risks of the expected cash flows attributable to the achievement of various milestones.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Concentrations and Credit Risk</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s principal financial instruments subject to potential concentration of credit risk are cash and cash equivalents (including restricted cash), and investments, including amounts held in money market funds, commercial paper, and corporate bonds. The Company places cash deposits with a federally insured financial institution. The Company maintains its cash at banks and financial institutions it considers to be of high credit quality; however, the Company’s domestic cash deposits may at times exceed the Federal Deposit Insurance Corporation’s insured limit. Balances in excess of federally insured limitations may not be insured. The Company has not experienced losses on these accounts, and management believes that the Company is not exposed to significant risks on such accounts. Investments are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s investments consist of various major corporations, financial institutions, and government agencies of high credit standing.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s accounts receivable are derived from sales and leases to customers located throughout the world. The Company evaluates its customers’ financial condition and, generally, requires no collateral from its customers. The Company had <span style="-sec-ix-hidden:c451"><span style="-sec-ix-hidden:c452">one</span></span> customer that accounted for 83% and 69% of the Company’s net accounts receivable as of December 31, 2023 and December 31, 2022, respectively. The Company had <span style="-sec-ix-hidden:c455">two</span> customers that accounted for 33% and 19% of revenue in 2023, and <span style="-sec-ix-hidden:c458">one</span> customer who accounted for 47% of revenue in 2022, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.83 0.69 0.33 0.19 0.47 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Accounts Receivable</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Accounts receivable are recorded at net realizable value, which includes an allowance for expected credit losses. The allowance for expected credit losses is based on the Company’s assessment of collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current and future economic conditions that may affect a customer’s ability to pay. The allowance for expected credit losses was $1.6 million as of December 31, 2023 and 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 1600000 1600000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Inventories</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Inventories are stated at the lower of cost (determined on a first-in, first-out basis) or net realizable value. Inventory costs include direct materials, direct labor, and normal manufacturing overhead. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers historical consumption and forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Any inventory on hand at the measurement date in excess of the Company's current requirements based on anticipated levels of sales is classified as long-term on the Company's consolidated balance sheets. The Company's classification of long-term inventory requires it to estimate the portion of on hand inventory that can be realized over the upcoming twelve months.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Definite-Lived Intangible Assets - Intellectual Property</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Intellectual property consists of purchased patent rights and developed technology acquired as part of a business acquisition. Developed technology includes reclassified in-process research and development (“IPR&amp;D”) assets related to (i) the Senhance System acquired in 2015 and reclassified in 2017 and (ii) a 2018 acquisition and reclassified in 2020. Amortization of the patent rights is recorded using the straight-line method over the estimated useful life of the patents of 10 years. Amortization of the developed technology is recorded using the straight-line method over the estimated useful life of 7 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company periodically evaluates intellectual property for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. To determine the recoverability, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the assets, then such assets are written down to their fair value. <span style="-sec-ix-hidden:c464"><span style="-sec-ix-hidden:c465">No</span></span> impairment of intellectual property was identified during the years ended December 31, 2023 and 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> P10Y P7Y <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Property and Equipment</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Property and equipment consists primarily of operating lease Senhance System assets, machinery, manufacturing equipment, demonstration equipment, computer equipment, furniture, and leasehold improvements, which are recorded at cost less accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Years</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets – Senhance System leasing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">5</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">3</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">5</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Lesser of lease term or 3-10</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company reviews its property and equipment assets for possible impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine the recoverability of its long-lived assets, the Company evaluates the probability that future estimated undiscounted net cash flows will be less than the carrying amount of the assets. If such estimated cash flows are less than the carrying amount of the long-lived assets, then such assets are written down to their fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">During the years ended December 31, 2023 and 2022, the Company recorded a non-cash asset impairment charge of $0.4 million and $1.4 million, respectively, to reduce the carrying value of property and equipment to its estimated fair value. The property and equipment impairment is associated with returned Senhance Systems under operating leases and Senhance Systems currently under operating leases that are not expected to generate future cash flows sufficient to recover their net book value. The fair value was estimated based on the discounted cash flows expected to be produced by the property and equipment. The impairment was recorded in property and equipment impairment on the consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Years</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets – Senhance System leasing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">5</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">3</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">5</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Lesser of lease term or 3-10</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> </tbody></table> P5Y P3Y P5Y P3Y P5Y 400000 1400000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Operating Leases</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has operating leases for its corporate office buildings, vehicles, and machinery and equipment. At inception, the Company determines whether an agreement represents a lease, and at commencement, it evaluates each lease agreement to determine whether the lease constitutes an operating or financing lease.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for lease components and non-lease components as a single component. Non-lease components consist of common area maintenance payments for most real estate leases, which are determined based on costs incurred by the lessor. Many of the Company’s leases include base rental periods coupled with options to renew or terminate the lease, generally at the Company’s discretion.  In evaluating the lease term, the Company considers whether renewal is reasonably certain.  To the extent a significant economic incentive exists to renew the lease, the option is included within the lease term.  Based on the Company’s leases, renewal options generally do not provide a significant economic incentive and are therefore excluded from the lease term. While its operating leases range from <span style="-sec-ix-hidden:c475">one</span> year to <span style="-sec-ix-hidden:c476">ten</span> years, some may include options to extend the lease generally between <span style="-sec-ix-hidden:c477">one</span> year and <span style="-sec-ix-hidden:c478">six</span> years, and some may include options to terminate the leases within one year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Implementation Costs in a Cloud Computing Arrangement</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company capitalizes qualified implementation costs incurred in a hosting arrangement that is a service contract. These capitalized implementation costs are recorded within other current and long-term assets, and are generally amortized over the fixed, non-cancellable term of the associated hosting arrangement on a straight-line basis and included within operating expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Employee Retention Tax Credit Receivable </i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) included an Employee Retention Tax Credit (“ERTC”) provision designed to encourage employers to keep employees on their payroll. The ERTC is a refundable tax credit against certain payroll taxes paid by employers for eligible wages. During the year ended December 31, 2021, the Company submitted an ERTC refund for $1.3 million and recorded the amount into Other Income (Expense) on the consolidated statements of operations and comprehensive loss. The Company received $0.7 million of the ERTC refund during the year ended December 31, 2022 and received the remaining $0.6 million during the year ended December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 700000 600000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Contingent Consideration</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a Monte-Carlo simulation utilizing significant unobservable inputs including the probability of achieving each of the potential milestones, future Euro-to-USD exchange rates, revenue volatility and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from Sofar S.p.A., an Italian company (“Sofar”), an Italian company, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery now known as the Senhance System. Under the terms of the Purchase Agreement, as amended in 2016, as of December 31, 2023, the Company has accrued $2.2 million of estimated fair value of remaining contingent consideration related to a milestone of <span style="-sec-ix-hidden:c482">€15.0</span> million which shall be payable upon achievement of trailing revenues from sales or services contracts of the Senhance System of at least <span style="-sec-ix-hidden:c483">€25.0</span> million over a calendar quarter or in the event that (i) the Company or Asensus International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the Senhance System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the Senhance System. In 2022, Sofar assigned its right to receive the contingent payment to Three Heads Investment S.r.l.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2200000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Warrant Liabilities</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s warrants (see “Note 14 – Equity Offerings,”) are measured at fair value using a Black-Scholes-Merton model option-pricing model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected stock price volatility, the expected dividend yield which is assumed to be zero since The Company has not paid and does not anticipate paying cash dividends on its shares of common stock and the risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the term of the warrant (see “Note 6 – Fair Value,”). The warrant liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Revenue Recognition</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s revenue consists of product revenue resulting from the sale of Senhance Systems, Senhance System components, and instruments and accessories. Service revenue consists of revenue related to Senhance System service agreements. Lease revenue consists of revenue generated from utilizing the Senhance System, instruments and accessories, and servicing of the Senhance System under operating lease agreements. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company's revenues are measured based on considerations specified in the contract with each customer, net of any sales incentives and taxes collected from customers that are remitted to government authorities. The Company’s Senhance System sale arrangements could include a <span style="-sec-ix-hidden:c484">five</span>-year service period; the first year of service is generally free and included in the Senhance System sale arrangement with an option to purchase the remaining <span style="-sec-ix-hidden:c485">four</span> years at a stated service price.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s Senhance System sale arrangements generally contain multiple products and services. For these consolidated sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the consolidated package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s Senhance System sale arrangements may include a combination of the following performance obligations: system(s), system components, instruments, accessories, and system services.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">For arrangements that contain multiple performance obligations, revenue is allocated to each performance obligation based on its relative estimated standalone selling price. When available, standalone selling prices are based on observable prices at which the Company separately sells the products or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes revenues when or as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations as follows:</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tbody><tr> <td style="width:18pt;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">System sales. For Senhance Systems and Senhance System components sold directly to end customers (including those arising from Senhance System purchases under lease rights to purchase), revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. For lease buyouts, where the customer has already acknowledged installation of the system, transfer of control occurs when the Company receives an executed contract for the lease buyout of the Senhance System. For Senhance Systems sold through distributors, for which distributors are responsible for installation, revenue is recognized generally upon delivery. The Company’s Senhance System arrangements generally do not provide a right of return. The Senhance Systems are generally covered by a one-year warranty. Warranty costs were not material for the periods presented.</p> </td> </tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tbody><tr> <td style="width: 18pt; text-align: justify;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Instruments and accessories. Revenue from sales of instruments and accessories is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but also occurs at the time of delivery depending on the customer arrangement.</p> </td> </tr> </tbody></table> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"> <tbody><tr> <td style="width: 18pt; text-align: justify;"> </td> <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">●</p> </td> <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Service. Service revenue is recognized ratably over the term of the service period as the customers benefit from the service throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed.</p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due 30 to 60 days from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements and are included in accounts receivable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In connection with assets recognized from the costs to obtain a contract with a customer, the Company determined that the sales incentive programs for its sales team do not meet the requirements to be capitalized as the Company does not expect to generate future economic benefits from the related revenue from the initial sales transaction and such costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Senhance System Leasing</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company enters into lease arrangements with certain qualified customers. Revenue related to arrangements including lease elements are allocated to lease and non-lease elements based on their relative standalone selling prices. Lease elements generally include a Senhance System, while non-lease elements generally include instruments, accessories, and services. For some lease arrangements, the customers are provided with the right to purchase the leased Senhance System at some point during and/or at the end of the lease term. In some arrangements lease payments are based on the usage of the Senhance System. For the years ended December 31, 2023 and 2022, variable lease revenue related to usage-based arrangements was not material.  </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In determining whether a transaction should be classified as a sales-type, operating, or direct financing lease, the Company considers the following terms at lease commencement: (1) whether title of the Senhance System transfers automatically or for a nominal fee by the end of the lease term, (2) whether the present value of the minimum lease payments equals or exceeds substantially all of the fair value of the leased Senhance System, (3) whether the lease term is for the major part of the remaining economic life of the leased System, (4) whether the lease grants the lessee an option to purchase the leased Senhance System that the lessee is reasonably certain to exercise, and (5) whether the underlying Senhance System is of such a specialized nature that it is expected to have no alternative use to the Company at the end of the lease term. All such arrangements through December 31, 2023 are classified as operating leases. Revenue related to lease elements from operating lease arrangements is generally recognized on a straight-line basis over the lease term or based upon Senhance System usage. As of December 31, 2023, future minimum lease payments due from customers was $2.2 million, which is expected to be received over the next one to two years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 2200000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Cost of Revenue</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Cost of revenue consists of contract manufacturing, materials, labor and manufacturing overhead incurred internally to produce the products. Depreciation expense related to leased systems is included in the cost of revenue. Shipping and handling costs incurred by the Company are included in the cost of revenue.  We expense all inventory obsolescence provisions as cost of revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Research and Development Costs</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Research and development expenses primarily consist of engineering, product development and regulatory expenses, incurred in the design, development, testing and enhancement of our products. Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Stock-Based Compensation</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes expenses for share-based awards exchanged for services rendered equal to the estimated fair value of these awards over the requisite service period. The Company recognizes as expense, the grant-date fair value of stock options and other stock-based compensation issued to employees and non-employee directors over the requisite service periods, which are typically the vesting periods. The Company uses the Black-Scholes-Merton model to estimate the fair value of stock options. The volatility assumption used in the Black-Scholes-Merton model is based on the Company’s historical volatility. The expected term of options granted has been determined based upon the simplified method, because the Company does not have sufficient historical information regarding its options to derive the expected term. Under this approach, the expected term is the mid-point between the weighted average of vesting period and the contractual term. The risk-free interest rate is based on U.S. Treasury rates whose term is consistent with the expected life of the stock options. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be <span style="-sec-ix-hidden:c487">zero</span>. The Company estimates forfeitures based on its historical experience and adjusts the estimated forfeiture rate based upon actual experience. For performance-based restricted stock awards with performance conditions, we begin recognizing compensation expense when it becomes probable that the performance condition will be attained.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value of restricted stock units is determined by the market price of the Company’s common stock on the date of grant. See “Note 13 – Stock-Based Compensation,” for a detailed discussion of the Company’s stock plans and stock-based compensation expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Income Taxes</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets or liabilities for the temporary differences between financial reporting and tax basis of the Company’s assets and liabilities, and for tax carryforwards at enacted statutory rates in effect for the years in which the asset or liability is expected to be realized. The effect on deferred taxes of a change in tax rates is recognized in income during the period that includes the enactment date. In addition, valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amounts expected to be realized. The Company has elected to account for global intangible low-taxed income (“GILTI”) as a period expense in the year the tax is incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes the financial statement benefit of an income tax position only after determining that the relevant taxing authority would more likely than not sustain the position following audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require application of significant judgment. The Company is subject to U.S. federal and various state, local and foreign jurisdictions. Due to the Company’s net operating loss carryforwards, the Company may be subject to examination by authorities for all previously filed income tax returns.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Comprehensive Loss</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Segments</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company operates in <span style="-sec-ix-hidden:c488">one</span> business segment—the research, development and sale of medical device robotics to improve MIS. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Impact of Recently Issued Accounting Standards</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In November 2023, the FASB issued Accounting Standards Update, or ASU, No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>. This ASU looks to provide improvements to the segment disclosure by providing users with more decision-useful information about reportable segments in a public entity. The main provisions require a company to disclose, on an annual and interim basis, significant expenses included within each reported measure of segment profit or loss, an amount for other segment items by reportable segment and a description of its composition. It also requires all annual disclosures about a reportable segments’ profit or loss and assets to be reported on an interim basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The ASU is to be applied retrospectively to all prior periods presented in the financial statements with an effective date for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In December 2023, the FASB issues ASU No. 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>. This ASU looks to enhance the transparency and decision usefulness of income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The main provisions to the rate reconciliation disclosure require public entities on an annual basis to: disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. The main provisions to the income taxes paid disclosure require that all entities disclose on an annual basis: the amount of income taxes paid disaggregated by federal, state and foreign taxes and the amount of income taxes paid disaggregated by individual jurisdictions in which income taxes paid meets a quantitative threshold. This ASU also requires all entities to disclose: income (loss) from continuing operations before income tax expense (benefit) disaggregated between domestic and foreign and income tax expense (benefit) from continuing operations disaggregated by federal, state and foreign.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This ASU is to be applied on a prospective basis with an effective date for all public entities for annual periods beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this ASU.</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>3.</b></p> </td> <td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Revenue Recognition</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents revenue disaggregated by type and geography:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31, </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>U.S.</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">205</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">211</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">294</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">300</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">196</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;">Total U.S. revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">695</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">767</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outside of U.S. ("OUS")</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,645</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,551</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,669</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,565</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">758</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,073</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,810</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,131</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;">Total OUS revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,882</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,320</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,645</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,551</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,874</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,776</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,052</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,373</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,006</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;">Total revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,577</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,087</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Remaining Performance Obligations</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to service obligations performed under the Company's system sales contracts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations as of December 31, 2023 was $0.9 million, which is expected to be recognized over <span style="-sec-ix-hidden:c558">one</span> to <span style="-sec-ix-hidden:c559">four</span> years. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Contract Assets and Liabilities</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Deferred revenue for the periods presented was primarily related to service obligations, for which the service fees are billed up-front, generally annually. The associated deferred revenue is generally recognized ratably over the service period. The Company did not have any significant impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2023 and 2022 was $0.5 million, which was included in the deferred revenue balance of $0.5 million as of December 31, 2022 and 2021.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following information summarizes the Company’s contract assets and liabilities:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">95</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">116</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">711</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">465</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31, </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>U.S.</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">205</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">211</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">294</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">300</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">196</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;">Total U.S. revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">695</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">767</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Outside of U.S. ("OUS")</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,645</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,551</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,669</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,565</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">758</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,073</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,810</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,131</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;">Total OUS revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,882</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,320</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Systems</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,645</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,551</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Instruments and accessories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,874</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,776</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Services</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,052</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,373</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leases</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,006</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,387</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;">Total revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,577</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,087</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 205000 211000 294000 300000 196000 256000 695000 767000 3645000 2551000 1669000 1565000 758000 1073000 1810000 1131000 7882000 6320000 3645000 2551000 1874000 1776000 1052000 1373000 2006000 1387000 8577000 7087000 900000 500000 500000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">95</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">116</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred revenue</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">711</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">465</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 95000 116000 711000 465000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>4.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cash, Cash Equivalents, and Restricted Cash</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash, cash equivalents and restricted cash consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,588</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,473</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,521</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,856</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. treasuries</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">6,987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">17,096</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,329</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,642</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">18,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">7,470</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Restricted cash at December 31, 2023 and 2022 includes $1.6 million and $1.1 million, respectively, in cash accounts held as collateral primarily under the terms of an office operating lease, credit cards, automobile leases, and a guarantee required by the government of a country for a 2019 VAT refund.</p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,588</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,473</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,521</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,856</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. treasuries</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">6,987</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">17,096</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,329</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,642</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">18,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">7,470</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 4588000 3473000 5521000 2856000 6987000 0 17096000 6329000 1642000 1141000 18738000 7470000 1600000 1100000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>5.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Investments, available-for-sale</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The aggregate fair values of investment securities along with cumulative unrealized gains and losses determined on an individual investment security basis and included in other comprehensive loss are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cost</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gain</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Loss</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Short-term </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>investments</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cost</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gain</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Loss</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Short-term</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>investments</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Long-term </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>investments</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,364</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(49</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">55,201</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(447</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">54,754</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">50,889</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,865</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government agencies</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">999</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">991</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">991</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,564</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(504</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,060</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">64,195</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,865</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes the contractual maturities of the Company’s available-for-sale investments:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cost</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Mature in less than one year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Actual maturities may differ from contractual maturities because certain borrowers have the right to call or prepay certain obligations. There were <span style="-sec-ix-hidden:c675"><span style="-sec-ix-hidden:c676">no</span></span> sales of investments for the years ended December 31, 2023 or 2022, respectively. There were <span style="-sec-ix-hidden:c677"><span style="-sec-ix-hidden:c678">no</span></span> realized gains or losses for the years ended December 31, 2023 and 2022 respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cost</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gain</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Loss</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Short-term </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>investments</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cost</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gain</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Loss</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Short-term</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>investments</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Long-term </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>investments</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,364</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(49</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,315</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate bonds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">55,201</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(447</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">54,754</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">50,889</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,865</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. government agencies</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">999</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">991</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">991</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,564</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(504</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,060</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">64,195</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,865</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 3981000 0 10000 3971000 3971000 3981000 0 10000 3971000 3971000 12364000 0 49000 12315000 12315000 0 55201000 0 447000 54754000 50889000 3865000 999000 0 8000 991000 991000 0 68564000 0 504000 68060000 64195000 3865000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cost</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Mature in less than one year</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,981</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 3981000 3971000 3981000 3971000 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>6.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Fair Value</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following are categories of assets and liabilities measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices<br/> in Active </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Markets for<br/> Identical Assets<br/> (Level 1)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant<br/> Other<br/> Observable<br/> Inputs (Level 2)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant<br/> Unobservable<br/> Inputs (Level 3)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; vertical-align: bottom;"><b>Description</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Assets measured at fair value</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents<sup style="vertical-align:top;line-height:120%;"> (1)</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">17,096</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">17,096</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,642</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,642</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">18,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">22,709</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Liabilities measured at fair value</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,220</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,220</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Warrant Liabilities</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,888</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,888</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities measured at fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,108</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,108</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices in</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Active Markets</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for Identical </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Assets (Level 1)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Observable </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs (Level 2)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant Unobservable</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs (Level 3)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; vertical-align: bottom;"><b>Description</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Assets measured at fair value</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents<sup style="vertical-align:top;line-height:120%;"> (1)</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,329</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,329</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">64,195</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">64,195</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">7,470</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,060</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">75,530</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Liabilities measured at fair value</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities measured at fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">(1) </sup>Includes investments that are readily convertible to cash with original maturities of 90 days or less.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The carrying values of accounts receivable, prepaid expenses, employee retention tax credit receivables, other current assets, accounts payable, accrued employee compensation and benefits, accrued expenses, deferred revenue, and other current liabilities as of December 31, 2023 and December 31, 2022, approximate to their fair values due to the short-term nature of these items and are considered to be Level 1.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company’s financial liabilities consisted of contingent consideration payable to Three Heads Investment S.r.l., related to the Company’s 2015 acquisition of the Senhance Surgical System from an assignor to Three Heads Investment S.r.l. (the “Senhance Acquisition”). Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statements of operations and comprehensive loss.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements for contingent consideration utilizing a Monte-Carlo simulation as of December 31, 2023 and December 31, 2022:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Valuation<br/> Methodology</b><br/>  </p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant<br/> Unobservable</b><b> </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Input</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,<br/> 2023</b><br/>  </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,<br/> 2022</b><br/>  </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Probability<br/> weighted<br/> income<br/> approach</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Milestone dates</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2032</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2032</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue volatility</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EUR-to-USD exchange rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.07</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents the long-term portion of the contingent consideration for the year ended December 31, 2023 and summarizes the change in fair value, as determined by Level 3 inputs for the contingent consideration for the year ended December 31, 2023 and 2022:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%; vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td class="q2qselectedlineitem" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,371</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,115</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">964</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,220</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Warrant Liabilities</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During 2023, the Company recorded warrant liabilities related to common stock warrants issued in the registered direct offering in July 2023 (for additional information about the offering, please refer to Note 14 -Equity Offerings).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Warrant liabilities were recorded at their initial estimated fair value. Adjustments associated with changes in fair value of the warrant liabilities are included in the Company’s consolidated statements of operations and comprehensive loss. The following table summarizes changes in estimated fair value of the warrant liabilities for the warrants issued in July 2023 as of December 31, 2023:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of warrants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,120</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,232</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,888</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair value of the warrant liabilities were estimated using the Black-Scholes option pricing model, which is based on unobservable inputs and is designated as Level 3 in the fair value hierarchy. The following table summarizes the assumptions used in determining fair value of warrant liabilities:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices<br/> in Active </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Markets for<br/> Identical Assets<br/> (Level 1)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant<br/> Other<br/> Observable<br/> Inputs (Level 2)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant<br/> Unobservable<br/> Inputs (Level 3)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; vertical-align: bottom;"><b>Description</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Assets measured at fair value</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents<sup style="vertical-align:top;line-height:120%;"> (1)</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">17,096</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">17,096</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,642</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,642</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">18,738</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,971</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">22,709</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Liabilities measured at fair value</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,220</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,220</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Warrant Liabilities</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,888</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,888</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities measured at fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,108</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8,108</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Quoted Prices in</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Active Markets</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>for Identical </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Assets (Level 1)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Other</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Observable </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs (Level 2)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant Unobservable</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Inputs (Level 3)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%; vertical-align: bottom;"><b>Description</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Assets measured at fair value</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents<sup style="vertical-align:top;line-height:120%;"> (1)</sup></p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,329</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,329</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Short-term investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">64,195</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">64,195</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term investments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">3,865</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">7,470</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">68,060</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">75,530</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Liabilities measured at fair value</span></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities measured at fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 17096000 0 0 17096000 1642000 0 0 1642000 0 3971000 0 3971000 18738000 3971000 0 22709000 0 0 2220000 2220000 0 0 5888000 5888000 0 0 8108000 8108000 6329000 0 0 6329000 1141000 0 0 1141000 0 64195000 0 64195000 0 3865000 0 3865000 7470000 68060000 0 75530000 0 0 1256000 1256000 0 0 1256000 1256000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Valuation<br/> Methodology</b><br/>  </p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Significant<br/> Unobservable</b><b> </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Input</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,<br/> 2023</b><br/>  </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,<br/> 2022</b><br/>  </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Contingent consideration</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Probability<br/> weighted<br/> income<br/> approach</p> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Milestone dates</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2032</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%; vertical-align: top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2032</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Discount rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue volatility</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EUR-to-USD exchange rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.07</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31, </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">117</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 0.10 0.165 0.35 0.45 1.1 1.07 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%; vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2021</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td class="q2qselectedlineitem" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,371</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,115</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,256</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">964</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,220</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 2371000 1115000 1256000 -964000 2220000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of warrants</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,120</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair value</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,232</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,888</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 7120000 1232000 5888000 0 1.17 0.038 4.6 <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>7.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Inventories</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The components of inventories are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,200</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">11,208</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,545</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">11,215</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">13,753</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current Portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,172</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8,284</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">4,043</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,469</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">11,215</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">13,753</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,200</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">11,208</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,015</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">2,545</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">11,215</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">13,753</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current Portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,172</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8,284</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term portion</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">4,043</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">5,469</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">11,215</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">13,753</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 9200000 11208000 2015000 2545000 11215000 13753000 7172000 8284000 4043000 5469000 11215000 13753000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>8.</b>         <b>Property and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment consisted of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,089</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,450</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets - Senhance System leasing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,848</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,251</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">603</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">600</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">831</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,721</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,654</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in process</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">436</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,046</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,222</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,087</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,680</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,959</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,542</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Depreciation expense was approximately $3.3 million and $3.4 million for the years ended December 31, 2023 and 2022, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Machinery, manufacturing, and demonstration equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,089</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,450</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets - Senhance System leasing</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,848</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,251</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">603</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">600</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">831</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,721</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,654</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Construction in process</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">436</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,046</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,222</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accumulated depreciation and amortization</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,087</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,680</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment, net</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,959</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,542</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 9089000 8450000 12848000 10251000 603000 600000 715000 831000 1721000 1654000 70000 436000 25046000 22222000 16087000 12680000 8959000 9542000 3300000 3400000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>9.</b>         <b>Intellectual Property</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The components of gross intellectual property, accumulated amortization, and net intellectual property are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross Carrying Amount</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Amortization</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Foreign </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Currency </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Translation </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Impact</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net Carrying </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">68,838</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,902</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(837</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,099</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Technology and patents purchased</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">400</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(279</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">17</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">138</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intellectual property</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69,238</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(67,181</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(820</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,237</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross Carrying Amount</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Amortization</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Foreign </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Currency </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Translation</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Impact</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net Carrying </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">68,838</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,562</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(874</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,402</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Technology and patents purchased</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">400</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(239</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">13</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">174</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intellectual property</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69,238</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(66,801</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(861</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,576</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The weighted average remaining useful life of the developed technology and technology and patents purchased was 3.2 years and 3.3 years, respectively, as of December 31, 2023. The weighted average remaining useful life of the developed technology and technology and patents purchased was 4.2 years and 4.3 years, respectively as of December 31, 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The estimated future amortization expense of intellectual property as of December 31, 2023 is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ending<br/> December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">388</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">388</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">389</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,237</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross Carrying Amount</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Amortization</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Foreign </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Currency </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Translation </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Impact</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net Carrying </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">68,838</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,902</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(837</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,099</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Technology and patents purchased</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">400</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(279</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">17</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">138</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intellectual property</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69,238</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(67,181</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(820</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,237</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Gross Carrying Amount</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Amortization</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Foreign </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Currency </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Translation</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Impact</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Net Carrying </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Developed technology</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">68,838</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,562</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(874</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,402</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Technology and patents purchased</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">400</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(239</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">13</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">174</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intellectual property</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">69,238</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(66,801</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(861</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,576</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 68838000 66902000 -837000 1099000 400000 279000 17000 138000 69238000 67181000 -820000 1237000 68838000 66562000 -874000 1402000 400000 239000 13000 174000 69238000 66801000 -861000 1576000 P3Y2M12D P3Y3M18D P4Y2M12D P4Y3M18D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ending<br/> December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">388</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">388</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">389</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,237</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 388000 388000 389000 72000 1237000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>10.</b>         <b>Leases</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Lessee Information</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Components of operating lease expense are primarily recorded in general and administrative on the consolidated statements of operations and comprehensive loss were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15%;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term operating</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,888</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,557</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Supplemental balance sheet information related to operating leases was as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">5.7</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">6.8</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">9.2%</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">8.4%</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incremental borrowing rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">7.1%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.0%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">6.1%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.5%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Maturities of finance and operating lease obligations as of December 31, 2023 were as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 82%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td class="q2qselectedlineitem" style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,491</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,377</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,160</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">904</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">834</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,406</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total minimum lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,172</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount of lease payments representing interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,490</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of future minimum lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,682</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15%;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term operating</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,888</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,557</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 1888000 1557000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 27%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"> </p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average remaining lease term (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">5.7</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">6.8</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted-average discount rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">9.2%</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">8.4%</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incremental borrowing rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">7.1%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">23.0%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">6.1%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.5%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> P5Y8M12D P6Y9M18D 0.092 0.084 0.071 0.23 0.061 0.145 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 82%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td class="q2qselectedlineitem" style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,491</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,377</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,160</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">904</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">834</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,406</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total minimum lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,172</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: Amount of lease payments representing interest</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,490</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of future minimum lease payments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,682</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 1491000 1377000 1160000 904000 834000 1406000 7172000 1490000 5682000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>11.</b>         <b>Accrued Expenses and Other Current Liabilities</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents the components of accrued expenses and other current liabilities:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Consulting and other vendors</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">461</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">155</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Royalties</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">24</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal and professional fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">275</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Taxes and other assessments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">755</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">839</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,636</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,293</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Consulting and other vendors</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">461</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">155</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Royalties</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">24</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal and professional fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">411</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">275</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Taxes and other assessments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">755</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">839</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,636</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,293</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 461000 155000 9000 24000 411000 275000 755000 839000 1636000 1293000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>12.</b>         <b>Income Taxes </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The components for the income tax expense are as follows for the years ended December 31 (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current income taxes</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">196</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">239</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred income taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">118</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">79</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total income tax expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">314</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">318</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The United States and foreign components of loss from operations before taxes are as follows for the years ended December 31 (in thousands):</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(53,226</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(44,802</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(24,893</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(30,441</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total loss from operations before taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(78,119</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(75,243</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;"> </p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">Significant components of the Company’s deferred tax assets consist of the following at December 31 (in thousands):</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred Tax assets:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 59.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,119</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,840</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,666</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,538</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research credit carryforward</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,859</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,341</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">319</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">162</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized start-up costs and other intangibles</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">644</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">921</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,064</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,382</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">93,332</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">83,908</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">112,003</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">96,092</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(110,511</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(94,704</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,492</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,388</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed assets and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,448</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,214</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,448</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,214</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">44</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">174</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">At December 31, 2023 and 2022, the Company has provided a full valuation allowance against its net deferred assets in the U.S., Canada, Italy, Luxembourg, Switzerland, and Taiwan tax jurisdictions, since realization of these benefits is not more likely than not. The valuation allowance increased approximately $15.8 million from the prior year. At December 31, 2023, the Company had U.S. federal net operating loss carryforwards of $446.7 million, of which $253 million are expected to expire unused under the limitations imposed by Internal Revenue Code Section 382. Of the total amount of Federal NOLs (notwithstanding the 382 limitation), $254.5 million begin to expire in 2027, while the remaining $192.2 million carry forward indefinitely. At December 31, 2023, the Company had U.S. state net operating loss carryforwards of $336.3 million, of which $199 million are expected to expire unused under the state tax law equivalents of Internal Revenue Code Section 382. Of this amount (notwithstanding the 382 limitations), $323.0 million of state NOLs begin to expire in 2024, while the remaining $13.3 million carry forward indefinitely. At December 31, 2023, the Company had federal research credit carryforwards in the amount of $11.7 million. These carryforwards begin to expire in 2027. However, under the limitations of Internal Revenue Code Section 383, it is expected that $8.8 million of this carryforward will expire unused. The utilization of the federal net operating loss carryforwards and credit carryforwards will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the carryforwards.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">At December 31, 2023, the Company had foreign operating loss carryforwards in Italy of approximately $25.0 million, which can be carried forward indefinitely; foreign operating loss carryforwards in Luxembourg of approximately $95.6 million, which will begin to expire in 2034; foreign operating loss carryforwards in Switzerland of approximately $135.3 million, which begin to expire in 2024, and foreign operating loss carryforwards in Canada of approximately $1.4 million, which begin to expire in 2040.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has evaluated its tax positions to consider whether it has any unrecognized tax benefits. As of December 31, 2023, the Company had gross unrecognized tax benefits of approximately $0.7 million. Of the total, none would reduce the Company’s effective tax rate if recognized. The Company does not anticipate a significant change in total unrecognized tax benefits or the Company’s effective tax rate due to the settlement of audits or the expiration of statutes of limitations within the next twelve months. Furthermore, the Company does not expect any cash settlement with the taxing authorities as a result of these unrecognized tax benefits as the Company has sufficient unutilized carryforward attributes to offset the tax impact of these adjustments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following is a tabular reconciliation of the Company’s change in gross unrecognized tax positions at December 31 (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">335</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross increases for tax positions related to current periods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">328</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross decreases related to 382 limitations</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">52</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">335</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes. As of December 31, 2023 and 2022, the Company had <span style="-sec-ix-hidden:c1200"><span style="-sec-ix-hidden:c1201">no</span></span> accrued interest or penalties related to uncertain tax positions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company has analyzed its filing positions in all significant federal, state, and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. With few exceptions, the Company is no longer subject to United States Federal, state, and local tax examinations by tax authorities for years before 2020, although carryforward attributes that were generated prior to 2020 may still be adjusted upon examination by the taxing authorities if they either have been or will be used in a future period. No income tax returns are currently under examination by taxing authorities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Taxes computed at the then-current statutory federal income tax rate of 21% are reconciled to the provision for income taxes as follows for the years ended December 31:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"><b>2023</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"><b>2022</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent of</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Pretax </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Earnings </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent of</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Pretax</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Earnings </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States federal tax at statutory rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(16,405</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(15,801</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes (net of deferred benefit)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,493</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,912</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.9</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nondeductible expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">755</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair market value of contingent consideration</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">244</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(283</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant remeasurement and financing costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(140</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,898</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(970</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in unrecognized tax benefits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">380</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign tax rate differential</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,176</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(4.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,676</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(3.6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">True-up to stock compensation - cancellations</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">49</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in enacted tax rates and other, net</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">659</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(96</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">16,036</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(20.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">16,384</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(21.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense (benefit)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">314</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(0.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding: 0px 0px 3px;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">318</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(0.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%)</td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current income taxes</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58.2%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">196</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">239</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred income taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Federal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">State</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">118</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">79</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total income tax expense</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">314</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">318</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 0 0 0 196000 239000 0 0 0 0 118000 79000 314000 318000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(53,226</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(44,802</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(24,893</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(30,441</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total loss from operations before taxes</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(78,119</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(75,243</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </tbody></table> -53226000 -44802000 -24893000 -30441000 -78119000 -75243000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred Tax assets:</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 59.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,119</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,840</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,666</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,538</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research credit carryforward</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,859</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,341</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">319</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">162</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized start-up costs and other intangibles</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">644</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">921</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,064</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4,382</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">93,332</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">83,908</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">112,003</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">96,092</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(110,511</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(94,704</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,492</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,388</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Fixed assets and other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,448</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,214</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax liability</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,448</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(1,214</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">44</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">174</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 3119000 2840000 2666000 2538000 2859000 1341000 319000 162000 644000 921000 9064000 4382000 93332000 83908000 112003000 96092000 110511000 94704000 1492000 1388000 1448000 1214000 1448000 1214000 44000 174000 15800000 446700000 253000000 254500000 192200000 336300000 199000000 323000000 13300000 11700000 8800000 25000000 95600000 135300000 1400000 700000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">335</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">141</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross increases for tax positions related to current periods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">328</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross decreases related to 382 limitations</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">52</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">715</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">335</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 335000 141000 328000 194000 52000 0 715000 335000 0.21 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"><b>2023</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"><b>2022</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent of</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Pretax </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Earnings </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percent of</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Pretax</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Earnings </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="14" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;">(in thousands)</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States federal tax at statutory rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(16,405</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(15,801</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State taxes (net of deferred benefit)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,493</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,912</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.9</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nondeductible expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">755</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,077</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in fair market value of contingent consideration</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">244</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(283</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Warrant remeasurement and financing costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(140</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research &amp; development</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,898</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(970</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in unrecognized tax benefits</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">380</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">194</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Foreign tax rate differential</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,176</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(4.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,676</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(3.6</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">True-up to stock compensation - cancellations</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">49</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in enacted tax rates and other, net</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">659</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(96</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.0</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">16,036</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(20.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">16,384</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(21.8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%)</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense (benefit)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">314</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(0.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding: 0px 0px 3px;">%)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">318</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(0.4</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%)</td> </tr> </tbody></table> -16405000 0.21 -15801000 0.21 -2493000 0.032 -2912000 0.039 755000 -0.01 1077000 -0.014 244000 -0.003 -283000 0.004 -140000 0.002 0 0 1898000 0.024 970000 0.013 380000 -0.005 194000 -0.003 3176000 -0.041 2676000 -0.036 0 0 49000 -0.001 659000 -0.008 -96000 0 16036000 -0.205 16384000 -0.218 314000 -0.004 318000 -0.004 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>13.</b>         <b>Stock-Based Compensation</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Incentive Compensation Plan Information</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On June 6, 2023, at the 2023 Annual Meeting of Stockholders, the Company’s stockholders voted to approve an amendment and restatement of the Company’s Incentive Compensation Plan (“the Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. As of December 31, 2023, there were 54,072,307 shares authorized for issuance, and 22,185,899 shares available for future issuance under the Plan. To date all equity awards under the Plan have consisted of nonqualified stock options, incentive stock options, restricted stock units and stock awards.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Under the Plan, which is administered by the Compensation Committee, the Company may grant stock options, stock appreciation rights, restricted stock units, restricted stock or stock awards to employees, officers, non-employee directors, consultants, and vendors. The exercise price of stock options or stock appreciation rights may not be less than the fair market value of the Company’s shares at the date of grant. Additionally, no stock options or stock appreciation rights granted under the Plan may have a term exceeding <span style="-sec-ix-hidden:c1374">ten</span> years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Stock Options </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table summarizes the Company’s stock option activity, including grants to non-employees, for the year ended December 31, 2023:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual Term </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Years)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,584,967</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.22</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,047,615</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.71</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(149,430</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.78</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancelled</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25,173</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27.32</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(13,300</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">0.38</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,444,679</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.80</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The weighted-average grant date fair value of stock options was $0.59 during the years ended December 31, 2023 and 2022. The aggregate intrinsic value of stock options exercised under the Company’s stock plans was not material during the years ended December 31, 2023 and 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table summarizes information about stock options outstanding at December 31, 2023:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual Term (Years)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic Value (Millions)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,726,280</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,105,084</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.28</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.77</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The fair value of options granted were estimated using the Black-Scholes-Merton option pricing model based on the assumptions in the table below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 27%;"><b>Years Ended December 31, </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><b>2023</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><b>2022</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">0%</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">0%</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">124%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">130%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">126%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">133%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.53%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.14%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">1.25%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.40%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.8</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.8</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Restricted Stock Units </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following is a summary of the restricted stock unit activity, including performance restricted stock units, for the year ended December 31, 2023:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Restricted Stock</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Units Outstanding</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date Fair </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,483,491</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.04</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8,616,931</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,937,130</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(837,115</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">0.76</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,326,177</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.81</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Performance Restricted Stock Units</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In 2023 and 2022, the Company granted performance-based restricted stock units (“PRSUs”). The number of shares earnable under the 2023 and 2022 awards were based on achieving certain operational targets by December 31, 2023 (for the PRSUs granted in 2023) and October 1, 2023 (for the PRSUs granted in 2022), respectively. In February 2024, the Board determined that the operational targets for PRSU awards granted in 2023 were 50% achieved and as a result, the 2023 PRSUs were 50% earned and remain subject to <span style="-sec-ix-hidden:c1431">three</span>-year time-based vesting requirements. The other 50% of the 2023 PRSUs were forfeited. The operational targets were achieved for the PRUSs granted in 2022, therefore the 2022 PRSUs were fully earned and remain subject to <span style="-sec-ix-hidden:c1433">three</span>-year time-based vesting requirements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Stock-based Compensation Expense</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table summarizes non-cash stock-based compensation expense by award type for the years ended December 31, 2023, and 2022:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31, </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="7" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: center;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,654</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,954</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,319</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Performance restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,626</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,443</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">7,918</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">8,416</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As of December 31, 2023, the unrecognized stock-based compensation expense related to unvested stock options was approximately $1.6 million, which is expected to be recognized over an estimated weighted-average period of 1.4 years. As of December 31, 2023, the unrecognized stock-based compensation expense related to unvested restricted stock units and performance restricted stock units was approximately $4.4 million, which is expected to be recognized over a weighted average period of approximately 1.2 years.</p> 22000000 54072307 22185899 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Remaining</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual Term </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Years)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,584,967</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.22</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.31</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,047,615</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.71</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(149,430</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.78</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancelled</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25,173</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27.32</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercised</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(13,300</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">0.38</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,444,679</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3.20</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4.80</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 7584967 4.22 P5Y3M21D 3047615 0.71 149430 0.78 25173 27.32 13300 0.38 10444679 3.2 P4Y9M18D 0.59 0.59 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Average Exercise </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Price</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average Remaining </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Contractual Term (Years)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Intrinsic Value (Millions)</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,726,280</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.02</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested or expected to vest at December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,105,084</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.28</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.77</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 5726280 5.02 P4Y1M13D 0 10105084 3.28 P4Y9M7D 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 27%;"><b>Years Ended December 31, </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><b>2023</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><b>2022</b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">0%</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">0%</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">124%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">130%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">126%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">133%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.53%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.14%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">1.25%</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.40%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (in years)</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.8</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.8</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.5</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody></table> 0 0 1.24 1.30 1.26 1.33 0.0353 0.0414 0.0125 0.044 P3Y9M18D P4Y6M P3Y9M18D P4Y6M <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Restricted Stock</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Units Outstanding</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-Average </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Grant Date Fair </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Value</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested December 31, 2022</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,483,491</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.04</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8,616,931</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">0.70</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,937,130</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(837,115</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">0.76</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested December 31, 2023</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,326,177</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.81</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 8483491 1.04 8616931 0.7 3937130 1.1 837115 0.76 12326177 0.81 0.50 0.50 0.50 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31, </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="7" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: center;">(in thousands)</p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,338</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,654</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,954</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,319</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Performance restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,626</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,443</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 69%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">7,918</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">8,416</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </tbody></table> 2338000 3654000 3954000 3319000 1626000 1443000 7918000 8416000 1600000 P1Y4M24D 4400000 P1Y2M12D <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>14.</b>         <b>Equity Offerings</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Equity financing transactions for the years ended December 31, 2023 and 2022, include:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>2022</i></b> <b><i>At-The-Market Offering</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On March 18, 2022, the Company entered into a Controlled Equity Offering Sales Agreement (the “2022 Sales Agreement”) with Cantor Fitzgerald &amp; Co. and Oppenheimer &amp; Co. Inc., collectively, “the Agents”. The Company commenced an at-the-market offering (the “2022 ATM Offering”) pursuant to which the Company could offer and sell, from time to time, at its option, shares of its common stock for an aggregate offering price of up to $100.0 million. The aggregate compensation payable to the Agents was 3.0% of the aggregate gross proceeds from each sale of the Company’s common stock. No shares were sold under the 2022 ATM Offering in 2022.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents details about common stock issued pursuant to the 2022 ATM Offering (in thousands, except share and per share amounts):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total shares of common stock sold</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">933,672</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Average price per share</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.43</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross proceeds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">403</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commission paid to agents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net proceeds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">391</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>2023 Registered Equity Offering</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On July 27, 2023, the Company sold, in a registered direct offering, an aggregate of 23,809,524 shares of common stock, and warrants to purchase 23,809,524 of the Company’s common stock shares at an exercise price of $0.42 per common share (the “warrants”), for an aggregate purchase price of $10.0 million. The warrants are exercisable at any time on or after the date of issuance and will expire <span style="-sec-ix-hidden:c1529">five</span> years after the date of issuance. Based on the assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 – Distinguishing Liabilities from Equity and ASC 815 – Derivatives and Hedging, the Company determined that warrants did not meet the requirements for equity classification. Accordingly, the warrants were recorded as a liability on the Company’s balance sheet at their initial estimated fair value on the date of issuance. For additional information regarding the fair value of warrant liabilities, please refer to Note 4 – Fair Value Measurements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company allocated $7.1 million of the aggregate proceeds to warrants based on their estimated fair value, with the residual amount of $2.9 million allocated to common stock. Offering related issuance costs were approximately $1.0 million and consisted primarily of placement agent’s fees and legal expenses. Issuance costs were allocated to common stock and warrant liability proportionally to the allocation of the purchase price. During the year ended December 31, 2023, the Company recorded $0.7 million of other expense, net, in the consolidated statement of operations related to issuance costs allocated to warrant liabilities.</p> 100000000 0.03 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total shares of common stock sold</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">933,672</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Average price per share</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.43</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross proceeds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">403</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commission paid to agents</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net proceeds</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">391</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 933672 0.43 403000 12000 391000 23809524 23809524 0.42 10000000 7100000 2900000 1000000 700000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>15.</b>         <b>Basic and Diluted Net Loss per Share</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all potential dilutive common shares that were outstanding during the period. Potential dilutive common shares consist of incremental shares issuable upon exercise of stock options, restricted stock units, and warrants. <span style="-sec-ix-hidden:c1543"><span style="-sec-ix-hidden:c1544">No</span></span> adjustments have been made to the weighted average outstanding common shares figures for the years ended December 31, 2023 or 2022 as the assumed exercise of outstanding options, warrants and restricted stock units would be anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Potential common shares not included in calculating diluted net loss per share are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">10,444,679</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,584,967</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nonvested restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,326,177</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8,483,491</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock warrants</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td class="q2qselectedlineitem" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">24,830,500</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td class="q2qselectedlineitem" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,021,076</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">47,601,356</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">17,089,534</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">10,444,679</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,584,967</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nonvested restricted stock units</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">12,326,177</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8,483,491</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock warrants</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td class="q2qselectedlineitem" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">24,830,500</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td class="q2qselectedlineitem" style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,021,076</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">47,601,356</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">17,089,534</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 10444679 7584967 12326177 8483491 24830500 1021076 47601356 17089534 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>16.</b>         <b>Commitments and Contingencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>License and Supply Agreements</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As part of the Company’s acquisition of the Senhance System in 2015, the Company assumed certain license and supply agreements. The Company has purchase orders with various suppliers for certain tooling, supplies, contract engineering and research services. Commitments related to license agreements and purchase orders are as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,263</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">300</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">320</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total commitments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Fiscal Year</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,263</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">300</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">320</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total commitments</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3,883</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody></table> 3263000 300000 320000 3883000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>17.</b>         <b>Segments and Geographic Areas</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The Company operates in <span style="-sec-ix-hidden:c1577">one</span> business segment—the research, development, and sale of medical devices to improve MIS. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents consolidated assets and long-lived assets by geographic area, which includes property and equipment, intellectual property, and operating lease assets:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Long-Lived Assets</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total Assets</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EMEA</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asia</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Long-Lived Assets</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total Assets</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td class="q2qselectedlineitem" colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EMEA</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asia</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The following table presents sales by geographic area based on the country in which the customer is based.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31, </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EMEA</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">82</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asia</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Long-Lived Assets</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total Assets</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EMEA</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asia</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Long-Lived Assets</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total Assets</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td class="q2qselectedlineitem" colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EMEA</p> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">62</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td class="q2qselectedlineitem" style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27</td> <td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asia</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> 0.29 0.46 0.68 0.52 0.03 0.02 1 1 0.35 0.72 0.62 0.27 0.03 0.01 1 1 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31, </b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2023</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EMEA</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">82</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Asia</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 31%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">100</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </tbody></table> 0.08 0.11 0.82 0.77 0.10 0.12 1 1 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>18.</b>         <b>Related Party Transactions</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In March 2018, Asensus Surgical Europe S.à r.l. entered into a Service Supply Agreement with 1 Med S.A. for certain regulatory consulting services. Andrea Biffi, a current member of the Company’s Board of Directors, owns a non-controlling interest in 1 Med S.A. Expenses under the Service Supply Agreement were approximately $0.1 million and $0.3 million for the years ended December 31, 2023 and 2022, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">In October 2023, Asensus Surgical US, Inc. entered into an agreement with Synchrony Labs, LLC to support preclinical evaluation of the LUNA Surgical System. William Starling, a current member of the Company’s Board of Directors, owns more than 10% of Synchrony Labs, LLC. Expenses under the agreement were approximately $0.1 million for the year ended December 31, 2023.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> 100000 300000 0.10 100000 <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a href="#" id="other" title="other"></a>ITEM</b> <b>9.B.</b>       <b>OTHER INFORMATION</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the three months ended December 31, 2023, <span style="-sec-ix-hidden:c1644"><span style="-sec-ix-hidden:c1645"><span style="-sec-ix-hidden:c1646"><span style="-sec-ix-hidden:c1647">none</span></span></span></span> of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as such terms are defined in Item 408 of Regulation S-K.</p> Includes investments that are readily convertible to cash with original maturities of 90 days or less.

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�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